

Developing Consensus on Tobacco Control and Research

Cathy L. Backinger, PhD, MPH, Mary E. O'Connell, MA

In June 2006, the National Institutes of Health (NIH) held its first State-of-the-Science Conference on tobacco control and prevention titled, Tobacco Use: Prevention, Cessation, and Control. State-of-the-Science Conferences are convened as part of the NIH Consensus Development Program, to form "unbiased, independent, evidence-based assessments of complex medical issues."¹ The NIH Consensus Statements and State-of-the-Science Statements produced by these Conferences are disseminated widely to healthcare practitioners, policymakers, patients, the media, and the general public. Since the program's inception in 1977, NIH has held more than 130 such Conferences.

The State-of-the-Science Conference on the prevention, cessation, and control of tobacco was sponsored by the NIH Office of Medical Applications of Research, the National Cancer Institute (NCI), and twelve other NIH Institutes and Centers (ICs) along with six other federal agencies that served as conference partners.² Together, the co-sponsoring and partner agencies formed a planning group that determined the six questions to be answered by the Conference:

1. What are the effective population- and community-based interventions to prevent tobacco use in adolescents and young adults, including among diverse populations?
2. What are the effective strategies for increasing consumer demand for and use of proven, individually-oriented cessation treatments, including among diverse populations?
3. What are the effective strategies for increasing the implementation of proven, population-level, tobacco-use cessation strategies, particularly by healthcare systems and communities?
4. What is the effect of smokeless tobacco product marketing and use on population harm from tobacco use?
5. What is the effectiveness of prevention and of cessation interventions in populations with co-occurring morbidities and risk behaviors?

From the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Address correspondence and reprint requests to: Mary E. O'Connell, MA, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd., MSC 7337, Rockville MD 20852. E-mail: oconnellm@mail.nih.gov.

6. What research is needed to make the most progress and greatest public health gains nationally and internationally?

Given the focused nature of the process, the Conference questions were not designed as a comprehensive assessment of tobacco control and prevention; rather they were intended to address a small number of priority issues.

The strength of the Consensus Development Program lies in its objectivity, independence, and its focus on specific, predetermined questions. State-of-the-Science panel members are drawn from physicians, scientists, and representatives of the public, **from outside the field to be evaluated**; they may not have scientific or financial conflicts of interest, hold advocacy opinions relevant to the Conference, or be employed by the U.S. Department of Health and Human Services (USDHHS). Panel members are not known to the co-sponsoring ICs and partners prior to the Conference, and interaction between panel members and co-sponsors or partners before or during the Conference is prohibited. A range of expertise on the panel contributes to its ability to deliberate thoughtfully on the scientific material presented; panel members are reimbursed for their travel expenses, but otherwise receive no payment for their work. Conference statements represent an independent report of the Conference panel and are not policy statements of the NIH or the U.S. Federal Government.

Being a member of a Consensus Development Panel is a very large responsibility. Panel members prepare for the Conference by studying a systematic literature review, prepared under contract to Agency for Healthcare Research and Quality (AHRQ) by RTI International—University of North Carolina Evidence-Based Practice Center, on the questions they will be asked to address.³ This literature review is made available to the public at the end of the Conference. Over the course of the public portion of the Conference, the panel hears presentations from invited experts as well as questions, comments, and statements from members of the public. Additionally, the panel receives and reviews comments sent by e-mail, for those attending the conference via the Internet. Following the conclusion of the public session, panel members begin their closed deliberations, to together develop their Conference State-

ment. It is not uncommon for a panel to work through the night to reach consensus and finalize their statement, which is released to the conference attendees, the media and the general public on the morning of the next day.

The NIH State-of-the Science Conference on Tobacco Use was attended by more than 400 people from 21 countries, either in person or via the live webcast. The Conference Panel was chaired by David Ransohoff, MD, Professor of Medicine at the University of North Carolina at Chapel Hill School of Medicine. Other members of the panel included experts in the fields of medicine, general and pediatric psychiatry, addiction medicine, nursing, social work, population science, cancer prevention, minority health and health disparities, clinical study methodology, and clinical epidemiology, as well as a representative of the public. Invited experts from pertinent fields made presentations at the Conference, focusing their remarks on information the Conference Panel needed to answer their assigned questions. Additionally, more than 130 written comments and statements were received and reviewed by the Conference Panel.

Following an intense night of deliberation, the panel's Conference Statement was presented to the public on June 14, 2006. The Statement outlined what, in the view of the panel, we know and what we need to learn for each of the questions the panel was asked to address. The overall conclusion as published on the *Annals of Internal Medicine* website is below⁴:

"Tobacco use remains a very serious public health problem. Coordinated national strategies for tobacco prevention, cessation, and control are essential if the United States is to achieve the *Healthy People 2010* goals.⁵ Most adult smokers want to quit, and effective interventions exist. However, only a small proportion of tobacco users try treatment. This gap represents a major national quality-of-care problem. Many cities and states have implemented effective policies to reduce tobacco use; public health and government leaders should learn from these experiences.

Because smokeless tobacco use may increase in the United States, it will be increasingly important to understand net population harms related to use of smokeless tobacco. Prevention, especially among youth, and cessation are the cornerstones of strategies to reduce tobacco use. Tobacco use is a critical and chronic problem that requires close attention from healthcare providers, healthcare organizations, and research support organizations."

Our nation has made enormous progress in reducing tobacco use, preventing the premature deaths of literally millions of Americans. Since the release of the first Surgeon's General report on smoking in 1964,⁶ adult smoking prevalence has been cut in half, from about 42% in 1965 to 21% in 2005.^{7,8} Nonetheless, as the Conference Statement noted, "tobacco use **remains** a

very serious public health problem" (emphasis added). The panel identified numerous areas for future research including:

Improving and implementing effective interventions such as increasing and sustaining demand for smoking-cessation treatment, examining components of telephone-based counseling programs, and developing and enhancing both pharmacologic and non-pharmacologic treatments.

Improving and implementing effective policies such as identifying barriers to implementing successful comprehensive tobacco-control programs, developing effective policies for reimbursing healthcare providers, and conducting economic studies to tobacco prevention, cessation, and control.

Developing new population- and community-based interventions such as evaluating social marketing strategies, learning from natural experiments, determining the effectiveness of interventions in various settings, and evaluating approaches to reduce tobacco use in vulnerable populations.

Conducting research on smokeless tobacco including impact of marketing, measuring nicotine and toxins, evaluating advantages and disadvantages of regulation, and assessing cancer and other disease risks.

The Conference Statement on Tobacco Use represents the culmination of a lengthy effort by an independent, unbiased panel of scholars who have not previously considered the issue of tobacco use. It is hoped that their diligent efforts, as well as this supplement to the *American Journal of Preventive Medicine*^{9–20} containing articles from many of the Conference's invited experts, will bring new energy, ideas and enthusiasm to reducing our nation's burden of tobacco use.

No financial disclosures were reported by the authors of this paper.

References

1. Office of Medical Applications of Research, National Institutes of Health (NIH). NIH Consensus Development Program. 2005. Available online at: consensus.nih.gov/ABOUTCDP.htm.
2. U.S. Department of Health and Human Services (USDHHS), NIH. Program and Abstract Book for the NIH State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control. 2006. Available online at: consensus.nih.gov/2006/2006TobaccoSOS029Program.pdf.
3. Ranney L, Melvin C, Lux L, McClain E, Morgan L, Lohr K. Tobacco Use: Prevention, Cessation, and Control. Evidence Report/Technology Assessment No. 140, in Prepared by the RTI International—University of North Carolina Evidence-Based Practice Center under Contract No. 290-02-0016. 2006, AHRQ Publication No. 06-E015. Agency for Healthcare Research and Quality: Rockville MD.
4. NIH State-of-the-Science conference statement on tobacco use: prevention, cessation, and control. NIH Consens State Sci Statements 2006. 23(3):1–26.
5. USDHHS. Healthy People 2010, 2nd edn. Available online at: www.healthypeople.gov/publications/.
6. U.S. Public Health (USPHS). Service. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service, 1964. Available online at: <http://profiles.nlm.nih.gov/NN/B/C/X/B/>.

7. Giovino GA, Schooley MW, Zhu BP, et al. Surveillance for selected tobacco-use behaviors—United States, 1900–1994. *MMWR CDC Surveill Summ*, 1994. 43(3):1–43.
8. Tobacco use among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:1145–8.
9. Giovino GA. The tobacco epidemic in the United States. *Am J Prev Med* 2007;33(6S):S318–S326.
10. Pierce JP. Tobacco industry marketing, population-based tobacco control, and smoking behavior. *Am J Prev Med* 2007;33(6S):S327–S334.
11. Forster JL, Widome R, Bernat DH. Policy interventions and surveillance as strategies to prevent tobacco use in adolescents and young adults. *Am J Prev Med* 2007;33(6S):S335–S339.
12. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments: reaping the full health benefits of tobacco control science and policy gains—in our lifetime. *Am J Prev Med* 2007;33(6S): S340–S348.
13. Fiore MC, Keller PA, Curry SJ. Health system changes to facilitate the delivery of tobacco-dependence treatment. *Am J Prev Med* 2007;33(6S):S349–S356.
14. McAfee TA. Quitlines: a tool for research and dissemination of evidence-based cessation practices. *Am J Prev Med* 2007;33(6S):S357–S367.
15. Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. Changing smokeless tobacco products: new tobacco-delivery systems. *Am J Prev Med* 2007;33(6S):S368–S378.
16. Kozlowski LT. Effect of smokeless tobacco product marketing and use on population harm from tobacco use: policy perspective for tobacco-risk reduction. *Am J Prev Med* 2007;33(6S):S379–S386.
17. Tomar SL. Epidemiologic perspectives on smokeless tobacco marketing and population harm. *Am J Prev Med* 2007;33(6S):S387–S397.
18. Lerman CE, Schnoll RA, Munafò M. Genetics and smoking cessation: improving outcomes in smokers at risk. *Am J Prev Med* 2007;33(6S): S398–S405.
19. Hall SM. Nicotine interventions with comorbid populations. *Am J Prev Med* 2007;33(6S):S406–S413.
20. Gritz ER, Vidrine DJ, Cororve Fingeret MC. Smoking cessation: a critical component of medical management in chronic disease populations. *Am J Prev Med* 2007;33(6S):S414–S422.

Charting the Science of the Future Where Tobacco-Control Research Must Go

Kenneth E. Warner, PhD

The state of the science of tobacco control is, in a word, impressive. In fields ranging from epidemiology to biology, from psychology to operations research, from brain chemistry to economics, research on tobacco use, prevention, cessation, and control has had a profound impact on the public's knowledge and practices regarding the single greatest behavior-related cause of illness and death. The behavioral response, in turn, has generated an enormous public health benefit in the form of large reductions in avoidable illness, disability, and premature mortality.

The heart of the science lies in the original epidemiology in the 1950s that established cigarette smoking as the principal cause of lung cancer.¹⁻⁵ That work forever altered the world's perception of smoking. Even though it was applied research, it helped to define the very field of epidemiology and elevated its stature in a world of medical science previously slavishly devoted to germ theory, laboratory analysis, and pure clinical observation.⁶

More recently, epidemiologic science has fed the increasing demand for smoke-free environments. Beginning with Hirayama's ground-breaking study of lung cancer in the nonsmoking wives of smoking husbands,⁷ this body of work⁸ has established the scientific basis for what is now a profusion of smoke-free laws throughout the United States (more than half of the states now ban smoking in all workplaces, including all restaurants and bars) and countries of the world (more than a dozen at this count). The other crucial line of research with regard to secondhand-smoke exposure—work demonstrating that restaurants and bars that go smoke-free do not suffer financial losses as a result⁹—is itself a form of epidemiology typically utilizing a case-control method (i.e., comparing sales in establishments in newly smoke-free jurisdictions with sales in establishments in jurisdictions lacking smoke-free policies).

Biological, behavioral, and social sciences have contributed mightily as well, ranging from the development of novel smoking-cessation treatments and trials demonstrating their efficacy¹⁰ to economic analysis that

has made taxation a cornerstone of sound tobacco-control policy worldwide.¹¹ Indeed, most of what we know about tobacco and health and effective tobacco control derives from research pursued for more than a half century now. This is without doubt one of history's greatest public health research success stories.^{12,13} The articles in this supplement to the *American Journal of Preventive Medicine*¹⁴⁻²⁵ vividly illustrate the wealth of research-based knowledge on multiple important subjects related to tobacco use, prevention, cessation, and control. The tremendous public health impact to which that explosion of knowledge has contributed is reflected in data on smoking prevalence and outcome: the former has declined in the U.S. by more than half since its peak in the early 1960s, with the consequence that perhaps 3 million Americans have avoided premature smoking-related deaths.¹²

And yet, the glass remains half empty.¹³ If progress against smoking ranks as the developed world's greatest public health achievement in the past half-century, as I would contend, smoking also remains unarguably the greatest cause of premature death. That the rate of decline in smoking has slowed substantially in affluent countries, and has actually risen slightly in a few, is a source of great concern. That the "brown plague" is metastasizing throughout the developing world is frightening and, given the role of the multinational tobacco companies, unconscionable.

The future of tobacco control will never rest solely on the development of new research-based knowledge; it never has. Almost certainly the future will depend far more on effective politics and activism. Still, science can and must continue to contribute. In developing countries, reproduction of basic epidemiology and social science research will be essential to contextualize the problem and make it relevant to policymakers. In the developed world, the issues demanding attention are, in many ways, far more complicated than those that confronted earlier generations of tobacco-control researchers. So too will be the science needed to resolve them.

I leave the hard task of formulating that science to others. Here I will simply identify some of the challenging issues with which, collectively, we will have to grapple.

First and foremost is the question of "what's next" in tobacco control in affluent countries. Scores of studies

From the School of Public Health, University of Michigan, Ann Arbor, Michigan

Address correspondence and reprint requests to: Kenneth E. Warner, PhD, Dean & Avedis Donabedian Distinguished University Professor of Public Health, School of Public Health, University of Michigan, 109 S. Observatory, Ann Arbor MI 48109-2029. E-mail: kwarner@umich.edu.

have documented the reduction in smoking produced by taxation; smoke-free indoor-air policies; sizable, sustained, professionally-developed countermarketing campaigns; and bans on tobacco advertising and promotion.¹² But what do you do after you have implemented all of these policies? Consider the case of Ireland, the first country to adopt a comprehensive smoke-free workplace policy. Today the price of cigarettes in Ireland exceeds \$9 a pack. With the exception of point-of-sale, virtually all forms of tobacco advertising and promotion are banned. (The Irish authorities are targeting point-of-sale advertising now.) Before implementation of the smoke-free workplace law, smoking prevalence exceeded 25%. A year later it had dropped to 23%. One year thereafter it was back up to 25%.²⁶ The Irish could benefit from a large and sustained norm-changing media campaign. But short of banning smoking anywhere in public, what are public health officials to do to combat the ongoing scourge of tobacco in Ireland?

Similar problems are seen emerging in many countries, including the U.S., in which the decline in smoking has slowed and threatens to level off. To be sure, pockets of success give reason for hope—California recently reported a decline in adult daily smoking to below 10%²⁷—but one senses considerable pessimism about the potential to sustain substantial progress against smoking.

In part, this reflects diminished resources and diminished expectations about resources. The entire field of public health was deeply disappointed by the failure of the states to use Master Settlement Agreement allotments to fund comprehensive tobacco-control programs. Long-time champions of tobacco control research, most notably the Robert Wood Johnson Foundation, have moved on to other issues. The challenge of making tobacco-control research, a now “aging” field, fresh, relevant, and compelling to the new generation of funders must be confronted.

More fundamentally, however, the slowing of progress against smoking reflects a fact that is frequently acknowledged but then seemingly forgotten when policies and interventions are designed and when the future of tobacco control is contemplated: today’s smokers differ from the smokers of “yesteryear,” many of whom have quit. Some in the remaining smoking population—possibly a sizable proportion—may be true “hardcore smokers,” those who are unable or unwilling to quit and likely to remain so.²⁸ But in my judgment, the most important fact about today’s smokers is that many of them—perhaps as many as half—are suffering from some form of mental illness or (other) substance abuse.²⁹ As a group, they find quitting more difficult, and perhaps of less interest. For many, the behavior of smoking is not simply a matter of addiction, nor one of self-image; rather, many of today’s smokers are self-administering nicotine, and perhaps other

chemicals in smoke, to treat symptoms of their comorbidities. We ignore this at our peril, and theirs. Increasingly, tobacco-control policies and smoking-cessation treatments must focus on addressing the needs of this growing population who smoke to deal with a variety of problems that may have had little relevance to previous generations of smokers who quit relatively easily.

Speaking of smoking-cessation treatments, new ones must be found that are more effective. That could mean simply more effective medications. But it also likely means two other things. First, it means developing products that are effective in everyday practice. There is a small but thought-provoking literature that questions whether over-the-counter (OTC) nicotine replacement therapy (NRT) products actually work in everyday settings, as opposed to the carefully controlled and monitored clinical trial research that has found them efficacious.³⁰ Given increasing attention devoted to finding ways to get more NRT products in the hands (and in the mouths and on the arms) of smokers, it is crucial to understand whether OTC products do work, and if so, how well.

The second implication, closely related to the first, is that cessation products that are far more attractive to smokers than today’s offerings need to be designed. To get over the hurdle of U.S. Food and Drug Administration (FDA) regulation, many NRT products have been intentionally designed to be consumer-unattractive. To win FDA approval, the original nicotine “gum” was designed to taste bad and, of course, not to be addictive. Yet cessation products have to compete with smoking, an obviously attractive, even seductive, product.

So how does one create a treatment product that can compete with cigarettes? That question raises others: how can a timid FDA be brought to recognize that, if we are to get serious about fighting smoking, the agency may need to authorize new products that pose risks currently deemed unacceptable? Would a true pulmonary nicotine inhaler, certain to sustain addiction, be a bad thing when dealing with the most hardcore of nicotine addicts?

Questions such as this one inevitably lead to the issue that, in my 30 years in tobacco control, I have found the single most perplexing: “tobacco harm reduction.”³¹ The debate on harm reduction generates its own set of challenging questions: Should products less hazardous than cigarettes, including tobacco products, be promoted as alternatives to smoking for smokers who are unable, or unwilling, to quit? If so, is it possible to target promotion so finely, thereby avoiding encouraging others to use a product, still risky, when otherwise they would have abstained entirely? What kinds of products should be considered as acceptable members of the tobacco harm reduction arsenal? For example, is it advisable to promote low-nitrosamine smokeless tobacco products as much less hazardous than cigarettes (which they certainly are³²)? How can the population

impact that would follow from the introduction and promotion of ostensibly less hazardous products be assessed? What surveillance system could evaluate use patterns, and ultimately health consequences, when confronted with possibly a dozen or more qualitatively different types of products and the hundreds of mixed use patterns that would emerge? Indeed, short of waiting 30 years for the (possibly inadequate) epidemiologic evidence, how can risk reduction potential be evaluated scientifically? The questions are endless, with none of them lending themselves to easy resolution. Yet “harm reduction” may be an important wave of the future. Will it join prevention, cessation, and protection of others as the fourth pillar of comprehensive tobacco control?

The most important questions about the future of tobacco control include some that have challenged us for decades. How can we prevent children from experimenting with cigarettes, and, for many, going on to become addicted smokers? Sadly, knowledge in this all-important domain is sorely lacking. Clearly we need far better understanding of what motivates youthful experimentation with tobacco, and—more importantly, I believe—what converts experimentation into long-term smoking. And then we need to understand how to intervene to prevent the latter, if not the former. While probing the depths of behavioral research, we should also urge basic science and laboratory colleagues to seek the Holy Grail of smoking prevention: a vaccine that would prevent the onset of addiction.³³

And perhaps most importantly, as we look to the future, how can we, as a global tobacco-control community, reduce the toll that the World Health Organization foresees for tobacco in the present century? During the course of this century, WHO predicts that, without changes in currently anticipated trends, tobacco will kill one billion citizens of the globe.³⁴ That is an unimaginable disaster. The Framework Convention on Tobacco Control,³⁵ a global treaty based on tobacco-control science, now ratified by 148 countries, provides a vehicle to avoid much of that disaster. But how, and how well, will we implement its important life-sparing provisions?

The state of the science of tobacco control is indeed impressive. So too are the challenges confronting it for the future.

No financial disclosures were reported by the author of this paper.

References

1. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: A study of 684 proved cases. *JAMA* 1950;143:329–96.
2. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: A preliminary report. *BMJ* 1954;1:1451–5.
3. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking habits: A second report on the mortality of British doctors. *BMJ* 1956;2:1071–81.

4. Hammond ED, Horn D. Smoking and death rates – report on forty-four months of follow-up on 187,783 men. I. Total mortality. *JAMA* 1958; 166:1159–72.
5. Hammond ED, Horn D. Smoking and death rates – report on forty-four months of follow-up on 187,783 men. II. Death rates by cause. *JAMA* 1958; 166:1294–308.
6. Brandt AM. *The cigarette century: The rise, fall, and deadly persistence of the product that defined America*. New York: Basic Books, 2007.
7. Hirayama T. Non-smoking wives of heavy smokers have a higher risk of lung cancer: A study from Japan. *BMJ Clinical Research Ed* 1981;282:183–5.
8. National Cancer Institute. *Health Effects of Exposure to Environmental Tobacco Smoke: The Report of the California Environmental Protection Agency*. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Smoking and Health Monograph No. 10. Bethesda MD, 1999.
9. Scollo M, Lal A, Hyland A, et al. Review of the quality of studies on the economic effects of smoke-free policies on the hospitality industry. *Tob Control* 2003;12:13–20.
10. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A U.S. Public Health Service report. *JAMA* 2000;283:3244–54.
11. Chaloupka FJ, Hu TW, Warner KE, et al. The taxation of tobacco products. In Jha P, Chaloupka F, eds. *Tobacco control in developing countries*. New York: Oxford University Press, 2000, pp. 237–72.
12. Warner KE. Tobacco policy research: insights and contributions to public health policy. In Warner, KE, ed. *Tobacco control policy*. San Francisco: Jossey-Bass, 2006, pp. 3–86.
13. Bonnie RJ, Stratton K, Wallace RB, eds. *Ending the tobacco problem: A blueprint for the nation*. Washington: National Academies Press, 2007.
14. Giovino GA. The tobacco epidemic in the United States. *Am J Prev Med* 2007;33(6S):S318–S326.
15. Pierce JP. Tobacco industry marketing, population-based tobacco control, and smoking behavior. *Am J Prev Med* 2007;33(6S):S327–S334.
16. Forster J, Widome R, Bernat D. Policy interventions and surveillance as strategies to prevent tobacco use in adolescents and young adults. *Am J Prev Med* 2007;33(6S):S335–S339.
17. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments: reaping the full health benefits of tobacco-control science and policy gains—in our lifetime. *Am J Prev Med* 2007;33(6S): S340–S348.
18. Fiore MC, Keller PA, Curry SJ. Health system changes to facilitate the delivery of tobacco dependence treatment. *Am J Prev Med* 2007;33(6S): S349–S356.
19. McAfee TA. Quitlines: a tool for research and the dissemination of evidence-based cessation practices. *Am J Prev Med* 2007;33(6S):S357–S367.
20. Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. Changing smokeless tobacco products: new tobacco-delivery systems. *Am J Prev Med* 2007;33(6S):S368–S378.
21. Kozlowski LT. Effect of smokeless tobacco product marketing and use on population harm from tobacco use: policy perspectives for tobacco risk reduction. *Am J Prev Med* 2007;33(6S):S379–S386.
22. Tomar SL. Epidemiologic perspectives on smokeless tobacco marketing and population harm. *Am J Prev Med* 2007;33(6S):S387–S397.
23. Lerman C, Schnoll RA, Munafò M. Genetics and smoking cessation: improving outcomes in smokers at risk. *Am J Prev Med* 2007;33(6S): S398–S405.
24. Hall SM. Nicotine interventions with comorbid populations. *Am J Prev Med* 2007;33(6S):S406–S413.
25. Gritz ER, Vidrine DJ, Fingeret MC. Smoking cessation: a critical component of medical management in chronic disease populations. *Am J Prev Med* 2007;33(6S):S414–S422.
26. Office of Tobacco Control (Ireland). Available online at: <http://www.otc.ie/>.
27. California Department of Public Health. C-STATS. Available online at: <http://www.cstats.info/index.cfm?fuseaction=base.home>.
28. Warner KE, Burns DM. Hardening and the hard-core smoker: Concepts, evidence, and implications. *Nicotine Tob Res* 2003;5:37–48.
29. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: A population-based prevalence study. *JAMA* 2000;284:2606–10.
30. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA* 2002;288:1260–4.
31. Warner KE. Tobacco harm reduction: Promise and perils. *Nicotine Tob Res* 2002;4(suppl 2):S61–71.

32. Levy DT, Mumford E, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared to smoking cigarettes: Estimates of a panel of experts. *Cancer Epidemiol Biomarkers Prev* 2004;13:2035–42.
33. Heaton C. Remarks. Annual Meeting of the Society for Research on Nicotine and Tobacco. Seattle, March 23, 2001.
34. Cropley E. Smoking could kill 1 billion this century: WHO. Reuters July 2, 2007. Available online at: <http://www.reuters.com/article/healthNews/idUSBKK25206020070702>.
35. World Health Organization. Tobacco Free Initiative. WHO Framework Convention on Tobacco Control (WHO FCTC). Available online at: <http://www.who.int/tobacco/framework/en/>.

The Tobacco Epidemic in the United States

Gary A. Giovino, PhD, MS

Abstract: Tobacco use, primarily in the form of cigarettes and exposure to tobacco smoke pollution, has caused the premature deaths of more than 14 million Americans since 1964. The major diseases caused by tobacco and tobacco smoke include lung cancer, other cancers, coronary heart disease, other cardiovascular diseases, chronic respiratory diseases, pregnancy complications, and respiratory diseases in children. Per capita consumption of various tobacco products has declined substantially since 1950, with current consumption at approximately 3.7 pounds per capita. Whereas approximately two in five adults smoked cigarettes in 1965, approximately one in five did so in 2005.

Several factors can influence initiation and cessation, including product factors (e.g., ventilation holes, additives, and flavorings); host factors (intention to use, level of dependence); tobacco company activities (e.g., marketing strategies, efforts to undermine public health activities); and environmental factors (e.g., peer and parental smoking, smoke-free air laws and policies). Efforts to prevent initiation, promote quitting, and protect nonsmokers should reduce exposure to pro-tobacco marketing and increase (1) the price of tobacco products, (2) protection from tobacco smoke pollution, (3) effective mass media strategies, (4) provision of effective cessation support, (5) effective regulation, and (6) litigation that holds the industry responsible for its misdeeds. Adequate implementation of effective tobacco-control strategies and useful scientific advances will help to ensure that per capita consumption decreases to the lowest level possible. The economic benefits of tobacco in our society are replaceable and they pale in comparison to the extent of human life lost.

(Am J Prev Med 2007;33(6S):S318–S326) © 2007 American Journal of Preventive Medicine

Introduction

Tobacco use, primarily in the form of cigarettes, has caused more than 14 million premature deaths in the United States since 1964.^{1,2} It remains the single leading preventable cause of death in this country, with 400,000 current and former smokers dying annually from smoking-attributable diseases, and 38,000 nonsmokers dying annually because of exposure to tobacco smoke pollution.^{2,3} Approximately 8.6 million Americans live with serious disease(s) caused by their smoking.⁴ Peto and his colleagues⁵ estimate that one half of all smokers, especially those who began as teens, can expect to die of tobacco use. Of these, approximately one half will die in middle age, losing an average of 20–25 years of life expectancy.

This article provides an overview of the consequences and patterns of tobacco use, factors that can influence use, and efforts to control use. It documents the tremendous progress that has been made in reducing

use and discusses factors that either can promote or reduce use. A final section will describe possible future scenarios of tobacco consumption and discuss some economic considerations that would arise if U.S. consumption is reduced substantially.

Consequences of Tobacco Use and Exposure to Secondhand Smoke Active Cigarette Smoking

Using criteria that were described in the initial report of the Advisory Committee to the U.S. Surgeon General and later elaborated upon by A.B. Hill, scientists have documented a list of diseases for which sufficient evidence exists to conclude that they are caused by cigarette smoking (Table 1).^{1,6–8} Tobacco use remains the single leading preventable cause of death in the U.S.³ Nearly one of every five deaths in the U.S. is caused by cigarette smoking.²

Cigarette smoke contains 4800 identified chemicals, at least 250 of which cause cancer or are toxic in other ways.^{9,10} Hecht¹¹ estimates that 61 chemicals in tobacco smoke cause cancer, with polycyclic aromatic hydrocarbons, nitrosamines, and aromatic amines being major contributors. Carbon monoxide and other chemicals in tobacco smoke contribute to processes leading to car-

From the Department of Health Behavior, School of Public Health and Health Professions, University at Buffalo; State University of New York, Buffalo, New York

Address correspondence and reprint requests to: Gary A. Giovino, PhD, MS, Department of Health Behavior, School of Public Health and Health Professions, SUNY at Buffalo, 622 Kimball Tower, Buffalo NY 14214-8028. E-mail: giovino@buffalo.edu.

Table 1. Diseases/conditions caused by active cigarette smoking¹

Disease	Effects
Malignant neoplasms	Cancers of the lung, larynx, mouth, esophagus, urinary bladder, pancreas, kidney, cervix uteri, stomach, and acute myeloid leukemia
Cardiovascular diseases	Coronary heart disease, cerebrovascular disease, atherosclerosis, and aortic aneurysm
Respiratory diseases in adults	Chronic obstructive pulmonary disease (bronchitis, emphysema, chronic airway obstruction), pneumonia, premature onset of and an accelerated age-related decline in lung function, all major respiratory symptoms (e.g., coughing, phlegm, wheezing, dyspnea), poor asthma control
Respiratory diseases in young people	Impaired lung growth, respiratory symptoms, and asthma-related symptoms (e.g., wheezing) in childhood and adolescence; early onset of lung function decline during late adolescence and early adulthood
Reproductive and perinatal conditions	Sudden infant death syndrome, reduced fertility in women, fetal growth restriction, low birth weight, premature rupture of the membranes, placenta previa, placental abruption, preterm delivery and shortened gestation, respiratory distress syndrome
Miscellaneous	Cataracts, hip fractures, low bone density, peptic ulcer disease in persons who are <i>Helicobacter pylori</i> positive, diminished health status (i.e., increased absenteeism from work, increased use of medical care services); adverse surgical outcomes related to wound healing and respiratory complications

diovascular disease, such as endothelial injury and dysfunction, atherosclerosis, platelet aggregation, thrombosis, low-grade inflammation, and increased levels of carboxyhemoglobin.¹ Active smoking induces processes such as oxidative stress, inflammation, and protease-antiprotease imbalances that injure airways and alveoli and if sustained contribute to chronic obstructive pulmonary disease.¹ Smokers of light and ultralight cigarettes are at the same risk for diseases as smokers of full-flavor cigarettes.^{1,12} This is true despite the published tar yields for light and ultralight cigarettes that inaccurately suggest that smokers are exposed to lower concentrations of toxic chemicals. The published tar yields are based on the Federal Trade Commission (FTC)'s testing method, which does not reflect actual human smoking patterns.¹³ Hecht and his colleagues¹⁴ have demonstrated similar uptakes of lung carcinogens

and nicotine among smokers of ultralight, light, and full-flavor cigarettes.

Use of Other Tobacco Products

Cigar smoke is composed of the same carcinogenic and toxic constituents as in cigarette smoke.¹⁵ Regular cigar smoking causes cancers of the oral cavity, larynx, esophagus, and lung. Heavy cigar smokers and those who inhale deeply are at increased risk of coronary heart disease and chronic obstructive pulmonary disease. Pipe smoking increases the risk of cancers of the oral cavity, larynx, esophagus, and lung, as well as of chronic obstructive pulmonary disease.¹⁶ Use of smokeless tobacco (such as snuff and chewing tobacco) causes cancer of the oral cavity and increases the risk of oral leukoplakia and gingival recession.^{10,17,18} As Hatsukami and her colleagues¹⁹ discuss in this issue, many different forms of smokeless tobacco exist, with variability in the levels of toxins. The available scientific literature suggests that disease risk may also vary by product type.^{19,20}

Bidis are small, thin, hand-rolled cigarettes consisting of tobacco wrapped in a tendu or temburni leaf and wrapped in a string.^{21,22} In studies from India, bidi smoking has been associated with increased risk of cancers of the oral cavity, esophagus, stomach, and lung, as well as of coronary heart disease and chronic bronchitis.^{23–26} Also known as clove cigarettes, kreteks contain tobacco, clove, and other additives.²⁷ Eugenol, a product of the clove buds, is a mild anesthetic that permits deeper inhalation.²⁸ Kretek use increases the risk of acute lung injury, especially among individuals with asthma or respiratory infections; it also increases risk of abnormal lung function.^{27,29}

Addiction

Because they contain nicotine, all tobacco products produce addiction.³⁰ The pharmacologic and behavioral processes that determine addiction to tobacco products are similar to those that determine addiction to illicit drugs such as heroin or cocaine.³⁰ The tobacco industry is capable of manipulating the bioavailability and reinforcing properties of nicotine,^{31–33} even modest exposure of which can initiate the dependence process.^{34–37}

Involuntary Exposure to Tobacco Smoke Pollution

The smoke emanating from the tip of a burning tobacco product is called sidestream smoke; the smoke that the smoker inhales is called mainstream smoke.³⁸ Sidestream smoke and exhaled mainstream smoke are the main contributors to the tobacco smoke pollution that is often inhaled involuntarily by nonsmokers and is also known as secondhand smoke and environmental




Figure 1. Trends in per capita consumption of various tobacco products—United States, 1880–2004.^{39,40,45,46} Source: United States Department of Agriculture.

tobacco smoke. There is no risk-free level of exposure to tobacco smoke pollution, which causes premature disease and death in children and adults who do not smoke. Tobacco smoke pollution causes respiratory effects in children (e.g., lower respiratory illnesses; middle ear disease, including acute and recurring otitis media and chronic middle ear effusion; cough, phlegm, wheeze, and breathlessness among school-aged children; asthma; persistent adverse effects on lung function and lower levels of lung function), low-birthweight babies, and sudden infant death syndrome (SIDS). Among adults, tobacco smoke pollution causes approximately 3000 deaths from lung cancer and 35,000 deaths from heart disease each year.^{2,38} Separating smokers from nonsmokers, cleaning the air, and ventilating buildings do not eliminate nonsmokers' exposures to second-hand smoke.³⁸ Eliminating smoke from indoor places is the only way to fully protect nonsmokers from exposure to tobacco smoke pollution.

Overall Mortality

Counting deaths attributable to both active and involuntary smoking, approximately 39% (about 173,000) of smoking-attributable deaths (SADs) are from cardiovascular diseases, with approximately 121,900 of these due to ischemic heart disease.² Another 37% (about 161,500 annually) of smoking-attributable deaths are from malignant neoplasms, with approximately 126,900 due to cancers of the trachea, bronchus, or lung. Twenty-three percent (101,500) of smoking-attributable deaths are from respiratory diseases other than lung cancer (e.g., chronic airway obstruction, bronchitis, emphysema). From a different perspective, approximately 18% of cardiovascular disease deaths, 30% of malignant neoplasms, and 79% of chronic respiratory diseases in U.S.

adults are attributable to smoking or exposure to tobacco smoke pollution.

Patterns of Use

In the early 1880s the tobacco in manufactured cigarettes accounted for only 1% of all tobacco consumed in the U.S. (Figure 1). By 1950, this figure was 80%; and by 2006, 79% of tobacco consumed in the U.S. was in cigarettes.^{39–41} Overall tobacco consumption peaked in the early 1950s, at about 13 pounds per person; by 2006, per capita consumption was down to 3.7 pounds per capita, the lowest estimate since recordkeeping began in 1880. Some of this decline is due to greater efficiencies over time on the part of cigarette manufacturers who make cigarettes with the stems and leaf ribs of tobacco plants and use expanded tobacco.^{42,43} In addition, the addition of the filter tip has decreased the size of the tobacco column.⁴³ Thus, while the production of 1000 cigarettes required 2.7 pounds of tobacco in the early 1950s, only 1.5 pounds was used in 2004.^{40,42} Still, the number of cigarettes consumed also has declined substantially during this time period.⁴⁴

While overall U.S. consumption of tobacco products has been declining for several decades (Figure 1),^{39,40,45,46} consumption increased from 1995 through 2006 for cigars (by 73%), snuff (by 23%), and smoking tobacco (i.e., pipe or roll-your-own) (by 15%).^{40,45} From 1995 through 2006, consumption declined for cigarettes (by 31%) and chewing tobacco (by 45%).^{40,45} The prevalence of cigarette smoking among U.S. adults (aged ≥ 18 years) declined substantially, from 42.4% in 1965 to 20.8% in 2006 (Figure 2).^{47–51} Of the 45.1 million U.S. smokers in 2005, 80.8% smoked every day and 19.2% smoked on some days.⁵⁰ The decline in




Figure 2. Trends in cigarette smoking among adults aged ≥ 18 years, by gender—United States, 1955–2006.^{47–51} Before 1992, current smokers were defined as people who reported having smoked ≥ 100 cigarettes and who currently smoked. Since 1992, current smokers were defined as people who reported having smoked ≥ 100 cigarettes during their lifetime and who reported now smoking every day or on some days. Source: 1955 Current Population Survey; various 1965–2006 National Health Interview Surveys.

cigarette consumption in the U.S. is consistent with that of most higher-income nations.⁵²

In 2005, U.S. cigarette smoking prevalence was higher for men (23.9%) than for women (18.1%); for American Indians/Alaska Natives (32.0%) than for Hispanics (16.2%) and Asians (13.3%); for those with a general equivalency diploma (GED) (43.2%) or 9–11 years of education (32.6%) than for those with an undergraduate (10.7%) or graduate (7.1%) degree; and for those living in poverty (29.9%) than for those living at or above the poverty line (20.6%).⁵⁰ Patterns of prevalence suggest that future tobacco-attributable disease increasingly will be concentrated in socially disadvantaged populations, further exacerbating health disparities. Among the estimated 42.5% (91.8 million) of people who have ever smoked at least 100 lifetime cigarettes, 50.8% (46.5 million) were former cigarette smokers. In 2005, 2.2% of adults (4.3% of men and 0.2% of women) smoked cigars; 2.3% of adults used smokeless tobacco (4.5% of men and 0.2% of women). Use of bidis and kreteks among U.S. adults is negligible. Recent data from the National Health Interview Survey (NHIS) indicate that smoking prevalence among U.S. adults leveled off at about 21% during 2004–2006.⁵¹

Among U.S. secondary school students, cigarette smoking prevalence increased markedly in the 1990s, peaking in 1996 for 8th and 10th graders and in 1997 for 12th graders (Figure 3) and has since declined significantly.⁵³ Data from 2005 and 2006 suggest that progress toward fewer student smokers is slowing and may even be stopping among younger teens.^{53,54}

The 2004 National Youth Tobacco Survey collected data on current use (during the 30 days preceding the survey) of various tobacco products among middle school and high school students.⁵⁵ The prevalence of use of various products among high school students (most of whom were 14–18 years old) were: any tobacco (28.0%); cigarettes (22.3%); cigars (12.8%); smokeless tobacco (6.0%); pipes (3.1%); bidis (2.6%); and kreteks (2.3%). With the exception of pipes and




Figure 3. Trends in cigarette smoking anytime in the past 30 days by grade in school—United States, 1975–2006.⁵³ Source: Monitoring the Future Surveys, University of Michigan.

bidis, high school students were more likely to use each of the specific products and to use any tobacco product than were middle school students.

Factors Influencing Use

This section incorporates the traditional epidemiologic model of agent, host, vector, and environment as a framework for understanding factors influencing the development of nicotine addiction and strategies to prevent initiation, promote quitting, and protect non-smokers.^{44,56} This model recognizes that factors operating at multiple levels contribute to use, addiction, disease, and death. Specifically, tobacco products are the agents of addiction and disease; smokers and users of other tobacco products are the hosts; the tobacco industry is the vector (i.e., the organism that distributes the agent); and familial, social, legal, political, economic, cultural, historic, and media influences are the environmental factors that can contribute to or prevent use.⁵⁷

Several characteristics of the agent can influence use. For example, filter ventilation (the insertion of rings of tiny holes in filters that permit air to dilute the smoke) makes cigarettes taste lighter and milder, thus contributing to the false impression that they are less dangerous.^{58,59} Ventilation also promotes compensation by allowing smokers to take larger puffs and by permitting them to block the vent holes with either their fingers or lips.^{58,59} Cigarettes have been designed to allow the smoker to obtain all the nicotine he or she needs while scoring low in tar and nicotine yields on the government machine testing regimens.^{13,58} Light, ultralight, and ultrasmooth cigarettes tacitly promise health benefits, but are as hazardous as full-flavor varieties.^{1,13,60} Cigarette companies have made their products taste smoother and have special flavorings in response to young smokers' concerns about harsh taste.^{61–64} In addition, the bioavailability and reinforcing properties of nicotine can influence use.^{31,33} Research on traditional products and potential reduced-exposure products (PREPs) is needed to determine likely human exposure to nicotine and toxic/carcinogenic compounds and to better understand how tacit claims might influence use.⁶⁵

Host factors that can influence initiation include social skills, self-efficacy, school performance/orientation, self-esteem, intentions to smoke, expectancies about smoking, other problem behaviors, and prior experimentation.^{18,66–69} Biological susceptibility to nicotine addiction, in utero exposure to nicotine, and adverse childhood experiences also may play a role.^{70–72} Among smokers, the number of cigarettes smoked each day and indicators of dependence are the major predictors of quitting.^{73–76} Other notable predictors include self-efficacy about quitting and the duration of previous quit attempts.^{73–75}

In epidemiology, the vector is the organism that transports the agent to susceptible individuals.⁵⁷ Tobacco companies market their products to maximize appeal and allay health concerns.^{18,77-79} They adapted to the health concerns raised in the 1950s and 1960s with public relations strategies designed to reassure the public that cigarettes were safe, new products such as filtered and then “light” cigarettes (i.e., technologic fixes), and marketing strategies designed to communicate safety without raising concerns about health risks.⁸⁰⁻⁸⁴ They adapted to recent restrictions imposed by the Master Settlement Agreement by focusing resources on the retail environment, bar promotions, and direct mail marketing (Chaloupka, submitted manuscript).^{79,85} Companies have used pricing strategies, such as discount coupons and multipack discounts, to offset the effects of tax increases.⁸⁶ They undermine public health efforts by resisting the implementation of health-promoting programs and policies.^{77,87-90} They attempt to manipulate the work of scientists studying the health effects of their products.^{89,91-93}

Environmental factors include familial, social, cultural, economic, historic, political, and media-based influences. For example, smoking by peers, siblings, and parents, as well as norms established in the home, can influence uptake.^{18,94} In the U.S., as well as in other countries, tobacco growing and tobacco product manufacturing have become culturally established and economically powerful enterprises that greatly influence political decisions and attitudes about use.^{88-90,95-97} Other environmental factors that can influence behavior include smoke-free air laws and policies,^{98,99} advice to quit from a health professional,^{100,101} and media influences, such as appearances of smoking in movies, pro-tobacco advertising and promotion, and anti-tobacco messages from the public health sector.^{43,79,102-104} The number of states passing smoke-free laws protecting workers in private workplaces, restaurants, and/or bars has increased recently, to 27 as of July 2007.¹⁰⁵ Approximately 57.5% of Americans of all ages live in areas where smoking is prohibited in private workplaces, restaurants, and/or bars.¹⁰⁵ Still, many workers, especially those in the hospitality industry, remain unprotected.^{38,106} Laws protecting nonsmokers also can help smokers reduce consumption.⁹⁸ In addition, substantial progress has been made in reducing children’s exposure in homes.¹⁰⁷ Well-funded tobacco-control programs are associated with reduced cigarette consumption and with lower rates of smoking among youth and adults.¹⁰⁸⁻¹¹⁰ In addition, the price of the product influences use, with increasing prices leading to decreased use, both by reducing the number of users and decreasing consumption among continuing users.¹¹¹ State variation in cigarette price is influenced primarily by different state cigarette excise taxes. Figure 4 shows the remarkable inverse relationship between price and consumption.




Figure 4. Total cigarette sales and cigarette prices in the United States, 1970–2006 (Chaloupka, submitted book manuscript).

Tobacco Control

Warner^{104,112} estimates that the antismoking campaign in the U.S., initiated following the release of the first Surgeon General’s report in 1964, has averted the premature deaths of more than 3 million Americans, each of whom has gained on average 15 years of life. This campaign is likely the most successful public health effort of the past 50 years. Numerous reports document the evidence base in support of tobacco control.^{77,103,104,113} One dynamic of the tobacco-control movement in the U.S. is that some researchers and practitioners focus on individuals and others focus on policies and programs operating at the societal level. Both are important, and individual and societal factors often interact. Imagine a person who needs either to negotiate adolescence and young adulthood without becoming addicted to nicotine or someone who smokes cigarettes and is trying to stop smoking and maintain abstinence. The probability of success in either endeavor will be influenced by both individual and societal factors. For example, a young person raised on a tobacco farm in Kentucky; surrounded by parents, older siblings, and friends who smoke and who exhibits conduct problems in school would probably be more likely to start smoking than someone raised in an affluent home in California, with no smokers in his or her immediate environment, and with no conduct problems. Similarly, a smoker of 30 years who is highly addicted to nicotine and is surrounded by friends and loved ones who also are addicted to tobacco would likely have a more difficult time quitting than would someone who is only mildly dependent on nicotine and is surrounded by friends and loved ones who do not use tobacco. Individuals bring their own challenges to the task. Still, society can help, by decreasing pro-tobacco forces (e.g. tobacco company marketing) as much as possible and by (1) making cigarettes and other tobacco products more expensive; (2) decreasing the

number of places where smoking is permitted (thus reducing cues to smoke, making the effort to smoke more time-consuming, and changing the social norm); (3) providing messages in the media that motivate abstinence and educate people about how to achieve or maintain a smoke-free lifestyle; (4) increasing access to effective cessation strategies, through the provision of telephone quitlines, healthcare provider advice, and effective pharmaceutical treatments^{100,114}; (5) disseminating effective prevention strategies¹¹⁵; (6) implementing effective regulation of nicotine-containing tobacco products; and (7) ensuring that the tobacco industry is held accountable for its misdeeds.

These and other policies and programs are included in the World Health Organization Framework Convention on Tobacco Control, which at the time of this writing has not been ratified by the U.S. but has been ratified by 148 other nations.^{116–118} The possibility of federal legislation that would regulate the tobacco industry is also being debated in the U.S.^{119–120}

The Future

The data on pounds of various tobacco products consumed per capita in the U.S. through 2004 shown in Figure 1 have been projected to depict three hypothetical scenarios in Figures 5–7, which are presented for heuristic purposes. The simple linear projection of Figure 5 suggests that work on this public health problem will be completed in about 30 years. Of course, the probability that no tobacco will be consumed in the U.S. by 2035 is infinitesimally small, for three main reasons. First, some consumers may be “hardcore,” and thus unwilling or incapable of discontinuing use of one or more tobacco products. The degree to which possible “hardening” of the tobacco-consuming population influences future consumption will be influenced by the degree to which alternate reinforcing strategies and effective treatments can be identified and made attrac-




Figure 5. Trends in per capita consumption of various tobacco products—United States, 1880–2004 and linear projection to 2035.




Figure 6. Trends in per capita consumption of various tobacco products—United States, 1880–2004 and possible projection to 2060.

tive to consumers. Second, the tobacco industry will fight for survival, developing innovative marketing strategies of extant and new products. It will also exert its considerable political and economic influence, using lobbying and litigation to try to block effective health promotion programs and policies. Industry efforts will focus on influencing government institutions and agencies, as well as mass media outlets. Third, governments may be unwilling to forego the revenues they would lose as a result of decreased sales of tobacco products. In the short-term, lower consumption results in reduced revenues from tobacco excise taxes. In the long term, governments would pay more benefits to people for living longer. The point at which the decline begins to level off will be influenced by the relative strength of these factors.

No one really knows where and when progress will stall. Figure 6 depicts progress stalling at about 1.6 pounds per capita and more snuff being consumed




Figure 7. Trends in per capita consumption of various tobacco products—United States, 1880–2004 and extremely undesirable projection to 2060.

than cigarettes (some cigarette smokers may substitute the use of snuff to try to reduce harm without giving up tobacco). Figure 7 would eventuate if pro-tobacco forces overwhelmed health-promoting activities, a scenario that is possible, given that tobacco companies strive to maximize shareholder value. It should serve as a reminder of what could happen in the absence of vigilance and diligence on the part of those concerned with protecting public health. These and multiple other scenarios are possible.

Gray and colleagues¹²¹ describe a long-term policy option in which cigarettes and other tobacco products are replaced by clean nicotine, defined as nicotine that is free of toxic tobacco products to an extent that would pass regulatory approval. As science advances, other scenarios (e.g., discovery of safe, attractive, and effective alternative reinforcing strategies and treatments) may also become reality. Regardless of which scenarios come into play, concerns are frequently raised about the economic impact of declining cigarette sales.^{122,123} Warner and his colleagues,¹²³ using a macroeconomic simulation model, demonstrated that as tobacco consumption falls, employment rises in eight nontobacco regions (44 states) and drops only in the Southeast Tobacco region. Overall, there would be a gain in employment. As Warner¹²⁴ and Chaloupka (submitted book manuscript) argue, the money that is spent on tobacco does not go away. Rather, it is spent on other segments of the economy, stimulating job maintenance and creation. Warner¹²⁴ estimates that 400,000 jobs exist in the U.S. in the tobacco segment of the economy and contrasts that number with the >400,000 smoking-attributable deaths that occur annually. So 1 year of employment comes at the expense of one person losing 15 years of life from a disease caused by the product supporting the job. Because money not spent on tobacco would be spent on other goods and services, the job is replaceable. The life, however, is not.

Conclusion

This article has incorporated a holistic approach to understanding and controlling the tobacco epidemic. Continuation of the progress that has been achieved will require application of the what is already known, for as former U.S. Surgeon General David Satcher stated, "Our lack of greater progress in tobacco control is more the result of failure to implement proven strategies than it is the lack of knowledge about what to do."⁷⁷ In addition to the political will to make health-promoting policy decisions, the public also should benefit from scientific advances that help us to better prevent initiation and promote cessation of tobacco use.

My thanks to Karl Wende, PhD, for assistance with data for the figures.

No financial disclosures were reported by the author of this paper.

References

1. U.S. Department of Health and Human Services (USDHHS). The health consequences of smoking: a report of the Surgeon General. Atlanta GA: USDHHS, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
2. Armour BS, Woolery T, Malarcher A, Pechacek TF, Husten C. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. *MMWR Morb Mortal Wkly Rep* 2005; 54:625–8.
3. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA* 2004;291:1238–45.
4. Hyland A, Vena C, Bauer J, et al. Cigarette smoking-attributable morbidity—United States, 2000. *MMWR Morb Mortal Wkly Rep* 2003;52:842–4.
5. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries 1950–2000: indirect estimation from national vital statistics. Oxford: Oxford University Press, 1994.
6. U.S. Public Health Service Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington DC: U.S. Department of Health Education, and Welfare, Public Health Service, Center for Disease Control. PHS publication no. 1103, 1964.
7. Hill AB. The environment and disease: association or causation? *Proc R Soc Med* 1965;56:295–300.
8. Hamill PVV. Re: Invited commentary: response to Science article, 'Epidemiology faces its limits'. *Am J Epidemiol* 1997;146:527.
9. Hoffman D, Hoffman I, El-Bayoumy KE. The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. *Chem Res Toxicol* 2001;14:767–90.
10. USDHHS. Report on carcinogens, 11th edn. Washington DC: USDHHS, Public Health Service, National Toxicology Program. Available online at: <http://ntp.niehs.nih.gov/ntp/roc/toc11.html>.
11. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. *Nat Rev Cancer* 2003;3:733–44.
12. Harris JE, Thun MJ, Mondul AM, Calle EE. Cigarette tar yields in relation to mortality from lung cancer in the Cancer Prevention Study II prospective cohort, 1982–1988. *Br Med J* 2004;328:7431–8.
13. National Cancer Institute (NCI). Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13. Bethesda MD: USDHHS, National Institutes of Health (NIH), NCI; October 2001. NIH Publication No. 02-5074.
14. Hecht SS, Murphy SE, Carmella SG, et al. Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. *Cancer Epidemiol, Biomarkers Prev* 2005;14:693–8.
15. NCI. Cigars: health effects and trends. Smoking and Tobacco Control Monograph No. 9. Bethesda MD: USDHHS, NIH, NCI; February 1998. NIH Publication No. 98–4302.
16. Nelson DE, Davis RM, Chrismon JH, Giovino GA. Pipe smoking in the United States: Prevalence and attributable mortality. *Prev Med* 1996;25: 91–9.
17. USDHHS. The health consequences of using smokeless tobacco. A report of the advisory committee to the Surgeon General, 1986. USDHHS, Public Health Service. NIH Publication No. 86–2874, April 1986.
18. USDHHS. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta GA: USDHHS, Public Health Service, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1994.
19. Hatsukami DK, Feuer RM, Ebbert JO, Stepanov I, Hecht SS. Changing smokeless tobacco products: new tobacco delivery systems. *Am J Prev Med* 2007;33(6S):S368–S378.
20. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. *Cancer Epidemiol Biomarkers Prev* 2004;13:2035–42.
21. CDC. Bidi use among urban youth—Massachusetts, March–April 1999. *MMWR Morb Mortal Wkly Rep* 1999;48:796–9.
22. Yen KL, Hechavarria E, Bostwick SB. Bidi cigarettes: an emerging threat to adolescent health. *Arch Pediatr Adol Med* 2000;154:1187–9.

23. Pais P, Pogue J, Gerstein H, et al. Risk factors for acute myocardial infarction in Indians: a case-control study. *Lancet* 1996;348:358–63.
24. Rahman M, Fukui T. Bidi smoking and health. *Public Health* 2000; 114:123–7.
25. Rahman M, Sakamoto J, Fukui T. Bidi smoking and oral cancer: a meta-analysis. *Int J Cancer* 2003;106:600–4.
26. Sankaranarayanan R, Duffy SW, Padmakumary G, Nair SM, Day NE, Padmanabhan TK. Risk factors for cancer of the oesophagus in Kerala, India. *Int J Cancer* 1991;49:485–9.
27. Council on Scientific Affairs. Evaluation of the health hazard of clove cigarettes. *JAMA* 1988;260:3641–4.
28. Guidotti TL. Critique of available studies on the toxicology of kretek smoke and its constituents by routes of entry involving the respiratory tract. *Arch Toxicol* 1989;63:7–12.
29. Mangunegoro H, Sutoyo DK. Environmental and occupational lung diseases in Indonesia. *Respirology* 1996;1:85–93.
30. USDHHS. The health consequences of smoking: nicotine addiction. A report of the Surgeon General. Rockville MD: USDHHS, Public Health Service, CDC, Center for Health Promotion and Education, Office on Smoking and Health; 1988. DHHS publication no. (CDC) 88–8406.
31. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. *Tob Control* 1999;8: 387–92.
32. Hurt RD, Robertson CR. Prying open the door to the cigarette industry's secrets about nicotine: The Minnesota Tobacco Trial. *JAMA*. 1998;280: 1173–81.
33. U.S. Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to children and adolescents; Final rule. 61 Federal Register 44395–44618. August 28, 1996.
34. CDC. Reasons for tobacco use and symptoms of nicotine withdrawal among adolescent and young adult tobacco users—United States, 1993. *MMWR Morb Mortal Wkly Rep* 1994;43:745–50.
35. DiFranza JR, Savageau JA, Rigotti NA, et al. Development of symptoms of tobacco dependence in youths: 30 month follow-up data from the DANDY study. *Tob Control* 2002;11:228–35.
36. McNeill AD, West RJ, Jarvis M, Jackson P, Bryant A. Cigarette withdrawal symptoms in adolescent smokers. *Psychopharmacol* 1986;90:533–6.
37. O'Loughlin J, DiFranza J, Tyndale RF, et al. Nicotine-dependence symptoms are associated with smoking frequency in adolescents. *Am J Prev Med* 2003;25:219–25.
38. USDHHS. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Atlanta GA: USDHHS, CDC, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
39. Milmore BK, Conover AG. Tobacco consumption in the United States, 1880–1955. Addendum in Haenszel W, Shimkin MB, Miller HP. U.S. Department of Health, Education, and Welfare. Tobacco smoking patterns in the United States. Public Health Monograph No. 45. Department of Health, Education, and Welfare, Public Health Service. DHEW Publication no. (PHS) 463; May 1956:107–111.
40. Capehart T. Tobacco outlook. Leaf production rebounds. Washington DC: United States Department of Agriculture (USDA), Economic Research Service; TBS 261; September 26, 2006. Available online at: <http://usda.mannlib.cornell.edu/usda/current/TBS/TBS-09-26-2006.pdf>.
41. Shopland DR. Effect of smoking on the incidence and mortality of lung cancer. Chapter 1 in Johnson BE, Johnson DH, eds. *Lung Cancer*. New York: John Wiley, 1995. pp. 1–14.
42. USDA. Tobacco situation. USDA, Economic Research Service, TS-105; September 1963.
43. USDHHS. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. Rockville MD: USDHHS, Public Health Service, CDC, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS publication no. (CDC) 89–8411; 1989.
44. Giovino GA. Epidemiology of tobacco use in the United States. *Oncogene*. 2002;21:7326–40.
45. Capehart T. Tobacco outlook. Leaf production plummets with end of program. Washington DC: USDA, Economic Research Service, TBS-259; September 23, 2005. Available online at: <http://usda.mannlib.cornell.edu/reports/erssr/specialty/tbs-bb/2005/tbs259.pdf>.
46. USDA. Tobacco situation and outlook report. USDA Commodity Economics Division, Economic Research Service, TS 228; 1994.
47. Haenszel W, Shimkin MB, Miller HP. U.S. Department of Health, Education, and Welfare. Tobacco Smoking patterns in the United States: Public Health Monograph No. 45. Department of Health, Education, and Welfare, Public Health Service. DHEW Publication no. (PHS) 463; May 1956.
48. National Center for Health Statistics. Health, United States, 2006 with chartbook on trends in the health of Americans with special feature on pain. Hyattsville MD: National Center for Health Statistics; 2006.
49. Maurice E, Trosclair A, Merritt R, et al. Cigarette smoking among adults—United States, 2004. *MMWR Morb Mortal Wkly Rep* 2005;54: 1121–4.
50. Mariolis P, Rock VJ, Asman K, et al. Cigarette smoking among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:1145–8.
51. Early release of selected estimates based on the 2006 National Health Interview Survey. Available online at: <http://www.cdc.gov/nchs/about/major/nhis/released200706.htm>.
52. Milenkovich Z. The global market for cigarettes. *Tobacco Journal International*. Oct/Nov 2004:70–9.
53. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. (December 21, 2006). Decline in daily smoking by younger teens has ended. Ann Arbor MI: University of Michigan News and Information Services. Available online at: <http://www.monitoringthefuture.org>.
54. CDC. Cigarette use among high school students—United States, 1991–2005. *MMWR Morb Mortal Wkly Rep* 2006;55:724–6.
55. Bloch AB, Mowery PD, Caraballo RS, et al. Tobacco use, access, and exposure to tobacco in media among middle and high school students—United States, 2004. *MMWR Morb Mortal Wkly Rep* 2005;54:297–301; with corrections online at http://www.cdc.gov/tobacco/nyts/pdf/Table_1.pdf and http://www.cdc.gov/tobacco/nyts/pdf/Table_2.pdf.
56. Orleans CT, Slade J. Nicotine addiction: principles and management. New York: Oxford University Press; 1993:ix.
57. Last JM. A dictionary of epidemiology. New York: Oxford University Press, 2001.
58. Kozlowski LT, Henningfield JE, Brigham J. Cigarettes, nicotine and health. Thousand Oaks CA: Sage Publications, Inc, 2001.
59. Kozlowski LT, O'Connor RJ. Cigarette filter ventilation is a defective design because of misleading taste, bigger puffs, and blocked vents. *Tob Control* 2002;11:i40–i50.
60. Laugesen M, Fowles J. Marlboro UltraSmooth: a potentially reduced exposure cigarette? *Tob Control* 2006;15:430–5.
61. Carpenter CM, Wayne GF, Pauly JL, Koh HK, Connolly GN. New cigarette brands with flavors that appeal to youth: tobacco marketing strategies. *Health Affairs* 2005;24:1601–10.
62. Cummings KM, Morley CP, Horan JK, Steger C, Leavell NR. Marketing to America's youth: evidence from corporate documents. *Tob Control* 2002;11(Supplement 1):i5–i17.
63. Lewis MJ, Wackowski O. Dealing with an innovative industry: a look at flavored cigarettes promoted by mainstream brands. *Am J Public Health* 2006;92:244–51.
64. Wayne GF, Connolly GN. How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983–93. *Tob Control* 2002;11(Suppl. 1): i32–i39.
65. Hatsukami DK, Giovino GA, Eissenberg T, Clark PI, Lawrence D, Leischow S. Methods to assess potential reduced exposure products. *Nicotine Tob Res* 2005;7:827–44.
66. Flay BR, Petraitis J. The theory of triadic influence: a new theory of health behavior with implications for preventive interventions. *Adv Med Sociol* 1994;4:19–44.
67. Flay BR. Understanding environmental, situational, and intrapersonal risk and protective factors for youth tobacco use: the theory of triadic influence. *Nicotine Tob Res* 1999;1(Suppl.):S111–S114.
68. Pierce JP, Choi WS, Gilpin EA, Farkas AJ, Merritt RK. Validation of susceptibility as a predictor of which adolescents take up smoking in the U.S. *Health Psychol* 1996;15:355–61.
69. USDHHS. Women and Tobacco: A Report of the Surgeon General. Rockville MD: USDHHS, Public Health Service, Office of the Surgeon General, 2001.
70. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. *Pediatrics* 2006;119:e264–e274.
71. Buka SL, Shenassa ED, Niaura R. Elevated risk of tobacco dependence among offspring of mothers who smoked during pregnancy: a 30 year prospective study. *Am J Psychiatr* 2003;160:1978–84.
72. Anda RF, Croft JB, Felitti VJ, et al. Adverse childhood experiences and smoking during adolescence and adulthood. *JAMA* 1999;282:1652–8.
73. Farkas AJ, Pierce JP, Zhu SH, et al. Addiction versus stages of change models in predicting smoking cessation. *Addiction* 1996;91:1271–80.

74. Hyland A, Li Q, Bauer J, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. *Nicotine Tob Res* 2004;6(Suppl. 3):S363-S369.
75. Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviors among participants in the International Tobacco Control (ITC) Four Country Survey. *Tob Control* 2006;15:iii83-iii94.
76. West R. Assessment of dependence and motivation to stop smoking. *Br Med J* 2004;328:338-9.
77. USDHHS. Reducing tobacco use: a report of the Surgeon General. Atlanta GA: USDHHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000.
78. Pollay RW, Dewhirst T. The dark side of marketing seemingly "light" cigarettes: Successful images and failed fact. *Tob Control*. 2002;11(Suppl. 1):i18-i31.
79. Slade J. Marketing policies. In: Rabin RL, Sugarman S, eds. *Regulating tobacco*. New York: Oxford University Press; 2001. 72-110.
80. Warner KE. Tobacco industry response to public health concern: a content analysis of cigarette ads. *Health Educ Q* 1985;12:115-27.
81. Cummings KM, Morley CP, Hyland A. Failed promises of the cigarette industry and its effect on consumer misperceptions about the health risks of smoking. *Tob Control* 2002;11(Suppl. 1):i110-i117.
82. Kozlowski LT. Some lessons from the history of American tobacco advertising and its regulation in the 20th century. In: Ferrence R, Slade J, Room R, Pope M, eds. *Nicotine and public health*. Washington DC: American Public Health Association, 2000.
83. Stratton K, Shetty P, Wallace R, Bondurant S, eds. *Clearing the smoke: assessing the science base for tobacco harm reduction*. Washington DC: National Academies Press, 2001.
84. Swedrock TL, Hyland A, Hastrup JL. Changes of the focus of cigarette advertisements in the 1950s. *Tob Control* 1999;8:111-2.
85. Wakefield MA, Terry YM, Chaloupka FJ, et al. Tobacco industry marketing at point of purchase after the 1998 MSA billboard advertising ban. *Am J Public Health* 2002;92:937-40.
86. Chaloupka FJ, Cummings KM, Morley CP, Horan JK. Tax, price and cigarette smoking: evidence from the tobacco documents and implications for tobacco company marketing strategies. *Tob Control* 2002;11(Suppl 1):i62-i72.
87. Glantz SA, Balbach ED. *Tobacco war. Inside the California battles*. Berkeley CA: University of California Press, 2000.
88. Jamieson KH. "Tax and Spend" Vs. "Little Kids": Advocacy and Accuracy in the Tobacco Settlement Ads of 1997-8. Philadelphia PA: Annenberg Public Policy Center of the University of Pennsylvania, 1998.
89. Kluger R. *Ashes to ashes. America's hundred-year cigarette war, the public health, and the unabashed triumph of Philip Morris*. New York: Alfred A. Knopf, 1996.
90. Saloojee Y, Dagli E. Tobacco industry tactics for resisting public policy on health. *Bull World Health Org* 2000;78:902-10.
91. Garne D, Watson M, Chapman S, Byrne F. Environmental tobacco smoke research published in the journal *Indoor and Built Environment* and associations with the tobacco industry. *Lancet* 2005;365:804-9.
92. Muggli M, Hurt RD, Blanke DD. Science for hire: A tobacco industry strategy to influence public opinion on secondhand smoke. *Nicotine Tob Res* 2003;5:303-14.
93. Ong EK, Glantz SA. Constructing "sound science" and "good epidemiology": Tobacco, lawyers, and public relations firms. *Am J Public Health* 2001;91:1749-57.
94. Wakefield MA, Chaloupka FJ, Kaufman NJ, Orleans CT, Barker DC, Ruel EE. Effect of restrictions on smoking at home, at school, and in public places on teenage smoking: Cross-sectional study. *Br Med J* 2000;321:333-7.
95. Noland MP, Kryscio RJ, Hinkle J, et al. Relationship of personal tobacco-raising, parental smoking, and other factors to tobacco use among adolescents living in a tobacco-producing region. *Addict Behav* 1996;21:349-61.
96. Von Gernet A. Origins of nicotine use and the global diffusion of tobacco. In: Ferrence R, Slade J, Room R, Pope M, eds. *Nicotine and public health*. Washington DC: American Public Health Association, 2000.
97. World Bank. *Curbing the epidemic: Governments and the economics of tobacco control*. Washington DC: The World Bank, 1999.
98. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. *Br Med J* 2002;325:188-94.
99. Siegel M, Albers AB, Cheng DM, Biener L, Rigotti NA. Effect of local restaurant smoking regulations on progression to established smoking among youths. *Tob Control* 2005;14:300-6.
100. Fiore MC, Bailey WC, Cohen SJ, et al. *Treating tobacco use and dependence. clinical practice guideline*. Rockville MD: USDHHS, Public Health Service, 2000.
101. Russell MAH, Wilson C, Taylor C, Baker CD. Effect of general practitioners' advice against smoking. *Br Med J* 1979;2:231-5.
102. Dalton M, Sargent J, Beach M, et al. Effect of viewing smoking in movies on adolescent smoking initiation: a cohort study. *Lancet* 2003;362:281-5.
103. Fielding JE, Briss PA, Carande-Kulis VG, et al. Tobacco. In: Zaza S, Briss PA, Harris KW, eds. *The guide to community preventive services*. New York: Oxford University Press, 2005.
104. Warner KE. Tobacco policy research: insights and contributions to public health policy. In: Warner KE, ed. *Tobacco control policy*. San Francisco: Jossey-Bass, 2006. Pp. 3-86.
105. American Nonsmokers' Rights Foundation. Summary of 100% smokefree state laws and population protected by state and local laws. Available online at: <http://www.no-smoke.org/pdf/SummaryUSPopList.pdf>.
106. Shopland DR, Gerlach KK, Burns DM, Hartman AM, Gibson JT. State-specific trends in smoke-free workplace policy coverage: The current population survey tobacco use supplement, 1993 to 1999. *J Occup Environ Med* 2001;43:680-6.
107. Soliman S, Pollack HA, Warner KE. Decrease in the prevalence of environmental tobacco smoke exposure in the home during the 1990s in families with children. *Am J Public Health* 2004;94:314-20.
108. Farrelly MC, Pechacek TF, Chaloupka FJ. The impact of tobacco control expenditures on aggregate cigarette sales: 1981-2000. *J Health Econ* 2003;22:843-59.
109. Tauras JA, Chaloupka FJ, Farrelly MC, et al. State tobacco control spending and youth smoking. *Am J Public Health* 2005;95:338-44.
110. Farrelly MC, Pechacek TF, Thomas KY, Nelson D. The impact of tobacco control programs on adult smoking. *Am J Public Health*. In press.
111. Chaloupka FJ, Wakefield M, Czart C. Taxing tobacco: The impact of tobacco taxes on cigarette smoking and other tobacco use. In: Rabin RL, Sugarman S, eds. *Regulating tobacco*. New York: Oxford University Press, 2001. Pp. 39-71.
112. Warner KE. Effects of the antismoking campaign: an update. *Am J Public Health* 1989;79:144-51.
113. Bonnie RJ, Stratton K, Wallace RB, eds. *Ending the tobacco problem. A blueprint for the nation*. Washington DC: National Academy of Sciences, Institute of Medicine, National Academies Press, 2007.
114. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2007;1:CD006103.
115. Thomas RE, Baker P, Lorenzetti D. Family-based programmes for preventing smoking by children and adolescents. *Cochrane Database Syst Rev* 2007;1:CD004493.
116. World Health Organization Framework Convention on Tobacco Control. Available online at: <http://www.who.int/tobacco/framework/en/>.
117. Yach D, Wipfli H. Century of smoke. *Ann Trop Med Parasitol* 2006;100:465-79.
118. Frieden TR, Bloomberg MR. How to prevent 100 million deaths from tobacco. *Lancet* 2007;369:1758-61.
119. Lee C. New push grows for FDA regulation of tobacco. *Washington Post* February 17, 2007, page A08. Available online at: <http://www.washingtonpost.com/wp-dyn/content/article/2007/02/16/AR2007021602017.html>.
120. Will FDA regulation of tobacco protect public health? *Medical News Today* July 24, 2006; Available online at: <http://www.medicalnewstoday.com/medicalnews.php?newsid=47836>.
121. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. *Tob Control* 2005;14:161-5.
122. Liang L, Chaloupka FJ, Ierulli K. Chapter 6: Measuring the impact of tobacco on state economics. In: NCI. *Evaluating ASSIST. A blueprint for understanding state-level tobacco control*. Smoking and Tobacco Control Monograph No. 17. Bethesda MD: USDHHS, NIH, NCI, 2006.
123. Warner KE, Fulton GA, Nicolas P, Grimes DR. Employment implications of declining tobacco product sales for the regional economics of the United States. *JAMA* 1996;275:1241-6.
124. Warner KE. Economics of tobacco. Presentation made to the Framework Convention Alliance Journalists' Programme; Washington DC: July 12, 2005.

Tobacco Industry Marketing, Population-Based Tobacco Control, and Smoking Behavior

John P. Pierce, PhD

Abstract: Two of the major influences of cigarette smoking behavior are tobacco industry marketing and public health tobacco-control activities. These vie with each other to influence the proportion of each generation who initiate smoking, the intensity level reached by smokers, and the time before smokers are able to quit successfully. This article provides a brief summary of the evidence associating tobacco marketing practices (organized under the four “Ps” of marketing), with smoking behavior. The evidence for causality in this association is considered convincing.

Publicly funded, comprehensive, statewide tobacco-control programs were introduced into the United States in the late 1980s, with money either from tobacco taxes or from legal settlements of states with the tobacco industry. These programs use organized statewide approaches to implement current recommendations on “best practices” to discourage tobacco use, recommendations that have changed over time. During the 1990s, “best practices” evolved to include protection against secondhand smoke, sale of cigarettes to minors, and restrictions on tobacco advertising. Evaluations have been published on four statewide tobacco-control programs (Sydney/Melbourne, California, Massachusetts, and Florida) and a national program aimed at youth (American Legacy Program). For each program, there was a positive association with reduced smoking. The evidence supporting the conclusion that tobacco-control programs reduce smoking behavior is evaluated as strong.

(Am J Prev Med 2007;33(6S):S327-S334) © 2007 American Journal of Preventive Medicine

Introduction

In 1931, Count Corti concluded his definitive history of tobacco smoking with a prediction that future efforts to curtail the spread of smoking would “result only in a miserable fiasco.”¹ He based this conclusion on the history of 400 years of tobacco smoking outside of the Americas that included many fruitless attempts by powerful governments and churches to curtail this behavior. At the time of his writing, tobacco smoke was generally viewed as beneficial to health and cigarette smoking was rapidly taking over as the predominant form of tobacco consumption. During both world wars, cigarettes were provided free to soldiers; this resulted in a large increase in cigarette smoking.² In addition, from its inception in the late 1880s, the tobacco industry has used large-scale advertising campaigns to promote sales. Between 1930 and 1950, per capita cigarette consumption doubled in the United States.

However, Corti could not foresee the dramatic change that would occur 20 years later, when scientific research

labeled cigarette smoking as the cause of the rapidly growing epidemic of lung cancer.^{3,4} The early evidence of this link to cancer led to the first national survey on smoking in 1955.⁵ At that time, only 21% of U.S. men had never smoked. Cigarette smoking was still increasing in women; approximately 50% of young adult women had smoked. Among male and female ever-smokers, only 10% were former smokers. The rate of successful quitting among regular smokers increased from approximately 0.5% per year prior to the 1950 scientific publications on the health consequences of smoking to just over 1% per year by 1955.⁵

In the U.S., public health consensus that smoking caused lung cancer was reached with the landmark Surgeon General’s report in 1964.⁶ This year marked the start of an ongoing tobacco-control program that has progressively evolved and strengthened over time. In 1999, the Centers for Disease Control and Prevention (CDC) summarized the evidence from demonstration programs in its publication *Best Practices for Tobacco-Control Programs*.⁷

Population Behaviors to Target Reduction of Tobacco Use

As lung cancer is a disease caused almost entirely by cigarette smoking,^{2,6} the study of how smoking behavior is related to this disease provides a good focus for

From the Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California.

Address correspondence and reprint requests to: John P. Pierce, PhD, Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California, San Diego, La Jolla CA 92093-0901. E-mail: jppierce@ucsd.edu.




Figure 1. Smoking initiation status by age in California. 2002 California Tobacco Survey.

behaviors that should be targeted by tobacco-control campaigns. There is scientific consensus that the vast majority of lung cancer incidence can be attributed to exposure to cigarette smoke. Indeed, the best models of lung cancer indicate that rates vary with the power functions of both duration of smoking and daily consumption level.^{8,9} In these models, duration of smoking is raised to the power 4 or 5, although this term also includes the variation with age, and the rates of all cancers rise rapidly through middle and older ages.¹⁰ The number of cigarettes smoked per day is raised to the 2nd power in these models. Thus, both the duration of smoking and the intensity of smoking have a major impact on health outcomes. To minimize health consequences, public health goals need to reduce initiation, promote cessation, reduce consumption in continuing smokers, and prevent exposure to second-hand smoke in nonsmokers.

Initiation of Smoking

The first national survey of smoking behavior in the U.S. identified that most smokers started smoking regularly between the ages of 14 and 24 years.⁵ However, smoking initiation is widely viewed as a process that starts with cognitions about smoking.¹¹ These cognitions have been combined into a measure called susceptibility to smoke,¹² which has been shown consistently to be a strong predictor of who will experiment with smoking (odds ratio [OR] consistently in the 1.7–2.2 range).^{13–16} In the U.S., there is consensus that anyone who has smoked 100 cigarettes in their lifetime has established a smoking behavior.² Not all those who experiment go on to become established smokers. The

consensus estimate is that approximately 50% of experimenters will progress to become established smokers.

Figure 1 shows the distribution of smoking status by age for a representative sample of California adolescents and young adults in 2002. Committed never-smokers are the lowest level on this continuum and include approximately 50% of each age group from 12 through 29 years. The next largest classification for early adolescents is susceptible never-smokers. Smoking experimentation starts as young as 12 years¹⁷ and continues until around 21 years;¹⁸ at that age, there are few never-smokers who are susceptible to start smoking. Established smoking starts at around age 14 years and levels off in the early 20s. People who become daily smokers do so starting at around age 16 years and most appear to have achieved this level by their early 20s.

Smoking Intensity and Cessation

As previously noted, established smokers can be daily or nondaily smokers. To avoid the number bias associated with reporting in units of half-packs, daily smokers are often divided into the following three levels of intensity: light smokers, smoking less than 15 cigarettes/day; moderate smokers, smoking 15–24 cigarettes/day; and heavy smokers, smoking 25 or more cigarettes/day.² From 1974 through 1985, a consistent one quarter of smokers were heavy smokers.¹⁹ There were also nondaily smokers that were former daily smokers who transition in and out of daily smoking. There is extensive evidence that in any given year, a high proportion of smokers make a quit attempt that lasts for at least a day²; however, the majority of these quit attempts result in relapse within a week. The probability of relapse




Figure 2. Age distribution of smoking intensity and smoking status from a national sample of smokers. Tobacco Use Supplements-Current Population Surveys, 2003.

does not get below 5% until the quit attempt has lasted at least 12 months, and quit attempts over this duration are labeled successful.²⁰

The age distribution of this smoking intensity and quitting continuum is presented for a national sample of smokers from 2002 to 2003 (see Figure 2). Starting with people in their early 60s, each younger age group had a higher proportion classified as never-smokers (did not smoke 100 cigarettes in their lifetime). Current smokers made up approximately 20% of the population from age 18 through 50 years. The proportion of heavy smokers (>25 cigarettes/day) has declined with age and is considerably below 25% for all smokers in recent cohorts. A small and fairly consistent proportion of each age group is recent smokers (quit within past year). As smokers age, they are much more likely to become successful quitters. In this 2003 sample, approximately half of ever-smokers had successfully quit by their early 50s. The current rate of successful quitting has been estimated at 3%–4% of smokers per year, and there is little difference in this rate between younger and older smokers.²¹

The Influence of Tobacco Industry Marketing of Cigarettes

Marketing is the business of building demand for a product and is often divided into four categories: product presentation, unit price, promotion, and placement. Building product demand involves encouraging non-users to experiment and become regular users, as well as incentivizing current users not to quit or former

smokers to start using again. Cigarettes are a legal product and the U.S. has relatively few restrictions on tobacco-marketing practice.

Product Presentation

Presentation includes the size of the packet and its functioning in obtaining a cigarette, along with the colors and text on the package. Standard package size in the U.S. has been 20 cigarettes, which seems well suited to the size of pockets and purses. Providing smaller quantities for sale has been attempted in different countries. In the U.S., this has been achieved by merchants breaking open packs and selling smaller quantities of cigarettes.²² Restrictions on product packaging have focused on requiring warning labels; in different countries, this has involved regulating the content, minimum text size, and color presentation of the warnings. The U.S. courts prohibit tobacco companies from implying health benefits through using misleading terms such as “light,” “mild,” or “low-tar”, or through other indirect means.²³ Similar restrictions exist in Europe, Canada, Australia, and other countries, and are part of the World Health Organization (WHO) framework convention on tobacco control (FCTC).^{24,25} Very limited Surgeon General warning labels on the health risks of smoking were introduced in the 1960s in the U.S.; although they have been changed twice, these minimal warning labels remain in effect. Other countries (e.g., Canada, Australia, Brazil, Thailand, Finland) have been more aggressive in replacing product advertising on the pack with counteradvertising. Starting in

December 2000, Canada required their cigarette labels to feature one of 16 full-color and sometimes graphic health warnings that cover more than 50% of the front and back of cigarette packages. A study of the effectiveness of these labels demonstrated that over half of smokers were influenced emotionally by the labels, and these smokers were more likely to quit or reduce their smoking behavior.²⁶ A recent multicountry survey suggests that smokers are more likely to notice such labels and to think that they are effective.²⁷ The WHO in its first public health treaty, the Framework Convention on Tobacco Control,^{28,29} calls for large, clear health warnings that cover at least 30% of the principal display areas on the pack surfaces.

Unit Price

It is a fundamental tenet of economics that, all else being equal, higher prices lead to reduced demand. With highly addictive substances such as cigarettes, past consumption is an important determinant of consumption choices, even in the face of significant price increases. The literature has been reviewed numerous times and all of the reviews concluded that price has a major impact on smoking behavior.^{30,31} Many studies, using both individual- and aggregate-level data, have estimated the price elasticity of demand for cigarettes, the percentage change in the demand from a 1% increase in price. These studies provide a very consistent estimate that cigarette price elasticity is between -0.3 and -0.5 .³² There are three separate effects associated with an increase in cigarette price: many smokers reduce their intensity of smoking, some smokers use a price increase as a cue for quitting, and there is a decline in the proportion of young people progressing to regular smoking after experimentation.

Promotion

The right to advertise tobacco products on television and in other broadcast media was removed in 1971 in the U.S. Following this ban, there was a marked decline in incidence of initiation of adolescents aged 14–17 years; this remained in effect through the mid-1980s, suggesting that restricting advertising might be effective in decreasing product use for those under the legal age to purchase cigarettes.³³ This declining trend in adolescent smoking was associated with an increasing trend in the amount of money expended on advertising and promotions by the tobacco industry.³² There has also been a dramatic re-orientation of how the tobacco industry spends its promotional dollar. In 1990, 30% of the \$3.7 billion total expenditures were on traditional advertising line items, including outdoor advertising, magazines, point-of-sale advertising, and direct mail. By 2003, this type of advertising represented only 3% of promotional expenditures. In 2005, approximately \$10 billion was spent on providing price discount promo-

tions to merchants and the annual expenditure on promoting cigarettes was approximately \$60 for every adult in the country, or approximately \$300 per year for every smoker in the country.³⁴

These tobacco-industry, price-subsidizing promotions may have overcome the downward pressure of higher prices on initiation of regular smoking.³³ Time-series studies of innovative tobacco-industry campaigns that were established to launch products to a new demographic group also demonstrated that significant advertising in the mass media could bring new users into the smoking market; the new users were primarily between the ages of 14 and 17 years.^{35,36}

Additionally, longitudinal studies have identified that these advertising campaigns appeared to work the way that theory suggested that they would. Communication theories suggest that to be effective, non-users need to be engaged with advertising messages so that they become curious about trying the product.³⁷ These theories argue that there should be a hierarchy of effects that target individuals receptive to the advertising message, so they are not only exposed to it, but also like the message and act on that liking. Such receptivity is correlated with smoking behavior³⁸ and predicts which committed never-smokers will experiment with smoking over a 3-year period,¹⁴ as well as which committed never-smokers will be adult smokers 6 years later.³⁹ As envisioned by advertising theories, adolescents who are receptive to cigarette-brand advertising are also more likely to be curious about smoking, increasing the probability of experimenting with smoking.⁴⁰ Recent reviews of this literature on the effect of marketing in smoking initiation have concluded that the results of the nine published longitudinal studies are consistent in their evidence that receptivity to tobacco advertising and promotions is predictive of later smoking among nonsmokers and early-stage smokers.^{41–43}

During the 1990s, the growth of this evidence on the effectiveness of tobacco marketing in encouraging adolescents to start smoking led to further restrictions on the marketing practices of the tobacco industry, as part of the negotiated Master Settlement Agreement (MSA) between tobacco companies and State Attorneys General in 1998.^{44,45} Ecologic evidence of the effectiveness of these restrictions is that they coincided with a downturn in adolescent smoking following 10 consecutive years of increasing rates. This evidence is consistent in a number of surveillance data sets including the Monitoring of the Future (MTF) surveillance system, which has examined smoking behavior in a random sample of high school students every year since 1976.⁴⁶

Placement

Placing tobacco products in movies also is a well-recognized form of marketing. The price of this advertising varies with the character who uses the product (a

hero using a product is priced highest) and whether or not use of the product helps with the plot.^{47–49} Two longitudinal studies demonstrated that young adolescents whose favorite movie stars smoke on screen or who are exposed to a large number of movies portraying smokers are more likely to start smoking.^{50,51} A large, national, random sample of young teens (aged 10–14 years) identified that those who were most exposed to smoking in movies were 2.6 times more likely to have started smoking than those in the lowest category of exposure.⁵²

Placement of displays and advertising at the point of sale can also be considered under this heading. Cigarette pack displays have been associated with increased students' perceptions about the ease of purchasing cigarettes^{53,54} and for promoting brand recall. One study suggests that point-of-sale advertising is associated with encouraging youth to try smoking.⁴²

Summary

There is now considerable evidence on the association of tobacco-industry marketing and smoking behavior from many different studies using a variety of research designs. This evidence that tobacco marketing encourages smoking initiation is evaluated as convincing.

The Influence of Population-Based Tobacco-Control Programs

Tobacco-control programs are coordinated community-wide programs aimed at reducing tobacco usage. Early evidence of successful community programs appeared in the 1970s, when both the North Karelia Project⁵⁵ and the Stanford Three Communities Project⁵⁶ demonstrated that a community-wide program could lead to population behavior changes. In the early 1980s, a statewide "Quit for Life" program in Sydney, Australia focused on innovative and provocative mass-media messages delivered through paid television, radio, and newspaper advertisements and was shown to effectively reduce prevalence.^{57–59}

Comprehensive statewide tobacco-control programs were introduced in the U.S. in 1988, when California voters approved part of an excise tax increase to be used in a tobacco-control program.⁶⁰ The goal of the California program (1990–present) was to change the social norms surrounding tobacco, to affect all smoking behavior (adult and youth) by implementing "best practices" strategies for tobacco control, using research and development activities to improve the knowledge base for best practices. The paper describing the start of the California campaign⁶⁰ documented that best practices included: (1) increasing the price on tobacco products⁶¹; (2) conducting a mass media campaign⁶²; (3) having appropriate school curriculum and restrictions on smoking on school grounds⁶³; (4) implementing an appropriate service to assist smokers to quit both in

the physician's office,⁶⁴ in the workplace,⁶⁵ and in the community^{66,67}; and (5) providing locally-based community-education activities.⁶⁸

The following are examples of changes in best practices that have occurred after the start of the California program and demonstrate the importance of having a comprehensive program that can adjust to new developments. In 1992, the Environmental Protection Agency (EPA) classified secondhand smoke as a Group-A carcinogen.⁶⁹ Using technical support from the local programs initiative of the California statewide program, local advocates were successful in obtaining a plethora of local ordinances, which eventually led California to pass the first statewide smoke-free workplace law in the country in 1994. Additionally, smoke-free public school campuses were mandated by 1996.⁷⁰ In 1992, Congress made substance-abuse block grants from the federal government contingent on state performance in preventing minors from purchasing tobacco products. Prior to this amendment, purchase tests in many California cities demonstrated that minors could purchase tobacco over 80% of the time.⁷¹ The final regulations on this law were published in 1996 and required statewide surveys to demonstrate achievement of a sales violation rates that did not exceed 20%.⁷² The California program was one of the leaders in the nation in its aggressive enforcement practices and quickly met the standard.^{72,73} Another example is the evidence that tobacco advertising and promotions encourage youth to start smoking. While the first suggestive evidence was presented in 1991, the first time-series evidence was presented in 1994, and the key evidence from cohort studies came from studies designed to help evaluate the California program.^{14,39} Three major California cities (San Francisco, Los Angeles, and San Diego) had implemented ordinances restricting tobacco advertising before the MSA was enacted.⁴⁴




Figure 3. 30-day smoking prevalence by school grade. Youth Tobacco Survey, 1998–2005.

As the most populous state in the nation, smoking behavior in California was compared with the rest of the nation to assess the impact of the program. Using a significant pre-program period to establish baseline trends, both per capita cigarette sales and adult smoking prevalence declined as a result of the California program.⁷⁴ The program that operated throughout the 1990s has been demonstrated to significantly increase successful quitting. However, this effect was limited to adults under 35 years of age.²¹ The California program also was associated with a decline in consumption among older adult smokers,⁷⁵ and with a major decline in adolescent smoking.⁷⁶

Massachusetts was the second state to implement a large tobacco-control program in 1993, with a voter initiative directing support from a tobacco excise tax increase. Although modeled on the multicomponent California program, Massachusetts was characterized by a strong mass-media campaign and support from local boards of health and health departments.⁷⁷ Use of cigarette-sales data for evaluation of the Massachusetts program was complicated by evidence of significant out-of-state purchases because of the proximity of New Hampshire. The Massachusetts program was shown to be associated with a larger decline in prevalence than occurred in states without a program,^{78,79} and the effect was seen in college students.⁸⁰ There is also evidence that the program may have reduced adolescent progression from experimentation to established smoking.⁸¹ However, the program effect in reducing prevalence was not seen in all groups, with a lack of effect noted among women, the lower educated, and minority groups.⁷⁷ This program was similar to California (both were funded following a voter initiative process) but unlike California, this process did not require a supermajority of the legislature to remove the program. The Massachusetts program was effectively eliminated approximately 10 years after it began.⁷⁷

A very different approach was taken by the Florida tobacco pilot program. This program was established with monies the state received from its 1997 lawsuit settlement with the tobacco industry. The program initially was managed directly from the governor's office before it was transferred to the health department and focused on youth smoking only, with input from Florida youth in planning the program focus and materials. The signature component of this program was the "Truth" multichannel media campaign that was coordinated with public events. A youth group called Students Working Against Tobacco was established and supported; in the first few years, chapters were active in all 67 counties. This campaign directly attacked the image of smoking as cool and rebellious,³² and a downward trend in smoking behavior among youth was reported over a number of years.^{82,83} The most recent data are presented in Figure 3, which show a consistent decline in smoking rates within each school grade over

the duration of the program. While early evidence suggested that this decline was markedly different to that observed in other states that did not have tobacco-control programs,⁸⁴ a definitive analysis of the comparative adolescent data has not yet been presented. The Florida program was discontinued in 2003.

Following the Florida lead of using settlement monies to conduct a population campaign against smoking, the American Legacy Foundation was established as part of the MSA.⁸⁵ This foundation was established in 2000 for the express purpose of conducting a national education campaign, the first national antismoking campaign in the U.S., aimed at discouraging tobacco use among youths. This campaign focused on a national media purchase that averaged \$100 million per year during its first few years. The advertisements used in this campaign used graphic images aimed at exposing the death and disease caused by the manipulative marketing practices of the tobacco industry. Evaluation of this campaign used the largest and longest-running youth surveillance system for substance use, MTF.⁸⁶ This study reported that national smoking prevalence among all high school students declined from 25.3% to 18.0% between 1999 and 2002 and that the "Truth" campaign accounted for approximately 22% of this decline. While the American Legacy Foundation continues its aggressive tobacco-control program, there was a significant drop in tobacco settlement revenue in 2004 that has resulted in a smaller overall program than in the first 5 years.

In what is considered to be a major marketing initiative, Altria (parent company of Philip Morris) has created a website and materials that suggest that the company is an appropriate clearing house for all information on the health consequences of tobacco, as well as for ways to reduce tobacco use among minors. They have conducted a number of well-publicized advertising campaigns (e.g., "Think. Don't Smoke"). The tobacco industry also has provided grants-in-aid for schools to purchase the "Life skills training program," that has been evaluated as a model smoking-prevention curriculum with evidence from randomized trials that suggest it can reduce smoking.⁸⁷⁻⁸⁹ The tobacco-industry "prevention" advertising campaigns have been demonstrated to have effects more likely to increase than decrease smoking.⁸⁸ Tobacco industry documents noted in their internal evaluation of the "Life skills" curriculum that it did not reduce smoking behavior after the second year of operation. However, this negative evaluation had no impact on the industry grant program to schools to promote the program.⁹⁰

Summary

The evaluation of the effectiveness of tobacco-control programs to influencing cigarette smoking behavior has been compromised by a somewhat roller-coaster ride with funding. Numerous programs, funded initially with to-

bacco settlement agreement monies, were discontinued when there was a downturn in the economy. While the California program has continued to function, it has had to survive a number of attempts by different administrations to strip it of its media campaign. There also is evidence that the tobacco industry has targeted states that have tobacco-control programs with marked additional tobacco marketing efforts, an endeavor aimed at blunting the effects of the programs on smoking behavior. The overall differential in spending in 2003 was more than 25 times in favor of the tobacco industry. The evidence from studies of tobacco-control programs in Australia and California appears definitive, and studies from other states are supportive of an effect of tobacco-control program. As a whole, the evidence is evaluated as strong, although not yet convincing.

Evidence of the success of these tobacco-control programs has demonstrated that Count Corti was wrong when he concluded that attempts to introduce a smoke-free society would result in a "miserable fiasco." However, he was not wrong in indicating the strength of the opposition to these programs. The attack on the state programs has come from elected representatives, many of whom have enjoyed political contributions from the tobacco industry. In some ways, the aggressiveness of the effort to close down these tobacco-control programs is, in itself, evidence of their effectiveness.

Preparation of this manuscript was supported by TRDRP 15RT-0238. The author thanks Christine Hayes and Hollie Ward for their editorial support.

No financial disclosures were reported by the author of this paper.

References

- Corti ECC. A history of smoking (trans. Paul England). London: George C. Harrap, 1931.
- U.S. Department of Health and Human Services (USDHHS). Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. Report No. (CDC) 89-8411. Rockville MD: USDHHS, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1989.
- Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *Br Med J* 1950;2:739-48.
- Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. *JAMA* 1950;143:329-36.
- Haenszel W, Shimkin MB, Miller HP. Tobacco smoking patterns in the U.S. *Public Health Monograph No. 45* 1956:1-111.
- U.S. Department of Health Education and Welfare (USDHEW). Smoking and health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington DC: USDHEW, Public Health Service (PHS), CDC, 1964.
- CDC. Best practices for comprehensive tobacco control programs—August 1999. Atlanta GA: USDHHS, CDC, National Center for Disease Prevention and Health Promotion, Office on Smoking in Health, 1999.
- Peto R. Influence of dose and duration of smoking on lung cancer rates. In: Zaridze DG, Peto R, eds. *Tobacco: a major international health hazard*. Lyon: IARC; 1986. pp. 23-33.
- Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. *Cancer Res* 2003;63:6556-62.
- Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. *Environ Health Perspect* 1993;101(Suppl 5):35-44.
- USDHHS. Preventing tobacco use among young people: a report of the Surgeon General. Rockville MD:USDHHS, 1994.
- Pierce JP, Choi WS, Gilpin EA, Farkas AJ, Merritt RK. Validation of susceptibility as a predictor of which adolescents take up smoking in the United States. *Health Psychol* 1996;15:355-61.
- Choi WS, Gilpin EA, Farkas AJ, Pierce JP. Determining the probability of future smoking among adolescents. *Addiction* 2001;96:313-23.
- Pierce JP, Choi WS, Gilpin EA, Farkas AJ, Berry CC. Tobacco industry promotion of cigarettes and adolescent smoking. *JAMA* 1998;279:511-5.
- Gritz ER, Prokhorov AV, Hudmon KS, et al. Predictors of susceptibility to smoking and ever smoking: a longitudinal study in a triethnic sample of adolescents. *Nicotine Tob Res* 2003;5:493-506.
- Haddock CK, Lando HA, Pyle SA, et al. Prediction of adult-onset smoking initiation among U.S. Air Force recruits using the pierce susceptibility questionnaire. *Am J Prev Med* 2005;28:424-9.
- Gilpin EA, Choi WS, Berry C, Pierce JP. How many adolescents start smoking each day in the United States? *J Adolesc Health* 1999;25:248-55.
- Lantz PM. Smoking on the rise among young adults: implications for research and policy. *Tob Control* 2003;12(Suppl 1):i60-70.
- Kluger R. *Ashes to ashes: America's hundred-year cigarette war, the public health, and the unabashed triumph of Philip Morris*. New York: Alfred A. Knopf, 1996.
- Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. *J Natl Cancer Inst* 1997;89:572-6.
- Gilpin EA, Pierce JP. Demographic differences in patterns in the incidence of smoking cessation: United States 1950-1990. *Ann Epidemiol* 2002;12:141-50.
- Klonoff EA, Fritz JM, Landrine H, Riddle RW, Tully-Payne L. The problem and sociocultural context of single-cigarette sales. *JAMA* 1994;271:618-20.
- United States District Court for the District of Columbia. United States of America, Plaintiff, and Tobacco-Free Kids Fund, American Cancer Society, American Heart Association, American Lung Association, Americans for Nonsmokers' Rights, and National African American Tobacco Prevention Network, Intervenor v. Philip Morris Incorporated, et al, Defendants. Civil Action No. 99-CV-02496 (GK). In: United States District Court for the District of Columbia, 2006:i2454.
- Wipfli H, Stillman F, Tamplin S, et al. Achieving the Framework Convention on Tobacco Control's potential by investing in national capacity. *Tob Control* 2004;13:433-7.
- Anderson SJ, Ling PM, Glantz SA. Implications of the federal court order banning the terms "light" and "mild": what difference could it make? *Tob Control* 2007;16:275-9.
- Hammond D, Fong GT, McDonald PW, Brown KS, Cameron R. Graphic Canadian cigarette warning labels and adverse outcomes: evidence from Canadian smokers. *Am J Public Health* 2004;94:1442-5.
- Hammond D, Fong GT, Borland R, Cummings KM, McNeill A, Driezen P. Text and graphic warnings on cigarette packages: findings from the international tobacco control four country study. *Am J Prev Med* 2007;32:202-9.
- The Framework Convention Alliance for Tobacco Control (FCTC). Available online at: <http://www.fctc.org/>.
- Labeling and packaging (including health warnings). In: World Health Organization. WHO Framework Convention on Tobacco Control (WHO FCTC). Tobacco Free Initiative (TFI). <http://www.who.int/gb/fctc/PDF/inb6/einb65.pdf>.
- Liang L, Chaloupka F, Nichter M, Clayton R. Prices, policies and youth smoking, May 2001. *Addiction* 2003;98(Suppl 1):105-22.
- Chaloupka F, Grossman M. Price, tobacco control policies and youth smoking. Working paper #5740. National Bureau of Economic Research Cambridge, MA, September 1996. <http://www.nber.org/papers/w5740.pdf>.
- USDHHS. Reducing tobacco use: a report of the Surgeon General. Atlanta GA: USDHHS, CDC, National Center for Chronic Disease Prevention and Health, 2000.
- Pierce JP, Gilmer TP, Lee L, Gilpin EA, de Beyer J, Messer K. Tobacco industry price-subsidizing promotions may overcome the downward pressure of higher prices on initiation of regular smoking. *Health Econ* 2005;14:1061-71.
- Federal Trade Commission. Cigarette report for 2004 and 2005. Washington DC: FTC, 2007.
- Pierce JP, Lee L, Gilpin EA. Smoking initiation by adolescent girls, 1944 through 1988. An association with targeted advertising [see comments]. *JAMA* 1994;271:608-11.

36. Pierce JP, Gilpin EA. A historical analysis of tobacco marketing and the uptake of smoking by youth in the United States: 1890–1977. *Health Psychol* 1995;14:500–8.
37. Smith RE, Swinyard WR. Cognitive responses to advertising and trial: Belief strength, belief confidence and product curiosity. *Journal of Advertising* 1988;17(3):3–14.
38. Evans N, Farkas A, Gilpin E, Berry C, Pierce JP. Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. *J Nat Cancer Inst* 1995;87:1538–45.
39. Gilpin EA, White MM, Messer K, Pierce JP. Receptivity to tobacco advertising and promotions among young adolescents as a predictor of established smoking in young adulthood. *Am J Public Health* 2007;97:1489–95.
40. Pierce JP, Distefan JM, Kaplan RM, Gilpin EA. The role of curiosity in smoking initiation. *Addict Behav* 2005;30:685–96.
41. DiFranza JR, Wellman RJ, Sargent JD, Weitzman M, Hipple BJ, Winickoff JP. Tobacco promotion and the initiation of tobacco use: assessing the evidence for causality. *Pediatrics* 2006;117:e1237–48.
42. Slater SJ, Chaloupka FJ, Wakefield M, Johnston LD, O'Malley PM. The impact of retail cigarette marketing practices on youth smoking uptake. *Arch Pediatr Adolesc Med* 2007;161:440–5.
43. National Cancer Institute (NCI). The role of mass media in promoting and discouraging tobacco use. Tobacco control monograph No. 20. Bethesda MD: USDHHS, National Institutes of Health (NIH), NCI, in press.
44. Pierce JP, Gilpin EA. How did the Master Settlement Agreement change tobacco industry expenditures for cigarette advertising and promotions? *Health Promot Pract* 2004;5(3 Suppl):84S–90S.
45. Gilpin EA, Distefan JM, Pierce JP. Population receptivity to tobacco advertising/promotions and exposure to anti-tobacco media: effect of Master Settlement Agreement in California: 1992–2002. *Health Promot Pract* 2004;5(3 Suppl):91S–98S.
46. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975–2004: Vol. 1. Bethesda MD: National Institute on Drug Abuse (NIDA), 2004.
47. Distefan JM, Gilpin EA, Sargent JD, Pierce JP. Do movie stars encourage adolescents to start smoking? Evidence from California. *Prev Med* 1999;28:1–11.
48. DeLorme DC. Moviegoers' experiences and interpretations of brands in films revisited. *Journal of Advertising* 1999;28:71–3.
49. Higgins KT. There's gold in silver screen product plugs. *Advert Age* 1985;19:6.
50. Distefan JM, Pierce JP, Gilpin EA. Do favorite movie stars influence adolescent smoking initiation? *Am J Public Health* 2004;94:1239–44.
51. Sargent JD, Dalton M, Beach M, Bernhardt A, Heatheron T, Stevens M. Effect of cigarette promotions on smoking uptake among adolescents. *Prev Med* 2000;30:320–7.
52. Sargent JD, Beach ML, Adachi-Mejia AM, et al. Exposure to movie smoking: its relation to smoking initiation among U.S. adolescents. *Pediatrics* 2005;116:1183–91.
53. Henriksen L, Flora J, Feighery E, Fortmann S. Effects on youth of exposure to retail tobacco advertising. *J Appl Soc Psychol* 2002;32:1771–89.
54. Wakefield M, Germain D, Durkin S, Henriksen L. An experimental study of effects on schoolchildren of exposure to point-of-sale cigarette advertising and pack displays. *Health Educ Res* 2006;21:338–47.
55. Salonen JT, Puska P, Kotkale TE, Tuomilehto J. Changes in smoking, serum cholesterol and blood pressure levels during a community-based cardiovascular disease prevention program—the North Karelia Project. *Am J Epidemiol* 1981;114:81–94.
56. Farquhar JW, Maccoby N, Wood PD, et al. Community education for cardiovascular health. *Lancet* 1977;1:1192–5.
57. Pierce JP, Dwyer T, Fraple G, Chapman S, Chamberlain A, Burke N. Evaluation of the Sydney Australia quit for life anti-smoking campaign. Part 1. Achievement of intermediate goals. *Med J Aust* 1986;144:341–4.
58. Pierce JP, Macaskill P, Hill D. Long-term effectiveness of mass media led antismoking campaigns in Australia. *Am J Public Health* 1990;80:565–9.
59. Dwyer T, Pierce JP, Hannam CD, Burke N. Evaluation of the Sydney "Quit for Life" anti-smoking campaign. Part 2. Changes in smoking prevalence. *Med J Aust* 1986;144:344–7.
60. Bal DG, Kizer KW, Felten PG, Mozar HN, Niemeyer D. Reducing tobacco consumption in California. Development of a statewide anti-tobacco use campaign. *JAMA* 1990;264:1570–4.
61. Warner KE. The economics of smoking: dollars and sense. *N Y State J Med* 1983;83:1273–4.
62. Stein J. The Cancer Information Services: marking a large-scale national information program through the media. In: Leather D, Hastings G, O'Reilly K, Davies J, editors. *Health Ed Media*. London: Pergamon Press; 1986. pp. 3–10.
63. Glynn TJ. Essential elements of school-based smoking prevention programs. *J School Health* 1989;59:181–8.
64. Glynn T, Manley M. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Washington DC: USDHHS, PHS, NIH, 1989.
65. CDC. A decision-maker's guide to reducing smoking at the worksite. Washington DC: CDC, PHS, 1985.
66. Swartz J. Review and evaluation of smoking cessation methods: the United States and Canada. 1978–1985. Publication NIH 87–2940. Washington DC: USDHHS, 1987.
67. Glynn TJ, Boyd GM, Gruman JC. Essential elements of self-help/minimal intervention strategies for smoking cessation. *Health Educ Q* 1990;17:329–45.
68. Farquhar JW, Fortmann SP, Flora JA, et al. Effects of community-wide education on cardiovascular disease risk factors. The Stanford Five-City Project. *JAMA* 1990;264:359–65.
69. U.S. Environmental Protection Agency (EPA). Respiratory health effects of passive smoking: lung cancer and other disorders. Washington DC: EPA, Office of Research and Development, Office of Health and Environmental Assessment; 1992 January 31, 2007. Report No.: EPA/600/6–90/006F.
70. Gilpin EA, White MM, White VM, et al. Tobacco control successes in California: a focus on young people, results from the California tobacco surveys, 1990–2002. La Jolla, CA: University of California, San Diego, 2004.
71. Radecki TE, Zdunich CD. Tobacco sales to minors in 97 U.S. and Canadian communities. *Tobacco Control* 1993;2:300–5.
72. DiFranza JR, Dussault GF. The federal initiative to halt the sale of tobacco to children—the Synar Amendment, 1992–2000: lessons learned. *Tob Control* 2005;14:93–8.
73. Independent Evaluation Consortium. Final report. Independent evaluation of the California Tobacco Prevention and Education Program: Waves 1, 2, and 3 (1996–2000). Rockville MD: The Gallup Organization, 2002.
74. Pierce JP, Gilpin EA, Emery SL, et al. Has the California tobacco control program reduced smoking? *JAMA* 1998;280:893–9.
75. Al-Delaimy WK, Pierce JP, Messer K, White MM, Trinidad DR, Gilpin EA. The California Tobacco Control Program's effect on adult smokers: (2) Daily cigarette consumption levels. *Tob Control* 2007;16:91–5.
76. Pierce JP, White MM, Gilpin EA. Adolescent smoking decline during California's tobacco control programme. *Tob Control* 2005;14:207–12.
77. Koh HK, Judge CM, Robbins H, Celebucki CC, Walker DK, Connolly GN. The first decade of the Massachusetts Tobacco Control Program. *Public Health Rep* 2005;120:482–95.
78. Biener L, Harris JE, Hamilton W. Impact of the Massachusetts tobacco control programme: population based trend analysis. *Bmj* 2000;321:351–4.
79. Weintraub JM, Hamilton WL. Trends in prevalence of current smoking, Massachusetts and states without tobacco control programmes, 1990 to 1999. *Tob Control* 2002;11(Suppl 2):ii8–13.
80. Rigotti NA, Regan S, Majchrzak NE, Knight JR, Wechsler H. Tobacco use by Massachusetts public college students: long term effect of the Massachusetts Tobacco Control Program. *Tob Control* 2002;11(Suppl 2):ii20–4.
81. Siegel M, Biener L. The impact of an antismoking media campaign on progression to established smoking: results of a longitudinal youth study. *Am J Public Health* 2000;90:380–6.
82. Messer K, Pierce JP, Zhu SH, et al. The California Tobacco Control Program's effect on adult smokers: (1) Smoking cessation. *Tob Control* 2007;16:85–90.
83. Sly DF, Heald GR, Ray S. The Florida "truth" anti-tobacco media evaluation: design, the first year results, and implications for planning future state media evaluations. *Tob Control* 2001;10:9–15.
84. Niederdeppe J, Farrelly MC, Haviland ML. Confirming "truth": more evidence of a successful tobacco countermarketing campaign in Florida. *Am J Public Health* 2004;94:255–7.
85. Tobacco settlement summary. National Association of Attorneys General 1998; Available online at: www.naag.org/glance/htm.
86. Farrelly MC, Davis KC, Haviland ML, Messeri P, Heaton CG. Evidence of a dose-response relationship between "truth" antismoking ads and youth smoking prevalence. *Am J Public Health* 2005;95:425–31.
87. Wakefield M, Terry-McElrath Y, Emery S, et al. Effect of televised, tobacco company-funded smoking prevention advertising on youth smoking-related beliefs, intentions, and behavior. *Am J Public Health* 2006;96:2154–60.
88. Farrelly MC, Heaton CG, Davis KC, Messeri P, Hersey JC, Haviland ML. Getting to the truth: evaluating national tobacco countermarketing campaigns. *Am J Public Health* 2002;92:901–7.
89. Substance Abuse and Mental Health Services Association (SAMHSA). National registry of evidence-based programs and practices. Washington DC: USDHHS. Available online at: <http://nrepp.samhsa.gov/>.
90. Mandel LL, Bialous SA, Glantz SA. Avoiding "truth": tobacco industry promotion of life skills training. *J Adolesc Health* 2006;39:868–79.

Policy Interventions and Surveillance As Strategies to Prevent Tobacco Use in Adolescents and Young Adults

Jean L. Forster, PhD, Rachel Widome, PhD, Debra H. Bernat, PhD

Abstract: Tobacco-policy interventions are designed to change the environment with the ultimate goal of preventing young people from beginning to smoke or reducing the likelihood that they will accelerate and solidify their smoking patterns. Several studies show that smoking bans in the home, at school, at work, and in the community are associated with less progression to smoking, less consolidation of experimental into regular smoking, and more quitting among adolescents and young adults. Randomized community trials and cohort studies support an association between enforcement of youth access laws against businesses and lower adolescent smoking rates. Several decades of studies provide evidence that increasing cigarette price through excise taxes reduces smoking among adolescents and young adults, who are particularly price-sensitive. Ongoing surveillance of tobacco-use behaviors in adolescents and young adults is essential for monitoring smoking patterns and evaluating tobacco policies.

(Am J Prev Med 2007;33(6S):S335–S339) © 2007 American Journal of Preventive Medicine

Introduction

Tobacco-policy interventions are designed to change the environment with the ultimate goal of preventing young people from beginning to smoke and reducing the likelihood that they will accelerate and solidify their smoking patterns. These strategies can increase the difficulty in obtaining cigarettes from commercial and social sources, raise the price of cigarettes, and create a normative environment where smoking is unacceptable. Policy interventions focus only indirectly on youth, but more specifically on the adults and the institutions that create the environment within which youth develop healthy or unhealthy behavior patterns. This article summarizes the evidence for the effects of clean indoor-air policies, restrictions on tobacco access, and tobacco excise taxes on reducing youth and young adult tobacco use. The need for surveillance, essential for evaluating these policies, will also be discussed. Another article in this issue discusses the related topics of mass media campaigns and advertising and marketing restrictions.¹

From the Division of Epidemiology and Community Health, School of Public Health (Forster, Bernat) and Department of Pediatrics, School of Medicine (Widome, Bernat), University of Minnesota, Minneapolis, Minnesota

Address correspondence and reprint requests to: Jean Forster, PhD, School of Public Health, University of Minnesota, 1300 S. Second St., Suite 300, Minneapolis MN 55454. E-mail: forst001@umn.edu.

Policies to Restrict Exposure of Youth and Young Adults to Environmental Tobacco Smoke

Clean indoor-air policies are federal, state, local, and institutional policies that prohibit smoking in specified public places such as workplaces, schools, daycare centers, and healthcare facilities. While clean indoor-air policies have been in existence for more than 30 years, the number, strength, and breadth of these laws have escalated dramatically in recent years, including in such locations as bars, restaurants, and blue-collar worksites. Restaurants and bars in at least twelve countries in Europe, Africa, Asia, and Oceania are smoke-free. As of June 2007 fourteen states in the United States have adopted legislation that has or will result in 100% smoke-free workplaces, including bars and restaurants, and another seven states have 100% smoke-free bars and restaurants. In addition almost 500 U.S. cities have adopted clean indoor-air policies covering workplaces, restaurants, and/or bars that are stronger than their state laws.² Increasingly, organizations are adopting these policies, and 66% of households report that their homes are smoke-free.³

The primary purpose of these policies is to reduce the health risks of environmental tobacco smoke (ETS) exposure, officially labeled as a toxic air contaminant by the California Environmental Protection Agency, and as a Group A (Human) Carcinogen by the National Toxicology Program of the National Institute for Environmental Health Sciences.^{4,5} These adverse health effects are discussed thoroughly in the 2006 U.S. Sur-

geon General's Report. ETS exposure in children is causally associated with developmental problems such as low birth weight and sudden infant death syndrome, and with respiratory illnesses such as bronchitis and pneumonia, chronic respiratory symptoms, asthma induction and exacerbation, and middle ear infections.³ These problems are all less likely to occur and/or relieved by reducing exposure to ETS. Some studies have found that childhood exposure to ETS increases the risk of lung cancer as an adult.³

In addition, growing evidence suggests that clean indoor-air policies may have a negative effect on adolescent and young adult smoking. These laws can reduce the visibility of role models who smoke, limit the opportunities for youth to smoke alone or in groups and to exchange cigarettes with other smokers, and diminish the perceived social acceptability of smoking.⁶ Several studies show that smoking bans in the home, at school, at work, and in the community are associated with less progression to smoking, less consolidation of experimental into regular smoking, and more quitting among adolescents and young adults.⁷⁻¹⁰ Restrictions on smoking where alcohol is served are likely to be especially important, given the strong association between smoking and drinking in this age group.¹¹ The tobacco industry has exploited this link for young adults with their extensive tobacco promotions in bars and clubs with a young adult clientele.¹²

Policies to Restrict Youth Access to Tobacco

There are two general ways that youth obtain cigarettes—through commercial sources such as stores and vending machines and through social sources such as peers, family members, or other adults. Prior to the enactment of Section 1926 (Synar Amendment) of the Public Health Service Act,¹³ youth obtained cigarettes from commercial sources with relative ease.¹⁴⁻¹⁸ In an examination of 13 studies conducted between 1987 and 1993, the average over-the-counter purchase success rate for minors was 67%.¹⁵ With the hope that effectively limiting the supply of cigarettes to youth would lead to lower cigarette use, Congress mandated in the Synar Amendment¹³ that all states and territories must enact laws that prohibit the sale of tobacco to minors and enforce these laws with compliance checks by underage decoys.¹⁹

Research has shown that sale of cigarettes to youth can be reduced through active enforcement of these Synar laws.²⁰⁻²⁶ However, studies examining whether these policies reduce youth smoking have yielded mixed results. Several early reports found that active enforcement can reduce youth smoking;^{24,27,28} other examinations have found little or no effect.^{25,26,29} It is of note that most previous published studies on the effects of youth access policy were conducted in small,

isolated communities.²⁷ In the Monitoring the Future (MTF) survey of 8th- and 10th-grade students, the perceived availability of cigarettes began to decline in 1996 after remaining steady for years, perhaps due to the increased enforcement associated with Synar and U.S. Food and Drug Administration (FDA) regulation during this period.^{30,31} One recent study of cities in Minnesota showed that youth living in communities that use compliance checks and store penalties were less likely to become smokers over time than communities that did not use such enforcement.³² This study is especially relevant since such a large number and variety of communities were included.

Several studies have shown that restrictions on commercial access are linked to an increase in the use of social sources.^{28,33} Youth who rely solely on social sources of cigarettes tend to smoke less than those who use commercial sources to get their cigarettes. Wolfson et al.³⁴ postulated that this is due to the fact that being a heavy smoker may be based at least partially on having the greatest access to cigarettes. In the analysis by Harrison and colleagues³⁵ of the 1998 Minnesota Student Survey, teens who smoked heavily were less likely to report that social sources were their only sources of cigarettes. The 1999 National Youth Tobacco Survey³⁶ found that 36.1% of high school regular smokers bought cigarettes in a store while only 17.0% of high school nondaily smokers bought cigarettes in a store. A recent cohort study has shown that over time young smokers who use only social sources are less likely to become heavy smokers than adolescents who use both commercial and social sources.³⁷

Another tactic aimed at reducing youth access is penalizing youth for possession, use, and purchase (PUP) of tobacco. While Synar-type policies focus on reducing the supply of cigarettes to youth, PUP policies aim to stunt demand for cigarettes by introducing negative consequences that affect young smokers directly. Most tobacco-control advocates do not favor emphasizing PUP policy because they feel it reinforces the tobacco-industry messages that tobacco is for adults and implies that the individual holds sole responsibility for choosing to smoke.³⁸ Currently there is no strong evidence that PUP enforcement reduces youth smoking rates.^{24,39} Despite this, PUP laws and enforcement of these laws have become extremely common in the U.S.³⁸ A recent study in Minnesota demonstrated that youth are aware of these penalties and frequently know a peer who has been caught for a PUP violation.⁴⁰ However another study showed that applying PUP penalties was not associated with a reduction in youth smoking over time, unlike applying penalties to businesses, and that cities tended to focus on one or the other strategy.³²

Tobacco Excise Tax

Product-specific (excise) taxes, in addition to applicable sales taxes, are levied on tobacco products at the federal, state, and some local levels. The federal tax on cigarettes is currently \$0.39 per pack; state excise taxes range from 7¢ (South Carolina) to \$2.46 (Rhode Island) and average \$1.046 per pack.⁴¹ The range of state excise taxes reflects recent large increases enacted via statewide referenda and as a solution for recent budget shortfalls in many states. Beginning in 2002, 44 states and the District of Columbia have adopted 72 excise tax increases, averaging 43.7%.⁴² In addition, localities have added taxes, resulting in combined state–local tax rates as high as \$3.66 per pack in Chicago, \$3.30 in Anchorage, and \$3.00 in New York City.⁴¹ These tax increases do not necessarily translate directly into price increases, because price can be manipulated at the level of the distributor and retailer, and these practices vary by state. The best estimates of the average price of cigarettes, taking into account sales and excise taxes and variations in mark-ups and discounts, range from \$3.35 per pack in South Carolina to \$6.45 per pack in New Jersey.⁴³

Decades of econometric research show that smokers are price-sensitive, and that increasing the price of cigarettes reduces demand. Most reports indicate that adolescents are at least as price-sensitive as adults; however, most of the studies were conducted over a narrow range of taxes considerably lower than current excise taxes. Also, youth-smoking behaviors are often less intense and habitual compared to adult smoking, and thus their responses to price potentially less predictable. The largest effects of price are seen in heavier smokers, older-aged youth, and men,^{44–47} which is consistent with reports that young, experimental and female smokers obtain most of their cigarettes from social sources, and are less likely to purchase cigarettes.³⁶

A series of studies using the MTF longitudinal data from 1978 to 1994 found a greater effect of price on young adult smoking than on adult or adolescent smoking. Daily, moderate, and heavy young adult smoking were all negatively correlated with the price of cigarettes, and smoking cessation and regression to lighter smoking were positively correlated.^{10,47}

Additional studies are needed to examine the effects of recent large tax increases on all age groups, especially young adults, whose response to price or tax increases is largely unknown.

Tobacco Use Surveillance Systems

The primary goal of tobacco surveillance is to assess current tobacco use in a given population and to assess trends in use over time. In recent years, however, tobacco-surveillance systems have been expanded to include a variety of information that may be critical for

tobacco-use prevention, including access to tobacco, perceptions and attitudes about tobacco use, media and advertising, school-based prevention programs, environmental tobacco smoke, and cessation. These data are essential for guiding research, public health programming, and public policy related to tobacco-use prevention. Current best practices for tobacco control as defined by the Centers for Disease Control and Prevention (CDC) include participation in national and state surveillance systems.⁴⁸

National Surveillance Systems

Several surveillance systems currently exist to monitor tobacco use and tobacco-use–related information nationally. Many of these systems collect information on adolescents and young adults because the majority of prevention efforts focus on these age groups. The major national surveillance systems include the Youth Risk Behavior Surveillance System (YRBSS; 9th–12th graders), the Behavioral Risk Factor Surveillance System (BRFSS; ages 18+), the National Survey on Drug Use and Health (ages 12+), the Current Population Survey (CPS; ages 15+), and the MTF Survey (8th, 10th, 12th, and young adults). The only national surveillance system devoted solely to assessing tobacco use and related attitudes and beliefs is the National Youth Tobacco Survey.⁴⁹ This was also the first national survey to provide estimates of tobacco use for middle school students. This survey was administered in 1999, 2000, and every 2 years since then as a joint effort of the CDC and the American Legacy Foundation.

State-Level Surveillance

State-level surveillance is also a component of a comprehensive tobacco-control program, and is critical for assessing tobacco-use–prevention needs of individual states, as well as the effects of state-level policies and programs on rates of tobacco use. The majority of states collect some state-specific tobacco-use information through the Youth Tobacco Survey sponsored by the CDC. This is a self-administered classroom survey that began in 1998 with only three states participating, and is now administered in most states with some periodicity.

Future Directions

Given the importance of surveillance for tobacco-use–prevention assessment, planning and evaluation, planning for the ongoing collection of tobacco-related information is essential. Several issues warrant consideration including the need for community-level surveillance, poor or non-existent data for specific populations, lack of measures of social and environmental factors related to tobacco use, and problems with methods for surveillance.

First, because tobacco-control efforts are primarily implemented at the state and local levels, expanding surveillance data to include prevalence rates and trends in communities is needed. Community prevalence data would be valuable to evaluate local policies and assess community-level need for tobacco prevention. These data would also allow for a better understanding of how smoking rates vary by community and examine how community-level characteristics influence smoking in those communities.

Second, expanded surveillance is warranted for specific populations that show higher rates of smoking or who are at high risk for becoming regular smokers.⁵⁰ More comprehensive data, for example, are needed on trends in smoking among young adults (individuals aged 18–24 years). This group traditionally has received less attention than adolescents because smoking initiation often begins at younger ages and it is legal for youth between the ages of 18 and 24 to smoke. Young adults, however, have the highest smoking rate of any age group,⁵¹ and data show that young adults who did not smoke previously are becoming regular smokers during young adulthood.⁵² Surveillance systems could be very valuable in understanding factors that contribute to young adult smoking and identifying effective prevention programs for this age group.

Special surveys or over-sampling should be used to gather additional data on groups disproportionately affected by smoking to provide a stronger foundation for developing effective tobacco-control programs. A consequence of representative sampling is that relatively small groups within the population are represented by small numbers. As a result, for example, the reported prevalence of tobacco use among the >85,000 American Indians in Minnesota is based on 55 individuals surveyed over 2 years as part of the BRFSS.⁵³ Such a number has little meaning for tobacco-use prevention or evaluation among this group when response bias and cultural distinctions are also taken into account.

More measures are needed, as part of surveillance systems, to assess how social and environmental factors affect rates of tobacco use. Historically, tobacco surveillance focused on assessing current tobacco use and monitoring trends over time, but little information has been available through surveillance systems to understand how and why changes in tobacco use occur. Understanding how social and environmental factors are related to changes in tobacco use is important for developing effective interventions that target factors most strongly related to tobacco use.

Finally, new methods for conducting tobacco surveillance may need to be considered. Currently, many surveillance systems rely on responses to telephone surveys (e.g., BRFSS). Response to telephone surveys, however, has declined in recent years, due to advances in telephone technology and cellular phone use.⁵⁴ Youth surveillance typically has been conducted in

schools, where new constraints make data collection increasingly difficult. Results may underrepresent groups who are most likely to use tobacco. Given the importance of obtaining accurate estimates of the prevalence and trends in tobacco-related information from representative samples, new methods for obtaining this information may be necessary. Research combining several possible response modes, for example combining web-based and mailed surveys, may be an effective strategy for increasing response rates and obtaining representative samples in the future.⁵⁵

Conclusion

Research findings support the use of policy approaches to reduce youth tobacco use, including excise taxes to increase price, clean indoor-air laws, and restrictions on youth access to tobacco. These policies are part of a comprehensive tobacco-control program as outlined by the CDC, and need to be pursued at federal, state, and local levels of government, as well as in private organizations as applicable. Failure to adopt such proven strategies has been likened to withholding vaccines that are known to prevent disease. These policies and other tobacco-control strategies must be continually evaluated as well, requiring surveillance efforts that include detailed information about tobacco use and associated behaviors in all populations and all levels of organization. Programs and policies without such surveillance cannot meet the demand of accountability that is increasingly a part of government funding.

No financial disclosures were reported by the authors of this paper.

References

1. Pierce J. Tobacco industry marketing, population-based tobacco control, and smoking behavior. *Am J Prev Med* 2007;33(6S):S327–S334.
2. American Nonsmokers' Rights Foundation. Municipalities with Local 100% Smoke-free Laws. Current in effect or adopted as of April 2, 2007. Available online at: <http://www.no-smoke.org/pdf/100ordlist.pdf>.
3. U.S. Department of Health and Human Services (USDHHS). The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General—executive summary. Washington DC: USDHHS, Centers for Disease Control and Prevention (CDC), Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.
4. California Environmental Protection Agency. Proposed identification of environmental tobacco smoke as a toxic air contaminant. Sacramento CA: CalEPA, 2005.
5. National Toxicology Program. Report on carcinogens, 10th edn. Washington DC: USDHHS, Public Health Service (PHS), 2003.
6. Alesci NL, Forster JL, Blaine T. Smoking visibility, perceived acceptability, and frequency in various locations among youth and adults. *Prev Med* 2003;36:272–81.
7. Farkas AJ, Gilpin EA, White MM, Pierce JP. Association between household and workplace smoking restrictions and adolescent smoking. *JAMA* 2000;284:717–22.
8. Siegel M, Albers AB, Cheng DM, Biener L, Rigotti NA. Effect of local restaurant smoking regulations on progression to established smoking among youths. *Tob Control* 2005;14:300–6.

9. Wakefield MA, Chaloupka FJ, Kaufman NJ, Orleans CT, Barker DC, Ruel EE. Effect of restrictions on smoking at home, at school, and in public places on teenage smoking: cross sectional study. *BMJ* 2000;321:333-7.
10. Tauras JA. Can public policy deter smoking escalation among young adults? *J Policy Anal Manage* 2005;24:771-84.
11. Steele JR, Raymond RL, Ness KK, Alvi S, Kearney I. A comparative study of sociocultural factors and young adults' smoking in two Midwestern communities. *Nicotine Tob Res* 2007;9(Suppl 1):S73-82.
12. Ling PM, Glantz SA. Why and how the tobacco industry sells cigarettes to young adults: evidence from industry documents. *Am J Public Health* 2002;92:908-16.
13. USDHHS. Substance abuse prevention and treatment block grants: sale or distribution of tobacco products to individuals under 18 years of age. Washington DC: USDHHS; 1993. Federal Register 45 CFR Part 96.
14. Minors' access to tobacco—Missouri 1992, and Texas 1993. *MMWR Morb Mortal Wkly Rep* 1993;42:125-8.
15. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta GA: USDHHS, PHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1994.
16. Usual sources of cigarettes for middle and high school students—Texas, 1998-1999. *MMWR Morb Mortal Wkly Rep* 2002;51:900-1.
17. DiFranza JR, Brown LJ. The Tobacco Institute's "It's the Law" campaign: has it halted illegal sales of tobacco to children? *Am J Public Health* 1992;82:1271-3.
18. Naum GP 3rd, Yarian DO, McKenna JP. Cigarette availability to minors. *J Am Osteopath Assoc* 1995;95:663-5.
19. USDHHS. State oversight of tobacco sales to minors. Atlanta GA: USDHHS, Office of the Inspector General, 1995.
20. CDC. State tobacco activities tracking and evaluation (STATE) system. Available online at: <http://www.cdc.gov/tobacco/statesystem>.
21. Altman DG, Wheelis AY, McFarlane M, Lee H, Fortmann SP. The relationship between tobacco access and use among adolescents: a four community study. *Soc Sci Med* 1999;48:759-75.
22. Feighery E, Altman DG, Shaffer G. The effects of combining education and enforcement to reduce tobacco sales to minors. A study of four northern California communities. *JAMA* 1991;266:3168-71.
23. Gemson DH, Moats HL, Watkins BX, Ganz ML, Robinson S, Heaton E. Laying down the law: reducing illegal tobacco sales to minors in central Harlem. *Am J Public Health* 1998;88:936-9.
24. Jason LA, Ji PY, Anes MD, Birkhead SH. Active enforcement of cigarette control laws in the prevention of cigarette sales to minors. *JAMA* 1991;266:3159-61.
25. Rigotti NA, DiFranza JR, Chang Y, Tisdale T, Kemp B, Singer DE. The effect of enforcing tobacco-sales laws on adolescents' access to tobacco and smoking behavior. *N Engl J Med* 1997;337:1044-51.
26. Stead LF, Lancaster T. A systematic review of interventions for preventing tobacco sales to minors. *Tob Control* 2000;9:169-76.
27. Cummings KM, Hyland A, Perla J, Giovino GA. Is the prevalence of youth smoking affected by efforts to increase retailer compliance with a minors' access law? *Nicotine Tob Res* 2003;5:465-71.
28. Forster JL, Murray DM, Wolfson M, Blaine TM, Wagenaar AC, Hennrikus DJ. The effects of community policies to reduce youth access to tobacco. *Am J Public Health* 1998;88:1193-8.
29. Fichtenberg CM, Glantz SA. Youth access interventions do not affect youth smoking. *Pediatrics* 2002;109:1088-92.
30. Johnston L, O'Malley PM, Bachman J, Schulenberg J. Monitoring the Future: National survey results on drug use, 1975-2003: Volume I, secondary school students. Bethesda MD: National Institute on Drug Abuse (NIDA), 2004.
31. FDA regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents (executive summary). *Tob Control* 1996;5:236-46.
32. Widome R. City-level effects of tobacco youth access control. PhD dissertation. Minneapolis MN: Division of Epidemiology and Community Health, University of Minnesota, 2006.
33. DiFranza JR, Coleman M. Sources of tobacco for youths in communities with strong enforcement of youth access laws. *Tob Control* 2001;10:323-8.
34. Wolfson M, Forster JL, Claxton AJ, Murray DM. Adolescent smokers' provision of tobacco to other adolescents. *Am J Public Health* 1997;87:649-51.
35. Harrison PA, Fulkerson JA, Park E. The relative importance of social versus commercial sources in youth access to tobacco, alcohol, and other drugs. *Prev Med* 2000;31:39-48.
36. Ringel JS, Pacula RL, Wasserman J. Youth access to cigarettes: results from the 1999 National Youth Tobacco Survey. Washington DC: American Legacy Foundation, 2000.
37. Widome R, Forster J, Hannan P, Perry C. Longitudinal patterns of youth access to cigarettes and smoking progression: Minnesota Adolescent Community Cohort (MACC) Study (2000-2003). *Prev Med* 2007; in press doi:10.1016/j.ypmed.2007.07.016.
38. Wakefield M, Giovino G. Teen penalties for tobacco possession, use, and purchase: evidence and issues. *Tob Control* 2003;12(Suppl 1):i6-13.
39. Livingood WC, Woodhouse CD, Sayre JJ, Wludyka P. Impact study of tobacco possession law enforcement in Florida. *Health Educ Behav* 2001;28:733-48.
40. Lazovich D, Forster J, Widome R, Van Coevering P. Tobacco possession, use and purchase laws in Minnesota: enforcement, tobacco diversion programs, and youth access. *Nicotine Tob Res* 2007;9(Suppl 1):S57-S64.
41. Campaign for Tobacco-Free Kids. State cigarette excise tax rates and rankings. Available online at: <http://www.tobaccofreekids.org/research/factsheets/index.php?CategoryID=18>.
42. Campaign for Tobacco-Free Kids. State cigarette tax increases since January 1, 2002. Available online at: <http://www.tobaccofreekids.org/research/factsheets/index.php?CategoryID=18>.
43. Campaign for Tobacco-Free Kids. State cigarette prices, taxes and costs per pack. Available online at: <http://www.tobaccofreekids.org/research/factsheets/index.php?CategoryID=18>.
44. Cawley J, Markowitz S, Tauras JA. Lighting up and slimming down: the effects of body weight and cigarette prices on adolescent smoking initiation. *J Health Econ* 2004;23:293-311.
45. Gruber J. Youth smoking in the U.S.: prices and policies. Working paper no. 7506. Cambridge MA: National Bureau of Economic Research; 2000.
46. Liang L, Chaloupka FJ. Differential effects of cigarette price on youth smoking intensity. *Nicotine Tob Res* 2002;4:109-14.
47. Tauras JA, Chaloupka FJ. Determinants of smoking cessation: an analysis of young adult men and women. In: Grossman M, Hsieh C-R, eds. Economics of substance abuse. Northampton MA Edward Elgar Publishing Limited; 2001:337-64.
48. USDHHS. Best practices for comprehensive tobacco control programs—August 1999. Atlanta GA: USDHHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1999.
49. CDC. Tobacco use among middle and high school students—United States, 1999. *JAMA* 2000;283:1134-6.
50. Troscclair A, Caraballo RS, Malarcher A, Husten C, Pechacek T. Cigarette smoking among adults—United States, 2003. *JAMA* 2005;294:172-3.
51. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: national findings. NSDUH Series H-28, DHHS Publication No. SMA 05-4062. Rockville MD: Office of Applied Studies; 2005.
52. Lantz PM. Smoking on the rise among young adults: implications for research and policy. *Tob Control* 2003;12(Suppl 1):i60-i70.
53. CDC. Current smoking (Adults)—BRFSS (2 yrs—Race/Ethnicity) Minnesota 2004-2005. Available online at: <http://apps.nccd.cdc.gov/statesystem/>.
54. Tuckel P, O'Neill H. The vanishing respondent in telephone surveys. *J Advert Res* 2002;42:26-48.
55. Galesic M, Tourangeau R, Couper MP. Complementing random-digit-dial telephone surveys with other approaches to collecting sensitive data. *Am J Prev Med* 2006;31:437-43.

Increasing the Demand for and Use of Effective Smoking-Cessation Treatments

Reaping the Full Health Benefits of Tobacco-Control Science and Policy Gains—In Our Lifetime

C. Tracy Orleans, PhD

Abstract: More adults in the United States have quit smoking than remain current smokers. But 45 million adults (20.9%) continue to smoke, with highest rates among low socioeconomic status (SES), blue-collar, and Native American populations. More than two thirds (70%) of adult smokers want to quit, and approximately 40% make a serious quit attempt each year, but only 20%–30% of quitters use an effective behavioral counseling or pharmacologic treatment. The lowest rates of treatment use are seen in the populations with the highest rates of tobacco use. Fully harvesting the last 4 decades of progress in tobacco-control science and policy to increase smokers' demand for and use of cessation treatments represents an extraordinary opportunity to extend lives and reduce healthcare costs and burden in the next 30–40 years. This paper uses the “push–pull capacity” model as a framework for illustrating strategies to achieve this goal. This model recommends: (1) improving and communicating effective treatments for wide population use; (2) building the capacity of healthcare and other systems to deliver effective treatments; and (3) boosting consumer, health plan, and insurer demand for them through policy interventions shown to motivate and support quitting (e.g., clean indoor-air laws, tobacco tax increases, expanded insurance coverage/reimbursement) and efforts to improve treatment access and appeal, especially for smokers who use them least. Innovations recommended by the National Consumer Demand Roundtable for achieving “breakthrough” improvements in cessation treatment demand and use are described.

(Am J Prev Med 2007;33(6S):S340–S348) © 2007 American Journal of Preventive Medicine

Introduction

Enormous progress has been made in reducing adult smoking prevalence from the time of the first Surgeon General's Report on tobacco in 1964, when almost one of two adults in the United States were smokers, to 2005, when one of five adults were smokers (20.9%).^{1,2} The number of ever-smokers who have quit now exceeds the number of current smokers in the U.S., and the proportion of current smokers who are heavy smokers (>25 cigarettes/day) has declined substantially over the past decade, from 19.1% in 1993 to 12.1% in 2004.² In 2005, fewer cigarettes were sold in the U.S. than in any year since 1951, when the population was half its present size.^{3,4} These changes are the result of four decades of comprehensive science- and policy-based tobacco control aimed at denormalizing tobacco use, preventing youth

initiation, helping addicted smokers quit, and reducing secondhand-smoke exposure.^{1,2,5}

These tobacco-control advances have been hailed as one of the greatest public health achievements of the past century. However, recent annual declines in adult smoking prevalence have stalled, making it virtually certain that the *Healthy People 2010* goal of 12% adult smoking prevalence will not be reached.^{1,2} An estimated 45.1 million American adults continue to smoke, with highest rates among working-class adults, those with least income and formal education, and American Indians/Native Alaskans.^{2,4,6} Tobacco use remains the nation's leading cause of preventable death and disease, annually claiming 438,000 lives and accounting for \$167 billion in preventable healthcare costs and lost productivity—with growing socioeconomic and racial/ethnic disparities in these health impacts.⁷ Tobacco-use cessation confers substantial and immediate health and economic benefits across the lifespan, even after 50 years of smoking.^{8–10} In fact, Levy et al.⁸ estimate that if youth initiation were eliminated, the nation's smoking rate would change little in the near term; they project that the greatest declines in smoking-attributable death and

From the Robert Wood Johnson Foundation, Princeton, New Jersey
Address correspondence and reprint requests to: C.T. Orleans,
PhD, Robert Wood Johnson Foundation, College Road East, Princeton
NJ 08543. E-mail: cto@rwjf.org.

disease in the U.S. over the next 30–40 years will come from adult tobacco-use cessation.

Many of the pieces are in place for substantial increases in annual cessation rates. Hard-won progress in comprehensive national, state, and local tobacco control (e.g., clean-air laws, tobacco tax increases, public education and counter-advertising, social denormalization) has moved us much closer to a world that seemed almost unimaginable 25 years ago—a world in which “nonsmoking cues and cessation information” would be “persistent and inescapable,”¹¹ generating unprecedented support and motivation for smokers’ quitting efforts. Effective and cost-effective behavioral and pharmacologic treatments have been developed to help smokers quit and achieve long-term abstinence.^{9,10} Moreover, these treatments are increasingly covered by insurers and accessible through primary care offices, provider organizations and health plans, pharmacies, telephone quitlines, and emerging online services.^{12,13} Unfortunately, the hoped-for progress in national smoking and quitting rates has not occurred. While 70% of current adult smokers want to quit, only about 40% make a serious quit attempt each year, and the national annual quit rate has not changed much over the past 20 years.^{2,4}

Clearly, continued progress in reducing tobacco use and increasing cessation attempts and successes among U.S. adults will require comprehensive tobacco-control policies that address both initiation and cessation and will reach all smokers. However, to reap the fullest health benefits of the impressive tobacco-control science and policy gains achieved in the past 4 decades, over the next in 4 decades, tobacco-control efforts must focus more intentionally on increasing the demand for and use of effective smoking-cessation treatments among current smokers and quitters. Today, the vast majority of U.S. smokers who try to quit still are doing so “on their own,” without the benefit of treatments demonstrated to achieve quit rates substantially higher than current 5%–7% “unaided” quit rates.^{9,14} In 2000, only 20%–30% of U.S. quitters reported using an evidence-based treatment, only a modest increase from the 15% reported in 1986.¹⁵ And, disparities in treatment use continue to compound disparities in tobacco use; smokers with the least income and education, who try as often to quit as others, are the least likely to use effective treatments, and the most likely to fail when they make a serious quit attempt.^{2,4,6,13} Strategies that can increase the reach, appeal, and use of effective cessation treatments hold untapped potential to reduce overall adult smoking prevalence and growing disparities in tobacco use and tobacco-caused death and disease.

To realize this potential, six leading U.S. tobacco-control funders—the American Cancer Society (ACS), American Legacy Foundation (ALF), Centers for Disease Control and Prevention (CDC), National Cancer Insti-

tute (NCI), National Institute on Drug Abuse (NIDA), and Robert Wood Johnson Foundation (RWJF)—recently joined forces to organize and fund a multidisciplinary, multisector Consumer Demand Roundtable with the aim of identifying strategies and innovations that could lead to “breakthrough improvements” in treatment demand, use, and disparities in the next 5 years (www.consumer-demand.org). The Roundtable’s chief findings and recommendations will be released in a 2007 report.

This paper uses the model outlined in [Figure 1](#), a model developed to help guide broader cancer control and health promotion research-to-practice efforts, to categorize the major challenges and opportunities addressed by the Roundtable.^{14–17} It illustrates the need to work simultaneously on three fronts: (1) strengthening “science push” by proving, improving, and communicating effective treatments for wider population use; (2) building the capacity of relevant systems and institutions to deliver them; and (3) boosting demand, or market “pull,” for these treatments among consumers, healthcare purchasers, and policymakers. The next sections highlight selected accomplishments and innovations in each area with the potential, when combined, to bring about substantial reductions in adult smoking prevalence and in needless tobacco-caused death, disease, and healthcare burden in the next 30–40 years.

Science Push

The science base for efforts to expand cessation-treatment use and reach is a strong one. Formal clinical practice guidelines based on over 6000 articles using well-established measures for assessing long-term effectiveness have identified efficacious and cost-effective interventions (behavioral and pharmacologic) that can be delivered at a population level in a variety of settings and modalities (e.g., healthcare, community, quitline, online), and in many cases individually tailored or targeted to the needs of priority populations.⁹ [Table 1](#) summarizes the treatments that received a grade of “A” for strength of evidence based on a consistent pattern of findings from multiple, well-designed efficacy and effectiveness trials. The odds ratios (ORs) reported in the guidelines for these treatments range from 1.3 to 2.8, with most doubling quit rates compared to unaided quitting, usual care, placebo, no medication, or other controls, and with absolute long-term quit rates ranging from 10% to 30%.^{9,18}

The brief primary care intervention known as the 5A’s (Ask every patient about tobacco use; Advise all smokers to quit; Assess quitting readiness; Assist those who are ready to quit with brief cessation counseling and appropriate medication and those who are not with brief motivational counseling; Arrange follow-up for continued support and intervention and more intensive treatment if needed) deserves special attention




Figure 1. Increasing the use and impact of evidence-based treatments for tobacco use and dependence: science push, capacity building, and market pull.
NRT, nicotine replacement therapy.

given that 70% of smokers see their physicians each year.^{9,19–21} The National Commission on Prevention Priorities recently identified the 5A's intervention as potentially the single most effective and cost effective of all clinical preventive services recommended for adults

in the general population, with estimated cost savings of \$500 per smoker.^{19,20} Closing the gap between current rates of delivery of the 5A's and ideal rates of delivery (i.e., 90% of eligible adults) was projected to save as many quality-adjusted life years as closing the

Table 1. Treating tobacco use and dependence: U.S. PHS 2000 Clinical Practice Guideline Recommendations

Recommended treatments	Estimated odds ratio (95% CI)	Estimated abstinence rate (95% CI)
Physician advice to quit	1.3 (1.1–1.6)	10.2 (8.5–12.0)
Primary care minimal intervention (<3 minutes)	1.4 (1.1–1.8)	14.4 (11.3–17.5)
Extended counseling (>3 minutes) for pregnant smokers	2.8 (2.2–3.7)	16.8 (13.1–20.5)
Face-to-face counseling		
Group	1.3 (1.1–1.6)	13.9 (11.6–16.1)
Individual	1.7 (1.4–2.0)	16.8 (14.7–19.1)
Proactive telephone counseling	1.2 (1.1–1.4)	13.1 (11.4–14.8)
Multiple-format counseling		
2 formats	1.9 (1.6–2.2)	18.5 (15.8–21.1)
3 or 4 formats	2.5 (2.1–3.0)	23.2 (19.9–26.6)
First-line FDA-approved cessation medications		
Bupropion (Zyban, Wellbutrin)	2.1 (1.5–3.0)	30.5 (23.2–37.8)
Nicotine gum (reported for 2 mg gum only)	1.5 (1.3–1.8)	23.7 (20.6–26.7)
Nicotine inhaler	2.5 (1.7–3.6)	22.8 (16.4–29.2)
Nicotine nasal spray	2.7 (1.8–4.1)	30.5 (21.8–39.2)
Nicotine patch	1.9 (1.7–2.2)	17.7 (16.0–19.5)

Treatments not recommended: Self-help materials alone, acupuncture, hypnosis

Treatments recommended for further research: Treatments for adolescents and for smokers with mental health and/or substance abuse comorbidities; culturally-tailored treatments for racial/ethnic minority populations

Treatments not reviewed: Individually-tailored computer-based/online treatments; combined counseling plus pharmacotherapy; nicotine lozenges; varenicline (Chantix)

similar “delivery gaps” for all the other clinical preventive services recommended for adults in the general population combined (e.g., breast, colon, and cervical cancer screening, cholesterol and blood pressure screening, screening/counseling for problem drinking, influenza vaccine). Given the magnitude of its potential to improve population health, and reduce healthcare costs, burden, and disparities, the Institute of Medicine (IOM) identified this intervention as one of the top 20 priorities for all national healthcare quality improvement efforts.²¹

As Table 1 shows, the 2000 guideline panel reviewed and did not recommend self-help materials alone, acupuncture, or hypnosis. The panel did not review combined counseling/pharmacologic treatments, emerging computer-tailored and online behavioral interventions, or two newly FDA-approved efficacious medications (nicotine lozenges, varenicline), and it recommended further research for adolescent smokers and for smokers with psychiatric comorbidity and/or chemical dependency.^{9,10,22} Several of these topics will be reviewed as part of the 2008 guideline update that is now underway. “A-rated” guideline treatments were recommended for wide population use, with appropriate precautions in medically high-risk groups, and with cultural tailoring for smokers in racial/ethnic minority populations.^{9,23,24} The guideline update will also review new data from population-level trials, such as those recently reviewed by Cummings and Hyland,²⁵ exploring why increased use of over-the-counter nicotine replacement products has not influenced quit rates more substantially in the population at large (e.g., possible use by less motivated quitters and/or by non-quitters seeking short-term relief from nicotine withdrawal in smoke-free environments).

These science-based guidelines have been widely promoted to healthcare providers, health plans, policymakers, and advocates, and have furnished a powerful rationale for many healthcare practice, systems, and policy changes. These advances have included increases in: (1) the numbers of primary care providers routinely assessing tobacco-use status and advising smokers to quit, (2) the tracking and reporting provider quitting advice and assistance as core healthcare quality measures, and (3) healthcare benefits and coverage for tobacco-cessation treatments.^{9,10,12–14,25,27–30} One of the chief “lessons learned” from these successes is that simply having strong scientific evidence and respected evidence-based guidelines is not enough. Strategic leadership, advocacy, and communications have been critical to translating this science base into policy and practice.^{5,10,13,26,27}

These strong science-based guidelines have not, however, been widely communicated or promoted to consumers—to smokers and their families. Recent survey and focus-group data reveal wide public uncertainty about the value of these treatments, reflected in diffi-

culties discriminating effective and ineffective aids and in wide misconceptions about the harms of nicotine replacement therapy (NRT) use. For instance, a 2006 RWJF national telephone survey of 1076 U.S. adults aged 18 and over (21% smokers, 47% with a high school education or less, 67% Caucasian) found limited public knowledge about effective versus ineffective treatments.³¹ This survey asked which of 13 different treatments (seven evidence-based, six non-evidence-based) they believed had been “proven effective” to help smokers quit, typically doubling a quitter’s chances of success.²⁷ While more than half rated getting help from a doctor or other healthcare professional (77%), going to a stop-smoking clinic or class (73%), and nicotine patches (58%) as effective, fewer than half placed Zyban/Wellbutrin (47%), NRTs (37%–45%), and using a telephone quitline (24%) in this category. In fact, unproven acupuncture (32%), hypnosis (39%), and quit-smoking programs offered by tobacco companies (32%) were more often endorsed as “effective” than quitlines. McMenamin et al.³² documented similar misconceptions among Medicaid enrollees and found that the perceived effectiveness of varied tobacco-dependence treatments was significantly related to their use in this low-income population. There is growing evidence as well for public doubt and misconceptions about how over-the-counter (OTC) NRT products work, with many smokers, particularly those in low socioeconomic status (SES) and racial/ethnic minority populations, concerned about their safety and addiction potential.^{25,33} Bansal et al.³⁴ recently surveyed adult smokers and found that only 60% agreed that nicotine patches and gum improved smokers’ chances of quitting, and that fewer than half believed that these products were less likely than cigarettes to cause a heart attack.

Compounding these misperceptions and uncertainties, evidence-based cessation products and services are facing growing competition from new tobacco products promoted for “harm reduction,”^{35,36} from record-level tobacco industry spending (\$15.15 billion/year) on cigarette advertising and promotion,³⁷ and from a growing proliferation of untested and unproven “miracle cures” and remedies (e.g., laser therapy, herbal remedies) exempt from U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) labeling and advertising regulations.^{38,39} These factors combine to make effective consumer-oriented marketing and communications for evidence-based treatments more important now than ever. Direct-to-consumer marketing has been shown to help “demystify” and enhance the appeal and use of quitline services⁴⁰; to boost the use and perceived effectiveness of NRT⁴¹; to generate greater treatment use when targeted specifically to underserved priority populations, including racial/ethnic minority smokers⁴²; and to boost quit attempts, quit rates, and treatment use.^{40–42} The intro-

duction of new medications (i.e., nicotine lozenges, varenicline)¹⁰ and the direct-to-consumer marketing campaigns for them, and the release and promotion of 2008 U.S. Public Health Service (PHS) guideline update²⁸ will create new opportunities to boost the awareness, appeal, and use of treatments that work and to help smokers discriminate effective and ineffective quitting aids. They also will provide the context for innovative theory-driven studies to explore consumer treatment perceptions, expectations, and decision-making processes.

Delivery Capacity

Policymakers and healthcare, public health, and tobacco-control leaders and advocates have succeeded in greatly expanding the nation's capacity to deliver effective treatments over the past decade. Remarkable changes have occurred in the healthcare system. An increasing number of national, state, and professional groups (medicine, nursing, pharmacy, dentistry, mental health, cessation specialists) offer cessation-related training and assistance to deliver brief cessation advice and treatment.^{10,12,13} Based on evidence that healthcare provider training alone is not sufficient in the absence of systems supports to increase cessation-treatment delivery,^{9,43} the proportion of health plans using some system to identify smokers has risen from 15% in 1997 to 91% in 2003,³⁸ and the majority (over 60%) of smokers currently report physician advice to quit—advice that is associated with increased use of effective smoking-cessation treatments (counseling, medication) and with greater patient healthcare satisfaction.^{12,13,19,32,44} Advances in health information technology are rapidly expanding capacity for computerized reminder systems that have been found to improve the delivery of advice, counseling and medication in 5A's primary care interventions.^{11–13,28,44} There also has been considerable growth in understanding and implementing broad multicomponent healthcare systems changes to improve treatment delivery, approaches that typically combine provider training, computerized provider reminder and patient referral systems, patient self-management support programs, performance measurement, feedback, and incentives for evidence-based care.^{12,13,21,26,28} The fact that tobacco-cessation advice and treatment are now metrics in the nation's leading national healthcare quality measurement systems means that pay-for-performance initiatives using these measures will bring new incentives for their delivery as part of routine primary care.^{12,13}

Complementing these healthcare system changes, telephone quitlines are now available in 50 states and the District of Columbia through a single toll-free access portal (1-800-QUIT-NOW) providing smokers and providers an unprecedented barrier-free conduit to effective counseling.^{10,45,46} A 2005 survey of state

quitline directors found that 90% of quitlines offered materials and/or counseling in Spanish, 71% offered broader language translation services for counseling, and 35% provided free or low-cost nicotine medication to eligible adult callers, especially to low-income and uninsured smokers.⁴⁷ In addition, OTC availability of NRT gum, patches, and lozenges has widened their use, and the growth in online services hold the potential for “24/7” access to individually tailored quit smoking counseling and valuable quitting peer networking and social support.^{32,48,49}

One of the most exciting possible by-products of the growth in each of these individual treatment delivery systems is the emergence of integrated multichannel, multimodality systems of care that can tailor treatment modalities and content for individuals and targeted populations, achieving higher reach, especially among low-income smokers, and possibly higher quit rates as well.^{13,47,49–55} Fiore et al.,⁴⁶ Graham et al.,⁴⁹ and Abrams⁵⁰ have advocated for making the full range of cessation treatments (healthcare provider, medication, quitline, online, community-based clinics) accessible and freely available in a seamless, coordinated system of care management. For example, primary care practices increasingly are turning to telephone quitlines to provide the counseling assistance that is much less likely to be offered during brief quitting sessions by providers limited to 14-minute office visits.¹³ The “Ask-Advise-Refer” campaign of the American Dental Hygienists Association and the “Ask and Act” campaign of the American Academy of Family Physicians encourage providers to conduct the first two A's of the 5A's intervention (Ask and Advise) in their offices, and to refer patients to quitlines and other external services for additional help (Assess, Assist, Arrange). In 2005, 77% of state quitlines used faxed MD referrals to facilitate such primary care–quitline linkages.⁴⁷ Under the best of these models, quitline counselors work with primary care clinicians in a team-based approach that includes follow-up collaboration.^{10,13} Statewide programs in Maine, Minnesota, and New York are providing OTC NRT patches/gum to screened, eligible quitters.^{51–53} In studies conducted in three states, such efforts have greatly boosted quitline call volumes, have been particularly effective in reaching and assisting low-income and minority smokers, and have improved on the quit rates achieved in the same populations with quitline-only or NRT-only interventions.^{51–53} The integration of online services, particularly as the “digital divide” continues to erode, will further extend the reach, efficiencies, and social networking support of these multicomponent interventions—for both patients and providers.^{48–50}

The inclusion of tobacco-use screening and treatment in the nation's leading healthcare quality improvement agendas will spur new multisystem efforts to widen the delivery of proven treatments to the smokers

who need them.^{13,19–21} Public–private quitline service partnerships,⁴⁵ pharmaceutical company investments in product promotion and in individually-tailored computer-based counseling programs for FDA-approved medications,⁵⁴ and innovative minimal-contact NRT counseling and distribution strategies (such as brief pharmacist counseling in pharmacy-based health clinics serving low-income smokers)⁵⁵ are examples of promising and potentially profitable (financially sustainable) delivery systems that work around the constraints of busy primary care office practices. However, as outlined in the National Cessation Action Plan,⁴⁶ sustaining and expanding the nation’s quit-smoking treatment capacity and infrastructure ultimately depends on securing needed funding from federal, state, and local tobacco-control funds, excise tax revenues, as well as original (1998) and bonus (2008) Master Settlement Agreement (MSA) funds—only a small fraction of which are currently devoted to tobacco control.^{2,56}

Consumer and Market Demand

While the supply of cessation products and services has grown enormously, especially over the past decade, demand for them has not caught up, either among smokers themselves or among the public and private health plans and employers who purchase cessation products and services on their behalf. Major strides in public-policy supports for cessation and treatment use over the past decade have substantially improved national prospects for higher consumer and market demand for effective quit-smoking treatments, but further efforts are needed to reap the full benefits of these policy advances.

As outlined below, population-based public health policies recommended by the CDC to increase quitting and/or treatment use (i.e., tobacco tax increases, clean indoor-air laws, reduced out-of-pocket treatment costs, cessation media campaigns),⁴⁴ are currently reaching unprecedented numbers of smokers.

Since 1998, the combined average state and federal cigarette tax has increased from \$0.59 to \$1.33 per pack, with prospects for additional increases in the coming year.⁵⁶ A positive change of 10% in cigarette prices increase the probability of a quit attempt by 10%–12% and of a successful quit by 1%–2%, with greatest effects on smokers with the least income.^{46,57} State tobacco tax increases not only induce quitting and deter smoking, they also hold (mostly unrealized) potential for funding comprehensive tobacco-control initiatives.

Americans for Nonsmokers’ Rights reports that there are now 22 states and hundreds of additional municipalities with 100% smoke-free laws in workplaces, restaurants, and/or bars, and that 54.8% of Americans are now protected from harmful secondhand smoke in one or more of these settings.⁵⁸ These restrictions increase

population quit attempts and successes, and when coupled with treatment promotions and cost reductions, appear to increase treatment use and demand.^{53,59}

In 1995, only one state Medicaid program covered tobacco-dependence treatment. In 2005, 42 state Medicaid programs and 96% of U.S. health plans provided coverage for some form of evidence-based counseling or pharmacotherapy.^{30,60} Medicare now covers both counseling and medication, and the Veterans’ Affairs Health Administration now covers cessation counseling.¹² Unfortunately, many, if not most, smokers eligible for these benefits are unaware they have them, making them essentially “stealth” benefits.^{13,14,29,32,60}

Public health anti-tobacco advertising and cessation media campaigns and promotions have been shown to increase population quit rates, quitline calls, NRT use, and the utilization of treatment benefits.^{5,11,27,32,40–42,46,61–63} However, funding for these campaigns from MSA and state tobacco excise tax revenues is only a fraction of what it could or should be.^{1,2}

Demand is increased most when these public health strategies are combined. The New York City Department of Health paired a strong clean indoor-air law and recent state and local tobacco tax increases with a citywide cessation media campaign, primary care physician educational campaign, and the offer and promotion of free quitline counseling and NRT. The result was an 11% decline over 1 year in the citywide smoking rate from 2003 to 2004 (the fastest drop in U.S. smoking rates ever recorded) and a 15% decline over 2 years from 2003 to 2005, producing 200,000 new ex-smokers and averting an estimated 60,000 premature deaths.^{53,59,63} Citywide mass media and neighborhood-targeted promotions offering a free 6-week supply of NRT patches to the first 35,000 eligible adult quitline callers stimulated 400,000 calls, with disproportionate response from nonwhite, foreign-born smokers in the targeted low-income neighborhoods.^{53,59}

These results illustrate, at a local level, the potential synergistic effects that could be achieved nationally through the comprehensive strategies recommended by the National Cessation Action Plan (i.e., tax increases, physician training, free quitline counseling and NRT, effective treatment promotion). Replicating New York City’s success at the national, state, or local levels will require proactive efforts to assure that adequate cessation resources are in place to meet the demand generated by tobacco tax increases, clean indoor-air laws, and well-publicized cessation treatment benefits. The rapid spread of clean indoor-air laws and the presence of quitlines in 50 states and the District of Columbia offer unprecedented opportunities for such planning and coordination. However, the kind of alignment achieved by New York City is rare, and limited state and local tobacco-control funding is an obstacle. The enhanced surveillance system created by the New

York City Department of Health to target and evaluate their efforts also is rare, providing much stronger epidemiologic surveillance of smokers' quitting efforts and treatment use than now exists nationally or at the state and local levels.

Boosting market demand also requires marketing efforts aimed at employers, insurers, and health plans, the nation's powerful intermediary "consumers." New evidence and tools establishing the "business case" for tobacco-dependence treatment and the inclusion of tobacco-use screening and treatment in national pay-for-performance quality metrics will be helpful, although the full return on investment is delayed by 3–5 years.^{12,13,30,45} Insurers and employers also place great weight on direct employee and enrollee request, an emphasis projected to increase with the growth of consumer-directed health insurance products.⁶⁴ This places a premium on informing smokers of the cessation-treatment benefits that are available, and on discovering ways to design, package, promote, and deliver evidence-based treatments so that they are more appealing and more likely to inspire smoker demand for them as part of their basic health benefit packages.

An exciting new frontier in tobacco-cessation research and practice involves applying design principles and processes used to build demand for other consumer products to meet this challenge. The need to "design for demand" was given a high priority by the Consumer Demand Roundtable, which reached out to IDEO, a top global consumer product design firm, for help to identify possible "breakthrough innovations" in product design and delivery. The initial design principles proposed for tobacco-cessation treatments are based on: (1) IDEO's similar work redesigning other consumer products, including lifestyle and behavior-change products, to better meet their users' latent unmet needs⁶⁵; and (2) the view that current cessation treatments and delivery systems will need to engage and support quitters all along their "quitting journeys," not just during the initial active quit attempt.⁶⁶ The following initial IDEO design principles propose strategies for building cessation product appeal, use and demand by:

- (1) allowing smokers to **kick the tires** by giving them an opportunity to test or experiment with a service/product before buying into it (e.g., pharmacy-administered "trial" packages of multiple forms of NRT);
- (2) **lowering the bar** to make the initial quit attempt less costly, both psychologically and financially (e.g., short-term "practice" quit attempts);
- (3) **designing aesthetically pleasing products, tools, and services** that create a positive experience for consumers, especially for smokers in underserved populations;
- (4) **facilitating transitions** by giving smokers appropri-

- ate tools and professional and social support as they move through the multiple stages of quitting;
- (5) **making progress tangible** by allowing smokers to see and celebrate the small steps that are bringing them closer to their goal (e.g., cutting back before quitting);
- (6) **integrating multiple often disparate treatment elements in a unified system of care** (e.g., integrated multimodality treatment and support systems);
- (7) **fostering community** by linking smokers and quitters to real or virtual social support networks that prevent stigmatization and help smokers/quitters succeed; and
- (8) **connecting to the rest of smokers' lives** by showing an understanding that, for many smokers, quitting is a lifestyle decision—not exclusively a health decision—that affects them in many ways and by linking them to services and supports in other arenas (e.g., exercise, weight control, appearance, and stress and mood management).

These preliminary design principles will be applied and refined through a series of pilot design projects conducted by IDEO and Roundtable members to discover innovations that will increase the appeal and use of proven cessation products, especially among the low-income and racial/ethnic minority smokers who currently use them least. While not yet formally tested, these principles are congruent with several promising innovations already in the field, including: (1) pre-quitting use of NRT to facilitate smoking cessation⁶⁷; (2) 6-month "re-cycling" treatments for smokers who do not succeed in quitting⁶⁸; (3) combination treatments that offer multiple medications as well as face-to-face and phone counseling over a 12-month period⁶⁹; (4) the ALF's "Become an Ex" cessation campaign that is being designed to draw quitters and ex-smokers into an ongoing "brand community" using the same kinds of marketing techniques that the tobacco industry uses to maintain relationships with its customers⁷⁰; and (5) programs that successfully integrate tobacco-cessation treatment into multiple-risk behavioral interventions, including diet, physical activity, and cancer screening.⁷¹ Innovations that address smokers' obesity- and weight-related concerns may be especially appealing: Quitters in a recent study of consumer demand expressed willingness to pay more for cessation products that would help them to quit and to minimize quitting-related weight gain.⁷² Innovations such as these, if found to be effective, could help guide the next generation of smoking-cessation treatment studies to discover treatments that are both effective and appealing.

An Extraordinary Opportunity

In sum, the push-pull capacity model outlines the need for efforts that: (1) strengthen and better communicate

the strong evidence for treatments that help smokers overcome tobacco use and addiction; (2) capitalize on progress in building the nation's capacity to deliver these treatments especially through multichannel, multimodality systems of care that relieve some of the burden on primary care practices; and (3) increase market and consumer demand for them by harnessing public policy changes that motivate and support smokers' quitting efforts and by designing more appealing cessation products and services. These efforts must especially target the low-SES and racial/ethnic minority populations with the highest rates of tobacco use and lowest rates of treatment use. In combination, these strategies present an extraordinary opportunity to reap the full health benefits of the past four decades of tobacco-control science and policy gains, translating these gains into longer, healthier lives and reduced healthcare costs for the 45 million American adults who continue to smoke, and addressing the nation's widening disparities in tobacco use and tobacco-caused death and disease. Combining these strategies, as demonstrated in New York City and recommended by the National Cessation Action Plan and the National Consumer Demand Roundtable, holds great promise for breakthrough reductions in tobacco use among current adult smokers and among current adolescents who do not escape future tobacco addiction. This is an opportunity that cannot be missed.

I am grateful to the organizers, participants, and funders of the Consumer Demand Roundtable (www.consumer-demand.org) and the National Institutes of Health State-of-the-Science Conference on Tobacco Prevention, Cessation and Control for the many presentations, insights and recommendations that helped to shape this brief overview—with special thanks to David Abrams, Elaine Arkin, Cathy Backinger, Peter Coughlan, Carlo DiClemente, Cheryl Heaton, Corinne Husten, Kay Kahler Vose, Ann Malarcher, Marjorie Paloma, John Pinney, Todd Phillips, Karen Siener, Stephanie Smith-Simone, Amber Thornton-Hardy, and Frank Vocci. I also thank Edie Burbank-Schmitt and Anita Roberts for their help with references and manuscript production. While the views in this paper do not necessarily reflect those of the Robert Wood Johnson Foundation, I am grateful to Risa Lavizzo-Mourey and Jim Knickman for the opportunity to explore building consumer demand for proven cessation treatment as a way to maximize the health and healthcare impacts of the Foundation's many investments in tobacco-control research, practice, and policy.

No financial disclosures were reported by the author of this paper.

References

1. Warner KE. Tobacco policy in the United States: Lessons for the obesity epidemic. In: Mechanic D, Rogut L, Colby D, Knickman J, editors. *Policy challenges in modern health care*. New Brunswick NJ: Rutgers University Press, 2005.

2. Centers for Disease Control and Prevention (CDC). Cigarette-smoking among adults—United States 2005. *MMWR Morb Mortal Wkly Rep* 2006; 55:1145–8.
3. National Association of Attorneys General. Cigarette sales in U.S. reach historic 55-year low. News Release, March 8, 2006. Available online at: <http://www.hooah4health.com/news/2006/pr-20060308-cig-decrease.pdf>.
4. Giovino G. Overview: The tobacco epidemic in the United States. *Am J Prev Med* 2007;33(6S):S318–S326.
5. Hammond D, Fong GT, Zanna MP, Thrasher JF, Borland R. Tobacco denormalization and industry beliefs among smokers from four countries. *Am J Prev Med* 2006;31:225–32.
6. Barbeau EM. Increasing demand for and use of cessation treatments among low-income and blue-collar populations. *Am J Prev Med* 2007; submitted.
7. CDC. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. *MMWR Morb Mortal Wkly Rep* 2005;54:625–8.
8. Levy DT, Cummings KM, Hyland A. A simulation of the effects of youth initiation policies on overall cigarette use. *Am J Public Health* 2000;90: 1311–4.
9. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville MD: U.S. Department of Health and Human Services (USDHHS), Public Health Service (PHS), 2000.
10. Schroeder SA. What to do with a patient who smokes. *JAMA* 2005; 294:482–7.
11. Curry SJ, Orleans CT, Keller P, Fiore M. Promoting smoking cessation in the healthcare environment 10 years later. *Am J Prev Med* 2006;31:269–72.
12. Orleans CT, Woolf SH, Rothenich SF, Marks JS, Isham GJ. The top priority: building a better system for tobacco cessation counseling. *Am J Prev Med* 2006;31:103–6.
13. Glynn TJ, Boyd GM, Gruman JC. Essential elements of self-help/minimal intervention strategies for smoking cessation. *Health Educ Q* 1990;17:337.
14. Orleans CT, Alper J. Helping addicted smokers quit: the Foundation's tobacco-cessation programs. In: Isaacs SL, Knickman JR, eds. *To improve health and health care*. San Francisco: Jossey-Bass, 2003.
15. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments. *Am J Prev Med* 2005;28:119–22.
16. Office of Behavioral and Social Sciences Research. Putting evidence into practice. National Institutes of Health (NIH). Bethesda MD: Offices of Behavioral and Social Sciences Research, 1999.
17. Kerner J, Rimer BK, Emmons K. Dissemination research and research dissemination: how can we close the gap? *Health Psychol* 2005;24:443–7.
18. Stead LF, Perera R, Lancaster T. Telephone counseling for smoking cessation (Cochrane Review). *Cochrane Database Syst Rev* 2006;3:CD002850.
19. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities for improving utilization of clinical preventive services results. *Am J Prev Med* 2006;31:52–61.
20. Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. Repeated tobacco-use screening and intervention in clinical practice health impact and cost effectiveness. *Am J Prev Med* 2006;31:62–71.
21. Institute of Medicine (IOM). Priority areas for national action: Transforming health care quality. Washington DC: IOM, 2003.
22. Hall SM. Nicotine interventions with comorbid populations. *Am J Prev Med* 2007;33(6S):S406–S413.
23. Griz ER. Smoking cessation: a critical component of medical management in chronic disease populations. *Am J Prev Med* 2007;33(6S):S414–S422.
24. Perez-Stable E. Innovations and outreach to Latino populations in the United States and abroad. *Am J Prev Med* 2007; submitted.
25. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. *Ann Rev Public Health* 2005;26:583–99.
26. Green LW, Orleans CT, Ottoson JM, Cameron R, Pierce JP, Bettinghaus EP. Inferring strategies for disseminating physical activity policies, programs, and practices from the successes of tobacco control. *Am J Prev Med* 2006;31:S66–S81.
27. Orleans CT. Commentary on smoking cessation policy. In: Isaacs S, ed. *VA in the vanguard: building on success in smoking cessation*. San Francisco: UCSF School of Medicine. 2005, pp. 31–40.
28. Fiore MC, Keller PA, Curry SJ. Health systems changes to facilitate the delivery of tobacco-dependence treatment. *Am J Prev Med* 2007;33(6S): S349–S356.
29. Halpin HA, Bellows NM, McMenamin SB. Medicaid coverage for tobacco-dependence treatments. *Health Affairs* 2006;25:550.

30. McPhillips-Tangum C, Rehm B, Carreon R, Erceg CM, Bocchino C. Addressing tobacco in managed care: results of the 2003 survey. *Prev Chronic Dis* 2006;3:1-11.
31. Napier M, Smith-Simone S, Paloma MA, Orleans CT. Public perceptions of tobacco cessation treatment efficacy. Unpublished research brief. Princeton NJ: Robert Wood Johnson Foundation. July 2006.
32. McMenamin SB, Halpin HA, Bellows NM. Knowledge of Medicaid coverage and effectiveness of smoking treatments. *Am J Prev Med* 2006;31:369-74.
33. Levinson AH, Perez-Stable EJ, Espinoza P, Flores ET, Byers TE. Latinos report less use of pharmaceutical aids when trying to quit smoking. *Am J Prev Med* 2004;26:105-11.
34. Bansal MA, Cummings M, Hyland A, Giovino GA. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? *Nicotine Tob Res* 2004;6(Suppl 3):S303-S310.
35. Hatsukami D, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. Changing smokeless tobacco products: new tobacco delivery systems. *Am J Prev Med* 2007;33(6S):S368-S378.
36. O'Connor RJ, Hyland A, Giovino GA, Fong GT, Cummings KM. Smoker awareness of and beliefs about supposedly less-harmful tobacco products. *Am J Prev Med* 2005;29:85-90.
37. U. S. Federal Trade Commission (FTC). Cigarette report for 2003. Washington DC: FTC, 2005.
38. Barry M. Quitting and reducing tobacco use: Inventory of products. Available online at: <https://secure.tobaccofreekids.org/Cessation/>.
39. Avery R, Kenkel D, Lillard D, Mathios A. Regulating advertisements: the case of smoking cessation products. Working Paper 12001. Cambridge MA: National Bureau of Economic Research, 2006.
40. Wakefield M, Borland R. Saved by the bell: the role of telephone helpline services in the context of mass-media anti-smoking campaigns. *Tob Control* 2000;9:117-9.
41. Tauras JA, Chaloupka FJ, Emery S. The impact of advertising on nicotine replacement therapy demand. *Soc Sci Med* 2005;60:2351-8.
42. Boyd NR, Sutton C, Orleans CT, et al. Quit today: A targeted communications campaign to increase use of the cancer information service by African-American smokers. *Prev Med* 1998;27:S50-S60.
43. Hopkins DP, Briss PA, Ricard CJ, et al. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. *Am J Prev Med* 2001;20(2S):16-66.
44. Quinn VP, Stevens VJ, Hollis J, et al. Tobacco-cessation services and patient satisfaction in nine nonprofit HMOs. *Am J Prev Med* 2005;29:77-84.
45. McAfee T. Quitlines: a tool for research and dissemination of evidence-based cessation practices. *Am J Prev Med* 2007;33(6S):S357-S367.
46. Fiore M, Croyle R, Curry S, et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. *Am J Public Health* 2004;94:205-10.
47. North American Quitline Consortium and the European Network of Quitlines. Quitlines of North America and Europe 2006. Phoenix AZ: North American Quitline Consortium, 2006.
48. Etter JF. The Internet and the industrial revolution in smoking cessation counseling. *Drug Alcohol Rev* 2006;25:79-84.
49. Graham A, Bock B, Cobb N, Niaura R, Abrams D. Characteristics of smokers reached and recruited to an Internet smoking cessation trial: a case of denominators. Unpublished manuscript. Providence RI: Brown University Medical School, 2006.
50. Abrams DB. Comprehensive smoking cessation for all smokers: systems integration to save lives and money. Paper presented at the meeting of the Consumer Demand Roundtable. Washington DC: Academy for Educational Development. December 7, 2005.
51. Swartz SH, Cowan TM, Klayman JE, Welton MT, Leonard BA. Use and effectiveness of tobacco telephone counseling and nicotine therapy in Maine. *Am J Prev Med* 2005;29:288-94.
52. An LC, Schillo BA, Kavanaugh A, Luxenberg MG, Joseph AM, McAfee T. Access to nicotine replacement therapy as part of a statewide tobacco telephone helpline. *Am J Health Promot* 2006;20:267-71.
53. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, Hyland A. Reach, efficacy, and cost effectiveness of free nicotine medication giveaway programs. *J Public Health Manag Pract* 2006;12:37-43.
54. Strecher VJ, Shiffman S, West R. Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. *Addiction* 2005;100:682-8.
55. Kemper K. Innovative models for OTC NRT marketing and treatment. Paper presented at the meeting of the Consumer Demand Roundtable. Washington DC: Academy for Educational Development, December 7, 2005.
56. Campaign for Tobacco-Free Kids. State cigarette tax increases vs cigarette company price increases 1993-2002. Available online at: <http://www.tobaccofreekids.org/research/factsheets/index.php?CategoryID=18>.
57. Tauras J. An empirical analysis of adult cigarette demand. *Eastern Econ J* 2005;31:361-75.
58. American Nonsmokers' Rights Foundation. Percent of U.S. state populations covered by local or state 100% smoke-free air laws, April 2, 2007. Available online at: <http://www.no-smoke.org/pdf/percentstatepops.pdf>.
59. Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;365:1849-54.
60. CDC. State Medicaid coverage for tobacco-dependence treatments—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;54:1194-7.
61. Hyland A, Wakefield M, Higbee C, Szczyka G, Cummings KM. Anti-tobacco television advertising and indicators of smoking cessation in adults: a cohort study. *Health Educ Res* 2006;21:348.
62. Biener L, Reimer RL, Wakefield M, et al. Impact of smoking cessation aids and mass media among recent quitters. *Am J Prev Med* 2006;30:217-24.
63. New York City Department of Health and Mental Hygiene. Nearly 200,000 fewer smokers in New York City since 2002; at least 60,000 early deaths prevented. June 9, 2005. Available online at: <http://www.nyc.gov/html/doh/html/pr/pr062-05.shtml>.
64. Bondi MA, Harris JR, Atkins D, et al. Employer coverage of clinical preventive services in the United States. *Am J Health Promot* 2006; 20:214-22.
65. Kelley T. The art of innovation. New York: Random House, 2001.
66. Coughlan P. Proposed IDEO consumer-centered design principles for tobacco cessation products and services. Paper presented at the meeting of the Consumer Demand Roundtable. Washington DC: Academy for Educational Development, December 7, 2005.
67. Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. *Nicotine Tob Res* 2006; 8:89-101.
68. Fu SS, Partin MR, Synder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested in "recycling"? *Amer J Manage Care* 2006;12:235-43.
69. Hall SM, Humfleet GL, Reus VI, Muñoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. *Am J Psychiatry* 2004;161:2100-7.
70. Byrnes N. Leader of the packs: Marlboro is still smokin' at 50, thanks to buzz marketing. *Business Week-Online*, 2005. Available online at: http://www.businessweek.com/magazine/content/05_44/b3957107.htm?chan=search.
71. Velicer WF, Prochaska JO, Redding CA. Tailored communications for smoking cessation: past successes and future directions. *Drug Alcohol Rev* 2006;25:49-57.
72. Busch SH, Falba TA, Duchovny N, et al. Value to smokers of improved cessation products: evidence from a willingness-to-pay survey. *Nicotine Tob Res* 2004;6:631-4.

Health System Changes to Facilitate the Delivery of Tobacco-Dependence Treatment

Michael C. Fiore, MD, MPH, Paula A. Keller, MPH, Susan J. Curry, PhD

Abstract: In 1996, the Agency for Health Care Policy and Research (AHCPR, now AHRQ, the Agency for Healthcare Research and Quality) released the first federal clinical practice guideline for smoking cessation that was updated in 2000 by the United States Public Health Service (USPHS). The innovative guideline identified six evidence-based strategies for healthcare systems to facilitate the institutionalization of tobacco dependence treatment so that smokers received evidence-based treatments as a routine part of health care.

A growing body of evidence demonstrates the importance of systems approaches. This paper discusses the evidence for the systems-level strategies outlined in the guidelines, as well as future directions and needed systems-level research. Promising strategies include: (1) clinical systems organized to cue assessment of smoking status and assistance to smokers, (2) leveraging clinical information systems to provide performance feedback, (3) providing full insurance coverage for evidence-based cessation treatment, and (4) including tobacco-cessation treatment as a measured standard of care by national accreditation organizations. These systems-level approaches increase the likelihood that tobacco use is addressed systematically in the healthcare delivery system. Further research to optimize the effectiveness and adoption of these strategies will help ensure that patients receive evidence-based interventions that foster tobacco-use cessation.

(Am J Prev Med 2007;33(6S):S349–S356) © 2007 American Journal of Preventive Medicine

Introduction

In 1996, the Agency for Health Care Policy and Research (AHCPR, now AHRQ, the Agency for Healthcare Research and Quality) released the first federal clinical practice guideline for smoking cessation.¹ Both the 1996 AHCPR guideline and its update published by the United States Public Health Service (USPHS) in 2000 were innovative in that they identified six evidence-based strategies for healthcare systems to facilitate the institutionalization of tobacco-dependence treatment.

Systems-level changes are policies and practices designed to integrate the identification of smokers and the subsequent offering and receipt of evidence-based cessation treatments into the routine delivery of health care. Systems-level changes can be direct, such as regular training of clinicians in brief cessation interventions, or indirect, such as removing cost barriers to treatment to increase use of those treatments. These strategies,² depicted in Table 1, are:

Implementing a tobacco-user identification system in every clinic. The goal of this strategy is to ensure that all patients are asked about tobacco use as part of every clinical encounter. Such prompts have been shown to increase the rate at which clinicians intervene with tobacco-using patients.^{3–6} Such prompts also encourage clinicians to approach tobacco use as a chronic disease, requiring ongoing care similar to that offered to patients identified with hypertension or hyperlipidemia.

Providing education, resources, and feedback to promote provider intervention. The intent of this effort is to ensure that clinicians have the information and tools needed to assist their patients in making a quit attempt. Additionally, providing performance feedback also can serve as a strategy to increase rates of intervention. In essence, these strategies serve as systematic levers, prompting clinicians to take action.

Dedicating staff to provide tobacco-dependence treatment and assessing the delivery of this treatment in staff performance evaluations. Having a core staff member who takes a lead role in providing tobacco-dependence treatment to patients (or ensuring that this treatment is provided) has the potential to improve treatment delivery. This is also consistent with the team-based disease-management approach effectively applied to other chronic diseases.⁷ Additionally, measuring the delivery of tobacco-dependence treatment in

From the University of Wisconsin Center for Tobacco Research and Intervention (Fiore, Keller), Madison, Wisconsin; Institute for Health Research and Policy, University of Illinois–Chicago (Curry), Chicago, Illinois

Address correspondence and reprint requests to: Michael C. Fiore, MD, MPH, Professor of Medicine, Director, Center for Tobacco Research and Intervention, 1930 Monroe Street, Suite 200, Madison WI 53711. E-mail: mcf@ctri.medicine.wisc.edu.

Table 1. Systems-level strategies to facilitate treatment of tobacco dependence²

1. Implement a tobacco-user identification system in every clinic.
2. Provide education, resources and feedback to promote provider intervention.
3. Dedicate staff to provide tobacco dependence treatment and assess the delivery of this treatment in staff performance evaluations.
4. Promote hospital policies that support and provide inpatient tobacco dependence services.
5. Include tobacco dependence treatments (both counseling and pharmacotherapy) identified as effective in this guideline as paid or covered services for all subscribers or members of health insurance packages.
6. Reimburse clinicians and specialists for delivery of effective tobacco dependence treatments and include these interventions among the defined duties of clinicians.

staff performance evaluations raises awareness of the importance of addressing tobacco use to improve health and further integrates such treatment into routine medical care.

Promoting hospital policies that support and provide tobacco-dependence services. Hospitalization is an important opportunity to intervene with smokers and address tobacco use in a more intensive manner during the inpatient stay.⁸ This is particularly relevant given all hospitals in the U.S. are smoke-free and the recent Joint Commission for Accreditation of Healthcare Organizations (JCAHO) mandate to document the provision of smoking cessation counseling for patients diagnosed with certain conditions (acute myocardial infarction, congestive heart failure, community-acquired pneumonia).⁹ By utilizing the hospital stay as an opportunity to offer evidence-based cessation treatment, clinicians may be able to help more hospitalized patients successfully quit using tobacco.

Including all tobacco-dependence treatments (both counseling and pharmacotherapy) identified as effective as paid or covered services for all subscribers or members of health insurance packages. Tobacco-dependence treatment is both clinically effective and cost-effective.^{2,10–13} Providing coverage for tobacco-dependence treatment removes or reduces cost barriers for accessing care. Studies have indicated that cost sharing results in lower rates of utilization of evidence-based tobacco-dependence treatment¹⁴; strategies for reducing or eliminating these costs have the potential to increase the number of people accessing services, successfully quitting, and ultimately reducing healthcare costs.

And, reimburse clinicians for delivering effective tobacco-dependence treatments and include these interventions among the defined duties of clinicians. Clinicians frequently cite lack of reimbursement as a barrier to providing preventive care.¹⁵ Reimbursing clinicians for

preventive care services has been shown to increase delivery of these services and improvements in health behaviors by patients, including a trend toward decreased smoking.¹⁶

Systems-level strategies represent a new way of thinking about treating tobacco dependence. Typically, interventions have targeted either the smoker or the clinician. In contrast, systems strategies are intended to ensure that tobacco use, the leading preventable cause of illness and death in the U.S. is systematically assessed and treated at every clinical encounter. Importantly, these strategies are designed to work synergistically with clinician- and patient-focused interventions, ultimately resulting in both activated clinicians and informed patients interacting in a seamless system that facilitates the treatment of tobacco dependence.⁷ Such strategies have the potential to have a significant effect on smoking at the population level. Levy et al. estimated that a 2%–3.5% relative reduction in smoking prevalence rates could result over time from widespread implementation of such strategies.¹⁷

Since these recommendations were first released in 1996, new research has expanded the scientific basis for systems changes, including reviews conducted by the U.S. Preventive Services Task Force (USPSTF) on Community Preventive Services and the Cochrane Collaboration.^{18–22} Manley et al. reviewed the literature on health plan implementation of both clinical and community interventions regarding tobacco use. Despite significant improvements in the implementation of systems approaches to address tobacco use by the late 1990s, opportunities for further gains remain.²³ Moreover, an evaluation conducted by the Cancer Research Network found that the adoption of health plan policies can result in the implementation of systems-level changes and increased delivery of these services to patients.²⁴

In this paper, the evidence supporting systems-level approaches to address tobacco use is examined in the healthcare setting. The evidence for four of the six strategies is quite robust and is described in detail. The remaining two strategies are reported in brief as there is a less substantial evidence base for these strategies. Future opportunities for research and implementation are also discussed.

Implementation of Tobacco-User Identification Systems in the Clinic Setting

There is significant evidence that implementing a clinic-based tobacco-user identification system increases the rate of smoker identification and facilitates the provision of advice to quit and, possibly, assistance in quitting. Fiore et al.³ conducted a prospective evaluation of expanding the vital signs to include tobacco use. Post-intervention, patients were more likely to report

being asked about smoking status, being advised to quit, and receiving specific advice on how to quit. Ahluwalia et al.⁴ evaluated whether a smoking status stamp would prompt clinicians to address tobacco use among African-American patients. In this study, patients were significantly more likely to be asked about smoking (odds ratio [OR]=4.28, 95% confidence interval [CI]=3.58–5.10), advised to quit (OR=1.81, 95% CI=1.36–2.40), and have follow-up arranged (OR=2.16, 95% CI=1.30–3.38) after the intervention was implemented. Improvements were not seen in specific advice to quit nor in setting a quit date. Papers published by Chang et al.⁵ and Robinson et al.⁶ also noted statistically significant increases in the rates of asking and advising about tobacco use after a vital signs stamp or chart reminder system was implemented. Recent research further describes the positive impact of including tobacco use as a vital sign on rates of asking about smoking status. Piper et al.²⁵ studied whether the expanded vital sign stamp would increase rates of smoker identification, advice to quit, provision of assistance, and abstinence rates. Rates of asking about smoking status increased significantly. Unfortunately, rates of advice to quit, provision of assistance, and abstinence rates either were constant or decreased. Boyle and Solberg²⁶ evaluated whether smoking as a vital sign improved clinician cessation support in primary care and yielded mixed results. Patient self-report of advice about smoking was unchanged after the intervention. Chart documentation of tobacco use during clinical visits more than doubled (from 38% to 78%), yet documentation of advice about smoking decreased by nearly half (from 34% to 19%).

Findings from a periodic survey of health plans conducted by America's Health Insurance Plans (AHIP) show that the percentage of health plans that were able to identify either some or all members who smoke increased from 15% in 1997 to 91% in 2003.²⁷ Improvements in rates of clinician intervention are also seen in national data sets. Comparison of 2003, 2004, and 2005 Healthcare Effectiveness Data and Information Set (HEDIS) data collected by the National Committee for Quality Assurance (NCQA) documented modest increases in the percentage of commercial enrollees, Medicaid enrollees, and enrollees who reported receiving advice to quit smoking (current rates range from 65% to 75%).²⁸

This summary indicates that implementing tobacco-user identification systems improves rates of identifying tobacco users and documenting this important information in the medical record. However, as both Piper et al.²⁵ and Boyle and Solberg²⁶ found, these systems do not by themselves consistently spur greater action by clinicians to intervene with their patients who use tobacco. Additional systems-level changes may be needed to create an environment that ensures that tobacco use

is addressed in a comprehensive manner with all patients.

Provision of Education, Resources, and Feedback to Clinicians

Multicomponent interventions that incorporate both provider education and reminder systems can facilitate delivery of evidence-based tobacco-dependence treatments.¹⁸ A review on audit and feedback in clinical practice published by the Cochrane Collaboration found that these strategies can improve provider performance, but improvements are small to modest. The effects of audit and feedback were likely to be larger when initial performance was low.¹⁹

Four recent studies add to the evidence base surrounding performance feedback. Swartz and colleagues²⁹ studied the feasibility of academic profiling, an intervention including both provider education and peer-comparison performance feedback generated from claims data and health plan data. As part of this process, the research team provided information on tobacco-related chart documentation, claims for nicotine replacement therapy and bupropion, and International Classification of Diseases (ICD)-9 coding (i.e., diagnosis coding) for tobacco use to primary care physicians. The physicians found the information understandable and indicated that it would help improve their performance, but almost half indicated that they did not believe the chart audit data accurately reflected their performance. McAfee et al.³⁰ evaluated the effect of automated performance feedback and senior-level incentives on provider compliance with a new system of tobacco status identification and intervention. The new system resulted in a tenfold increase in the rate of tobacco-user identification and over a threefold increase in documentation of provider advice and intervention. Middle managers reported that senior-level incentives were a powerful motivator, demonstrating a commitment to tobacco cessation among a long list of competing priorities and systems efforts. Andrews and colleagues³¹ tested a multicomponent intervention to improve primary care providers' adherence to the AHCPR smoking-cessation guideline. They found that educational sessions alone had no significant impact on provider performance; however, feedback resulted in significant improvements in advice, assistance, and follow-up arrangements. Bentz et al.³² measured the impact of practice feedback generated from electronic health record data on rates of referral to a state quitline. Rates of advice, assessment, and assistance were significantly higher in clinics receiving feedback than in control clinics. Additionally, a higher case-mix index (e.g., having a larger number of patients who were older and/or sicker than the general patient

population) and presence of a clinic champion were associated with increased rates of referral.

In sum, there is a modest but growing body of evidence indicating that provider feedback may be a promising practice for facilitating the delivery of these treatments. Additional research is needed to further evaluate how feedback should be given, what types of feedback are most effective in improving performance, and whether these findings can be replicated in other settings.

Hospital Policies that Support Inpatient Cessation Services

Hospitalization is an important opportunity to intervene with smokers and address tobacco use in a more intensive manner during the inpatient stay.^{8,33} By using hospitalization as an opportunity to offer evidence-based cessation services, clinicians may be able to help more hospitalized patients successfully quit using tobacco.

There is a clear body of evidence documenting the efficacy and effectiveness of smoking-cessation interventions in the inpatient setting. A 2007 Cochrane review evaluated the effectiveness of smoking-cessation interventions for hospitalized patients and concluded that high-intensity behavioral interventions that included at least 1 month of follow-up after discharge were effective in increasing the delivery of smoking cessation treatments to inpatients compared to interventions that did not include extensive posthospitalization follow-up or that were conducted only during the inpatient stay.²¹

Systems-level changes such as policies and performance measures are critical to ensure that patient interventions are actually delivered. In 1992, JCAHO issued a standard requiring that all accredited hospitals have a policy prohibiting smoking in the hospital; by 1994, Longo et al.³⁴ found that more than 96% of hospitals surveyed complied with the JCAHO standard, and over 40% had enacted policies that were stricter than the JCAHO standard. In 2002, for the first time, JCAHO added performance measures for adult smoking-cessation advice and counseling for patients presenting with acute myocardial infarction (AMI), community-acquired pneumonia (CAP), and heart failure (HF) to its core performance measure set. From October 2005 to September 2006, national average rates for providing advice or counseling were 96% (AMI), 91% (HF), and 88% (CAP).³⁵

The evidence is clear that hospitalization can be leveraged to help tobacco users successfully quit. Policies and performance measures, such as those adopted by JCAHO, coupled with other systems-level strategies and interventions (e.g., Smith and Taylor, 2006³⁶), can help facilitate change and improve delivery of treatment in the inpatient setting.

Inclusion of Efficacious Tobacco-Dependence Treatments in Insurance Packages

Over the last 15 years, there has been a substantial increase in the coverage of tobacco-dependence treatments by publicly funded insurance programs. In 2005, Medicare began covering cessation counseling for recipients diagnosed with a tobacco-related illness, and in 2006, prescription cessation medications were covered through the Medicare Prescription Drug Act (Medicare Part D). A growing number of state Medicaid programs provide some coverage for tobacco cessation; 42 states currently cover at least one evidence-based treatment.³⁷ In 2006, the Veteran's Administration eliminated co-payments for cessation counseling.

Increases in coverage are also seen in the private market. A periodic survey conducted by AHIP found that health maintenance organization (HMO) plans reporting full coverage for any behavioral or pharmacotherapy increased from 75% in 1997 to 96% in 2003.²⁷ Findings from a 2004 survey of Wisconsin insurers indicate that 74% covered at least one pharmacotherapy and 62% covered at least one behavioral intervention.³⁸ However, a survey conducted by Bondi and colleagues³⁹ in conjunction with the Mercer Group reported that only 20% of employers included cessation coverage as part of covered benefits. As noted by Curry et al.,³⁷ the differences between these two studies may be due to the AHIP survey asking about the bestselling HMO product, yet most U.S. employees receive care through preferred provider organizations (PPOs). Additional research is warranted to better understand trends in coverage both by insurers and employers.

Several studies have demonstrated the use and cost effectiveness of cessation services. A study by Curry et al.¹⁴ compared the use and cost effectiveness of three forms of coverage for smoking cessation services with a standard form of coverage. Smokers with full coverage had the highest rates of use of these services. While quit rates were lower among the group with full coverage compared to the other groups, the higher use rate resulted in more smokers who successfully quit compared to those with a cost-sharing requirement. The per member per month cost ranged from \$0.07 to \$0.41, depending on the nature of the coverage.¹⁴ Other studies also found cessation services to be cost effective.^{11,40,41} The Cochrane Collaboration evaluated the evidence regarding healthcare financing systems for increasing the use of tobacco-dependence treatment and concluded that offering full coverage of tobacco-dependence treatments can increase self-reported prolonged abstinence rates at relatively low costs when compared with a partial benefit or no benefit.²⁰

Researchers have begun to estimate the impact of various tobacco-control policies, including cessation

treatment, on quit rates and smoking prevalence. Levy and colleagues^{17,42} found that cessation treatment had the potential to increase quit rates by 5%–25% and to reduce smoking prevalence by 1%–2%, depending on the breadth of coverage, restrictions on use of such treatments, and support given to healthcare providers. While strategies such as increased excise taxes and clean-air laws were found to have a potentially greater population-wide impact, cessation treatments were noted as a key component of a comprehensive strategy that could be particularly beneficial in reaching low-income and heavy smokers.¹⁷

There is some evidence that full coverage of cessation treatment increases abstinence rates at a modest cost. As policy makers obtain a more robust understanding of the costs associated with tobacco use, policy changes at the federal and state level, as well as initiatives undertaken by states and insurers are helping to reduce cost barriers associated with tobacco-dependence treatment. However, challenges remain in increasing consumer demand for such treatments. Lack of consumer demand for treatment may contribute to insurers' and employers' reticence to provide barrier-free coverage. Curry et al.¹⁴ estimated that 10% of smokers per year would utilize treatment when a full benefit was provided, as compared to 2.4% of smokers with a partial benefit. While this represented a substantial increase in utilization among people with full coverage, significant room for improvement remains.

A related issue is whether consumers are aware that their health insurance includes coverage for tobacco-dependence treatment. A study by Boyle et al.⁴³ found no change in the use of pharmacotherapy or long-term quit rates after implementation of a smoking cessation benefit by two health plans. However, when members were asked if they were aware of the benefit, those who were aware of the benefit were significantly more likely to use the benefit and to make quit attempts; however, long-term cessation rates did not differ significantly. The authors note that greater efforts may be required to educate smokers about the availability of covered benefits in order to see an increase in the use of these benefits.

It is also important to continue efforts to ensure that a greater percentage of employers offer these treatments as part of their basic benefits package. Ensuring that tobacco-dependence treatments are part of basic benefits packages can help reduce barriers to accessing these treatments, particularly cost barriers.

Dedicated Staff to Provide Tobacco-Dependence Treatment

A significant challenge in clinical practice is having sufficient time to completely address patient concerns

and needs. An analysis of the 2004 National Ambulatory Medical Care Survey found that the median office visit lasted 14.7 minutes.⁴⁴ Conceptually, designating a tobacco-dependence treatment coordinator represents an opportunity to implement a team approach to address tobacco use and to systematize how tobacco use is addressed in the healthcare setting. There is evidence demonstrating the effectiveness of clinician intervention in increasing abstinence rates relative to self-help.² Additional evidence supports the use of team-based approaches for treating tobacco dependence, finding that such strategies increased the delivery of behavior change counseling in primary care.⁴⁵ Unfortunately, few health plans have implemented this strategy, nor has it been rigorously evaluated. A 2003 survey conducted by AHIP found that 16.1% of health plans reported having a full- or part-time tobacco-control staffperson, down from a high of 23.5% in 2000.²⁷ Given resource constraints faced by the U.S. healthcare system, it seems unlikely that this area will grow substantially, thus limiting opportunities for further implementation and evaluation of this strategy.

Inclusion of Tobacco-Dependence Treatment Among the Defined Duties of Clinicians and Reimbursing Clinicians for Providing Treatment

Few studies have evaluated the effects of financial incentives and provider reimbursement and the results are mixed.^{46,47} One challenge in attempting to implement and evaluate reimbursement strategies is that few clinicians are aware of a patient's insurance coverage and whether the patient's insurance will reimburse them for providing cessation treatment. As reported by Taylor and Curry,⁴⁷ this lack of information "highlights the importance of uniformity in providing reimbursement across the multiple plans with which providers can contract."

The Medicare program represents an opportunity for further study of this strategy. In 2005, Medicare Part B coverage was expanded and clinicians can be reimbursed for providing intermediate-level or intensive cessation-counseling services. Theoretically, this addresses the issue of uniformity in providing reimbursement raised by Taylor and Curry⁴⁸ for this population. It will be important to monitor the use of these reimbursement codes as well as use of the Medicare pharmacotherapy benefit to see whether this payment strategy increases the provision of cessation counseling services.

Future Directions

Systems changes have the potential to increase rates of tobacco-user identification and intervention, and

subsequently to improve the health of patients by facilitating quit attempts. A growing body of evidence demonstrates the promise of systems approaches and institutionalization of these approaches is essential to their long-term success. Performance measurement, via measures adopted by HEDIS and JCAHO, and evaluation are essential to allow systems to be recognized for areas in which they are doing well or have made improvements, as well as areas requiring additional attention.

Implementation of systems-level changes is not solely the purview of primary care and hospital settings. Improving the delivery of tobacco-cessation interventions in health systems that serve socioeconomically disadvantaged populations is particularly important, given their high rates of smoking.⁴⁹ There is encouraging evidence that health system strategies work in settings like federally qualified health centers.⁵⁰ Moreover, healthcare settings and professions, including dental practices and pharmacies also can effectively implement such strategies.^{51,52} Additional evaluation and dissemination of best practices is essential to facilitate the continued implementation of such strategies throughout the healthcare delivery system.

Despite the tremendous progress in this field over the past 15 years, further work is needed to ensure that all tobacco users are identified and are offered evidence-based treatment for tobacco dependence each time they present to the healthcare system. This goal is particularly salient given that tobacco use is responsible for approximately one third of cancer deaths and approximately 18% of all deaths in the U.S. annually.^{53–57} Further, since over 70% of smokers visit a primary care physician each year,⁵⁸ the healthcare delivery system increasingly must address tobacco dependence and implement evidence-based practices to facilitate delivery of such care. Manley et al.²³ called for health plans to become more actively involved in tobacco control and proposed a model—the 5C's (covering, counseling, capitalizing, collaborating, and counting) to facilitate their involvement.

In addition to the model proposed by Manley et al.,²³ several authors have identified key healthcare-systems research questions to better understand how to foster the routine assessment and addressing of tobacco use and dependence.^{18,48} Health services researchers and funders may wish to target some or all of these questions.

- Systems approaches such as tobacco-user identification are successful in improving documentation of patients' tobacco use, but do not necessarily result in further intervention. What strategies can be implemented and evaluated to foster provision of quit assistance and follow-up for patients who smoke?

- What are the most and least effective combinations of services in multicomponent interventions?
- How can population-based treatments such as quit-lines or web-based cessation services be integrated into clinical systems?
- How effective are the HEDIS and JCAHO measures in improving patient receipt of evidence-based treatment for smoking cessation and patient tobacco use cessation?
- What would be the impact of a JCAHO requirement mandating that tobacco use be addressed for all hospital admissions?
- How does the base rate of tobacco use in a managed care organization or insurance plan affect implementation of systems-level changes and outcomes?
- How can different types of tobacco-cessation interventions be most effectively integrated in managed care organizations?
- What are the costs, cost-benefit, and return on investment of system-level interventions?
- How can technologies such as patient registries and electronic medical records be used to facilitate delivery of evidence-based tobacco-dependence treatment?

Systems changes hold great promise and offer significant opportunities for addressing tobacco use in the healthcare delivery system. It is incumbent on all of us—researchers, policy makers, healthcare systems leaders, healthcare professionals, and advocates—to continue and expand efforts to ensure that tobacco use is addressed systematically throughout the healthcare delivery system. It is also our responsibility to continue to evaluate such strategies and share lessons learned and promising practices, to allow all patients—regardless of the type of healthcare delivery system they encounter—to receive evidence-based interventions that foster tobacco-use cessation.

Preparation of this paper was supported by Robert Wood Johnson Foundation grant #48283, Addressing Tobacco in Healthcare Research Network.

Over the last 5 years, Dr. Fiore has received honoraria for lectures and consulting fees from Pfizer and GlaxoSmithKline. In December 2005, he ceased accepting honoraria or consulting fees from pharmaceutical companies. Over the last 5 years, he has served as an investigator on research studies at the University of Wisconsin that were funded wholly or in part by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Nabi. In 1998, the University of Wisconsin (UW) appointed Dr. Fiore to a named Chair, made possible by an unrestricted gift to UW from GlaxoWellcome.

Ms. Keller has not accepted compensation or honoraria from the pharmaceutical industry. In the last 5 years, Ms. Keller served as a nontestifying consultant for the Department of Justice in its case against the tobacco companies.

Dr. Curry has received consulting fees and honoraria, as well as reimbursement for conference attendance from either

References

1. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking cessation: Clinical practice guideline No. 18. Rockville MD: U.S. Department of Health and Human Services (USDHHS), Public Health Service (PHS), Agency for Health Care Policy and Research, 1996.
2. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville MD: USDHHS, PHS, 2000.
3. Fiore MC, Jorenby DE, Schenky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: Impact on assessment and intervention with patients who smoke. *Mayo Clin Proc* 1995;70:209–13.
4. Ahluwalia JS, Gibson CA, Kenney RE, Wallace DD, Resnicow K. Smoking status as a vital sign. *J Gen Intern Med* 1999;14:402–8.
5. Chang HC, Zimmerman LH, Beck JM. Impact of chart reminders on smoking cessation practices of pulmonary physicians. *Am J Respir Crit Care Med* 1995;152:984–7.
6. Robinson MD, Laurent SL, Little JM, Jr. Including smoking status as a new vital sign: it works! *J Fam Pract* 1995;40:556–61.
7. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. *Health Aff (Millwood)* 2001;20:64–78.
8. Orleans CT, Kristeller JL, Gritz ER. Helping hospitalized smokers quit: new directions for treatment and research. *J Consult Clin Psychol* 1993;61:778–89.
9. Joint Commission on Accreditation of Health Care Organizations. A comprehensive review of development and testing for national implementation of hospital core measures. Available online at: <http://www.jointcommission.org>.
10. Coffield AB, Maciosek MV, McGinnis JM, et al. Priorities among recommended clinical preventive services. *Am J Prev Med* 2001;21:1–9.
11. Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. *Inquiry* 2004;41:57–69.
12. Maciosek MV, Edwards NM, Coffield AB, et al. Priorities among effective clinical preventive services methods. *Am J Prev Med* 2006;31:90–6.
13. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: Smoking cessation intervention strategies for adults and adults in special populations. *Ann Intern Med* 2006;145:845–56.
14. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. *New Engl J Med* 1998;339:673–9.
15. Henry RC, Ogle KS, Snellman LA. Preventive medicine: Physician practices, beliefs, and perceived barriers for implementation. *Fam Med* 1987;19:110–3.
16. Logsdon DN, Lazaro CM, Meier RV. The feasibility of behavioral risk reduction in primary medical care. *Am J Prev Med* 1989;5:249–56.
17. Levy DT, Chaloupka F, Gitchell J. The effects of tobacco control policies on smoking rates: a tobacco control scorecard. *J Public Health Manag Pract* 2004;10:338–53.
18. Hopkins DP, Briss PA, Ricard CJ, et al. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. *Am J Prev Med* 2001;20(2S):16–66.
19. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev* 2003(3):CD000259.
20. Kaper J, Wagena EJ, Severens JL, Van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. *Cochrane Database Syst Rev* 2005;(1):CD004305.
21. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev* 2007;(3):CD001837.
22. Hopkins DP, Husten CG, Fielding JE, Rosenquist JN, Westphal LL. Evidence reviews and recommendations on interventions to reduce tobacco use and exposure to environmental tobacco smoke: a summary of selected guidelines. *Am J Prev Med* 2001;20(2S):67–87.
23. Manley MW, Griffin T, Foldes SS, Link CC, Sechrist RA. The role of health plans in tobacco control. *Ann Rev Public Health* 2003;24:247–66.
24. Stevens VJ, Solberg LI, Quinn VP, et al. Relationship between tobacco control policies and the delivery of smoking cessation services in nonprofit HMOs. *J Natl Cancer Inst Monogr* 2005;75–80.
25. Piper ME, Fiore MC, Smith SS, et al. Use of the vital sign stamp as a systematic screening tool to promote smoking cessation. *Mayo Clin Proc* 2003;78:716–22.
26. Boyle R, Solberg LI. Is making smoking status a vital sign sufficient to increase cessation support actions in clinical practice? *Ann Fam Med* 2004;2:22–5.
27. McPhillips-Tangum C, Rehm B, Carreon R, Erceg CM, Bocchino C. Addressing tobacco in managed care: results of the 2003 survey. *Prev Chronic Dis* 2006;3:A87.
28. National Committee for Quality Assurance. The state of health care quality—2006. Available online at: <http://web.nca.org/tabid/447/Default.aspx>.
29. Swartz SH, Cowan TM, DePue J, Goldstein MG. Academic profiling of tobacco-related performance measures in primary care. *Nicotine Tob Res* 2002;4(Suppl. 1):S38–44.
30. McAfee T, Grossman R, Dacey S, McClure J. Capturing tobacco status using an automated billing system: Steps toward a tobacco registry. *Nicotine Tob Res* 2002;4(Suppl. 1):S31–7.
31. Andrews JO, Tinggen MS, Waller JL, Harper RJ. Provider feedback improves adherence with AHCPR Smoking Cessation Guideline. *Prev Med* 2001;33:415–21.
32. Bentz CJ, Bayley KB, Bonin KE, et al. Provider feedback to improve 5A's tobacco cessation in primary care: a cluster randomized clinical trial. *Nicotine Tob Res* 2007;9:341–9.
33. Brown DW, Croft JB, Schenck AP, Malarcher AM, Giles WH, Simpson RJ Jr. Inpatient smoking-cessation counseling and all-cause mortality among the elderly. *Am J Prev Med* 2004;26:112–8.
34. Longo DR, Feldman MM, Kruse RL, Brownson RC, Petroski GF, Hewett JE. Implementing smoking bans in American hospitals: Results of a national survey. *Tob Control* 1998;7:47–55.
35. Joint Commission on Accreditation of Healthcare Organizations. University of Wisconsin Hospitals and Clinics Authority Quality Report. Available online at: <http://www.qualitycheck.org>.
36. Smith PM, Taylor CB. Implementing an inpatient smoking cessation program. Mahwah NJ: Lawrence Erlbaum, 2006.
37. Curry SJ, Orleans CT, Keller P, Fiore MC. Promoting smoking cessation in the health care environment: Ten years later. *American J Prev Med* 2006;31:269–72.
38. University of Wisconsin Center for Tobacco Research and Intervention. Tobacco treatment coverage by Wisconsin health plans, 2002 and 2004. Available online at: <http://www.ctri.wisc.edu/Publications/publications/Insurance6.09.05.pdf>.
39. Bondi MA, Harris JR, Atkins D, French ME, Umland B. Employer coverage of clinical preventive services in the United States. *Am J Health Promot* 2006;20:214–22.
40. Schauflyer HH, McMenamin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J. Variations in treatment benefits influence smoking cessation: Results of a randomised controlled trial. *Tob Control* 2001;10:175–80.
41. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence and implications for coverage. *Pharmacoeconomics* 1997;11:538–49.
42. Levy DT, Nikolayev L, Mumford E, Compton C. The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States). *Cancer Causes Control* 2005;16:359–71.
43. Boyle RG, Solberg LI, Magnan S, Davidson G, Alesci NL. Does insurance coverage for drug therapy affect smoking cessation? *Health Aff (Millwood)* 2002;21:162–8.
44. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2004 summary. *Adv Data* 2006;374:1–33.
45. Dickey LL, Gemson DH, Carney P. Office system interventions supporting primary care-based health behavior change counseling. *Am J Prev Med* 1999;17:299–308.
46. Latts LM, Prochazka AV, Salas NM, Young DA. Smoking cessation in pregnancy: failure of an HMO pilot project to improve guideline implementation. *Nicotine Tob Res* 2002;4(Suppl. 1):S25–30.
47. Roski J, Jeddeloh R, An L, et al. The impact of financial incentives and a patient registry on preventive care quality: increasing provider adherence to evidence-based smoking cessation practice guidelines. *Prev Med* 2003;36:291–9.
48. Taylor CB, Curry SJ. Implementation of evidence-based tobacco use cessation guidelines in managed care organizations. *Ann Behav Med* 2004;27:13–21.
49. Centers for Disease Control and Prevention (CDC). Tobacco use among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:1145–8.
50. Fisher E, Musick J, Scott C, et al. Improving clinic- and neighborhood-based smoking cessation services within federally qualified health centers serving low-income, minority neighborhoods. *Nicotine Tob Res* 2005;7(Suppl. 1):S45–56.

51. Albert DA, Ahluwalia KP, Ward A, Sadowsky D. The use of 'academic detailing' to promote tobacco-use cessation counseling in dental offices. *J Am Dent Assoc* 2004;135:1700–6.
52. Hudmon KS, Kroon LA, Corelli RL, et al. Training future pharmacists at a minority educational institution: evaluation of the Rx for change tobacco cessation training program. *Cancer Epidemiol Biomarkers Prev* 2004;13:477–81.
53. USDHHS. The health consequences of smoking: A report of the Surgeon General. Atlanta GA: USDHHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
54. McGinnis JM, Foege WH. Actual causes of death in the United States. *JAMA* 1993;270:2207–12.
55. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA* 2004;291:1238–45.
56. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. Lyon: International Agency for Research on Cancer, 2004.
57. American Cancer Society. Cancer prevention and early detection: Facts and figures, 2005. Atlanta GA: American Cancer Society, 2005.
58. CDC. Physician and other health-care professional counseling of smokers to quit – United States, 1991. *MMWR Morb Mortal Wkly Rep* 1993;42:854–7.

Quitlines

A Tool for Research and Dissemination of Evidence-Based Cessation Practices

Timothy A. McAfee, MD, MPH

Abstract: Quitlines in the United States have grown dramatically over the past 15 years, from one state and a handful of health plans to all 50 states and over 200 health plans and employers. Over half a million tobacco users received help from state quitlines alone in 2005. Research to confirm and improve quitline effectiveness also has burgeoned, with multiple meta-analyses confirming a dose-related treatment effect. Quitlines are increasing the depth and breadth of services offered, including the integration of medication support and other electronic communication mediums such as web and e-mail.

Quitlines have the capacity to serve a larger fraction of the population than they currently serve. Accomplishing this is dependent on creating ambitious, multi-institution funding and delivery mechanisms, as well as further research and development to improve reach, effectiveness, and efficiency.

(*Am J Prev Med* 2007;33(6S):S357–S367) © 2007 American Journal of Preventive Medicine

Background

Despite decades of research and dissemination effort, use of evidence-based counseling support by those trying to quit smoking is infrequent. Only around 1% of smokers trying to quit report receiving any behavioral assistance beyond static printed materials.¹ One bright spot in this otherwise grim picture is the recent marked increase in the availability and use of a new medium for receiving behavioral support: the telephone.

In 1992, California had the only state-level quitline in the United States, with just a handful of health plan quitlines. By 2006, there were quitlines in all 50 states, all ten Canadian provinces, and 30 other countries, as well as over 200 employer and health plan quitlines. That year over half a million people received services from the U.S. state quitlines alone.² What explains this relatively rapid dissemination, and what lies ahead?

Quitlines provide a broad range of cessation-support services, primarily via the telephone. Services range from a single brief reactive coaching session provided at the time a caller reaches the quitline, to in-depth counseling via multiple proactive follow-up calls originating from the service provider, with pharmacotherapy mailed directly to the caller's home. Most counseling is provided by paraprofessionals following a semi-structured

protocol giving practical advice, encouragement, and assistance based on the evidence-based findings of the U.S. Public Health Services (USPHS) Clinical Practice Guideline.³ For example, callers are encouraged to set a quit date, remove smoking paraphernalia from their home and car, strive for total abstinence, and anticipate future triggers or challenges. They may receive problem-solving and skills training based on reviews of past quit attempts. In their provision of social support, phone counselors often blend elements of several counseling theories and approaches (i.e., Cognitive-Behavioral Therapy,⁴ Stages of Change,⁵ Motivational Interviewing,⁶ Solution-Focused Therapy⁷). Increasingly, cessation medication is being integrated into service provision,^{8,9} ranging from screening and decision support to fulfillment via mail order or pharmacy vouchers.¹⁰ Quitlines often provide brief coaching to proxy callers such as friends and relatives as well as healthcare providers. They also provide callers with cessation materials and referral to local resources.

Quitlines are a robust and promising venue for the rapid pursuit of practical behavioral and translational pharmacologic research. The large number of tobacco users receiving services based on centralized computer-driven protocols provides numerous opportunities to conduct large randomized and quasi-experimental trials. The 2006 Cochrane Review found 48 phone-based cessation studies meeting its strict criteria for evidence review, examining outcomes for 36,000 callers.¹¹ Numerous opportunities also exist to analyze results of natural experiments growing out of variations in service-provision policies in different settings and over time.

From the Department of Health Services, School of Public Health, University of Washington, Seattle, Washington

Address correspondence and reprint requests to: Timothy A. McAfee, MD, MPH, Free & Clear, Clinical and Behavioral Sciences, 999 Third Avenue, Suite 2100, Seattle WA 98104. E-mail: Tim.McAfee@freeclear.com.

This article reviews the evidence base and benefits of quitlines, as well as how services are delivered and promoted. The evolving role of public-private partnerships is examined, followed by an exploration of five policy and implementation challenges quitlines face in the future. Ten opportunities for development and research are then presented, focusing primarily on the U.S.

Evidence Summary

A strong evidence base supports quitline efficacy and effectiveness.^{12,13} The 2006 Cochrane Review found a 1.41 odds ratio (OR) (95% confidence interval [CI]=1.27–1.57) for long-term cessation for people receiving phone counseling compared to people trying to quit without counseling assistance.¹¹ A meta-regression detected a significant association between the maximum number of planned calls and effect size. The Cochrane Review concluded that: “Proactive telephone counseling helps smokers interested in quitting. There is evidence of a dose response; one or two brief calls are less likely to provide a measurable benefit. Three or more calls increase the odds of quitting compared to a minimal intervention such as providing standard self-help materials, brief advice, or compared to pharmacotherapy alone. Telephone quitlines provide an important route of access to support for smokers, and callback counseling enhances their usefulness.” Similar findings and conclusions resulted from earlier meta-analyses¹⁴ including ones conducted by the U.S. Preventive Services Task Force,¹⁵ the USPHS Clinical Practice Guideline,³ and the U.S. Community Preventive Services Task Force.¹⁶

The cost effectiveness of cessation treatment in general is well-established, with actual positive return on investment in worksite settings¹⁷ and one of the best cost-effectiveness ratios for any preventive or healthcare intervention from a healthcare^{18,19} perspective. Quitlines generally have similar costs and deliver similar quit effects as in-person interventions. A number of cost-effectiveness analyses have looked specifically at quitlines and have found them to be highly cost effective compared to most other healthcare or preventive interventions, even for modest increases in quit rates, with incremental costs to achieve a quit in the several thousand dollar or less range.^{20–23}

The interrelationship between the benefits of medication and the benefits of phone coaching is an area of some controversy. Most drug trials have embedded large doses of behavioral counseling (e.g., 25 brief sessions in Phase III varenicline trials^{24,25}), but most people using the medications in the real world do so without any counseling. Some insurance companies and states have strongly encouraged and even required quitters using medications also to receive some counseling, hoping to maximize quit success. Others have

argued against this approach, concerned that it will decrease use of medications, although there is no evidence to support this decrease for phone counseling.²⁶ There has also been some concern as to how much additional benefit is added by providing counseling for those using medications. In four large trials, Swan,¹⁰ Zhu,¹² Hollis,²² and McLeod²⁷ all found that repeated phone counseling increased the long-term effectiveness of cessation medications, although three much smaller studies (one had less than 40 phone users/cell) found no benefit.^{26,28,29}

Data on the demographics and smoking characteristics of quitline callers are collected at the state level, but have not yet been collated nationally. The California Smoker’s Helpline found that compared to users of other forms of cessation assistance, callers to quitlines tended to be younger, more evenly divided between men and women, and more racially and ethnically diverse, with African Americans calling the quitline at twice the expected rate.^{30,31} The New Zealand Quitline found a 67% increase from 2001 to 2005 in the number of under-25 smokers and a doubling in pregnant women callers.³² Many quitlines provide special services to those who are uninsured and on Medicaid, and these groups are often overrepresented in quitline callers.³³

Benefits of Quitlines

Quitlines help increase the reach of evidence-based services by increasing convenience and anonymity, and by providing multilingual services. They provide extended hours of operation and centralized quality control, and eliminate transportation barriers more easily than many face-to-face cessation services. They can help people gain access to pharmacotherapy as well as the behavioral and adherence support that maximize medication effectiveness. Quitlines provide a centralized triage point for all cessation services in a region. They can enhance population quit rates in clinical practices (e.g., from 4.1% to 13%³⁴), worksites, and geographic regions. This may be accomplished by direct effects for those calling, as well as by secondary effects such as inspiring quit attempts in noncallers exposed to promotion,³⁵ enabling clinicians to intervene more routinely with smokers, and encouraging legislators to continue funding multicomponent tobacco-control programs.

How Quitline Services Are Delivered and Financed

There is wide variation in the U.S. in the populations that quitlines serve, who delivers the services, and how they are financed. Quitlines have been set up to deliver services to all residents in some municipalities and counties, and in all states. Some limited services for special populations, such as pregnant women, have been provided at the national level. Quitlines also may

provide services to health plan members, employees, or union members. Services are delivered by a wide variety of providers, including academic and healthcare institutions, governmental and philanthropic organizations, as well as private companies, including wellness and disease management.

Financing for quitline services varies significantly including: (1) state funding from tobacco taxes, Master Settlement, and general funds; (2) health plans through benefit coverage or administrative services; (3) employer coverage as a health or wellness “carve-out”; (4) Federal funding to support state services and a single-number national triage function; (5) philanthropic support underwriting indirect service costs, serving special populations and promotions; and (6) financing for the development and research base for quitlines that have come from eclectic sources, including the National Institutes of Health (NIH) and other federal agencies, philanthropic organizations, state health departments, private investors, and healthcare systems.

Elements of service also can vary widely (see Table 1). Based on evidence that end-user payment markedly decreases use,²¹ very few quitlines charge users for service. States are spending over \$40 million/year on service provision (based on state self-report survey data showing a mean of \$828,000/year), which represents about 7% of their tobacco-control budgets (see Table 2).

How Quitlines Promote Services

A broad range of marketing techniques has been used to generate calls to quitlines. State-level quitlines initially relied primarily on mass media ads, especially television. This medium has proven reliable for call generation, but is quite expensive per call generated, sometimes requiring as much investment to generate a call as is spent on providing service for the caller. In addition, the promotional effect tends to be short-lived, tailing off after a few days or weeks. However, many state health departments believe that there are ancillary benefits to these mass media promotional campaigns, including exposure to important public health messages and increased quit attempts in the population.

Table 1. Quitline service delivery mechanisms

Who delivers	What is delivered
• States	• Reactive coaching
• Federal agencies	• Materials fulfillment
• Health plans	• Proactive coaching
• Employers	• Community referrals
• Philanthropies	• Interactive recorded messages
• Health systems	• Provider referrals
• Stand-alone companies	• Nicotine replacement therapy
• Universities	• Bupropion and varenicline decision support
• Disease management	• Integrated Web services

Table 2. Budget and utilization for state-level quitlines, July 2004 to June 2005 (\$)

	Quitline service (n=44)	Quitline promotion (n=32)	Tobacco control (n=43)
Range	40K–4.2M	20K–5.5M	280K–93.4M
Mean	828K	817K	12.6M
Median	622K	206K	6.1M

Note: Live calls to all quitlines numbered approximately 500,000 during the year.

Source: North American Quitline Consortium Survey.

Other common forms of promotion by state quitlines include: (1) outreach to health plans, hospitals, and medical groups; (2) outreach to local health department personnel and community organizations; (3) enhancement of “viral” marketing to encourage peer referrals, such as including pocket cards with the quitline number in materials sent to callers; (4) use of brief courses of nicotine replacement as an inducement to call, relying on earned media and word of mouth; and (5) inclusion of quitline information in targeted mailings, such as to Medicaid recipients. Many mature state quitlines have seen a shift in the mix of caller referral source over time, with a larger fraction made up of referrals from friends, family, and healthcare providers.

Public–Private Partnerships

There are increasingly sophisticated public–private partnerships extending the depth and breadth of services offered. Integration often occurs at the state level, with another layer at the national level. As of July 1, 2006, every state in the U.S. has some form of operational quitline. The National Cancer Institute (NCI) and the Centers for Disease Prevention and Control (CDC) have collaborated with states to create a formal national network of quitlines, with a single number (1–800–QUITNOW) available as a portal that automatically routes calls back to their respective state quitlines. There is not yet funding to support an ongoing paid national promotional campaign, although a public service announcement campaign is being developed to be made available by NCI in 2007.

Some states such as New York, Minnesota, Ohio, Oregon, Utah, and Washington are collaborating further with health plans and businesses that provide and/or fund in-depth telephonic coaching services and full pharmacotherapy. In these states, callers to the state quitline who have private health plan or employer-based cessation phone and pharmacotherapy benefits are triaged via a “warm transfer.” The caller stays on the line while the state operator connects them directly to the quitline service provider for the health plan or employer, with the operator staying on the line to confirm connection. These state lines thereby conserve limited government resources and thus can provide more full proactive service and

pharmacotherapy for those without alternate funding sources, such as the uninsured. Other states such as Massachusetts are providing state-supported proactive phone counseling services to health plan members if the health plans provide full pharmacotherapy. States that do not have these types of relationships frequently have to cut back on quitline promotion to ensure they have sufficient funds to provide services to callers or provide lesser service to some callers (such as a single call) as demand outstrips funding.

These ambitious, complex partnerships have been fostered by the creation of a North American Quitline Consortium (NAQC).³⁶ NAQC was initially supported through funding from the American Legacy Foundation (ALF) and is now incorporated as a separate nonprofit corporation with multiple funding sources. NAQC includes Federal agencies such as NCI and CDC, state health departments, state-level foundations set up to administer tobacco settlement funds, cessation-service providers, and researchers. Analogous Canadian institutions and researchers have been members since NAQC's inception, and Mexico will likely join in 2007. NAQC has provided a forum linking those involved in researching, overseeing, and operating quitlines, and conducts a yearly survey of all quitlines in North America and Europe.³⁷

A limitation affecting public-private partnership efforts in the U.S. has been the heterogeneity of services, promotion, and funding at the state level, as some states provide only limited services, (i.e., a single call, with minimal promotion) while other states provide robust promotion and services (either through direct provision such as in Maine, or via public-private partnerships as described above). Call rates range from less than 1% of smokers/year to over 8%³⁸ at the state level. Australia and the United Kingdom, during periods of more marketing and service funding, have averaged 4%–6%.^{39,40} Some employer-phone programs have reached into the 20% level, when combined with incentives such as healthcare premium differentials and smoke-free campuses.⁴¹

The heterogeneity of state funding has led to challenges implementing a national-level promotional campaign since many states do not have funds budgeted to handle increased demand. In 2006 and 2007, ALF is running mass media campaign pilots in four metropolitan areas that will include promotion of the 1-800-QUITNOW number. If successful, the pilot will be followed by a national media campaign, funded jointly by ALF and states.

Five Policy and Implementation Challenges for the Future

1. Under-utilization

The biggest current challenge for quitlines is that despite dramatic growth over the past decade, they are

under-utilized compared to their potential. This under-utilization is in part related to decisions by sponsoring organizations not to maximize participation, due to lack of sufficient funding to support both promotion and service provision.

The National Action Plan,⁴² created by the Subcommittee on Cessation of the Interagency Committee on Smoking and Health, convened by former U.S. Department of Health and Human Services (USDHHS) secretary Tommy Thompson, predicted that with unfettered access to proactive telephone counseling and pharmacotherapy coupled with robust promotion, at least 10% of smokers/year would use phone services nationally, with a 20% quit rate. This is a fivefold to tenfold increase over current use rates. From experience to date, this number appears ambitious, but achievable with markedly improved funding and sufficient infrastructure development. The Plan called for funding from a national cigarette tax to create a delivery and promotion infrastructure capable of actually reaching this level of promotion and use. It estimated that such an initiative could result in one million smokers quitting per year. Although there was support for the concept of such a bold societal intervention, there has not been funding support at the federal level beyond \$25 million by the NCI and CDC to support the 1-800-QUITNOW infrastructure and to create initial capacity in states without a quitline. Therefore, a critical challenge at this point is the further evolution of existing services and the creation of a mechanism to actually fund, promote, and deliver these services at a level that creates a more significant public health impact.

2. Who Funds and Delivers Services?

Initiatives begun at higher levels to fund and deliver quitline services run the risk of undercutting motivation for local or parallel efforts. For example, before the implementation of the National Network of Quitlines concept, several state legislatures opted to not fund state quitline activity and rather to rely on an NCI-funded "free" quitline service. Some regional health plans have decided to not cover phone and pharmacotherapy for their smokers as long as they can refer them to their state quitlines. If the higher-level services are robustly funded for service provision and promotion, these negative consequences may not outweigh the benefits of more uniform service access. However, the current reality is that services and promotion are diffusely underfunded. Having any institutional player opt-out decreases the fraction of smokers who receive services. This is particularly unfortunate if a lower-level or lateral potential funder is more motivated to achieve higher utilization rates. For example, employers stand to gain when an employee quits smok-

ing from both healthcare utilization decreases and improved productivity.⁴³

In addition, there are certain quitline functions that may be more achievable at specific institutional levels or when delivered by specific entities. For example, coordinating referrals to local resources and integrating a quitline into local tobacco-control campaigns may be more practical when delivered at a state level. Leveraging quitline availability to increase healthcare provider compliance with quality guidelines³ that encourage clinician identification and intervention with tobacco users may be more achievable with a health plan-administered quitline. Employers can provide participation incentives that are impractical at the state level.

In the absence of a dramatic breakthrough at the national level, such as a dedicated increase in the cigarette tax or a favorable ruling or settlement in the appeal of the Department of Justice case suing the tobacco industry, one can probably expect only evolution, not revolution, in funding support.

3. Creating Demand for Services

There is a related challenge to discover more effective and efficient means of creating demand for quitline services. Surveys indicate that most smokers are either unaware of the existence of quitlines⁴⁴ or, if they are aware, have little idea what type of service is available. Some fear they will be lectured if they call. Promotion campaigns that demystify and normalize getting help from a quitline are in the planning stages.

There is one straightforward policy solution to markedly increase demand that has been tested in several other countries, including Australia, Brazil, parts of the United Kingdom, and the Netherlands⁴⁵ requiring tobacco companies to place a national quitline number on all cigarette packs. This strategy has resulted in dramatic increases in call volumes at no promotional cost. For example, Brazil requires that tobacco companies print the national quitline number on every cigarette pack with large graphics, resulting in enormous call volumes (averaging over 2 million/year, more than the rest of the world combined).⁴⁶ This represents approximately 7% of their smoking population.

4. Cost of Service Comparison Issues

As with in-person interventions, quitlines cost more to deliver than wholly-automated services such as recorded messages and stand-alone websites due to personnel costs. However, the evidence base for recorded messages is nonexistent, and the evidence for stand-alone web interventions is nascent, with small effect sizes (see below). For many smokers, web-only interventions are unlikely to be acceptable as a complete substitute for human interaction.

Quitlines may be more expensive per quit than public policy changes that make continued smoking more onerous, such as increases in cigarette prices and clean indoor-air ordinances. Although primarily aimed at protecting nonsmokers, clean indoor-air ordinances and policies also denormalize smoking. Worksite smoking bans have been proposed as being more cost effective than cessation treatment as a means of getting individuals to quit.⁴⁷ However, public policy changes that make continued smoking more difficult can go only so far. In addition, policies that make it more challenging for people to smoke, without providing them with the tools to quit more effectively, inadvertently may discriminate against the most-vulnerable smokers, such as the highly addicted, poor, and those with psychiatric diagnoses, who find it harder to quit and have less access to help. Ideally, this is not an either/or question. When New York City went smoke-free in 2002, it simultaneously made nicotine patches and telephone counseling available, and saw the biggest decline in prevalence ever over a 1-year period recorded.⁴⁸

It may be more appropriate to compare quitline costs, especially when delivered by health plans or employers or when funded through tobacco taxes or settlement dollars, to other healthcare service costs that add life-years to smokers. When compared to interventions such as lung transplants, lung-computed tomography screening, and coronary artery bypass, quitline costs are a clear bargain. For example, single-lung transplants, which may be performed in endstage chronic obstructive pulmonary disease (COPD) patients, result in an average increase in quality-adjusted life-years (QALY) of 2.1.⁴⁹ Transplants can cost hundreds of thousands of dollars per surgery, and the cost per QALY is estimated at \$48,241. In comparison, phone counseling and medication support for quitting smoking cost well under \$500, and add 3 to 10 years to life expectancy.^{20,50}

5. Limitations of Quitlines

There are limitations to what can be accomplished via remote interactions. Some deeper nonverbal interaction cues are lost, although some smokers may prefer the increased anonymity of the phone. Current regulatory requirements make it more difficult to generate a prescription or to bill for services via the phone. For example, Medicare recently provided some coverage for tobacco treatment, but specifically excluded direct phone-only service.⁵¹ This decision was not based on concerns about effectiveness, but rather on general Medicare policies that do not allow reimbursement for any services delivered over the phone other than minimal follow-up for covered face-to-face encounters with a physician or psychologist.

A related concern sometimes expressed about quitlines is that they may diminish utilization of community-based in-person services. There is no published evidence to support or refute this concern, and even if true, no evidence to support this being a public health issue in terms of net benefit to the individual or society. Most quitlines maintain databanks of available community resources, and part of the intervention process includes exploring interest in nonphone services. These databanks usually include health department-supported programs, voluntary programs (such as groups run by the cancer, heart, and lung associations), health plan and employer programs, and private programs. Some quitlines have formal triage processes where individuals are queried as to their interest in web, phone, and in-person support. Given the very low utilization and promotion of in-person cessation programs, it is possible the availability of a line with triage capability actually could increase uptake of these services. However, the California Smoker's Helpline looked at callers referred to community resources, and found only 6% actually followed-up with referrals.⁵² Finally, there is some evidence that the availability of telephone support for those interested in quitting actually may increase healthcare provider delivery of brief interventions to smokers in busy clinics, as recommended by tobacco guidelines.

Top Ten Development and Research Opportunities for Quitlines

Promising innovations could increase the reach, effectiveness, and efficiency of quitlines even further. However, these need additional development and research. Ten of these are outlined below.

1. Use of a Chronic Care/Disease Management Approach with Quitlines

The USPHS Clinical Practice Guideline states that "tobacco dependence shows many features of a chronic disease."³ In the past 5 years, considerable progress has been made organizing medical care for patients with chronic conditions in a more effective manner. This includes employing centralized disease management services that proactively use databases to identify people who are likely to benefit from services, and then enrolling the high-risk individuals in phone outreach programs via "opt-out" models that assume they will consent to receipt of services. A chronic care model that emphasizes restructuring the delivery model for primary care to focus on proactive management has also been developed and studied.⁵³

To date most quitline activity has been delivered using an extended "episodic care" model. Individuals are recruited via mass media or other promotions. After

enrolling, callers are supported for their initial quit attempt with "relapse-sensitive" call schedules heavily weighted toward the first month or two. The 70% to 90% of participants who relapse at any time in the process are considered treatment failures, but typically no modification in protocol or provision of additional services is provided. It is left up to the individual to call back at a future time to re-enroll, and in some instances there are limits on how soon this can be done. This model may not provide optimal service, given the chronic, relapsing nature of nicotine dependence and the very high stakes involved. In fact, it is now known that most smokers who have relapsed are interested in making another quit attempt almost immediately.⁵⁴ Given the considerable costs for promoting use of services, it may be ill-advised to continue to ignore smokers who have relapsed.

A number of alternative approaches with attributes of chronic care management are under development and investigation, including: (1) proactive outreach to high-risk populations such as asthmatics, diabetics, COPD patients, and pregnant women, where smoking status may be available; high acceptance rates (exceeding 50%) have been seen in population-based nonvolunteer recruitment studies of smokers offered proactive phone counseling⁵⁵; (2) long-term follow-up and open-ended treatment, e.g., recurrent status checks with offers of re-enrollment for those who have relapsed; and (3) tighter integration with medical care, such as inserting chart notes into electronic health records with participating healthcare systems.

2. Integration of Phone Services with Other Remote Communication Media

Research in the area of integration and communication should focus primarily on: (1) web-based tailored content, social interaction via chat and discussion functions, and iterative quit plan interactive development tools; and (2) text messaging, cell phones, e-mail, and gaming.

The evidence base for these mediums is not as well established as the evidence base for phone counseling, but is growing. For example, a number of randomized trials have found modest but statistically significant improvements in quit rates for intervention participants who complete a fairly extensive survey, then receive deeply tailored cessation text and images at a website based on their answers.⁵⁶ Other forms of web support that focus on enhancing a participant's social support while providing a user-driven flexible menu of cessation information and exercises have less evidence. A large six-cell trial found a difference of a few percentage points, but only in a secondary analysis of the sites that were used more heavily.⁵⁷ Text messaging over cell phones was shown to be effective in creating a short-term (3-month) increased quit rate in a randomized

trial in New Zealand, including Maori users.⁵⁸ Although there is a strong established evidence base for phones that does not yet exist for these new media, they have potential advantages over standard phone-only quitlines, meriting further development and testing. For example, the new mediums: (1) may be cost effective in generating population-level quit attempts because they rely less on paid cessation counselors for delivery, even if the incremental quit rate improvement is modest; (2) are easily scalable; (3) are much more interactive and allow for more tailoring to the individual than printed materials; and (4) may appeal to people who enjoy new communications technology, or who find even phone counseling intimidating.

There have been no trials completed to date that examine more advanced, seamlessly integrated services that leverage the advantages of human interaction via phone, instant messaging, and e-mail with the efficiency of web-based and other e-communication encounters that do not require live input. However, several studies and development projects are underway, including randomized trials comparing modalities.

3. Further Integration and Innovation of Pharmacotherapy and Quitlines

The initial studies establishing quitline effectiveness predated pharmacotherapy, so there is a firmly established independent effect on long-term cessation achieved by phone coaching alone. Over the past 5 years, there has been increasing interest in using quitlines to address some of the challenges of how pharmacotherapy is used (or not used) in the real world.⁵⁹ These challenges include increasing proper use and adherence, ensuring quitters receive some instruction on the nonpharmacologic aspects of quitting, and increasing the fraction of quitters who use pharmacotherapy. Exactly how best to do this remains uncertain.

The following research areas are particularly in need of additional innovation and research: short-term nicotine replacement therapy (NRT), tighter relationships with healthcare providers to ease access to prescription-only medications for smoking cessation, and the safety, efficacy, and practicality of more aggressive pharmacotherapy approaches.

Offering brief courses of NRT through quitlines may be a more cost-effective way of generating calls than the use of mass media, and result in higher quit rates. New York City saw a marked increase in call volumes with a free patch offer in 2004, with almost 400,000 callers.³ New York State examined the cost effectiveness of time-limited nicotine patch promotions versus traditional media promotion and found patch promotion to be highly cost effective.⁶⁰ Minnesota⁶¹ and Oregon⁶² also saw a marked increase in calls based solely on earned (nonpaid) media announcing patch availability.

There are less data on the relative cost effectiveness of short courses of NRT versus longer courses.

Research and innovation are also needed to forge tighter relationships with healthcare providers to increase ease of prescription medication access. Many quitlines have determined ways to connect medically appropriate callers directly with over-the-counter medications without requiring a physician visit, using careful protocol screening and mail order or pharmacy voucher fulfillment. A handful of integrated healthcare systems with phone counseling programs have created fulfillment protocols that include physician prescription authorization.

Finally, research should also encompass the testing of safety, efficacy, and practicality of aggressive cessation pharmacotherapy approaches, including: combination and higher-dose therapy, initiation of pharmacotherapy while still smoking, new medications and vaccines, "test kits," and aggressive medication management.

4. Impact of the "Ask-Advise-Refer" Model on Quitlines and Healthcare Practice

Many health plans and healthcare practices have struggled to implement the USPHS guideline 5A's model⁶³ (Ask, Advise, Assess, Assist, Arrange follow-up) of clinical practice that assumes all care for smokers is delivered by busy primary care teams. To increase adoption, quitlines have been proposed as part of an "Ask-Advise-Refer" model where the last three A's (Assessment, Assistance, and Arranging follow-up) can be handled predominantly by active referral to a quitline.⁶⁴ New quitline tools such as fax referral systems and feedback loops back to providers are being created and implemented to facilitate this model. There have been a number of trials that have examined the impact of this type of model, and it appears very promising.^{21,65} However, there are unanswered questions, particularly regarding: (1) How many patients actually connect and receive service from quitlines, if they are referred by their healthcare provider? (2) Is a fax referral system more effective than a "call this number" approach? Which are healthcare providers more likely to adopt? (3) What is the clinic and population impact of "Ask-Advise-Refer" compared to the traditional clinic-based 5A's model?

5. Developing and Testing Improved and New Behavioral Interventions

The impact of varying the content of interventions delivered via quitlines has not been studied systematically. A recent British study by Gilbert et al.⁶⁶ did not find a quit rate difference between one and multiple calls, unlike most other previous studies. They posited that their failure may have been due to using a non-structured, client-led protocol with counselors given

little guidance as to what to talk about, treating each call like a separate, unrelated encounter.

There are multiple ways the content of interventions could be varied to attempt to improve quit rates and satisfaction. Many of these approaches are not specific to phone counseling, i.e., it is not known if they improve outcomes in an in-person setting either. Examples include:

1. Decreasing nicotine content over time via fading, scheduled smoking, or denicotinized cigarettes. More sophisticated approaches that include handheld devices to record use patterns and give realtime suggestions for scheduled smoking hold promise, and could be combined with quit coach availability.
2. Taking different theoretic approaches to coaching/counseling content. Trials specifically comparing the relative merits of Cognitive–Behavioral therapy, Motivational Interviewing, the 3 “T”s (creating motivational Tension, Triggering action, and Treatment availability)⁶⁷ or other theory-based counseling content, and determining their incremental added benefit compared to practical advice and social support will be helpful.
3. Examining the impact of increasing the number of calls or call time length on quit outcomes. A recent Veteran’s Administration trial that obtained higher than usual quit rates offered more calls.⁶⁵ There is evidence from in-person programs that more contact can increase quit rates markedly.⁶⁸ One randomized trial found that 10–12 calls focused around the quit date increased 90-day abstinence rates at 6 months.⁶⁹ However, because of the increased cost implications, replication and further study of what subpopulations may benefit from increased intensity are needed.
4. Relapse-sensitive versus recycle-sensitive timing of calls. The trend in timing of phone counseling calls has been to frontload them around the caller’s quit date (relapse-sensitive). This makes sense from the perspective of helping to prevent relapse. However, checking in with people over a more extended period also may be helpful to encourage those callers who have relapsed to call again (recycle-sensitive). Some earlier phone models stressed this approach.⁷⁰ There has never been a direct comparison of these two methods, nor of an integrated approach that does both.
5. More formative analysis of the experience of those going through treatment to identify modifiable influencers of success and relapse. This knowledge will benefit from the creation of multistate databases, and from more standardized processes and outcomes reporting so quit rates and influencers such as contact time can be compared reliably across states and service providers.

6. Cost Effectiveness of Different Promotional and Service Approaches

A quitline’s population impact depends not just on quit rates, but even more so on how effectively it is promoted. Promotion is critical for two reasons; promoting the availability of a quitline may increase quit attempts in the general population, and it will determine how many people call to use the service. Much remains to be learned in this critical arena.

Quitlines vary significantly from each other and over time as to how much emphasis they put on different promotional strategies such as mass media, community awareness, and healthcare system and provider referrals. Measuring the impact of these approaches on quitline utilization is straightforward, but measuring the impact of different strategies on the rate of quit attempts in the general population that do not result in a call to the quitline is more challenging.

Development and research is needed to explore highly efficient methods for recruiting callers, such as the placement of the 1–800–QUITNOW number on cigarette packages. Incentive programs such as “Quit & Win” contests, which have been used internationally, as well as decreased health insurance premiums also show considerable promise.

A deeper understanding of what drives tobacco users to make quit attempts and what types of support services they would find most attractive could help in the re-engineering of both cessation services and promotion. The Robert Wood Johnson Foundation (RWJF) is sponsoring an initiative applying innovative product development approaches to increase consumer demand for cessation, including quitlines.

Further cost effectiveness and return-on-investment studies for likely high-yield populations such as COPD, obstetrics, diabetes, and asthma are needed. Most cost-effectiveness analyses have concentrated on the entire population of smokers. Analyzing high-utilization subpopulations may help make a stronger case to employers or health plans for aggressive intervention support.

7. Development and Testing of Proxy (Helper) Interventions

Quitlines primarily serve smokers interested in quitting, relying on media, public policies that denormalize smoking, and healthcare providers to increase motivation to quit and seek help. However, many family members, friends, coworkers, and other former smokers are interested in and can be taught basic cessation-support skills similar to those used by healthcare providers.⁷¹ With no effort to recruit them, approximately 5% of calls to quitlines are from these proxy helpers. In some populations such as Asian immigrants, over 50% of calls are from proxies.⁷² Can quitlines be used more vigorously and effectively as a source of information,

support, and skillbuilding for proxies? If so, will this help to motivate and then support smokers attempting to quit, including increasing use of evidence-based services?

8. Experiments in Coordination of Public–Private Benefits to Increase Reach of Quitlines

As noted earlier, lack of sufficient funding is a prodigious obstacle to further dissemination of quitline services. Improved surveillance and tracking of the impact of different approaches to funding, promoting, and delivering service on quitline utilization and outcomes, as well as conscious experimentation with different public–private mixes, may shed light on what approaches hold the most promise for long-term solutions. Examples include: (1) risk-based sharing of financing for service and promotion among different institutions, such as in Massachusetts where the state pays for counseling and health insurers pay for medications, or Minnesota where the settlement trust funds are used to pay for statewide promotion and triage, with full service reserved for the uninsured, while insurers pay for all phone counseling and medications for their members; and (2) more aggressive government-funded service such as in Australia and Maine, where over 8% of smokers receive quitline service. Can it be determined more quantitatively how heavy government provision of service affects healthplan/employer financing and delivery?

9. Tailoring of Service and Promotion for Subpopulations

There is considerable public health interest in creating different versions of quitline services and promotion for various groups that may be less prone to use or benefit from standard cessation support. Examples include Native American/Alaska Natives, Medicaid recipients, gays and lesbians, youth, seniors, blue-collar workers, smokers with mental health or substance abuse diagnoses, obese and overweight smokers, pregnant women, and other ethnic/racial groups. However, other than providing services in people's native languages and being sensitive to cultural differences, so far there is little or no evidence that taking a substantially different clinical approach makes a difference.³ Is further population tailoring critical, given these groups' disproportionate prevalence or risk, or is it a distraction? Further surveillance, inquiry, and experimentation can help sort out whether focusing on better quitline publicity, cultural sensitivity, and accessibility will sufficiently serve the needs of these populations, or whether greater modification is necessary.

There is also a need to determine if tailoring treatment content, duration, frequency, and timing based

on other individual characteristics (such as level of addiction, past quit history, and motivational attributes) improves outcomes.

10. Disseminating Quitlines in the Developing World

There are now over 80 quitlines in North America, Europe, and Australia/New Zealand.⁷³ There are only four in the developing world.⁷⁴ As developing countries that are signatories to the Framework Convention on Tobacco Control (FCTC) move to implement the cessation provisions, quitlines increasingly are being considered as a strategy. Quitlines can create an impact even where healthcare services are disorganized. In addition, promotional campaigns for quitlines help to normalize quitting, thus increasing the rate of quit attempts. Developing countries may be able to take advantage of low labor and media costs. However, they may also be hampered by less-developed telephone systems and more limited overall resources for delivery and evaluation.

For quitlines to be disseminated effectively to less well-developed countries, financial and systems support for knowledge and technical expertise transfer need to be developed. In addition, further development and research is needed to create and test less-expensive options for high-volume situations, such as recorded messages and very short courses of counseling and medication.

Research Implications

Quitlines are creating a remarkable infrastructure for theoretic and applied research in numerous disciplines. They are collecting uniform minimum datasets on hundreds of thousands of tobacco users who attempt to quit each year. In the U.S., there is wide heterogeneity in recruitment and service strategies from state to state and institution to institution, providing numerous natural experiments. Because of the high volume of participants and computerized coaching support, quitlines also provide opportunities for "easy" large-scale social science, health services research, pharmacologic effectiveness, and other randomized trials to test theoretic models as well as to conduct practical clinical trials relating to cost effectiveness and equivalency of different approaches.

This new infrastructure for research is only beginning to be utilized to the extent possible. Despite having developed and implemented a state-level minimum data set, this data has not been integrated and analyzed even for basic information about the demographics of quitline users. New models to encourage and support quitline research are needed that take advantage of their ability to answer scientific and practical questions quickly and efficiently.

Conclusion

The new behavioral technology that formed the basis of quitlines easily could have languished in articles growing moldy on the shelves of libraries; instead, individuals in academia, state health departments, healthcare companies, philanthropic organizations, federal agencies, large employers, and service agencies created a vision and over time brought it to life. This has been a messy, sometimes painful process that never would have gotten as big as it has if the individuals involved had not seen its potential to improve individual and public health, and if they had not worked and argued together to make it real. The glass is now hopefully only half full, and much more will be discovered and done to further maximize the potential of this potent tool to help disseminate evidence-based treatments.

The author is employed by and owns stock in Free & Clear®, a service provider of quitlines.

References

- Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA* 2002;288:1260–5.
- North American Quitline Consortium. Quitlines of North America and Europe 2006. Phoenix AZ: North American Quitline Consortium. Available online at: http://www.naquitline.org/map_world.html.
- Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. clinical practice guideline. Rockville MD: U.S. Department of Health and Human Services (USDHHS) Public Health Service (PHS), 2000.
- Beck AT, Wright FD, Newman CF, Liese BS. Cognitive therapy of substance abuse. New York: Guilford Press, 1993.
- Prochaska JO, DiClemente CC. The transtheoretical approach : crossing traditional boundaries of therapy. Homewood IL: Dow Jones–Irwin, 1984.
- Miller WR, Rollnick S. Motivational interviewing. Preparing people to change addictive behavior, 2d edn. New York: Guilford Press, 2002.
- Gingerich WJ, Eisengart S. Solution-focused brief therapy: a review of the outcome research. *Family Process* 2000;39:477–98.
- Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, Hyland A. Reach, efficacy and cost effectiveness of free nicotine medication giveaway programs. *J Public Health Manag Pract* 2006;12:37–43.
- An L, Schillo BA, Kavanaugh A, Luxenberg M, Joseph A, McAfee T. Access to nicotine replacement therapy as part of a statewide tobacco telephone helpline. *Am J Health Promot* 2006;20:267–71.
- Swan GE, McAfee T, Jack LM, Javitz HS, Dacey S, Bergman K. Effectiveness of bupropion SR for smoking cessation in healthcare setting. *Arch Intern Med* 2003;163:2337–44.
- Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database Syst Rev* 2006;3:CD002850.
- Zhu SH, Tedeschi G, Anderson CM, Rosbrook B, Byrd M, Johnson CE, Gutiérrez-Terrell E. Telephone counseling as adjuvant treatment for nicotine replacement therapy in a “real-world” setting. *Prev Med* 2000;31(4):357–63.
- Ossip-Klein DJ, McIntosh S. Quitlines in North America: evidence base and application. *Am J Med Sci* 2003;326:201–5.
- Lichtenstein E, Glasgow RE, Lando HA, Ossip-Klein DJ, Boles SM. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. *Health Educ Res* 1996;11:243–57.
- U.S. Preventive Services Task Force (USPSTF). Guide to clinical preventive services, 2d edn. Alexandria VA: Internal Medical Publishing, 1996.
- The Guide to Community Preventive Services: Tobacco Use Prevention and Control. *Am J Prev Med* 2001;20(2S):1–88.
- Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a worksite smoking-cessation program: A simulation analysis. *J Occup Environ Med* 1996;38:981–92.
- Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. *Inquiry* 2004;41:57–69.
- Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services. *Am J Prev Med* 2006;31:52–61.
- Javitz HS, Swan GE, Zbikowski SM, et al. Cost effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. *Am J Manag Care* 2004;10:217–26.
- Curry SJ, Grothaus LC, McAfee TA, Pabiniak C. Utilization and cost effectiveness of smoking cessation services under four insurance coverage structures in a health maintenance organization. *N Eng J Med* 1998;339:673–9.
- Hollis JF, McAfee TA, Fellows JL, Zbikowski S, Stark M, Riedlinger K. The effectiveness and cost effectiveness of telephone counseling and the nicotine patch in a state tobacco quitline. *Tob Control* 2007; in press.
- Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: a cost-effectiveness analysis. *Int J Technol Assess Health Care* 2004;20:469–74.
- Gonzalez D, Rennard SI, Nides M, et al. Varenicline, an $\alpha 4\beta 2$ nicotinic receptor partial agonist, bupropion and placebo for a randomized controlled trial. *JAMA* 2006;296:47–56.
- Jorenby DE, Hayes JT, Rigotti NA, et al. Efficacy of varenicline, an acetylcholine receptor partial vs placebo or sustained-bupropion for smoking cessation a randomized controlled trial. *JAMA* 2006;296:56–64.
- Halpin HA, McMenamin SB, Rideout J, Boyce-Smith G. The costs and effectiveness of different benefit designs for treating tobacco dependence: results from a randomized trial. *Inquiry* 2006;43:54–65.
- Macleod ZR, Charles MA, Arnaldi VC, Adams IM. Telephone counselling as an adjunct to nicotine patches in smoking cessation: A randomised controlled trial. *Med J Aust* 2003;179:349–52.
- Reid RD, Pipe A, Dafoe WA. Is telephone counselling a useful addition to physician advice and nicotine replacement therapy in helping patients to stop smoking? A randomized controlled trial *CMAJ* 1999;160:1577–81.
- Solomon LJ, Scharoun GM, Flynn BS, Secker-Walker RH, Sepinwall D. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking. *Prev Med* 2000; 31:68–74.
- Zhu S-H, Rosbrook B, Anderson C, Gilpin E, Sadler G, Pierce JP. The demographics of help-seeking for smoking cessation in California and the role of the California Smokers' Helpline. *Tob Control* 1995;4(Suppl 1): S9–S15.
- Zhu S-H, Wong S, Anderson CM, Cummins S, Mills J, Gardiner P. Quitlines: reaching African-American smokers who want to quit. Symposium presentation at the National Conference on Tobacco or Health. Chicago IL: May 2005.
- Li J, Grigg M. Changes in characteristics of New Zealand Quitline callers between 2001 and 2005. *NZ Med J* 2007;120(1256):U2584.
- El-Bastawissi AY, McAfee T, Zbikowski SM, et al. The uninsured and Medicaid Oregon tobacco user experience in a real-world phone-based cessation program. *Tob Control* 2003;12:45–51.
- An L, Zhu SH, Nelson DB, et al. Benefits of telephone care over primary care for smoking cessation. *Arch Intern Med* 2006;166:536–42.
- Ossip-Klein DJ, Giovino GA, Megahed N, et al. Effects of a smoker's hotline: results of a 10-county self-help trial. *J Consult Clin Psychol* 1991;59:325–32.
- North American Quitline Consortium. Website available online at: <http://naquitline.org>.
- Keller PA, Bailey LA, Koss KJ, Baker TB, Fiore MC. Organization, financing, promotion, and cost of U.S. quitlines, 2004. *Am J Prev Med* 2007;32:32–7.
- Swartz SH, Haskins AE. Increasing reach of quitline services in a US state with comprehensive tobacco treatment. *Tob Control* 2007; in press.
- Tan N, Wakefield M, Freeman J. Changes associated with the National Tobacco Campaign: results of the second follow-up survey. In: Hassard K, ed. Australia's national tobacco campaign. Evaluation report, vol. 2. Canberra: Commonwealth Department of Health and Aged Care, 2000:21–75.
- Owen L. Impact of a telephone helpline for smokers who called during a mass media campaign. *Tob Control* 2000;9:148–54.
- Salley MK. Are your employees smoking their health away? CDHC Solutions 2006;2(5). Available online at: <http://www.cdhsolutionsmag.com/archives.shtml>.
- Fiore MC, Croyle RT, Curry SJ, et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. *Am J Pub Health* 2004;94:205–10.
- Bunn W, Stave G, Downs KE, Alvir JMJ, Dirani R. Effect of smoking status on productivity loss. *J Occup Environ Med.* 2006;48:1099–108.

44. Zhu SH, Anderson CM. Tobacco quitlines: where they've been and where they're going. In: Isaacs SL, Schroeder SA, Simon JA, eds. *VA in the vanguard: building on success in smoking cessation*. Proceedings of a conference held September 21, 2004 in San Francisco CA. 2005. pp. 219-34.
45. Willemsen MC, Simons C, Zeeman G. Impact of the new EU health warnings on the Dutch quit line. *Tob Control* 2002;11:381-2.
46. Pinho M, de Abreu Perez C, Cavalcante TM. Five years of Brazilian Quitline "Disque Pare de Fumar". Panel presentation at 13th World Conference on Tobacco OR Health. Washington DC, July 2006.
47. Ong MK, Glantz SA. Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. *Am J Public Health* 2005;95:969-75.
48. Frieden TR, Mostashari F, Kerker BD, Miller N, Hajat A, Frankel M. Adult tobacco use levels after intensive tobacco control measures: New York City, 2002-2003. *Am J Public Health* 2005;95:1016-23.
49. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of lung transplantation. *J Thorac Cardiovasc Surg* 2002;123:411-20.
50. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
51. USDHHS, Medicare Preventive Services. Smoking and tobacco-use cessation counseling services, ICN 006767. March 2006. Printed by: Medicare Learning Network.
52. Zhu S-H, Anderson CM. Bridging the clinical and public health approaches to smoking cessation: the California Smokers' Helpline. In Jamner M, Stokols D, eds. *Promoting human wellness: new frontiers for research, practice and policy*. Berkeley CA: UC Printing, 2006.
53. Wagner EH. Chronic disease management: What will it take to improve care for chronic illness? *Eff Clin Pract* 1998;1:2-4.
54. Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? *Am J Manag Care* 2006;12:235-43.
55. Britt J, Curry SJ, McBride C, Grothaus L, Louie D. Implementation and acceptance of outreach telephone counseling for smoking cessation with nonvolunteer smokers. *Health Educ Q* 1994;21:55-68.
56. Strecher VJ, Shiffman S, West R, Strecher VJ, Shiffman S, West R. Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. *Addiction*. 2005;100:682-8.
57. Rabius V, Pike KJ, Geiger A, Hunter J, McAlister A. American Cancer Society's QUITLINK: A Randomized Trial of Internet Assistance for Smoking Cessation. Panel presentation at 13th annual World Conference on Tobacco or Health. Washington DC, July 2006.
58. Rodgers A, Corbett T, Bramley D, et al. Do U smoke after txt? Results of a randomized trial of smoking cessation using mobile phone text messaging. *Tob Control* 2005;14:255-61.
59. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA* 2002;288:1260-4.
60. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, Hyland A. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *J Public Health Manag Pract* 2006;12:37-43.
61. An LC, Schillo BA, Kavanaugh AM, et al. Increased reach and effectiveness of a statewide tobacco quitline after the addition of access to free nicotine replacement therapy. *Tob Control* 2006;15:286-93.
62. Fellows JL, Bush T, McAfee T, Dickerson J. Cost effectiveness of the Oregon quitline Free Patch Initiative. *Tob Control* 2007; in press.
63. Bentz CJ, Bayley KB, Bonin KE, et al. Provider feedback to improve 5A's tobacco cessation in primary care: a cluster randomized clinical trial. *Nicotine Tob Res* 2006;2007;9:341-9.
64. Schroeder SA. What to do with a patient who smokes. *JAMA* 2005;294:482-7.
65. An LC, Zhu SH, Nelson DB, et al. Benefits of telephone care over primary care for smoking cessation: a randomized trial. *Arch Intern Med* 2006;166:536-42.
66. Gilbert H, Sutton S. Evaluating the effectiveness of proactive telephone counselling for smoking cessation in a randomized controlled trial. *Addiction* 2006;101:590-8.
67. West R, Sohal T. Catastrophic pathways to smoking cessation: findings from national survey. *BMJ* 2006;332:458-60.
68. Hall SM, Humfleet GL, Reus VI, Munoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. *Am J Psychiatry* 2004;161:2100-7.
69. McAfee T, Wassum K, Edris K, et al. The impact of increased phone contact and medication support around the quit date: initial randomized trial results. Poster presentation at Annual Meeting of the Society for Research on Nicotine and Tobacco. Austin TX, 2007.
70. Orleans CT, Schoenbach VJ, Wagner EH, et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. *J Consult Clin Psychol* 1991;59:439-48.
71. Shoham V, Rohrbaugh MJ, Trost SE, Muramoto M. A family consultation intervention for health-compromised smokers. *J Subst Abuse Treat* 2006;31:395-402.
72. Zhu SH, Nguyen QB, Cummins S, Wong S, Wightman V. Nonsmokers seeking help for smokers: a preliminary study. *Tob Control* 2006;15:107-13.
73. North American Quitline Consortium. *Quitlines of North America and Europe, 2006*. Phoenix AZ: North American Quitline Consortium, 2006.
74. World Bank. *Tobacco Quitlines at a glance*. Available as PDF online at: <http://siteresources.worldbank.org/INTPHAAG/Resources/AAGTobaccoQuitlines.pdf>.

Changing Smokeless Tobacco Products

New Tobacco-Delivery Systems

Dorothy K. Hatsukami, PhD, Jon O. Ebbert, MD, Rachel M. Feuer, BA, Irina Stepanov, PhD, Stephen S. Hecht, PhD

Abstract: Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and “spitless.” While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.

(Am J Prev Med 2007;33(6S):S368–S378) © 2007 American Journal of Preventive Medicine

Introduction

Marketing strategies and types of available smokeless tobacco products have been evolving in the United States. Products are being manufactured to appeal to cigarette smokers (e.g., spitless, in small tea-like packets, different flavorings) and promoted to be used in situations where they cannot smoke or as a substitute or alternative to smoking. The U.S. Smokeless Tobacco Company (USSTC; Greenwich CT) filed a request for an Advisory Opinion with the Federal Trade Commission (FTC) seeking guidance “regarding the acceptability of communicating in advertising that smokeless tobacco products are considered to be a significantly reduced risk alternative as compared to cigarette smoking” (letter submitted in February 2002, withdrawn August 2002, additional information submitted in May 2003). The availability and

marketing of these products address two primary concerns faced by cigarette smokers: increasing bans on smoking and health risks associated with smoking. For tobacco companies, these products may serve to maintain tobacco use among existing smokers and to recruit new tobacco users.

In the public health community, smokeless tobacco use as a complete substitute for cigarette smoking or as a method of cessation is gaining support, but remains hotly debated. Tobacco harm-reduction approaches, such as the use of smokeless tobacco among smokers unwilling or unable to quit, have been considered as a feasible alternative that can potentially reduce tobacco-related morbidity and mortality, even with continued use of products that contain tobacco constituents.¹ A thoughtful, unbiased examination of the feasibility of methods to reduce tobacco-related harms that do not preempt other tobacco-control measures such as prevention and cessation is urgently needed. Currently, cigarette smoking is the leading cause of death in the U.S., accounting for approximately one in six deaths (438,000 each year) and 5.5 million years of potential life lost. In 2005, approximately one fifth (45.1 million) of the U.S. adult population were smokers.² Although an estimated 70% of smokers (33.2 million) would like

From the Transdisciplinary Tobacco Use Research Center, University of Minnesota (Hatsukami, Feuer, Stepanov, Hecht), Minneapolis, Minnesota and the Department of Medicine, Mayo Clinic (Ebbert), Rochester, Minnesota

Address correspondence and reprint requests to: Dorothy K. Hatsukami, PhD, University of Minnesota Transdisciplinary Tobacco Use Research Center, 2701 University Avenue, SE, Suite 201, Minneapolis MN 55414. E-mail: hatsu001@umn.edu.

to quit, successful long-term abstinence remains low (2.5% or 1.2 million smokers per year).^{3,4} Worldwide, approximately 1.3 billion people smoke and about 4.9 million die from tobacco-related illnesses each year. If present consumption patterns continue, an estimated 10 million people will die each year from tobacco-related disease by the year 2020.^{5,6}

Excepting nicotine pharmaceuticals, of the various currently available potential reduced exposure products (PREPs) that may result in actual harm reduction, smokeless tobacco products have the greatest potential to reduce risk for disease if smokers completely switch from cigarettes to these products. For example, the relative risk for disease with “low-nitrosamine” smokeless tobacco is considered to be at least 90% less than cigarette smoking.⁷ In a report by the Tobacco Advisory Group of the Royal College of Physicians,⁸ smokeless tobacco use is considered 10–1000 times less hazardous than cigarette smoking, depending on the product. Unlike cigarette smoking, smokeless tobacco use has not been linked to many of the smoking-related cancers^{9,10} or to pulmonary disease.¹¹ Epidemiologic data from Sweden have been used to support the hypothesis that switching from cigarettes to smokeless tobacco products can significantly reduce tobacco-related morbidity and mortality among tobacco consumers. A reduction in lung cancer in Sweden has been observed in men. This reduction has been attributed by some investigators to the increased use of “snus” (i.e., Swedish snuff) and a corresponding reduction in cigarette smoking.^{12,13} The decline in smoking has not been as dramatic in women, potentially due to the limited uptake of snus among women. Other researchers have debated this interpretation based on the observation that the prevalence of smokeless tobacco use is “not consistently associated with a reduction in smoking initiation or prevalence.”¹⁴ Many public health scientists and advocates are concerned that the Swedish experience would not be replicated elsewhere. However, if a significant number of current smokers who would not have otherwise quit switched completely to “low-nitrosamine” oral tobacco products, then a significant reduction in prevalence of tobacco-related disease is likely to occur.⁷

The aims of this article are to describe the extant literature on newer smokeless tobacco products directed at smokers, the currently existing literature on the toxicity of these products, including nicotine addiction, and future directions for research.

Types of Smokeless Tobacco Products

Several types of smokeless tobacco products are available which can be administered orally or nasally. Moist snuff is finely ground or shredded tobacco sold either loose or in packets (i.e., sachets) and used orally. A user places a pinch or dip between the cheek and gum. Dry

snuff is fine powdered tobacco and can be used either orally or nasally. Chewing tobacco comes as twist, plug, or loose leaf. The user places a “wad” of this product inside the cheek. Moist snuff and chewing tobacco may require spitting and therefore has been referred to as “spit tobacco.” Other smokeless tobacco products are tobacco mixed with other substances. Alaskan natives, for example, mix tobacco leaves with ash from a woody fungus that grows on the bark of birch trees (i.e., punk ash). This product is frequently referred to as Iq-mik.¹⁵ In India, Southeast Asia, or the United Kingdom, tobacco is mixed with areca nut, lime, flavorings, or spices and is either manufactured or handmade (e.g., betel quid in India). Newer products being marketed primarily to cigarette smokers are sold as pouched, “spitless” moist snuff or compressed tobacco lozenges. Swedish Match (Stockholm, Sweden) introduced a Swedish snus, Exalt, to the U.S., but this product is no longer sold in this country. The processing of Swedish snus involves heat treatment or pasteurization rather than fermentation. This leads to lower levels of tobacco-specific nitrosamines (TSNAs) than in some American products. Furthermore, Swedish Match has introduced voluntary standards, called GothiaTek® (www.gothiatek.com) that set limits for oral tobacco constituents, and specify standards for manufacturing and for the provision of consumer information. Because snus is included in the Swedish Food Act, only additives and flavorants that are permitted in foods are allowed in snus. In addition, Swedish Match reports that the nontobacco-specific compounds have established limits that are comparable to food products. The manufacturers recommend that retailers refrigerate the products to keep them “fresh” (e.g., prevent further nitrosamine formation) and to meet the “best-before” criteria.

The U.S. Smokeless Tobacco Company (USSTC) introduced Revel in 2001. This product is marketed as a “unique, discreet option for adult smokers seeking an alternative that allows them to enjoy real tobacco satisfaction without lighting up.” Revel was developed “for smokers living in a no-smoking world” and is described as “not like nicotine gum or tobacco-cessation product.” The products are 100% American tobacco and available in mint, wintergreen, and cinnamon. In 2006, USSTC manufactured and now is test-marketing Skoal Dry, which is likely to replace Revel. This product uses a bigger pouch than Revel and comes in regular and mint flavors. The method of curing and processing of these products is publicly unknown. Also, in 2006, Camel Snus (marketed by Reynolds American, Inc., Winston-Salem NC) and Taboka Tobaccopak (manufactured by Phillip Morris, Richmond VA) were introduced for test marketing. Camel Snus is manufactured by Swedish Match and adheres to the same manufacturing standards as the other Swedish snus products. Furthermore, retailers store Camel snus in a chilled container, but the product does not have to be




Figure 1. Historic levels of tobacco-specific nitrosamines in noncombusted oral tobacco products.²⁵ ppm, parts per million; TSNA, tobacco-specific nitrosamine.

refrigerated during use. Camel snus is sold in spice, menthol, and original flavors. Taboka, similar to Swedish snus, contains pasteurized tobacco. However, compared to Swedish snus, this product is lower in moisture content, includes a flavor-strip technology, has a reduced salt content, and does not require refrigeration. It comes in original (Taboka) or mint (Taboka Green) flavors. Recently, Phillip Morris announced that it was test-marketing Marlboro snus.¹⁶

In 2001 and 2003, Star Scientific (Chester VA) introduced two smokeless tobacco potentially-reduced-exposure products, Ariva and Stonewall. Ariva was also designed to be used by smokers in situations where they cannot smoke, while Stonewall was designed as an alternative to moist snuff.¹⁷ Both products have been through the process of “Star-curing,” an innovative method of curing tobacco which may nearly eliminate the TSNA, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-nitrosornicotine (NNN), from the tobacco. Star-curing is a patented two-step process that does not involve chemicals, solvents, or other additives. The leaf is dried in a barn for approximately 24–36 hours at about 100–110°F, until it turns yellow. It is then pressed to remove moisture and microwaved until moisture is reduced by an additional 10%.¹⁸ According to research by Star Scientific and independent sources, the StarCured process preserves the normal nicotine and monoamine oxidase (MAO) inhibitor content, while reducing TSNA to “almost undetectable levels.”^{19,20}

The newer smokeless tobacco products make the term “spit tobacco” seem antiquated. Furthermore, because newer cigarette-like devices that are being developed have been shown to emit minimal second-hand smoke,²¹ the term smokeless tobacco appears to lack specificity. In this paper, these products are predominantly referred to as “noncombusted oral tobacco products,” which seems to be a more specific and descriptive terminology for the current “smokeless tobacco” products.

Toxicants of Noncombusted Oral Tobacco Products

Although oral tobacco products lack the toxicants associated with combustion, they include 28 known carcinogens.²² Some of these carcinogens are TSNA. The TSNA that have been most strongly linked to cancer are NNK and NNN. These TSNA are formed during curing, processing, and aging of tobacco and are present in both burned and unburned tobacco. According to the International Agency for Research on Cancer (IARC), these TSNA are considered Group 1 carcinogens. They cause tumors of the oral cavity, esophagus, pancreas, and lung in laboratory animals.^{23,24} The TSNA in some noncombusted oral tobacco products manufactured in Sweden and the U.S. have decreased over time. Products in Sweden are now typically below 10 ppm and products in the U.S. are typically below 20 ppm (Figure 1).²⁵ Several studies have examined amounts of TSNA in oral tobacco products in various countries.^{26–30} Figure 2 shows a compilation of a few of the recent studies that have measured NNN and NNK in the U.S.,²⁸ Sweden,³⁰ and India²⁹ and illustrates three primary points. First, there is a wide variability in carcinogen levels among oral tobacco forms found in the U.S., Sweden, and India. The highest levels reported are found in a product made in Sudan called toombak, which is a mixture of tobacco and sodium bicarbonate (amounts not shown in Figure 2). The levels of TSNA in this type of product are in the thousands of micrograms per gram dry weight.²⁶ Second, there are significant differences in TSNA among the various U.S. brands despite the general decrease in overall levels of carcinogens (Figure 1). These differences occur even within the same U.S. brand bought in different locations^{31,32} (e.g., Copenhagen had NNK values varying from 1.45 to 3.20




Figure 2. NNK and NNN levels in noncombusted oral tobacco products across and within countries. NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN, nitrosornicotine.

Table 1. Tobacco-specific nitrosamine levels²⁸

Tobacco products	Tobacco-specific nitrosamine level ($\mu\text{g/g}$ product wet weight)				
	NNN	NNK	NAT	NAB	Total
New tobacco products					
Hard snuff					
Ariva	0.019	0.037	0.12	0.008	0.19 ^a
Stonewall	0.056	0.043	0.17	0.007	0.28 ^b
Swedish snus					
General	0.98	0.18	0.79	0.06	2.0 ^c
Spit-free tobacco packets					
Exalt					
Purchased in Sweden	2.3	0.27	0.98	0.13	3.7 ^d
Purchased in the U.S.	2.1	0.24	0.68	0.05	3.1 ^b
Revel					
Mint flavor	0.62	0.033	0.32	0.018	0.99 ^b
Wintergreen flavor	0.64	0.032	0.31	0.017	1.0 ^b
Camel Snus					
Original	0.79	0.16	0.19	0.008	1.15 ^b
Spice	0.87	0.09	0.20	0.010	1.17 ^b
Frost	0.83	0.16	0.13	0.006	1.12 ^b
Taboka					
Taboka	0.91	0.06	0.30	nd	1.27 ^b
Taboka Green	0.82	0.07	0.24	0.002	1.13 ^b
Nicotine replacement therapy products					
NicoDerm CQ (patch, 24-mg nicotine) ^e	nd	0.008	nd	nd	0.008 ^b
Nicorette (gum, 4-mg nicotine) ^e	0.002	nd	nd	nd	0.002 ^b
Commit (lozenge, 2-mg nicotine) ^e	nd	nd	nd	nd	nd ^b
Conventional smokeless tobacco products					
Copenhagen					
Snuff	2.2	0.75	1.8	0.12	4.8 ^b
Long cut	3.9	1.6	1.9	0.13	7.5 ^b
Skoal					
Long cut straight	4.5	0.47	4.1	0.22	9.2 ^b
Bandits	0.9	0.17	0.24	0.014	1.3 ^b
Kodiak					
Ice	2.0	0.29	0.72	0.063	3.1 ^b
Wintergreen	2.2	0.41	1.8	0.15	4.5 ^b

^aMean of five analyses, each performed in duplicate.^bSingle analysis performed in duplicate.^cMean of two analyses, each performed in duplicate.^dMean of three analyses, each performed in duplicate.^eValues are expressed per piece.NNN, *N*-nitrosornicotine; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NAT, *N*-nitrosoanatabine; NAB, *N*-nitrosoanabasine; nd, not detected.

$\mu\text{g/g}$ dry weight with a coefficient of variation of 32.9%³²) and can vary depending on length of time on the shelves.³³ Products manufactured in Sweden and sold in the U.S. also show some variability and higher levels of TSNAs than the snus products sold in Sweden.²⁸ The differences in TSNAs among oral tobacco products used in India are more dramatic with values ranging from 1.2 to 128 $\mu\text{g/g}$ product wet weight. Third, products in Sweden tend to have uniformly lower nitrosamine levels than American products, which is, in part, due to the GothiaTek® standards developed and adhered to by the manufacturers of Swedish snus.

Table 1 shows data on the newer oral tobacco products²⁸ introduced in the U.S. This table clearly demonstrates that the levels of total TSNAs are highest in the conventional and most popular oral tobacco products

sold in the U.S (i.e., Copenhagen and Skoal),³⁴ with TSNAs ranging from 4.8 to 9.2 $\mu\text{g/g}$ product wet weight. The Swedish products such as General Snus and Exalt are somewhat lower in TSNAs with values ranging from 2.0 to 3.7 $\mu\text{g/g}$ product wet weight. The lowest levels of TSNAs are observed in oral tobacco products manufactured by Star Scientific, tobacco lozenges such as Ariva and Stonewall, 0.19 and 0.26 $\mu\text{g/g}$ product wet weight, respectively. The medicinal nicotine products tended to have extremely low or nondetectable levels of nitrosamines.

A critical question is how the levels of nitrosamines in tobacco products translate into the uptake of carcinogens in humans. Figure 3 shows the results from a compilation of studies that had been conducted. The concentrations of metabolites of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-butanol [NNAL]




Figure 3. Total NNAL concentrations in urine: users of different brands of noncombusted oral tobacco products, medicinal nicotine (Commit), and Marlboro cigarettes. NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-butanol.

and its glucuronides [NNAL-Glucs] or total NNAL, which serves as a biomarker for exposure to carcinogens, were examined across different brands of noncombusted oral tobacco products and compared to Commit (GlaxoSmithKline, Pittsburgh PA), a medicinal nicotine that is FDA-approved for smoking cessation. These data represent analyses of the information collected from separate studies³⁵⁻³⁹ and some of the studies involved subjects who were noncombusted oral tobacco users while others involved cigarette smokers who switched to noncombusted oral tobacco products. In spite of these limitations, the concentrations of total NNAL parallel the NNK levels in these products. This figure also illustrates the diversity of toxicant uptake across products and that some of the more conventional oral tobacco products result in higher total NNAL levels than smokers of Marlboro cigarettes, providing a cautionary note that switching to noncombusted oral tobacco products does not necessarily result in reduced toxicant exposure.

Unfortunately, the majority of existing studies have examined the human uptake of only a few of the carcinogens in these products.^{36,37,39-44} Table 2 lists other carcinogens that have been found in noncombusted oral tobacco products. To obtain an accurate picture of the potential harm associated with these products, a more comprehensive assessment of the levels and uptake of toxicants in these products is

necessary. Additionally, it is notable that these data are over 20 years old and require updating.

Reduction of Toxicant Exposure in Noncombusted Oral Tobacco Users and Cigarette Smokers

The variability of toxicants in noncombusted oral tobacco products begs the question of whether users of high nitrosamine cigarettes or “traditional” smokeless tobacco products can reduce their level of toxicant uptake through product substitution. Unfortunately, few studies have addressed this question. The studies conducted to determine the effects of switching smoke-

Table 2. Other carcinogens in processed tobacco^{45,46}

Carcinogen	Amount (per gram)
Benzo[<i>a</i>]pyrene	0.1-90 ng
Formaldehyde	1.6-7.4 μ g
Acetaldehyde	1.4-7.4 μ g
Crotonaldehyde	0.2-2.4 μ g
1,1-Dimethylhydrazine	60-147 ng
Ethyl carbamate	310-375 ng
Hydrazine	14-51 ng
Arsenic	500-900 ng
Nickel	2-6 μ g
Chromium	1-2 μ g
Cadmium	1.3-1.6 μ g
Lead	8-10 μ g
Polonium-210	0.2-1.2 pCi

less tobacco users to a lower nitrosamine noncombusted oral tobacco product demonstrate that a significant reduction in toxicants can occur.^{35,36,39} In one study, Copenhagen and Kodiak users were randomly assigned to General Snus, a Swedish product with about 60 to 75% lower NNK than the leading U.S. smokeless tobacco brands, or to nicotine patch for a period of 4 weeks. The results showed a significant reduction in concentrations of total NNAL when subjects switched from their usual brand to General Snus (about 50% reduction compared to baseline), but a significantly greater reduction with the nicotine patch (about 90% reduction compared to baseline³⁵). In another study, Copenhagen or Skoal Original users were switched to Skoal Bandits, which is lower in TSNAs.³⁶ Again, a significant reduction in total NNAL was observed, with concentrations that were similar to those observed with General Snus. General Snus is higher in nicotine content than Skoal Bandits and surprisingly, very little increased use of Skoal Bandits was observed even with this low nicotine content. Both these studies would indicate that smokeless tobacco users can significantly reduce their toxicant exposures by switching to a product with lower TSNAs.

Similarly, few studies have addressed whether or not cigarette smokers can reduce their toxicant exposure if they switched to the noncombusted oral tobacco products. Two pilot studies were conducted using a within-subject crossover design in which subjects were assigned, in randomized order, to medicinal nicotine lozenge for 2 weeks and an oral tobacco product for 2 weeks.³⁹ The oral tobacco product in the first study was Exalt, a Swedish Match snus product in a sachet. In the second study, the oral product was Ariva, a tobacco lozenge. The results from the first study showed that both Exalt and the nicotine lozenge resulted in a significant reduction in total NNAL concentrations; however, the nicotine lozenge led to a significantly greater reduction in total NNAL concentrations. In the second study, significant reductions in total NNAL concentrations were observed for both the nicotine lozenge and Ariva and the levels of reduction were similar. The main point of these studies is that smokers can dramatically reduce their exposure to a tobacco-specific carcinogen when they switch to lower nitrosamine oral tobacco products. Whether or not this reduction would reduce the risk for adverse health outcomes is unknown.

Health Effects from Noncombusted Oral Tobacco Products

In the U.S. in 2005, 7.7 million (3.2%) of Americans aged 12 or older were current (past month) noncombusted oral tobacco users.⁴⁷ Noncombusted oral tobacco use in the U.S. is higher among whites, men, American Indians/Alaska natives, people living in

southern or north central states, and among people who are employed in blue-collar occupations, service/laborer jobs, or are unemployed.⁴⁸ In India, it is estimated that 22% of men use noncombusted oral tobacco exclusively, and 8% use noncombusted oral tobacco and smoke concomitantly.⁴⁹ Approximately 23% of Swedish men report use of noncombusted oral tobacco (i.e., snus).¹³ In Sudan, about 40% of men and 10% of women use noncombusted oral tobacco (i.e., toombak).⁵⁰

Although the overall exposure to toxicants with noncombusted oral tobacco is significantly lower than with cigarettes, oral tobacco is addictive and not safe. The controversy centers on whether these products should be promoted as safer than cigarettes with the risk of the unintended consequence of misleading consumers into assuming they are safe.

As summarized by Critchley et al.,⁵¹ extant literature on the adverse effects of noncombusted oral tobacco is comprised of many studies with insufficient power to estimate precise risks, methodologic limitations, and inconsistency of findings, as well as by a paucity of studies on noncancer health effects. However, these studies provide the only means of assessing potential risks associated with use of these products. No data are available on the health effects of the newer “low-nitrosamine” noncombusted oral tobacco products aimed toward cigarette smokers. But, parallel to observations made with toxicant-concentration levels, the available literature suggests that adverse health consequences may vary by product type which is strongly associated with geography and the country of product origin.^{13,51} For example, some of the noncombusted oral tobacco products used in India have high concentration of TSNAs compared to products from other countries (i.e., Sweden and U.S.), and India also has the highest estimated deaths from oral cancer.^{27,51} In the U.S. where moist snuff widely used, the estimated number of deaths from oral cancer may be higher than in Sweden where snus is used.⁵¹ To date, published studies predominantly relate to oral tobacco product use in the U.S., Sweden, and India.^{13,51,52}

The link between oral tobacco use and adverse cardiovascular outcomes has been controversial.⁵¹ A recent large, multinational case-control study observed an association between nonfatal acute myocardial infarction (AMI) and chewing tobacco use.⁵³ However, the small number of snuff users precluded the ability to draw conclusions about the effects of this form of tobacco on AMI risk. In the U.S., data from the Cancer Prevention Study-I (CPS-I) and CPS-II suggest that current chewing tobacco and snuff use is associated with an increased risk of death from coronary heart disease and cerebrovascular disease.⁵⁴ In Sweden, an early case-control study observed a higher risk of death from all cardiovascular conditions among snus users.⁵⁵ However, four Swedish population-based case-control

studies observed no association between moist snuff and the incidence of myocardial infarction^{56–58} or stroke.⁵⁹

The relationship between oral tobacco use and the development of risk factors for cardiovascular disease (i.e., metabolic syndrome and diabetes) is also conflicting. High consumption of Swedish snus has been associated with the development of metabolic syndrome (i.e., obesity, impaired glucose regulation, dyslipidemia, and hypertension).⁶⁰ An association between snus use and diabetes has been observed in one study⁶¹ but not in another.⁶² In the U.S., data from the CPS-I and CPS-II suggest no relationship between smokeless tobacco use and diabetes.⁵⁴

Data from the U.S., Sweden, and India suggest an association between oral tobacco use and adverse health consequences for pregnant mothers and their fetuses. Oral tobacco (i.e., snuff) use in Sweden has been associated with lower birthweight, increased preterm delivery, and increased rate of pre-eclampsia.⁶³ Among Alaska natives who use Iq'mik, oral tobacco use is associated with neurobehavioral changes in newborns.⁶⁴ In India, the use of oral tobacco is associated with an increased risk for preterm delivery, low birthweight, and stillbirth.^{65,66} Oral tobacco use in India has also been associated with a general decrease in reproductive health.⁶⁷

Available data suggest a strong association between oral tobacco use and extra-oral cancer in India with several reports of an association from the U.S. and Sweden. In India, oral tobacco use has been associated with esophageal cancer.⁶⁸ In the U.S., data from CPS-I suggested an association between current smokeless tobacco use and death from cancer of the digestive system, and data from CPS-II observed a similar association for all cancer.⁵⁴ An association between oral tobacco use and kidney and pancreatic cancer was suggested by two U.S. case-control studies.^{69,70} Two Swedish studies found no association between snus use

and gastric or esophageal cancer^{71,72} but one observed an association with pancreatic cancer.⁷³

A systematic review of the literature concluded that available data strongly and consistently support an association between oral cancer and oral tobacco use in India, which leads to approximately 10,000 deaths annually.⁵¹ Data from the U.S. suggest an association between oral cancer and oral tobacco use.^{74,75} However, the U.S. data have been limited by small sample sizes and inadequate power to detect significant risks. Swedish studies have not shown an increased risk for oropharyngeal cancers among current oral tobacco users.^{76,77} Importantly, the IARC Monographs Working Group has reviewed the available evidence and has concluded that “there is sufficient evidence that smokeless tobacco causes oral cancer and pancreatic cancer in humans” and that smokeless tobacco is “carcinogenic to humans.”⁷⁸

No literature is available to elucidate if cigarette smokers or users of high-nitrosamine tobacco products who switch to low-nitrosamine products can reduce significantly their risk for disease.

Addiction Potential of Products

The addiction potential of a drug is also considered a tobacco-related harm. The addiction potential of a tobacco product depends on the amount of nicotine that is absorbed and the speed of nicotine delivery; the greater the magnitude of nicotine absorption and the faster the rate of absorption, the more addictive the product. The amount and speed of systemic absorption of nicotine are dependent on the product pH, nicotine content, and route of administration, with cigarette smoking resulting in the fastest rate of delivery. pH levels determine the amount of free nicotine. Higher pH levels (i.e., more alkalinity) create more free nicotine available for absorption in the bloodstream. Free or non-ionized nicotine is more readily absorbed

Table 3. Nicotine content in noncombusted oral tobacco products

Dose	Product	pH	Nicotine content (mg/g)	Free nicotine (mg/g)
Low	Hawken ^{31,82,84}			
	Wintergreen	5.2–5.7	3.2–4.3	0.01–0.02
	Skoal Bandits ^{31,84}			
	Straight	5.2–5.4	7.9–10.1	0.02–0.03
Medium	Skoal Bandits ^{31,82,83}			
	Wintergreen	6.9–7.1	7.1–8.5	0.5–1.0
	Skoal Long Cut			
	Straight ^{82,83}	7.5–7.6	10.3–12.9	2.4–3.7
	Wintergreen ^{31,83}	7.4–7.8	10.5–11.0	2.0–4.1
	Cherry ⁸³	7.5	11.4	2.6
High	Skoal Original ⁸³			
	Wintergreen	7.6	10.4	2.9
	Kodiak ^{31,82,84}			
	Wintergreen	8.2–8.4	8.6–10.9	5.8–6.5
	Copenhagen ^{31,82–84}	7.6–8.6	11.1–12.7	3.1–9.4




Figure 4. Mean plasma nicotine concentration, heart rate, and visual analog scale (product “strength”) after administration of each of four oral tobacco products or mint snuff.⁸⁵

through cell membranes than ionized nicotine. Oral tobacco products vary widely in pH and nicotine levels.^{26,31,33,79–82} Table 3 shows the amount of free nicotine in different oral tobacco products. The products with the highest free-nicotine levels are the most popular conventional brands (e.g., Copenhagen and Kodiak) used in the U.S., whereas products low in free-nicotine levels have lower use prevalence.⁴⁷ The free-nicotine content of the oral tobacco products parallels the plasma nicotine concentrations, as seen in Figure 4. Furthermore, the plasma-nicotine concentrations determine the perceived strength of the dip and the physiologic response.⁸⁵

To date few studies have examined the free-nicotine content of the newer oral tobacco products. Table 4

presents the nicotine content in some of these products.⁸⁶ In a recent study that examines the pharmacokinetics of the newer oral tobacco products,⁸⁷ products such as Ariva and Revel result in very low nicotine concentrations, whereas product such as Stonewall had concentrations that were comparable to 4-mg medicinal nicotine lozenges. Copenhagen showed the most rapid absorption and highest concentration of nicotine. The peak nicotine concentration is similar to concentrations observed for cigarettes.⁸⁸ Products such as Taboka have relatively low nicotine concentrations (data presented by Phillip Morris at a meeting at the Harvard School of Public Health), whereas Camel Snus is reported to have nicotine amounts that are similar to Camel cigarettes and blood nicotine concentrations potentially similar to levels in cigarette smokers (www.snuscamel.com). This information has not been publicly released by the manufacturers and the products have not been made widely available for analysis.

The pattern of use for low- and high-nicotine products requires research. The low-nicotine products have the advantage of being lower in addictive potential, but may not be readily used by oral tobacco users or may not provide a good substitute for cigarette smoking, potentially leading to dual use of the cigarettes and noncombusted oral tobacco products. The high-nicotine, low-nitrosamine products have potential for abuse and to sustain addiction, but may provide a better substitute for more toxic tobacco products such as cigarettes.

Summary

In summary, noncombusted oral tobacco products are changing. These products are now being targeted to cigarette smokers for use in situations where a smoker cannot smoke or as an alternative to smoking. They are manufactured to appeal to smokers. Although these products contain lower levels of total carcinogens compared to cigarettes or the most popular conventional brands of oral tobacco products sold in the U.S. or in the world, some of these products still contain considerable amounts of carcinogenic nitrosamines which are far higher than those permitted in food.⁸⁹ To date, medicinal nicotine products have the lowest toxicant concentrations. The amounts of free nicotine in these noncombusted oral tobacco products vary widely as well. Some of these newer products contain significant amounts of nicotine, whereas other products contain

Table 4. Nicotine content of newer noncombusted oral tobacco products marketed as alternatives to cigarette smoking.⁸²

Product	pH	Nicotine (mg/g)
Stonewall	7.7	1.5
Revel	7.2	1.1
Ariva	7.4	0.6

low levels of nicotine. The consequent pattern and persistence of use may depend on the nicotine content of the product but there are no data to determine this relationship.

Future Directions and Research

One of the conclusions in the Institute of Medicine (IOM) report, *Clearing the Smoke*,¹ was the following: "Regulation of all tobacco products, including conventional ones as recommended by the IOM,⁹⁰ as well as all other PREPs is a necessary precondition for assuring a scientific basis for judging the effects of using PREPs and for assuring that the health of the public is protected." The necessity for regulation of tobacco products is supported by: (1) the data showing tremendous variability in levels of toxicants in these products, (2) the capability of producers to reduce toxicant levels in tobacco products and to control degree of potential product addiction, and (3) the need for independent scientific evaluation of these products. Renewed efforts to discuss and implement the regulation of tobacco products is critical to: (1) significantly improve the public health of this nation, (2) ensure that any deceptive practices of the tobacco industry are caught, (3) not have to rely on litigation as the only method to set limits on these deceptive practices, and (4) ensure that consumers are provided accurate information. The research that is necessary to understand the public health impact of these products is extensive^{91,92} and includes preclinical and clinical research, consumer testing, and post-marketing surveillance.

Preclinical Research

Examine and identify the toxic constituents of the products and determine factors that may alter the levels of these toxicants including nicotine (e.g., shelf time, heat); and undertake *in vitro* and *in vivo* studies determining the toxicity of these products on cells and animals.

Clinical Research

Conduct human clinical trials that: (1) determine factors associated with palatability and maintenance of use of these products; (2) examine the uptake of toxicants using biomarkers for exposure and toxicity associated with different disease states⁹³; (3) examine the natural pattern of use of these products as a cessation tool, as a substitute for smoking in situations where smoking is prohibited or people cannot smoke, or as a method to reduce smoking and determine the toxicant exposure associated with these patterns of use; and (4) conduct clinical trials with noncombusted oral tobacco products as a cessation tool compared to existing pharmacologic therapies in an effort to improve existing cessation medications if noncombusted

oral tobacco products prove to be more efficacious. For example, development and approval of medications that have more rapid absorption of nicotine, higher levels of nicotine and greater palatability may be critical to compete against more toxic noncombusted oral tobacco products.

Consumer Testing

Conduct consumer testing of these products to: (1) examine how the labeling, messages, promotion, marketing and placement of these products affect consumer perception of these products; (2) determine how consumer feelings, beliefs, attitudes, and knowledge affects uptake or manner of use of these products; and (3) determine methods for labeling, messaging, promotion, marketing and placement of products that would reduce public health harm associated with the use of these products.

Post-Marketing Surveillance

Conduct post-marketing surveillance of these products to determine: (1) who is using them; (2) how they are being used; (3) toxicant exposure; (4) potential health harms associated with their use; (5) whether they serve as a gateway or substitute for cigarette smoking; and (6) the extent to which their introduction and marketing increases uptake, maintenance or relapse to tobacco products.

As a final word, the potential to do harm or to benefit the public health by the introduction of these products is tremendous. To circumvent public health harm, an infrastructure and funding that allow comprehensive and collaborative research efforts are necessary. To date, examination of the toxicity and impact of these products is occurring on an international level and U.S. efforts should coincide with these efforts. For example, WHO has convened a Study Group on Tobacco Regulation to produce documents that describe principles and provide guidelines for implementing articles of the WHO Framework Convention on Tobacco Control that are associated with tobacco product testing (Articles 9 and 10). One of the documents, "Guiding Principles for the Development of Tobacco Product Research and Testing Capacity and Proposed Protocols for the Initiation of Tobacco Product Testing"⁹⁴ provides guidelines for the testing and assessment and for the regulation of contents and emissions from tobacco products. A long-term vision and direction for tobacco control as well as coordinated and complimentary activities amongst organizations, tobacco-control advocates, policy makers, and researchers are critical at this juncture in tobacco control.

We would like to acknowledge Dr. Marc Mooney for analyzing the data for and constructing [Figure 3](#). We would also like to

acknowledge Transdisciplinary Tobacco Use Research Center P50 DA013333 for funding parts of the content in this review.

No financial disclosures were reported by the authors of this paper.

References

1. Stratton K, Shetty P, Wallace R, Bondurant S, eds. Clearing the smoke: assessing the science base for tobacco harm reduction. Institute of Medicine (IOM). Washington DC: National Academies Press, 2001.
2. Centers for Disease Control and Prevention (CDC). Tobacco use among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:1145–8.
3. CDC. Cigarette smoking among adults—United States, 1993. *MMWR Morb Mortal Wkly Rep* 1994;43:925–9.
4. CDC. Smoking cessation during previous year among adults—United States, 1990 and 1991. *MMWR Morb Mortal Wkly Rep* 1993;42:504–7.
5. World Health Organization (WHO). World Health Statistics 2006. Geneva: WHO Press, 2006.
6. Warren CW, Jones NR, Eriksen MP, Asma S. Patterns of global tobacco use in young people and implications for future chronic disease burden in adults. *Lancet* 2006;367:749–53.
7. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. *Cancer Epidemiol Biomarkers Prev* 2004;13:2035–42.
8. Tobacco Advisory Group of the Royal College of Physicians. Protecting smokers, saving lives. The case for a tobacco and nicotine regulatory authority. London: Royal College of Physicians of London, 2002.
9. International Agency for Research on Cancer (IARC). Tobacco smoke and involuntary smoking. *IARC Monogr Eval Carcinog Risks Hum* 2004;89.
10. IARC. Smokeless tobacco and some tobacco-specific nitrosamines. *IARC Monogr Eval Carcinog Risks Hum*. In press.
11. Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. *Am J Epidemiol* 2002;156:730–7.
12. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. *Tob Control* 2006;15:210–4.
13. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. *Tob Control* 2003;12:349–59.
14. Tomar SL. Epidemiological perspectives on smokeless tobacco product marketing and population harm. *Am J Prev Med* 2007;33(6S):S387–S397.
15. Renner CC, Enoch C, Patten CA, et al. Iqnik: a form of smokeless tobacco used among Alaska natives. *Am J Health Behav* 2005;29:588–94.
16. PhillipMorrisUSA. Marlboro Snus: Fact Sheet. 2007; Available online at: http://www.philipmorrisusa.com/en/popup_marlboro_snus_fact_sheet.asp?source=home_link.
17. Star Scientific Inc. Star scientific statement on Ariva® and Stonewall Hard Snuff®, Tobacco products for the twenty-first century, 2006. Available online at: <http://phx.corporate-ir.net/phoenix.zhtml?c=105863&p=irol-newsArticle&ID=852475&highlight=>.
18. Williams JR. Tobacco products having reduced nitrosamine content. United States patent pending, 2000.
19. Star Scientific Inc. The reduction of tobacco specific nitrosamines (TSNAs) in smokeless tobacco products: a serious and important health goal. Available online at: <http://starscientific.com/Components/ReleaseContainer/RTSNSummary%20of%20Quotes.pdf>.
20. O'Donnell FEJ, Williams JR. Regent Court Technologies assignee. Method of treating tobacco with microwave radiation to prevent formation of nitrosamines. United States Patent Office, 1998.
21. Roethig HJ, Kinsler RD, Lau RW, Walk RA, Wang N. Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. *J Clin Pharmacol* 2005;45:133–45.
22. National Cancer Institute (NCI). Smokeless tobacco or health. An international perspective: U.S. Department of Health and Human Services (USDHHS), Public Health Service (PHS), National Institutes of Health (NIH), 1992.
23. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. *Carcinogenesis* 1988;9:875–84.
24. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. *Chem Res Toxicol* 1998;11:559–603.
25. Rodu B, Jansson C. Smokeless tobacco and oral cancer: A review of the risks and determinants. *Crit Rev Oral Biol Med* 2004;15:252–63.
26. Idris AM, Ibrahim SO, Vasstrand EN, et al. The Swedish snus and the sudanese toombak: are they different? *Oral Oncol* 1998;34:558–66.
27. McNeill A, Bedi R, Islam S, Alkhatib MN, West R. Levels of toxins in oral tobacco products in the UK. *Tob Control* 2006;15:64–67.
28. Stepanov I, Jensen J, Hatsukami D, Hecht SS. Tobacco-specific nitrosamines in new tobacco products. *Nicotine Tob Res* 2006;8:309–13.
29. Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. *Int J Cancer* 2005;116:16–9.
30. Osterdahl BG, Jansson C, Paccou A. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. *J Agric Food Chem* 2004;52:5085–8.
31. CDC. Determination of nicotine, pH, and moisture content of six U.S. commercial moist snuff products—Florida, January–February 1999. *MMWR Morb Mortal Wkly Rep* 1999;48:398–401.
32. Hoffmann D, Djordjevic MV, Fan JG, et al. 5 Leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. *J Natl Cancer Inst* 1995;87:1862–9.
33. Brunnemann KD, Qi J, Hoffmann D. Chemical profile of two types of oral snuff tobacco. *Food Chem Toxicol* 2002;40:1699–703.
34. Substance Abuse and Mental Health Services Administration (SAMHSA). National survey on drug use and health, 2003 and 2004, 2004. Available online at: <http://www.DrugAbuseStatistics.SAMHSA.gov>.
35. Hatsukami D, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used “reduced exposure” tobacco products. *J Natl Cancer Inst* 2004;96:844–52.
36. Hatsukami D, Ebbert JO, Anderson A, et al. Smokeless tobacco brand switching: a means to reduce toxicant exposure? *Drug Alcohol Depend* 2007;87:217–24.
37. Hatsukami D, Ebbert JO, Edmonds A, et al. Smokeless tobacco reduction: tobacco free snuff vs no snuff. *Nicotine Tob Res* in press.
38. Joseph AM, Hecht SS, Murphy SE, et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. *Cancer Epidemiol Biomarkers Prev* 2005;14:2963–8.
39. Mendoza-Baumgart MI, Hecht SS, Zhang Y, et al. Pilot study on lower nitrosamine smokeless tobacco products compared to medicinal nicotine. *Nicotine Tob Res*. In press.
40. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. *Cancer Epidemiol Biomarkers Prev* 2005;14:885–91.
41. Lemmonds CA, Hecht SS, Jensen JA, et al. Smokeless tobacco topography and toxin exposure. *Nicotine Tob Res* 2005;7:469–74.
42. Kresty LA, Carmella SG, Borukhova A, et al. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. *Cancer Epidemiol Biomarkers Prev* 1996;5:521–5.
43. Hatsukami D, Edmonds A, Schulte S, et al. Preliminary study on reducing oral moist snuff use. *Drug Alcohol Depend* 2003;70:215–20.
44. Hecht SS, Carmella SG, Murphy SE, et al. Similar uptake of a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. *Cancer Epidemiol Biomarkers Prev* 2007;16:1567–72.
45. Hoffmann D, Adams JD, Lisk D, Fisenne I, Brunnemann KD. Toxic and carcinogenic agents in dry and moist snuff. *J Natl Cancer Inst* 1987;79:1281–6.
46. Hecht SS. Cigarette smoking and cancer. In: Rom WN, ed. Environmental and occupational medicine. New York: Lippincott-Raven, 1998. p. 1479–99.
47. SAMHSA. Results from the 2005 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHS Publication No. SMA 06-4194). 2006. Available online at: <http://oas.samhsa.gov/NSDUH/2k5NSDUH/2k5results.htm#TOC>.
48. CDC. Fact Sheet: Smokeless Tobacco. 2007. Available online at: http://www.cdc.gov/tobacco/data_statistics/Factsheets/smokeless_tobacco.htm.
49. WHO. Tobacco or health: a global status report; country profiles by region, 1997. Geneva: WHO Tobacco or Health Programme, 1997.
50. Idris AM, Prokopczyk B, Hoffmann D. Toombak: a major risk factor for cancer of the oral cavity in Sudan. *Prev Med* 1994;23:832–9.
51. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. *Thorax* 2003;58:435–43.
52. Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. *Eur J Cardiovasc Prev Rehabil* 2004;11:101–12.

53. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. *Lancet* 2006;368:647–58.
54. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). *Cancer Causes Control* 2005;16:347–58.
55. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. *Am J Public Health* 1994;84:399–404.
56. Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? *BMJ* 1992;305:1252–6.
57. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: A population-based study in middle-aged men. *J Am Coll Cardiol* 1999;34:1784–90.
58. Hergens MP, Ahlbom A, Andersson T, Pershagen G. Swedish moist snuff and myocardial infarction among men. *Epidemiology* 2005;16:12–6.
59. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. *Stroke* 2003;34:1754–59.
60. Norberg M, Stenlund H, Lindahl B, Weinehall L. Contribution of Swedish moist snuff to the metabolic syndrome: A wolf in sheep's clothing? *Scand J Public Health* 2006;34:576–83.
61. Persson PG, Carlsson S, Svanstrom L, et al. Cigarette smoking, oral moist snuff use and glucose intolerance. *J Intern Med* 2000;248:103–10.
62. Wallenfeldt K, Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. *J Intern Med* 2001;250:492–501.
63. England LJ, Levine RJ, Mills JL, et al. Adverse pregnancy outcomes in snuff users. *Am J Obstet Gynecol* 2003;189:939–43.
64. Hurt RD, Renner CC, Patten CA, et al. Iqmik—a form of smokeless tobacco used by pregnant Alaska natives: nicotine exposure in their neonates. *J Matern Fetal Neonatal Med* 2005;17:281–9.
65. Gupta PC, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. *BMJ* 2004;328(7455):1538.
66. Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: a cohort study in Mumbai, India. *Epidemiology* 2006;17:47–51.
67. Said TM, Ranga G, Agarwal A. Relationship between semen quality and tobacco chewing in men undergoing infertility evaluation. *Fertil Steril* 2005;84:649–53.
68. Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. *Br J Cancer* 2001;85:661–7.
69. Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. *Am J Epidemiol* 1986;124:926–41.
70. Muscat JE, Stellman SD, Hoffmann D, Wynder EL. Smoking and pancreatic cancer in men and women. *Cancer Epidemiol Biomarkers Prev* 1997;6:15–9.
71. Ye W, Ekstrom AM, Hansson LE, Bergstrom R, Nyren O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. *Int J Cancer* 1999;83:223–9.
72. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. *Int J Cancer* 2000;85:340–6.
73. Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. *Int J Cancer* 2005;114:992–5.
74. Stockwell HG, Lyman GH. Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. *Head Neck Surg* 1986;9:104–10.
75. Winn DM, Blot WJ, Shy CM, et al. Snuff dipping and oral cancer among women in the southern United States. *N Engl J Med* 1981;304:745–9.
76. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. *Cancer* 1998;82:1367–75.
77. Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. *Int J Cancer* 1998;77:341–6.
78. Coglianò V, Straif K, Baan R, et al. Smokeless tobacco and tobacco-related nitrosamines. *Lancet Oncol* 2004;5:708.
79. Andersson G, Warfvinge G. The influence of pH and nicotine concentration in oral moist snuff on mucosal changes and salivary pH in Swedish snuff users. *Swed Dent J* 2003;27:67–75.
80. Ayo-Yusuf OA, Swart TJP, Pickworth WB. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. *Tob Control* 2004;13:186–9.
81. Lunell E, Lunell M. Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: A crossover study. *Nicotine Tob Res* 2005;7:397–403.
82. Richter P, Spierto FW. Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content. *Nicotine Tob Res* 2003;5:885–9.
83. Henningfield J, Radziszewski A, Cone E. Estimation of available nicotine content of six smokeless tobacco products. *Tob Control* 1995;4:57–61.
84. Djordjevic M, Hoffman D, Glynn T, Connolly G. U.S. commercial brands of moist snuff, 1994. I. Assessment of nicotine, moisture, and pH. *Tob Control* 1995;4:62–6.
85. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. *Tob Control* 1999;8:387–92.
86. Brunnemann KD, Qi J, Hoffmann D. Analysis of nicotine, moisture, pH and tobacco-specific N-nitrosamines (TSNA) in 18 oral snuff samples. Boston MA: Department of Public Health, 2003.
87. Kotlyar M, Mendoza-Baumgart MI, Li ZZ, et al. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. *Tob Control* 2007;16:138–42.
88. Benowitz NL, Porchet H, Sheiner L, Jacob P 3d. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. *Clin Pharmacol Ther* 1988;44:23–8.
89. Connolly GN, Winn DM, Hecht SS, et al. The reemergence of smokeless tobacco. *N Engl J Med* 1986;314:1020–7.
90. Institute of Medicine (IOM). Growing up tobacco free. Preventing nicotine addiction in children and youths. Washington DC: National Academies Press, 1994.
91. Hatsukami D, Giovino GA, Eissenberg T, et al. Methods to assess potential reduced exposure products. *Nicotine Tob Res* 2005;7:827–44.
92. Savitz DA, Meyer RE, Tanzer JM, Mirvish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. *Am J Public Health* 2006;96:1934–9.
93. Hatsukami D, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. *Nicotine Tob Res* 2006;8:599–622.
94. World Health Organization. Guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing, 2003. Available online at: www.who.int/tobacco/global_interaction/tobreg/goa_2003_principles/en.

Effect of Smokeless Tobacco Product Marketing and Use on Population Harm from Tobacco Use

Policy Perspective for Tobacco-Risk Reduction

Lynn T. Kozlowski, PhD

Abstract: This article presents policy perspectives on the marketing of smokeless tobacco products to reduce population harm from tobacco use. Despite consensus that smokeless tobacco products as sold in the United States are less dangerous than cigarettes, there is no consensus on how to proceed. Diverse factions have different policy concerns. While the tobacco industry is exempted from U.S. Food and Drug Administration (FDA) oversight, the pharmaceutical industry whose nicotine replacement therapy (NRT) medicines compete with smokeless tobacco as noncombustible nicotine-delivery systems are regulated by the FDA. Some public health experts support smokeless tobacco use to reduce population harm from tobacco; other public health experts oppose promoting smokeless tobacco for harm reduction. Adult consumers can freely purchase currently-marketed smokeless tobacco products and even more-deadly cigarettes.

Concerns with and advantages of smokeless tobacco products are discussed. In that noncombustible medicinal nicotine-delivery systems have been proven to be effective smoking-cessation aids, smokeless tobacco, as another source of psychoactive doses of nicotine, could be used similarly, in a dose-response fashion as a smoking-cessation aid (consistent with FDA principles for evaluating generic versions of drugs). Price measures should be used on tobacco products to make costs to consumers proportional to product health risks (which would make smokeless tobacco much cheaper than cigarettes), and smokeless tobacco should be encouraged as an option for smoking cessation in adult smokers, particularly for those who have failed to stop smoking using NRT or other methods.

(Am J Prev Med 2007;33(6S):S379–S386) © 2007 American Journal of Preventive Medicine

Despite considerable scientific consensus that smokeless tobacco products as sold in the United States, although not safe, are less dangerous than cigarettes to physical health,¹ there has been fractious dissension within tobacco control, sometimes bitter and personal, on whether smokeless tobacco can be or should be used to help reduce population tobacco harm. Even if disagreed with, the perspectives reviewed here will hopefully enrich arguments and move thinking forward in this contentious area.

The Product

Fundamental to the four P's of marketing (product, placement, promotion, and price) is the product itself.² Some smokeless tobacco products (e.g., chewing tobacco and moist snuff) are known to stimulate saliva and result in spitting. Some newer, pressed, smokeless

tobacco products do not promote spitting; and some are taken into the nose. While some smokeless tobacco products as used in the U.S. today are probably more dangerous than others, this review will not evaluate that evidence.³ Smokeless tobacco products do not directly expose the lungs to tobacco toxins and do not deliver toxins to the lungs of passive (secondhand) smokers. Cigarettes are dominant causes of lung cancer, chronic obstructive pulmonary disease (COPD), and heart disease, while smokeless tobacco is very unlikely to be a cause of lung cancer or COPD, and probably a lesser cause of heart disease and oral cancer than cigarettes.^{3–8} A Royal College of Physician's Committee concluded that smokeless tobacco was "10–1000 times less hazardous than smoking depending on the product,"⁹ and clearly a lower-risk product than cigarettes.

Multiple Factions with Different Perspectives

Table 1 offers an outline of the major factions involved with smokeless tobacco marketing and policy in the U.S. and elsewhere. Juxtaposing these factions shows a complex system in which one faction's interests and

From the Department of Health Behavior, State University of New York–Buffalo, Buffalo, New York

Address correspondence and reprint requests to: Lynn T. Kozlowski, PhD, Professor and Chair, Department of Health Behavior, University at Buffalo, SUNY, 623 Kimball Tower, 3425 Main Street, Buffalo NY 14214-3079. E-mail: lk22@buffalo.edu.

Table 1. Overview of parallel factions involved in smokeless tobacco product marketing

Faction	A key function	Selected current marketing and policy status in the U.S.	Selected current marketing and policy status elsewhere in the world
Tobacco industry (smokeless)	Sell tobacco products	Can market to adults as long as they avoid explicit health claims (e.g., cannot say smokeless tobacco is an effective smoking-cessation aid or is lower risk to health than cigarettes); Congressional health warnings are on product and advertising.	Moist snuff (literally suckable tobacco) is banned in most of the EU
Pharmaceutical industry	Sell medicines	For prescription smoking-cessation aids, medical permission, and oversight; for OTC products, FDA-approved, with cautions and instructions. Selective marketing of prescription products; widespread marketing of OTC products for smoking cessation only, yet OTC products can be used in many ways by consumers.	In Austria, Brazil, Canada, France, Norway, Portugal, and Venezuela have “temporary abstinence” (i.e., temporarily abstaining from cigarettes in situations where smoking is prohibited) as an approved indication for NRT ¹⁰
Consumers	Buy or not	Consumers can in practice do whatever they choose with any OTC medicine or tobacco product available; prescription medicines subject to greater restrictions on consumers. For example, consumers can use smokeless tobacco as a temporary substitute for cigarettes or a permanent substitute for cigarettes or a multiweek smoking-cessation aid (as indicated for NRT).	Many EU smokers do not have the option of buying moist snuff. Sweden is an exception where moist snuff has become popular among men.
Public health workers—anti-tobacco and anti-tobacco-caused disease	Protect and promote health	These workers promote never using or ceasing use of all tobacco products and vary in their level of support for nicotine-based medicines for cessation.	Same as in the U.S.
Public health workers—anti-tobacco-caused disease (harm reduction)	Protect and promote health	These workers promote never using or ceasing use of all tobacco products and, for those who do use tobacco, the use of lower-risk nicotine-delivery systems (including smokeless tobacco) as ongoing substitutes for cigarettes (i.e., as smoking-cessation aids).	Same as in the U.S.

EU, European Union; FDA, Federal Trade Commission; NRT, nicotine replacement therapy; OTC, over-the-counter.

regulatory concerns may be irrelevant to another faction. The table includes two divergent public health approaches, each striving to improve public health, but also seeing somewhat different strategies as apt. Consumers, the tobacco industry, and the pharmaceutical industry are also important factions. The pharmaceutical industry is included because it is part of the countermarketing efforts against cigarettes and nicotine replacement therapy (NRT) medicines and smokeless tobacco products can be viewed as competing products. Notwithstanding the different goals and standards of the pharmaceutical and tobacco industries, NRT and smokeless tobacco are both effective, noncombustible nicotine-delivery systems. The example in Table 1 from elsewhere in the world indicates interestingly discrepant policies.¹⁰ While the U.S. has not formally approved use of NRT for temporary abstinence from cigarettes, such a use has been approved by authorities elsewhere in the world and happens to be identical to current uses promoted by the tobacco industry for smokeless tobacco in the U.S. (for “when you can’t smoke”).¹¹

Smokeless Tobacco Products Have Been and Are Being Sold in the U.S.

The U.S. Food and Drug Administration (FDA) does not presently regulate tobacco-based nicotine-delivery systems (cigarettes, cigars, smokeless tobacco). Smokeless tobacco products are advertised legally and sold widely to adults (and sometimes illegally to children). That pharmacologically active tobacco products are exempted from FDA regulation—as are, to some extent, widely sold pharmacologically-active herbal and food supplement products—should make us aware that, for some people, many of the drugs they take are not FDA-approved.¹²

Evidence that Smokeless Tobacco Is an Effective Cigarette Substitute and Cessation Aid

Popular forms of tobacco products deliver adequate doses of nicotine to the brains of users, stimulate the chemical senses (taste and smell), and are reasonably convenient to use.¹³ “Convenience” refers to many

issues: for example, cigarettes are inconvenient and smokeless tobacco products convenient in highly flammable environments. Depending on the historic period and place, popular tobacco products have been smoked (either inhaled into the lungs or just puffed into the mouth), chewed, sucked, or snorted.¹³ Demographic patterns of use have varied. In some times and in some places, men have been nearly exclusive users of a given product; and in other times and other places, women have resembled men in use of the same product.¹⁴ When smokeless tobacco became inconvenient to use in the late 1800s, because public spitting was outlawed (out of concern about the spread of disease), this dominant form of tobacco use decreased in popularity.¹³ Similarly, health-related bans of indoor smoking have been associated with declines in the popularity of cigarette smoking in the U.S.^{15,16} In neither case did the pharmacokinetics of smokeless tobacco or cigarettes change, rather it was the prevailing cultural context for the use of the product that changed. Note that smokeless tobacco was by far the most popular form of tobacco use in the early 19th century in the U.S.¹⁷ Up until the mid-1920s in the U.S., more smokeless tobacco than cigarettes (both measured in pounds) were sold per capita.¹⁸

Smokeless tobacco use was observed by the first Europeans in the Americas. Amerigo Vespucci published the first printed account of tobacco use in 1505, focusing on the use of smokeless tobacco, “. . . which they chewed like cattle to such an extent that they could scarcely talk . . .”¹⁹ Dickson also commented: “. . . certainly sailors have always chewed [tobacco] from the time of their landing on American soil up to the present.”¹⁹ Interestingly, the observation by Dr. Claes Lundgren in the 1960s of Swedish submariners using smokeless tobacco to cope when unable to smoke cigarettes led to the development of NRT (Nicorette®) as a smoking-cessation aid.²⁰

Smokeless tobacco was used as a smoking substitute by Catholic priests in Europe in the 1600s when forbidden to smoke.²¹ In workplaces where smoking was not allowed, smokeless tobacco was used as a substitute for smoking and sometimes as a preferred form of tobacco use both at work and when not at work—in mines, in sawmills, in munitions plants, and by soldiers in the field when smoking was impractical.¹⁷

Pharmacologic research has produced consistent evidence that smokeless tobacco is addictive (because it is a significant source of nicotine^{4–6}). Cigarettes and smokeless tobacco products both have been described as “highly engineered, drug delivery devices” that produce user-controllable and addictive doses of nicotine.²² Smokeless tobacco provides plasma nicotine levels that are similar to those from cigarettes.^{23,24} Smokeless tobacco users have been found to exhibit withdrawal symptoms when abstaining from smokeless tobacco.²⁴ Medicinal nicotine in general has not shown

great success in treating smokeless tobacco dependence,²⁵ but consistent with the high levels of nicotine delivered by smokeless tobacco, when high doses of medicinal nicotine are given, promising results have been found.²⁶ One direct study of smokeless tobacco as a smoking-cessation product has found encouraging results, indicating a key nicotine-based action.²⁷

Smokeless tobacco and smoking trends in Sweden have been the object of much attention,^{28–34} including evidence from Sweden that increased smokeless tobacco use was related to declines in daily smoking prevalence.^{28,29,32} Interpreting societal trends is challenging. Even if smokeless tobacco caused some of the drop in daily smoking among males in Sweden, this does not guarantee that the same would happen in the U.S.³⁰ One econometric study supports that smokeless nicotine (in the form of NRT) is cross-elastic with cigarettes³⁵; another study shows the same pattern for smokeless tobacco and cigarettes.³⁶ In other words, increased cigarette prices are associated with increased use of smokeless tobacco as well as with increased use of NRT. This is evidence for nicotine-based substitutability.

The FDA procedures for approving generic versions of pharmaceuticals offer support for smokeless tobacco as a smoking substitute and cessation aid.³⁷ In addition to the issue of safety, a key issue is the evaluation of generic drugs for “bioequivalence,” that is, does the new product deliver necessary doses of active ingredients. A tobacco company could likely engineer a smokeless tobacco product with similar pharmacokinetics to, for example, the Commit® (GlaxoSmithKline, Philadelphia PA) nicotine lozenge. If the pharmacokinetics indicated bioequivalence, since many placebo-controlled trials have established that nicotine is the active ingredient of smoking-cessation aids, there would be no requirement to repeat the trials with smokeless tobacco. Considering FDA rules for generic drugs, a smokeless tobacco product might be approvable, because of existing evidence on NRT, as an effective smoking-cessation aid, but it might not be marketable largely because of safety concerns, or marketed as a prescription-only product. FDA’s regulatory power may be viewed as most determining of product use when it serves to keep the product off the market completely. Given that smokeless tobacco is already available, consumers could in practice so use the product—without FDA approval of such use.

Smokeless tobacco products have been promoted in the U.S. as cigarette substitutes (for use when one cannot smoke),¹¹ but not as smoking-cessation aids, probably because tobacco products are exempted from FDA regulation. A major tobacco company would be unlikely to apply for smokeless tobacco to be marketed in direct competition with FDA-approved NRT. Applying for FDA approval could risk placing manufacturers under a new regulatory jurisdiction, possibly leading to

FDA regulation of all smokeless tobacco products. Such regulatory/policy issues do not nullify that, if submitted to the FDA as a smoking-cessation aid, the FDA likely would need to judge them as effective, but not necessarily safe.

Consumer Preferences

Even very similar consumer products (e.g., Coke® vs Pepsi®) are subject to complex and strong consumer preferences.³⁸ Many features can be distinguished between NRTs and smokeless tobacco products: cost, likely addictiveness, taste, and health risks; but they are nevertheless functionally similar as noncombustible, effective nicotine-delivery systems with potentially similar uses. One recent study has found that many, but not all, cigarette smokers preferred Commit lozenge to smokeless tobacco, based on descriptions of the products.³⁹ But, users of a strong moist snuff were found to much prefer that product to the Commit lozenge or to new compressed smokeless tobacco products.⁴⁰ To quit smoking cigarettes, some consumers would prefer to use smokeless tobacco, some nicotine gum, some the patch, and some no drug products.⁴¹ Such choices often are not a matter of efficacy, but of consumer preference. Consumer acceptability should not be confused with whether a product works. If one accepts that smokeless tobacco can work to help smoking cessation, the remaining issues include who might use it, when it might be used, and should these individuals have selected another way to quit smoking out of concern for safety? Concerning overall risk reduction, consumers should be encouraged by health professionals to prefer NRT to any smokeless tobacco product, as a substitute for smoking or as a smoking-cessation aid.^{33,42,43} Several potential issues such as product cost (especially per mg of nicotine delivered⁴⁴), taste, effectiveness, and image, could lead some consumers to prefer smokeless tobacco products to NRT. Most NRT sold in the U.S. is now available without prescription, and, in effect, consumers are essentially free to use it however they prefer.⁴³

Counter-Marketing of Cigarettes

The World Bank did an evidence-based review of the counter-marketing of cigarettes and concluded that price measures (e.g., higher cigarette taxes) were the most effective measure to reduce smoking. Several nonprice measures also helped to reduce smoking: consumer information, research, cigarette advertising and promotion bans, warning labels, and restrictions on public smoking. Increased access to NRT and other cessation strategies were also recommended.⁴⁵ With respect to smokeless tobacco policy, two modifications of the World Bank position should be considered.

More-Dangerous Tobacco Products Should Be Proportionately More Expensive to Purchase

Steps should be taken to ensure that more-dangerous tobacco products (especially cigarettes) are the more-expensive tobacco products. This is not fundamentally a new proposal. In 1962, the Royal College of Physicians recommended differential taxation with cigars and pipes being taxed less than cigarettes.⁴⁶ The econometric literature on tobacco taxation supports the general finding of substitutability of tobacco products, with higher cost related to reduced consumption of a given product.^{35,36,47} The pattern of results has led to the recommendation that differential taxation as a function of harm is an important aspect of differential taxation.⁴⁸ This process probably should not start with the current price of cigarettes and work down to cheaper and cheaper products, rather it would be desirable to make cigarettes very expensive (for example, several times the cost of NRT) and then start reducing the cost of other tobacco products in some way proportionate to disease risks. Such a differential taxation plan is part of the likely best strategy for reducing cigarette use; if smokeless tobacco costs the same or is more expensive, it could undermine the effects of tax increases on cigarette use, because of product substitutability.⁴⁸

Smokeless Tobacco Should Be Treated As an Alternative Smoking-Cessation Aid

Lower-cost NRT can promote smoking cessation³⁵ and, presumably,⁴⁷ promote NRT to be preferred to smokeless tobacco, therefore efforts should be made to have NRT cost significantly less than smokeless tobacco. As smokeless tobacco products can be effective smoking-cessation aids and may be able to function as useful alternatives to NRTs for those who prefer not to use NRTs (see discussion above on both points), then smokeless tobacco could be used as another tool to promote smoking cessation.⁴⁹ It also would be good to encourage the development of more consumer-attractive NRTs, that could be preferred to smokeless tobacco products.^{33,42,43} While solely promoting smokeless tobacco as a way to quit smoking would be likeliest to minimize adverse effects of smokeless tobacco marketing, it is unlikely to happen for the policy reasons indicated above. Health professionals should be willing to turn to suggesting smokeless tobacco as a smoking-cessation aid when NRT and other treatment aids and efforts have failed.

Concerns About Marketing Smokeless Tobacco As a Substitute for Cigarettes

The objections to claims of the public health value of the lower risk to individual users of smokeless tobacco

are generally of three interrelated types. Each type can be viewed as a form of “slippery slope” argument, holding that this first reduced-risk step may lead ultimately to greater risk overall. Slippery slope arguments are not considered strong logical arguments, and their force depends on sound and detailed analysis of what might happen, along with consideration of the likelihoods of such ill effects.⁵⁰ In other words, the specter of “what might happen” is not a convincing argument on its own. There needs to be an assessment of the likelihood of ill effects.

Research Is Needed on Health Risks of Smokers Switching to Smokeless Tobacco Products

One critique notes there is little research on the risk levels of various patterns of dual use of smokeless tobacco and cigarettes.⁵¹ While strictly true, it is also true that well-established dose–response principles should apply. Sequential “dual” use (moving completely off cigarettes to smokeless tobacco) will probably show reduction in smoking-caused diseases—as a function of duration of smoking and daily dose of smoking. Substituting only a few cigarettes a day with smokeless tobacco is unlikely to reduce significantly tobacco harm. The longer and more one has smoked, the less likely a reduction in smoking-caused diseases will take place. For some problems the health damage may already have been done (e.g., cancer), and it will take years for the problem to appear, even if the individual has stopped all tobacco use. For concurrent dual use of NRT and cigarettes in smokers who do not want to quit smoking, because nicotine intake is somewhat regulated, total intake of smoke toxins is unlikely to rise with dual use and will likely decrease.⁵² The greater the reduction in smoke toxins, the greater the reduction in smoke-caused diseases. While limited studies demonstrate this risk-reduction at present, it is also true that the current health risks of cigarette smoking are an urgent public health problem.

Risk of Increased Use and Increased Users of Tobacco Products

A second critique has been described by Hatsukami et al.⁵¹: “Aggressive marketing of smokeless tobacco as less-risky than cigarettes may not necessarily lead to reduced total tobacco use but increased use, especially newly initiated use.” Converting those who would have been nontobacco users without smokeless tobacco to any tobacco use would be a concern. The focus, from one public health perspective, should be on reducing total tobacco-related disease, not the total number of tobacco users. Of course, a lower-risk product could increase population risks, but as a function of the increase in use and the decrease in danger from the product. Even though smokeless tobacco is less danger-

ous than cigarettes to individual users, if many more people start using the product, is it likely to produce a net loss for public health? This has become a frequent question when considering the population effects of less-dangerous products for individuals. To get a sense of scale for the possible problems caused by increased use of a less-dangerous product, consider the risk/use equilibrium, an equilibrium achieved by increasing use as risk decreases.⁵³ If the level of use increases faster than risk is decreased, public health would be hurt. If risk levels are decreased faster than use rises, public health would be helped. Smokeless tobacco products appear to be very unlikely to increase harm to public health if they are substituted for cigarettes, because the risk reduction to individual users is large. For example, for a product that is 95% less dangerous than cigarettes, an impossible 400% of the population (i.e., 20 times greater) would need to use the product to equal the early death from smoking (assuming 20% of the population smoking to begin with). For a product that is 80% less dangerous than cigarettes, an impossible 100% of the population (i.e., 5 times greater) would need to use the product to equal the early death from smoking (i.e., from 20% of the population smoking). It is doubtful that close to 100% of the population would come to use any tobacco product. If smokeless tobacco is used to help cope with smoking restrictions, while the individual continues to be a cigarette smoker, this would be an example of a lower-risk product contributing to the ongoing use of a higher-risk product. This problem could arise from the use of either NRT or smokeless tobacco as a temporary substitute for cigarettes, but there is little evidence to date that such problems have been important.

Gateway Fears

The third common critique arises from concerns that smokeless tobacco may cause subsequent cigarette smoking and hence the reduced risk is only temporary,^{51,54,55} but other experts have found evidence inconsistent with a causal gateway,^{56–59} and have argued that smokeless tobacco may even act to prevent cigarette smoking in high-risk youth and that much of the association between smokeless tobacco and smoking is not causally linked. Counter-marketing and other prevention efforts to reduce cigarette smoking should be able to decrease the possible progression from smokeless tobacco to cigarettes. In a world where cigarettes are much more expensive than and recognized as much more dangerous than smokeless tobacco, the gateway should swing more toward the less-dangerous product than toward the more-dangerous product.

Unfortunately, inaccurate information that smokeless tobacco is just as dangerous as or even more dangerous than cigarettes has been widely promoted.^{60,61} A formal complaint under the Data Quality Act resulted in the

National Institute of Aging changing the information on its website on smokeless tobacco.⁶² One analysis concluded that overall there was a “misleading and harmful public message about smokeless tobacco” to be found on the Internet.⁶¹ There have since been recent improvements in the quality of health information on smokeless tobacco.⁶³

Health communications should do more than simply inform that “there is no safe tobacco product.”⁶⁴ The Congressionally-mandated rotating warning that “WARNING: This product is not a safe alternative to cigarettes” is in effect a “not safe” message. While this message is true, it is also a truism, in that “nothing is completely safe,” and it is of limited value in that the public largely knows that there is no safe tobacco product.⁶⁴ One of the lessons of the low-tar-cigarette disaster is that, while the public understood that “low-tar” cigarettes were not safe, a public health tragedy resulted from the simultaneous and nonparadoxical belief that low-tar cigarettes were “safer.”⁶⁵

Can, Will, or Should Smokeless Tobacco Marketing Be Used As Part of a Comprehensive Tobacco-Control Plan?

The reviewed evidence indicates that smokeless tobacco products as effective nicotine-delivery systems can function as cigarette substitutes and cessation aids. As with other consumer drug products, smokeless tobacco will be acceptable to some consumers and not to others as a function of both pharmacologic and non-pharmacologic factors.

Whether smokeless tobacco products will be substituted for cigarettes in the U.S. will likely depend on the entire pattern of comprehensive tobacco-control measures (including taxation, health information, smoking restrictions) and concerns about net population harm that might be the result of doing anything other than discouraging any smokeless tobacco use. Of course, not all possible adverse effects of any encouragement or opportunities to substitute smokeless tobacco for cigarettes have been reviewed and discussed here. The issue of moral hazard related to public health measures can be very complex; for example, it has been found that increased promotion of NRT—generally viewed as good for tobacco control—is associated with small increases in the number of cigarettes smoked per day by young smokers, perhaps because smokers know they have a way to stop when they desire to do so.⁶⁶ They estimated that if NRT advertising were eliminated, youth smoking would decrease from “5.77 cigarettes per day to about 5.27, or less, cigarettes per day.”⁶⁶ Another question not discussed is will former smokers be attracted back to tobacco use with the availability of safer, lower-cost smokeless tobacco? Consequentialist (ends-based) moral philosophies are often challenged

by the impracticality of a complete analysis of all possible costs and benefits of any action.⁶⁷ It is important to remember that smokeless tobacco is not essentially a new product. The longstanding, current, and legal availability of smokeless tobacco products gives some reason to believe that those who like smoking cigarettes will not readily come to prefer smokeless tobacco; if it were such an “easy sell,” the fears of cigarette smoking as a deadly product as well as bans on indoor smoking probably would have caused already a greater switch to smokeless tobacco or NRT. (The switch from high-yield cigarettes to misleading “low-yield” cigarettes is a switch from one cigarette to another, not a switch to an entirely different type of product.) Many smokers do quit without the use of any type of pharmacologic cessation aid.⁵

Should smokeless tobacco play a role in comprehensive tobacco control? This is both an ethical and a practical question. The Royal College of Physicians recently concluded, after a detailed bio-ethical analysis, that a comprehensive plan to discourage cigarette smoking (including pricing, marketing, and regulatory controls) should make alternatives to smoking tobacco more widely available.⁶⁸ Econometric research indicates that if one desires the maximum reduction in cigarette sales with a tax increase on cigarettes, it is also important to make other substitutable nicotine-delivery systems (NRT and smokeless tobacco) cost less than cigarettes.⁴⁸

Currently, proposed legislation on the regulation of tobacco products by the FDA may bring about little to no change in traditional tobacco products.⁶⁹ Any proposed legislation probably should attend to the interrelationships among nicotine-delivery products as a complex system, rather than focus so much on the control of claims about products. Manufacturers could avoid any cumbersome evaluation process involved with justifying claims for new products by simply focusing on making their billions on the sales of traditional tobacco products. Differentiating traditional nicotine-delivery systems in terms of knowledge of risks, price, and availability should be part of a comprehensive tobacco-control program, especially in a country where smokeless tobacco and deadly cigarette products are and will likely be widely available.

Despite scientific consensus that smokeless tobacco products as sold in the U.S. are much less dangerous to the health of users than are cigarettes, there remains no consensus on whether widely available smokeless tobacco can be or should be used to help reduce population tobacco harm. Research agendas have been proposed,^{1,6,8} but there will still be disputes about how many answers or terms are needed before action steps can be supported.⁵¹ The Precautionary Principle encourages us to be “better safe than sorry,”⁷⁰ and it can seem to be a public health virtue. This principle may be misapplied⁷¹ on this issue, but nevertheless it is being

applied. Saner has argued: "If precaution is one-sided (only considering the risk of commission, i.e., doing an action), then it can become an antinovelty principle."⁷² Overemphasis on precaution is not necessarily a public health virtue in the face of an existing public health crisis—the legal and widespread marketing and sale of deadly cigarettes.⁷³

The research was funded in part by the Roswell Park Transdisciplinary Tobacco Use Research Center (TTURC), 1 P50 CA111236.

No financial disclosures were reported by the author of this paper.

References

1. Stratton K, Shetty P, Wallace R, Bondurant S, eds. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington DC: Institute of Medicine, National Academies Press, 2001.
2. Borden NH. The concept of the marketing mix. *J Advert Res* 1964; 4(2):2-7.
3. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. *Cancer Epidemiol Biomarkers Prev* 2004;13:2035-42.
4. U.S. Advisory Committee to the Surgeon General. The health consequences of using smokeless tobacco: a report of the Advisory Committee to the Surgeon General. Bethesda MD: U.S. Department of Health and Human Services (USDHHS), Public Health Service (PHS), 1986.
5. U.S. Office on Smoking and Health. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. Washington DC: USDHHS, PHS, Centers for Disease Control and Prevention (CDC), Center for Health Promotion and Education, 1988.
6. Boyd GM, Darby CA. Smoking Tobacco and Cancer Program. Smokeless tobacco use in the United States: a compilation of papers on recent research and discussion of directions for future research. Washington DC: Smoking, Tobacco, and Cancer Program, Division of Cancer Prevention and Control, U.S. GPO, 1989.
7. Critchley JA, Unal B. The health effects associated with smokeless tobacco use: a systematic review. *Thorax* 2003;58:435-43.
8. Savitz DA, Meyer RE, Tanzer JM, Mivish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. *Am J Public Health* 2006;96:1934-9.
9. Tobacco Advisory Group of the Royal College of Physicians. Protecting smokers, saving lives. London: Royal College of Physicians, 2002. Available online at: <http://www.rcplondon.ac.uk/pubs/books/protsmokers/index.asp>.
10. Shiffman S, Fant RV, Buchhalter AR, Gitchell JG, Henningfield JE. Nicotine delivery systems. *Expert Opin Drug Deliv* 2005;23:563-77.
11. Polito JR. Fall 2004 nicotine industry cigarette and oral tobacco U.S. magazine advertising. Available from: <http://whyquit.com/ads/index.html>.
12. Grauer RP, Thomas RD, Tronson MD, Heard GC, Diacon M. Preoperative use of herbal medicines and vitamin supplements. *Anaesth Intensive Care* 2004;32:173-7.
13. Kozlowski LT. The determinants of tobacco use: cigarette smoking in the context of other forms of tobacco use. *Can J Public Health* 1982;73: 236-41.
14. Kozlowski LT, Henningfield JE, Brigham J. Cigarettes, nicotine, and health: a biobehavioral approach. Thousand Oaks CA: Sage, 2001.
15. Levy DT, Friend K. A framework for evaluating and improving clean indoor air laws. *J Public Health Manag Pract* 2001;7:87-96.
16. Jha P, Chaloupka FJ, Corrao M, Jacob B. Reducing the burden of smoking worldwide: effectiveness of interventions and their coverage. *Drug Alcohol Rev* 2006;25:597-609.
17. Robert JC. The story of tobacco in America. Chapel Hill NC: The University of North Carolina Press, 1949.
18. Psoter WJ, Morse DE. Annual per capita apparent consumption of tobacco products in the United States: 1900-1990. *Prev Med* 2001;32:1-9.
19. Dickson SA. Panacea or precious bane: tobacco in sixteenth-century literature. New York: New York Public Library, 1954.
20. Nicorette Gum: Product monograph. Available online at: http://www.hamline.edu/rkagan/Pictures_and_others/PDF/NicoretteMonoGUM.pdf.
21. Brooks JE. The mighty leaf. London: Alvin Redman Limited, 1953.
22. Henningfield JE, Fant RV. Tobacco use as drug addiction: the scientific foundation. *Nicotine Tob Res* 1999;1(Suppl. 2):S31-5.
23. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. *Tob Control* 1999;8: 387-92.
24. Pitsiu M, Gries JM, Benowitz N, Gourlay SG, Verotta D. Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum. *J Pharmacokinetic Pharmacodyn* 2002;29:383-402.
25. Hatsukami DK, Severson HH. Oral spit tobacco: addiction, prevention and treatment. *Nicotine Tob Res* 1999;1:21-44.
26. Ebbert JO, Rowland LC, Montori V, et al. Interventions for smokeless tobacco use cessation. *Cochrane Database Syst Rev* 2004(3):CD004306.
27. Ebbert JO, Dale LC, Patten CA, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. *Nicotine Tob Res* 2007;9:43-52.
28. Tilashalski K, Rodu B, Cole P. Seven-year follow-up of smoking cessation with smokeless tobacco. *J Psychoactive Drugs* 2005;37:105-8.
29. Henningfield JE, Fagerstrom KO. Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? *Tob Control* 2001;10:253-7.
30. Foulds J, Ramstrom L, Burke M, et al. The effect of smokeless tobacco (Snus) on smoking and public health in Sweden. *Tob Control* 2003;12: 349-59.
31. Tomar SL, Connolly GN, Wilkenfeld J, Henningfield JE. Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts? *Tob Control* 2003;12:368-71.
32. Stegmayr B, Eliasson M, Rodu B. The decline of smoking in northern Sweden. *Scand J Public Health* 2005;33:321-4, discussion 243.
33. Furberg H, Lichtenstein P, Pedersen NL, Bulik C, Sullivan PF. Cigarettes and oral snuff use in Sweden: prevalence and transitions. *Addiction* 2006;101:1509-15.
34. Foulds J, Kozlowski L. Snus—what should the public-health response be? *Lancet* 2007;369:1976-8.
35. Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. *Lancet* 2007;369:2010-4.
36. Tauras JA, Chaloupka FJ. The demand for nicotine replacement therapies. *Nicotine Tob Res* 2003;5:237-43.
37. Ohsfeldt RL, Boyle RG, Capilouto E. Effects of tobacco excise taxes on the use of smokeless tobacco products in the USA. *Health Econ* 1997;6:525-31.
38. U.S. Food and Drug Administration (FDA). Greater access to generic drugs: new FDA Initiatives to improve the drug review process and reduce legal loopholes. Available online at: <http://www.fda.gov/fdac/special/testtubetopatient/generics.html>.
39. McClure SM, Li J, Tomlin D, Cypert KS, Montague LM, Montague PR. Neural correlates of behavioral preference for culturally familiar drinks. *Neuron* 2004;44:379-87.
40. Shiffman S, Gitchell J, Rohay JM, Hellebusch SJ, Kemper KE. Smokers' preferences for medicinal nicotine vs. smokeless tobacco. *Am J Health Behav* 2007;31:462-72.
41. Kotlyar M, Mendoza-Baumgart MI, Li ZZ, et al. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. *Tob Control* 2007;16:138-42.
42. Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R, et al. Comparison of three nicotine treatments: initial reactions and preferences with guided use. *Psychopharmacology (Berl)* 2005;182:545-50.
43. Kozlowski LT, O'Connor RJ, Edwards BQ. Some practical points on harm reduction: what to tell your lawmaker and what to tell your brother about Swedish snus. *Tob Control* 2003;12:372-3.
44. Kozlowski LT, Giovino GA, Edwards B, et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. *Addict Behav* 2007;32:2140-50.
45. Lawson GM, Hurt RD, Dale LC, et al. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing. *J Clin Pharmacol* 1998 Jun;38:502-9.
46. Jha P, Chaloupka FJ. Curbing the epidemic: governments and the economics of tobacco control. Washington DC: World Bank, 1999.
47. Royal College of Physicians. Smoking and health. London: Pitman Medical Publishing, 1962.

48. Chaloupka FJ. Macro-social influences: the effects of prices and tobacco-control policies on the demand for tobacco products. *Nicotine Tob Res* 1999;1(Suppl. 1):S105-9.
49. Chaloupka F, Hu T, Warner KE, Jacobs R, Yurekli A. The taxation of tobacco products. In: Jha P, Chaloupka F, eds. *Tobacco control in developing countries*. New York: Oxford University Press, 2000. pp. 237-72.
50. Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. *Harm Reduct J* 2006;3:37.
51. Warburton N. *Thinking from A to Z*. New York: Routledge, 1996.
52. Hatsukami DK, Henningfield JE, Kodlyar M. Harm reduction approaches to reducing tobacco-related mortality. *Annu Rev Public Health* 2004;25:377-95.
53. Fagerstrom KO, Tejdning R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? *Tob Control* 1997;6:311-6.
54. Kozlowski LT, Strasser AA, Giovino GA, et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. *Tob Control* 2001;10:201-3.
55. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The U.S. experience. *Nicotine Tob Res* 2003;5:561-70.
56. Haddock CK, Weg MV, DeBon M, et al. Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males. *Prev Med* 2001;32:262-7.
57. O'Connor RJ, Flaherty BP, Edwards BQ, et al. Regular smokeless tobacco use is not a reliable predictor of smoking onset when psychosocial predictors are included in the model. *Nicotine Tob Res* 2003;5:535-44.
58. Kozlowski LT, O'Connor RJ, Edwards BQ, et al. Most smokeless tobacco use is not a causal gateway to cigarettes: Using order of product use to evaluate causation in a national U.S. sample. *Addiction* 2003;98:1077-85.
59. Furberg H, Bulik CM, Lerman C, Lichtenstein P, Pedersen NL, Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? *Tob Control* 2005;14:422-4.
60. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. *Tob Control* 2006;15:210-4.
61. Kozlowski LT, O'Connor RJ. Apply federal research rules on deception to misleading health information: An example on smokeless tobacco and cigarettes. *Public Health Rep* 2003;118:187-92.
62. Phillips CV, Wang C, Guenzel B. You might as well smoke; the misleading and harmful public message about smokeless tobacco. *BMC Public Health* 2005, 5:31. Available online at: www.biomedcentral.com/1471-2458/5/31.
63. National Legal and Policy Center. National Institute on Aging forced to re-examine policy on smokeless tobacco products. *PR Newswire* 200-07-14. Available online at: <http://www.tobacco.org/news/170153.html>.
64. American Cancer Society. Spit (smokeless) tobacco. Available online at: http://www.cancer.org/docroot/PED/content/PED_10_2x_Smokeless_Tobacco_and_Cancer.asp?sitearea=PED.
65. Kozlowski LT, Edwards BQ. "Not safe" is not enough: smokers have a right to know more than there is no safe tobacco product. *Tob Control* 2005; 14:iii3-7.
66. National Cancer Institute (NCI). Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. *Smoking and Tobacco Control Monograph 13*. Bethesda, MD: USDHHS, NIH, NCI, NIH Pub. No. 02-5074, 2001.
67. Saffer H, Wakefield M, Terry-McElrath Y. The effect of nicotine replacement therapy advertising on youth smoking. *National Bureau of Economic Research Working Paper Series*, No. 12964, 2007. Available online at: <http://www.nber.org/papers/w12964.pdf>.
68. Ridley A. *Beginning bioethics*. New York: St. Martin's Press, 1998.
69. Tobacco Advisory Group of the Royal College of Physicians. Ethics, human rights, and harm reduction for tobacco users. In: *Harm reduction in nicotine addiction: a report by the Tobacco Advisory Group of the Royal College of Physicians*, London: Royal College of Physicians, in press.
70. Kennedy, Waxman, Cornyn, and Davis Introduce Tobacco Legislation. February 15, 2007. Available online at: http://kennedy.senate.gov/newsroom/press_release.cfm?id=30D49497-D37D-4C82-87E1-3B6C9C51E4F1.
71. Grandjean P. Implications of the precautionary principle for primary prevention and research. *Annu Rev Public Health* 2004;25:199-223.
72. Bates C, Fagerstrom K, Jarvis MJ, Kunze M, McNeill A, Ramstrom L. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. *Tob Control* 2003;12:360-7.
73. Saner M, Capelli J, Michaelian K. A harm-based classification of PREPS. Institute on Governance. Available online at: http://www.iog.ca/publications/2005_tobacco_preps.pdf.

Epidemiologic Perspectives on Smokeless Tobacco Marketing and Population Harm

Scott L. Tomar, DMD, DrPH

Abstract: Moist snuff is the most popular form of orally-used smokeless tobacco in North America and parts of Europe. Because moist snuff use conveys lower risks for morbidity or mortality than does cigarette smoking, its use has been proposed as a tobacco harm-reduction strategy. This article critically reviews new and published epidemiologic evidence on health effects of moist snuff and its patterns of use relative to smoking in the United States, Sweden, and Norway. The available evidence suggests that: (1) moist snuff is a human carcinogen and toxin, (2) increased promotion of moist snuff has led to increased sales in those countries, (3) the uptake of moist snuff in these three countries during the past several decades has occurred primarily among adolescent and young adult men, (4) increased prevalence of snuff use has not been associated consistently with a reduction in smoking initiation or prevalence, (5) moist snuff use apparently plays a very minor role in smoking cessation in the U.S. and an inconsistent role in Sweden, (6) U.S. states with the lowest smoking prevalence also tend to have the lowest prevalence of snuff use, (7) there are no data on the efficacy of snuff as a smoking-cessation method, (8) the prevalence of cigarette smoking is relatively high among people who use snuff, and (9) snuff use is more consistently associated with partial substitution for smoking than with complete substitution. The evidence base for promotion of snuff use as a public health strategy is weak and inconsistent.

(Am J Prev Med 2007;33(6):S387-S397) © 2007 American Journal of Preventive Medicine

Introduction

One session in the National Institutes of Health (NIH) State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control asked the four invited panelists, "What is the effect of smokeless tobacco product marketing on population harm from tobacco use?" This article summarizes the available epidemiologic data to answer that question.

Hundreds of millions of people worldwide are addicted to smokeless tobacco, and use by young people is increasing in many countries.¹ The types of product vary widely around the world. The common defining characteristics of smokeless tobacco products are that they are not burned by the consumer at the time they are used, they deliver nicotine into venous circulation through passive absorption across oral or nasal mucosa, and virtually all products contain human carcinogens and toxins at levels substantially higher than are typically found in any nontobacco consumer product.¹ There does appear to be a range in levels of carcinogens and toxins among the various American and

Swedish moist snuff products, as discussed elsewhere in this supplement.²

There has been recent discussion within the tobacco-control community concerning the role, feasibility, and supporting evidence of a harm-decreasing strategy, through promotion of smokeless tobacco products, in reducing the societal burden of tobacco use.³ Because of lower risks for morbidity or mortality compared with cigarettes, various smokeless tobacco products, particularly moist snuff, have been suggested as potential reduced-exposure products for smokers who are unable or unwilling to quit using tobacco.⁴⁻⁶ Smokeless tobacco manufacturers have used that rationale in advocating and lobbying for regulatory changes in many countries.⁷⁻⁹

The objectives of this review are: (1) to briefly review the epidemiologic evidence for smokeless tobacco and disease, (2) to review the available epidemiologic data on patterns of smokeless tobacco usage and consumption relative to cigarette smoking, and (3) to discuss the implications of these data.

Health Effects

Compared with the large body of literature on the adverse health effects of cigarette smoking, the literature on adverse health effects associated with smokeless tobacco use is far smaller and, for some disease end-

From the University of Florida College of Dentistry, Gainesville, Florida

Address correspondence and reprint requests to: Scott L. Tomar, DMD, DrPH, University of Florida College of Dentistry, Department of Community Dentistry and Behavioral Science, 1329 SW 16th Street, Room 5180, PO Box 103628, Gainesville FL 32610-3628. E-mail: stomar@dental.ufl.edu.

points, less conclusive. In part, that limitation reflects the nature of smokeless tobacco use in most parts of the world. In general, smokeless tobacco use is far less prevalent than smoking in most developed nations, so observational studies that include an adequate sample size of exposed people are more difficult to assemble. In addition, a large proportion of smokeless tobacco users in most countries also have a history of using burned types of tobacco products such as cigarettes, bidis, or hookahs, a factor that creates challenges in identifying cohorts whose only form of tobacco use is smokeless tobacco.

There have been several large comprehensive reviews on the health effects of smokeless tobacco, so this article will not review most of the original studies in detail. Instead, it will summarize the conclusions of those reviews where possible.

Cancer

A working group convened by the International Agency for Research on Cancer (IARC) in 1984 reviewed the available epidemiologic, animal, and chemical literature to reach a determination on the carcinogenicity of smokeless tobacco.¹⁰ The working group concluded: "There is sufficient evidence that oral use of snuffs of the types commonly used in North America and Western Europe is carcinogenic to humans." The review also concluded: "There is limited evidence that chewing tobacco of the types commonly used in these areas is carcinogenic" and "Epidemiologic studies that did not distinguish between chewing tobacco and snuff provide sufficient evidence for the carcinogenicity of oral use of smokeless tobacco products, as reported in these studies." That working group summarized the findings as: "In aggregate, there is sufficient evidence that oral use of smokeless tobacco of the above types is carcinogenic to humans."

The question of carcinogenicity of smokeless tobacco products was revisited by the IARC in 2004, when it convened another working group to conduct a comprehensive review and evaluate the evidence. A summary of the review has been published,¹¹ but as of January 24, 2007, the full report has not yet been issued. The working group concluded that smokeless tobacco is "carcinogenic to humans." More specifically, the group concluded: "Overall, there is sufficient evidence that smokeless tobacco causes oral cancer and pancreatic cancer in humans, and sufficient evidence of carcinogenicity from animal studies." The working group also evaluated the evidence for carcinogenicity of two tobacco-specific *N*-nitrosamines, *N*'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which are the most abundant strong carcinogens in smokeless tobacco. The group concluded that exposure to NNN and NNK is "carcinogenic to humans," on the basis of sufficient evidence

from animals and strong mechanistic evidence in exposed humans.

The carcinogenicity of smokeless tobacco was also evaluated by an advisory committee to the U.S. Surgeon General in 1986.¹² That review concluded: "The scientific evidence is strong that the use of snuff can cause cancer in humans."

Critchley and Unal¹³ conducted a comprehensive review of the health effects of smokeless tobacco and concluded that there is a substantial risk of oral cancers associated with the types of smokeless tobacco used in India. Furthermore, they concluded that "most recent studies from the U.S. and Scandinavia are not statistically significant, but moderate positive associations cannot be ruled out due to lack of power."

Rodu and Cole¹⁴ conducted a review of 21 published epidemiologic studies on use of American or Swedish smokeless tobacco and the risk of cancers of the upper respiratory tract, and calculated summary relative risks by product type. The authors concluded that the lowest estimated relative risks (RRs) were found among users of chewing tobacco (0.6–1.7) and among users of moist snuff (0.7–1.2). They concluded that users of dry snuff have higher risks, with RRs from about 4 to 15. RRs for upper respiratory tract cancers were considered intermediate for unspecified type of smokeless tobacco used, speculating that it possibly reflected use of either the lower- or higher-risk products among different individuals. However, the conclusions were heavily influenced by the classification of the landmark case-control study by Winn et al.¹⁵ as a study of dry snuff. Winn et al. reported an estimated RR of 4.0 for snuff use and oral cancer, but that article did not specify whether study participants used dry or moist snuff. Laboratory assays conducted in the 1980s found no significant differences between moist snuff and dry snuff in the levels of carcinogenic tobacco-specific *N*-nitrosamines, suggesting those products carried comparable carcinogenic potential.¹⁶

Cardiovascular Diseases

A systematic review of smokeless tobacco and cardiovascular diseases published several years ago¹⁷ included just one cohort study¹⁸ and two case-control studies.^{19,20} The large prospective cohort study found a 40% excess risk of cardiovascular mortality among smokeless tobacco users,¹⁸ but the two case-control studies found no association between smokeless tobacco use and myocardial infarction. Critchley and Unal¹⁷ concluded there may be an association between smokeless tobacco use and cardiovascular disease, but further rigorous studies with adequate sample sizes are required to reach a more definitive determination. Since that review was published, two large prospective cohort studies²¹ and a large international case-control study²² have been reported. Henley et al.²¹ studied the

association between smokeless tobacco use and mortality among men enrolled in Cancer Prevention Study I (CPS-I) in 1959 or Cancer Prevention Study II (CPS-II) in 1982. Men who currently used snuff or chewing tobacco at baseline had higher death rates from cardiovascular diseases than men who did not in both CPS-I (hazard ratio [HR]=1.18; 95% confidence interval [CI]=1.11–1.26) and CPS-II (HR=1.23; 95% CI=1.09–1.39). All analyses excluded men who reported current or former smoking of cigarettes, cigars, or pipes. In both cohorts, current smokeless tobacco use was significantly associated with death from coronary heart disease or stroke. A large international case-control study²² found a significantly elevated risk for myocardial infarction associated with smokeless tobacco use among subjects with no history of using other tobacco products (odds ratio [OR]=2.23; 95% CI=1.41–3.52), which was only slightly lower than the risk associated with smoking (OR=2.95; 95% CI=2.77–3.14). One Swedish case-control study found no association between snuff use and stroke,²³ although just 42 subjects of the 827 in the study were snuff users with no history of cigarette smoking.

Reproductive Health Effects

There is evidence that smokeless tobacco use increases the risk for adverse reproductive health outcomes among pregnant women. An Indian prospective cohort study of more than 1100 pregnant women found an increased risk for low birthweight (OR=1.6; 95% CI=1.1–2.4); preterm delivery at <37 weeks (OR=1.4; 95% CI=1.0–2.1), <32 weeks (OR=4.9; 95% CI=2.1–11.8) or <28 weeks (OR=8.0; 95% CI=2.6–27.2); and stillbirth (HR=2.6; 95% CI=1.4–4.8).^{24,25} Consistent with that study, a Swedish cohort study²⁶ found an increased risk for preterm delivery (OR=1.98; 95% CI=1.46–2.68) associated with snuff use by pregnant women, which was greater than that associated with cigarette smoking (OR=1.57; 95% CI=1.38–1.80). Snuff use was also associated with a significantly increased risk for pre-eclampsia (OR=1.58; 95% CI=1.09–2.27), which also was higher than the risk for pre-eclampsia associated with smoking (OR=0.63; 95% CI=0.53–0.75). A cohort study conducted in South Africa found that women who used snuff during pregnancy had a significantly shorter mean gestational age (37.9 [\pm 1.4] weeks) than those who smoked (38.7 [\pm 2.4] weeks) or did not use tobacco (38.3 [\pm 1.5] weeks) during pregnancy.²⁷

Oral Health Effects

Oral health effects of smokeless tobacco use include localized gingival recession,^{28–34} oral soft tissue lesions,^{31,33–50} and possibly dental abrasion.^{51–55} There is some evidence that U.S. chewing tobacco may increase the risk for dental caries,⁵⁶ but there are relatively few

studies of smokeless tobacco and dental caries and the findings are inconsistent.^{30,33,57–61} A few studies suggest that smokeless tobacco use may be a risk factor for periodontitis.^{62,63}

Nicotine Addiction

All forms of oral smokeless tobacco are capable of delivering nicotine by absorption through the oral mucosa, into venous circulation, and to receptors in the central nervous system.⁶⁴ There is compelling evidence that smokeless tobacco use can result in nicotine addiction.^{12,65,66}

Comparative Mortality Risks for Cigarettes and Smokeless Tobacco

There is overwhelming consensus in the scientific community that cigarette smoking is the leading preventable cause of death in the U.S.⁶⁷ and globally.⁶⁸ It therefore follows that virtually any consumer product poses a lower risk for premature mortality than does cigarette smoking.

There are few cohort studies that directly compared the overall risk for death associated with western types of smokeless tobacco and cigarettes. In a large 12-year cohort study of Swedish men, Bolinder et al.⁶⁹ found an elevated risk for death due to all causes among smokeless tobacco users (RR=1.4; 95% CI=1.3–1.8). That mortality risk was lower than for men who smoked fewer than 15 cigarettes per day (RR=1.7; 95% CI=1.6–1.9) or those who smoked 15 or more cigarettes per day (RR=2.2; 95% CI=2.0, 2.4). Generally consistent with that, the large prospective cohort studies conducted by the American Cancer Society found that men who currently used snuff or chewing tobacco at baseline had higher death rates from all causes than men who did not in both CPS-I (HR=1.17; 95% CI=1.11–1.23) and CPS-II (HR=1.18; 95% CI=1.08–1.29).⁷⁰ Those age-adjusted RR estimates were lower than those associated with cigarette smoking among men in CPS-I (RR=1.7; 95% CI=1.7–1.8) and CPS-II (RR=2.3; 95% CI=2.3–2.4).⁷¹

The most appropriate research question to consider in the context of current smoking is not whether exclusive smokeless tobacco use conveys lower risks than does smoking, but whether people who switch from cigarettes to smokeless tobacco reduce their risks for death or disease. There are nearly no data on that research question. Just one cohort study examined the risk for death among smokers who switched to smokeless tobacco compared to those who quit all tobacco use.⁷² That study found that male “switchers” had a higher rate of death from any cause (HR=1.08; 95% CI=1.01–1.15), lung cancer (HR=1.46; 95% CI=1.24–1.73), coronary heart disease (HR=1.13; 95% CI=1.00–

1.29), and stroke (HR=1.24; 95% CI=1.01–1.53) than men who quit using tobacco entirely.

Possible Mechanisms for Smokeless Tobacco in Reducing Population Harm from Tobacco

Although smokeless tobacco has been established as a class of toxic, carcinogenic, and addictive products, its use has been suggested as a tobacco harm-reduction strategy.^{73,74} The underlying rationale for such a recommendation is that these products convey a substantially lower risk from morbidity and mortality than does cigarette smoking, and because of its nicotine delivery properties it could serve as an alternative to cigarettes as a nicotine delivery source. Thus, in theory, smokeless tobacco use could reduce population tobacco harm by: (1) preventing smoking initiation, (2) promoting complete smoking cessation, or (3) serving as a partial replacement for cigarettes among continuing smokers. The epidemiologic evidence for each of the three mechanisms is reviewed below.

Prevention of Smoking Initiation

In nearly all countries, initiation of smoking typically occurs during the adolescent or early adult years; smoking initiation after age 25 years is very uncommon.^{75,76} Long-term smoking-cessation rates are relatively low among established smokers under 25 years of age.^{77,78} If smokeless tobacco use were preventive for cigarette smoking in a population, several patterns of tobacco usage would be expected: (1) in prospective cohort studies, people who used smokeless would be less likely than those who did not use those products to initiate smoking, after adjusting for established risk factors for smoking initiation; and (2) if smokeless tobacco use increased among people under age 25 in a population, it would be accompanied by a decline in the prevalence of smoking in that age group.

Several prospective cohorts from the U.S. examined smoking initiation rates among young people who used smokeless tobacco at baseline but had not smoked. Two relatively recent cohort studies suggest that the use of smokeless tobacco may be a predictor of subsequent smoking among young men in the U.S. In a cohort study of Air Force recruits with a mean age of 19 years at baseline (N=7865), Haddock and colleagues⁷⁹ considered regular smokeless tobacco use to be the use of these products at least once per day. The 1-year outcome measure of smoking was defined in this study as any smoking within the preceding 7 days. Among current smokeless tobacco users, 27% initiated smoking, compared with 26.3% of former smokeless tobacco users and 12.9% of never-users. Adjusting for demographic characteristics, current users (OR=2.33; 95% CI=1.84–2.94) and former users (OR=2.27; 95%

CI=1.64–3.15) were significantly more likely than never-users to initiate smoking. There was no evidence of a protective effect of smokeless tobacco use.

In a 4-year follow-up study of adolescent and young adult men, Tomar⁸⁰ examined the relationship between smokeless tobacco use and initiation of smoking. Data were from the 1989 Teenage Attitudes and Practices Survey (TAPS) and its 1993 follow-up on a U.S. nationally representative cohort of 4000 male youth aged 11–19 years at baseline. Young men who were not smokers in 1989 but regularly used smokeless tobacco were more than three times as likely as never-users to be current smokers 4 years later (23.9% vs 7.6%; adjusted OR=3.45; 95% CI=1.84–6.47). More than 80% of baseline current smokers still were smokers 4 years later. In contrast, more than 40% of baseline current regular smokeless tobacco users became smokers, either in addition to or in place of smokeless tobacco use. Another analysis⁸¹ of the TAPS cohort suggested that smokeless tobacco use was no longer a statistically significant predictor of smoking initiation when psychosocial risk factors were included in multiple logistic regression modeling; the adjusted OR of smoking initiation was 1.97 (95% CI=0.69–5.65) for those who reported regular use of smokeless tobacco. Although not a statistically significant predictor of smoking initiation in that analysis, smokeless tobacco use clearly was not preventive against smoking initiation after adjusting for established psychosocial predictors of smoking. Similarly, a recent cohort study of 2100 boys in grades 7 or 9 at baseline found that those who used smokeless tobacco at baseline but had never smoked were significantly more likely than non-users to initiate smoking during the succeeding 2 years (OR=2.55; 95% CI=1.45–4.47), after adjusting for school grade, parental smoking, sibling smoking, close friend smoking, deviant behavior, low school performance, and past-month alcohol consumption.⁸² Although the role of smokeless tobacco as an independent risk factor for smoking initiation has been questioned,^{81,83–85} there is no evidence from prospective cohort studies of a preventive effect. Swedish cross-sectional studies that suggested a preventive effect of snuff use for subsequent smoking either excluded the birth cohorts most likely to have used snuff during adolescence or young adulthood⁸⁵ or ignored the substantial proportion of Swedish men who smoke on a less than daily basis (45% of all current male smokers)⁸⁴ in examining the association between snuff use and smoking initiation.

Secular trends in tobacco use among adolescents and young adults in Sweden, Norway, and the U.S. do not support a preventive effect of smokeless tobacco use for cigarette smoking. Official national data from Statistics Sweden suggest that daily snuff use among youth aged 16–24 years has increased over the past 15 years, from 23.0% in 1988–1989 to 26.5% in 2005 among men, and

from 0.6% to 3.9% among women (Figure 1).⁸⁶ Current smoking (i.e., daily or occasional) in that age group exhibited an increasing trend line for male youth during that time period and a declining trend line for female youth over the same time period. In 2004–2005, 33.4% of men and 30.2% of women aged 16–24 years in Sweden were current smokers. However, the prevalence of daily smoking was lower for men (9.3%) than for women (13.3%) in that age group. The secular patterns in tobacco use among Swedes aged 16–24 years suggest that snuff may have served as a partial substitute for smoking among men, but had a negligible effect, if any, on smoking initiation rates for either gender.

Consistent with the findings from Sweden, secular trends in tobacco use among young adults aged 16–24 years in Norway provide no evidence of a preventive effect of snuff use for smoking initiation (Figure 2). The prevalence of snuff use more than doubled among young Norwegian men during the past few decades, from 9% in 1985 to more than 21% in 2002 (snuff use is not reported for women in Norway). The prevalence of current smoking also increased among young men during most of that time, from 37% in 1988 to 47% in 1999. Smoking has remained about equally prevalent for men and women aged 16–24 years for most of the past 20 years, although snuff use by young women in Norway is very uncommon⁸⁷ and generally is not reported by Statistics Norway.⁸⁸ Nearly all adolescents and young adults in Norway who used snuff also were current smokers.^{87,89}

Trend data on the use of smokeless tobacco reveal no apparent preventive effect among U.S. high school




Figure 1. Trends in proportion of people aged 16–24 who used snuff daily or currently smoked (daily or occasionally), by gender. Sweden, 1988–1989 to 2004–2005. Data from Statistics Sweden ULF Surveys.⁸⁶




Figure 2. Trends in the proportion of people aged 16–24 who used snuff (daily or occasionally) or currently smoked (daily or occasionally), by gender. Norway, 1985–2002. Data from Statistics Norway.

students (Figure 3). Data from the Monitoring the Future⁹⁰ study suggest that daily smokeless tobacco use by U.S. high school seniors exhibited a flat to slight upward trend from 6.4% in 1993 to 8.6% in 1997, a time period during which current smoking increased sharply for both male and female high school seniors. Daily smokeless tobacco use by male high school seniors has generally trended downward since 1997, reaching a prevalence of 4.7% in 2005. Current smoking by male high school seniors also declined during that time period, from 37.3% in 1997 to 24.8% in 2005, and declined among female high school seniors from




Figure 3. Trends in the proportion of high school seniors who used smokeless tobacco (ST) daily or smoked within the preceding 30 days, by gender. United States, 1992–2005. Data from the Monitoring the Future Project.

35.2% in 1997 to 20.7% in 2005. Daily smokeless tobacco use has remained very rare among female U.S. high school seniors since the Monitoring the Future Project has been tracking smokeless tobacco use, with an estimated prevalence of 0.2% in 2005.

Smokeless Tobacco and Smoking Cessation

If smokeless tobacco use were an effective treatment or substitute for smoking, the expected pattern would be: (1) an increased prevalence of smokeless tobacco use among adults aged 35 years or older would be associated with an increased prevalence of smoking cessation in that age group, (2) a lower prevalence of smoking among states with a higher prevalence of smokeless tobacco use, (3) higher smoking quit rates in the treatment group assigned to use smokeless tobacco than in the control group in randomized controlled trials, and (4) higher smoking quit rates in observational studies that adjusted for relevant correlates of successful quitting such as level of nicotine dependence, stage of readiness to quit, and history of prior quit attempts.

To date, there are no published randomized clinical trials for smokeless tobacco as a smoking-cessation method. Only one published study explicitly examined the effectiveness of snuff use as a smoking-cessation method.⁹¹ That pilot study found that 16 of the 63 subjects (25%) in the study had quit smoking by using snuff at the 1-year follow-up, and six subjects (10%) had quit smoking by using another method. However, that study did not have a control group. In a 7-year follow-up of 62 of the original 63 subjects, 28 (45%) had quit smoking, although fewer than half of the subjects ($n=12$) who had quit smoking in that uncontrolled study reportedly had done so by using snuff.⁹²

Sweden has been cited as the one example in which moist snuff use apparently replaced smoking for a proportion of men. The pattern of smoking that appears to be emerging in Sweden is a declining but equal prevalence of current smoking for men and women, with a greater proportion of male current smokers than female smokers reporting smoking less than daily (Figure 4). Based on a cross-sectional study of current and former smokers in Sweden,⁹³ the apparent effectiveness of snuff in helping smokers to quit is modest. Among men, snuff was used at the most recent attempt to quit smoking by 28.7% of former smokers and 23.0% of current smokers ($p=0.072$). Only 4.8% of female current smokers in that study who had attempted to quit and 4.5% of female former smokers ($p=0.85$) reported using snuff during their most recent attempt to quit smoking. Data from one follow-up study conducted in northern Sweden, a region with a high prevalence of moist snuff use (approximately 23% of men and 2% of women), suggest that switching from cigarettes to snuff occurred primarily among men who had prior experience using snuff.^{94,95} In that study, complete switching




Figure 4. Trends in the proportion of people aged 16–84 years who smoked daily or occasionally, by gender. Sweden, 1988–2002. Data from Statistics Sweden ULF Surveys.

from cigarettes to snuff use was reported by just 8% of men who smoked but had never used snuff at the time of the baseline survey; nearly two thirds of men who smoked had never used moist snuff.

A recent cross-sectional study examined snuff use as a cessation strategy among Swedish adults.⁸⁴ Among the 1326 men in that study who were ever-daily smokers, 254 (19%) used snuff as a smoking-cessation aid and 165 (12%) were able to quit smoking completely by using snuff. That accounted for 21% of the 782 male ever-smokers in the survey who had quit smoking completely. Snuff use was a relatively uncommon method of smoking cessation for women; just 66 (5.3%) of the 1249 women who were ever-daily smokers and reported making a smoking quit attempt reported using snuff as their cessation aid. Of the 673 women in this study who had quit smoking completely, 38 (5.7%) reportedly quit by using snuff.

While there is little doubt that snuff has been a useful cessation strategy for some men and women in Sweden, the trend in tobacco use among adults aged 35 years and older does not support a major role for increased snuff use being associated with complete smoking cessation in that country. Figure 5 depicts trends from 1988–1989 through 2004–2005 in the proportion of men and women aged 35–44 years who used snuff daily or were former daily smokers who had stopped completely, based on official Swedish statistics.⁸⁶ Among men aged 35–44 years, the prevalence of daily snuff increased from 18.7% to 30.7% during that time period. Women aged 35–44 years also experienced an




Figure 5. Trends in the proportion of people aged 35–44 years who were former smokers or currently used snuff daily, by gender. Data from Statistics Sweden ULF Surveys.

increased prevalence of daily snuff use between 1988–1989 and 2004–2005, from 0.6% to 4.0%. Although there was an 18–26 percentage point difference between men and women in the prevalence of daily snuff use throughout the time period, the prevalence of former smoking declined for men and increased slightly for women during that time period, despite the prevalence of current smoking being essentially equal for men and women throughout the period.

Tobacco-use patterns men and women aged 35–44 years in Norway are generally consistent with those in Sweden (Figure 6): the prevalence of snuff use by men in that age group increased steeply from 2.9% in 1988 to 16.4% in 2002, but snuff use by women remained rare.⁸⁸ Yet, trends in current smoking were essentially identical for men and women aged 35–44 years during that period. While it is difficult to draw firm conclusions from these types of time-series data, the patterns in Sweden and Norway do not suggest that the very large gender differences in the prevalence of snuff use were associated with differences in smoking cessation rates.

There is little information on the proportion of U.S. smokers who have switched completely to the use of smokeless tobacco or have used smokeless tobacco as a method of quitting smoking. Fiore and colleagues⁹⁶ reported findings from the 1986 Adult Use of Tobacco Survey on the methods smokers used to quit. That study reported that, in the mid-1980s, 6.8% of former smokers who successfully quit smoking for at least 1 year had substituted other tobacco products (including snuff, chewing tobacco, pipes, or cigars) during any attempt at quitting, and 4.0% of successful quitters substituted other products during their last attempt at quitting. However, the proportions were nearly the same among relapsers: 6.8% of smokers who made a serious quit attempt in the past year but were not successful in

quitting tried substituting other tobacco products in any attempt, and 2.1% tried that strategy during their last attempt at quitting. An earlier report from that survey provided limited information specific to smokeless tobacco use for smoking cessation: 6.4% of current smokers and 7.0% of former smokers used smokeless tobacco to help them quit smoking.⁹⁷ More recent data come from the 2000 National Health Interview Survey, in which former smokers were asked what method they had used to quit smoking completely.⁹⁸ Just 1% of male former smokers aged 36–47 reported switching to snuff or chewing tobacco to quit smoking. Of male current smokers in that age group who attempted to quit, 0.3% reported switching to smokeless tobacco on their last attempt to quit. In a birth cohort in which 16% of men, including 19% of those who had ever smoked, had used smokeless tobacco by age 34, smokeless tobacco use accounted for a very small proportion of quitting.

In the U.S, the prevalence of smokeless tobacco use varies widely among the states. For example, current use of snuff or chewing tobacco by men aged 15 years or older in 2003 ranged from less than 1% in eight states (HI, NH, DC, MA, RI, MD, CT, and NJ) to more than 10% in three states (WV, MT, and WY) (unpublished data from the 2003 Current Population Survey Tobacco Use Supplement). If smokeless tobacco use were associated with smoking cessation, it might be expected that states with a higher prevalence of snuff use would tend to have a lower prevalence of current smoking among adult smokers and a higher prevalence of former smoking. However, the prevalence of daily snuff use among men aged 25–44 was significantly positively associated with the prevalence of daily smoking among the 50 U.S. states and the District of




Figure 6. Trends in the proportion of people aged 35–44 years who currently used snuff (daily or occasionally) or currently smoked (daily or occasionally), by gender. Norway, 1985–2002. Data from Statistics Norway.




Figure 7. Scatter plot and fitted linear regression line for prevalence of daily smoking and daily snuff use among men in the 50 states and the District of Columbia, United States, 2003. Data from the 2003 Current Population Survey Tobacco Use Supplement.

Columbia ($r=0.54$, $p<0.0001$; **Figure 7**) and significantly negatively associated with the prevalence of former smoking ($r=-0.27$, $p=0.06$; **Figure 8**).

Smokeless Tobacco and Cigarette Consumption

The third potential mechanism by which smokeless tobacco theoretically could reduce tobacco harm is by serving as a partial substitute for cigarettes among continuing smokers. There is some evidence that “dual users” of cigarettes and smokeless tobacco smoke fewer cigarettes, on average, than do exclusive smokers. An analysis of data from the 2000 National Household Survey on Drug Abuse found that dual users smoked on fewer of the preceding 30 days than did exclusive smokers (19.86 ± 12.16 vs 23.14 ± 10.92 ; $p<0.0001$) and smoked fewer cigarettes per day on the days they smoked (3.73 ± 1.59 vs 4.01 ± 1.52 ; $p<0.0001$).⁹⁹

Analysis of data from the 2000 National Health Interview Survey (NHIS) found that smokers who also used snuff every day smoked, on average, fewer cigarettes per day than did exclusive smokers (11.4 vs 18.4; $p=0.0001$).¹⁰⁰ However, smokers who used snuff only on some days did not differ from those who never used snuff in the mean number of cigarettes smoked per day (19.3 vs 18.4; $p=0.42$). Occasional snuff users consisted of 44% of all current snuff users, compared to 18% of current smokers who did not smoke every day. The prevalence of daily smoking was lower among daily snuff users (11.7%; 95% CI= $\pm 4.2\%$) than among men who never used snuff (20.9%; 95% CI= $\pm 0.9\%$). However, the prevalence of daily smoking (32.7%; 95% CI= $\pm 7.5\%$) and occasional smoking (6.2%; 95% CI= $\pm 3.2\%$) was fairly high among occasional snuff users. Dual users of cigarettes and snuff accounted for about one third of all current snuff users. Detailed histories of initiation and reasons for dual use cannot

be determined from these types of cross-sectional studies, but the patterns are consistent with a substantial proportion of the snuff consumed in the United States being used by current smokers as a complementary source of nicotine. Recent data suggest that more than one in four adult male smokers in ten U.S. states use another form of tobacco in addition to cigarettes.¹⁰¹

Responses to Smokeless Tobacco Marketing United States

Smokeless tobacco products, predominantly chewing tobacco, commanded a large share of the tobacco market in the U.S. in the early 20th century, but began a decline in popularity in the 1920s. Smokeless tobacco products were heading toward extinction by 1970, when chewing tobacco or snuff use was largely limited to people aged 65 years and older.¹⁰² A sharp increase in the use of smokeless tobacco in the U.S., especially use of moist snuff, began in the early 1970s. That increase was the result of the development of new products designed to appeal to novice users, a “graduation” marketing strategy intended to promote nicotine addiction, and heavy promotion by U.S. Tobacco Company (now called the U.S. Smokeless Tobacco Company), the major U.S. manufacturer of moist snuff.^{103,104} The greatest increase in the use of moist snuff occurred among young men. For example, the prevalence of moist snuff by men aged 18–24 years increased nine-fold between 1970 and 1987, from 0.7% to 6.4%, while it declined among men aged 45 years and older during that time period.¹⁰²

Sweden

Sweden experienced a pattern similar to the U.S. in response to aggressive marketing by the Swedish Match




Figure 8. Scatter plot and fitted linear regression line for prevalence of former smoking and daily snuff use among men aged 25–44 years in the 50 states and the District of Columbia, United States, 2003. Data from the 2003 Current Population Survey Tobacco Use Supplement.

Company, that country's primary manufacturer of smokeless tobacco products. By the late 1960s, less than 10% of boys and young men used snuff and the typical user was an older, rural male laborer.¹⁰⁵ Starting in the late 1960s, Swedish Match Company increased the attractiveness of its products' packaging, introduced new brands, and began an aggressive advertising campaign. As a result, moist snuff consumption, which had been declining for nearly 5 decades, began a sharp increase. Within 4 years, the prevalence of snuff use doubled among men aged 15–19 years, from 11% in 1969–1970 to 22% in 1972–1973. The prevalence of snuff use among men aged 30 years or older remained virtually unchanged during that time period. The median age of snuff users in Sweden declined from 41 years in 1969–1970 to 30 years in 1972–1973.

Conclusion

The available data suggest that there is weak and inconsistent evidence for smokeless tobacco promotion as a public health strategy for harm reduction. When aggressively promoted in industrialized countries, history suggests that initiation of moist snuff use occurs almost entirely among adolescent and young adult men. Although some proponents claim that uptake of snuff may prevent the initiation of smoking, the available evidence does not support that claim. To the contrary, prospective cohort studies of young people in the U.S. suggest that smokeless tobacco use is predictive of subsequent smoking. Trends in tobacco prevalence in the U.S. and Norway do not support the contention that the growth in moist snuff was associated with a reduction in smoking initiation. Trends in Sweden suggest that snuff provided a partial substitution for cigarettes mostly among men, but the prevalence of smoking in that country is essentially equal for men and women. Some adult smokers in Sweden clearly used snuff as a method for quitting smoking, but snuff use explains, at best, a relatively small proportion of the decline in smoking. The prevalence of smoking remains relatively high among snuff users in all three countries considered in this review. There are no data on the efficacy of snuff as a smoking cessation method.

Moist snuff products are addictive, carcinogenic, and destructive to periodontal tissues, and appear to increase the risk for adverse birth outcomes and possibly cardiovascular diseases. The abuse potential for these products is high. There are nearly no published cohort studies on risk reduction among smokers who switch to using moist snuff. In Sweden, the role of snuff in reducing smoking is unclear but almost certainly overstated. Those who embrace the "Swedish experience" as a model for tobacco harm reduction^{73,106–108} do not address the U.S. and Norwegian experiences with moist snuff, in which their growth in popularity simply added to the burden of tobacco use. Interestingly, 44 of the 50

states in the United States have achieved a prevalence of smoking equal to or lower than Sweden's, with very little use of smokeless tobacco in most states.¹⁰⁹ Five of the six states with a higher prevalence of smoking than Sweden have among the highest prevalence of smokeless tobacco use in the United States. Some proponents for smokeless tobacco as a harm reduction strategy for smoking advocate differential taxation on tobacco products based on their risk and communications from the public health community that conveys the varying levels of risk.^{6,110} These are directions that require future investigation. However, there presently remains little evidence that marketing or promotion of smokeless tobacco products as alternatives to cigarettes is an effective strategy for reducing smoking or societal harm from tobacco use.

Dr. Tomar has served as an expert witness for plaintiffs in several lawsuits against smokeless tobacco manufacturers.

References

1. International Agency for Research on Cancer. Smokeless tobacco and related nitrosamines. IARC Monogr Eval Carcinog Risk Chem Hum 2007;89.
2. Hatsukami DM, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. Changing smokeless tobacco products: new tobacco delivery systems. *Am J Prev Med* 2007;33(6S):S368–S378.
3. Institute of Medicine (IOM), Stratton K, Shetty P, Wallace R, Bondurant S, eds. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington DC: National Academies Press, 2001.
4. Rodu B. An alternative approach to smoking control [editorial]. *Am J Med Sci* 1994;308:32–4.
5. Ramstrom LM. Snuff: an alternative nicotine delivery system. In: Ferrence R, Slade J, Room R, Pope M, eds. Nicotine and public health. Washington DC: American Public Health Association, 2000. pp. 155–74.
6. Bates C, Fagerstrom K, Jarvis MJ, Kunze M, McNeill A, Ramstrom L. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. *Tob Control* 2003;12:360–7.
7. Swedish Match. The ban on snus survives ECJ challenge (press release). 2004.
8. Dillard JE. Letter to Ms. Katja Bromen, European Commission. Re: Smokeless Tobacco Products—Call for Information (letter). 2006. Available online at: <http://www.us smokeless.com/regulatory/31.pdf>.
9. International Smokeless Tobacco Company. Submission in Relation to Directive 2001/37/EC to the European Commission. 2004. Available online at: <http://www.us smokeless.com/regulatory/9.pdf>.
10. International Agency for Research on Cancer. Tobacco habits other than smoking. IARC Monogr Eval Carcinog Risk Chem Hum 1985;37.
11. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F. Smokeless tobacco and tobacco-related nitrosamines. *Lancet Oncol* 2004;5:708.
12. U.S. Department of Health and Human Services (USDHHS). The health consequences of using smokeless tobacco: a report of the Advisory Committee to the Surgeon General. NIH Publication No. 86-2874. Washington DC: USDHHS, Public Health Service, 1986.
13. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. *Thorax* 2003;58:435–43.
14. Rodu B, Cole P. Smokeless tobacco use and cancer of the upper respiratory tract. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2002;93:511–5.
15. Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, Fraumeni Jr. JF Snuff dipping and oral cancer among women in the southern United States. *N Engl J Med* 1981;304:745–9.
16. Hoffmann D, Adams JD, Lisk D, Fisenne I, Brunnemann KD. Toxic and carcinogenic agents in dry and moist snuff. *J Natl Cancer Inst* 1987;79: 1281–6.

17. Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? a systematic review of epidemiologic studies. *Eur J Cardiovasc Prev Rehabil* 2004;11:101-12.
18. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers [see comments]. *Am J Public Health* 1994;84:399-404. Comment in: *Am J Public Health* 1995;85:118-9.
19. Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? *BMJ* 1992;305:1252-6.
20. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. *J Am Coll Cardiol* 1999;34:1784-90.
21. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). *Cancer Causes Control* 2005;16:347-58.
22. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. *Lancet* 2006;368:647-58.
23. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. *Stroke* 2003;34:1754-9.
24. Gupta PC, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. *BMJ* 2004;328:1538.
25. Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: a cohort study in Mumbai, India. *Epidemiology* 2006;17:47-51.
26. England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. *Am J Obstet Gynecol* 2003;189:939-43.
27. Steyn K, de Wet T, Saloojee Y, Nel H, Yach D. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: the Birth To Ten Study. *Paediatr Perinat Epidemiol* 2006;20:90-9.
28. Robertson PB, Walsh M, Greene J, Ernster V, Grady D, Hauck W. Periodontal effects associated with the use of smokeless tobacco. *J Periodontol* 1990;61:438-43.
29. Robertson PB, Ernster V, Walsh M, Greene J, Grady D, Hauck W. Periodontal effects associated with the use of smokeless tobacco: results after 1 year. In: National Cancer Institute. *Smokeless tobacco or health: an international perspective. Smoking and Tobacco Control Monograph 2d edn.* Rockville MD: USDHHS, NIH, NCI, 1992. pp. 78-86.
30. Robertson PB, Walsh MM, Greene JC. Oral effects of smokeless tobacco use by professional baseball players. *Adv Dent Res* 1997;11:307-12.
31. Grady D, Greene J, Daniels TE, et al. Oral mucosal lesions found in smokeless tobacco users. *J Am Dent Assoc* 1990;121:117-23.
32. Wolfe MD, Carlos JP. Oral health effects of smokeless tobacco use in Navajo Indian adolescents. *Community Dent Oral Epidemiol* 1987;15:230-5.
33. Offenbacher S, Weathers DR. Effects of smokeless tobacco on the periodontal, mucosal and caries status of adolescent males. *J Oral Pathol* 1985;14:169-81.
34. Andersson G, Axell T. Clinical appearance of lesions associated with the use of loose and portion-bag packed Swedish moist snuff: a comparative study. *J Oral Pathol Med* 1989;18:2-7.
35. Robertson PB, Walsh MM, Greene JC. Oral effects of smokeless tobacco use by professional baseball players. *Adv Dent Res* 1997;11:307-12.
36. Wolfe MD, Carlos JP. Oral health effects of smokeless tobacco use in Navajo Indian adolescents. *Community Dent Oral Epidemiol* 1987;15:230-5.
37. Andersson G, Axell T, Curvall M. Reduction in nicotine intake and oral mucosal changes among users of Swedish oral moist snuff after switching to a low-nicotine product. *J Oral Pathol Med* 1995;24:244-50.
38. Creath CJ, Cutter G, Bradley DH, Wright JT. Oral leukoplakia and adolescent smokeless tobacco use. *Oral Surg Oral Med Oral Pathol* 1991;72:35-41.
39. Ernster VL, Grady DG, Greene JC, et al. Smokeless tobacco use and health effects among baseball players. *JAMA* 1990;264:218-24.
40. Greer RO, Poulson TC, Boone ME, Lindenmuth JE, Crosby L. Smokeless tobacco-associated oral changes in juvenile, adult and geriatric patients: clinical and histomorphologic features. *Gerodontology* 1986;2:87-98.
41. Poulson TC, Lindenmuth JE, Greer RO Jr. A comparison of the use of smokeless tobacco in rural and urban teenagers. *CA Cancer J Clin* 1984;34:248-61.
42. Greer RO Jr, Poulson TC. Oral tissue alterations associated with the use of smokeless tobacco by teen-agers. Part I. Clinical findings. *Oral Surg Oral Med Oral Pathol* 1983;56:275-84.
43. Kaugars GE, Riley WT, Brandt RB, Burns JC, Svirsky JA. The prevalence of oral lesions in smokeless tobacco users and an evaluation of risk factors. *Cancer* 1992;70:2579-85.
44. Little SJ, Stevens VJ, LaChance PA, et al. Smokeless tobacco habits and oral mucosal lesions in dental patients. *J Public Health Dent* 1992;52:269-76.
45. Sinusas K, Coroso JG, Sopher MD, Crabtree BF. Smokeless tobacco use and oral pathology in a professional baseball organization. *J Fam Pract* 1992;34:713-8.
46. Grasser JA, Childers E. Prevalence of smokeless tobacco use and clinical oral leukoplakia in a military population. *Mil Med* 1997;162:401-4.
47. Martin GC, Brown JP, Eifler CW, Houston GD. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. *J Am Dent Assoc* 1999;130:945-54.
48. Tomar SL, Winn DM, Swango PA, Giovino GA, Kleinman DV. Oral mucosal smokeless tobacco lesions among adolescents in the United States. *J Dent Res* 1997;76:1277-86.
49. Daniels TE, Hansen LS, Greenspan JS, et al. Histopathology of smokeless tobacco lesions in professional baseball players. Associations with different types of tobacco. *Oral Surg Oral Med Oral Pathol* 1992;73:720-5.
50. Stewart CM, Baughman RA, Bates RE. Smokeless tobacco use among Florida teenagers: prevalence, attitudes, and oral changes. *Fla Dent J* 1989;60:38-42.
51. Magnusson T. Is snuff a potential risk factor in occlusal wear? *Swed Dent J* 1991;15:125-32.
52. Dahl BL, Stolen SO, Oilo G. Abrasives in snuff? *Acta Odontol Scand* 1989;47:239-43.
53. Ekfeldt A, Hugoson A, Bergendal T, Helkimo M. An individual tooth wear index and an analysis of factors correlated to incisal and occlusal wear in an adult Swedish population. *Acta Odontol Scand* 1990;48:343-9.
54. Ekfeldt A. Incisal and occlusal tooth wear and wear of some prosthodontic materials. An epidemiological and clinical study. *Swed Dent J* 1989;65 (Suppl):1-62.
55. Bowles WH, Wilkinson MR, Wagner MJ, Woody RD. Abrasive particles in tobacco products: a possible factor in dental attrition. *J Am Dent Assoc* 1995;126:327-31; quiz 348.
56. Tomar SL, Winn DM. Chewing tobacco use and dental caries among U.S. men. *J Am Dent Assoc* 1999;130:1601-10.
57. Ernster VL, Grady DG, Greene JC, et al. Smokeless tobacco use and health effects among baseball players. *JAMA* 1990;264:218-24.
58. Parks ET, Nicholson T. The effects of smokeless tobacco use on the prevalence of dental caries. *Health Values* 1990;14:37-40.
59. Gregory RL, Kindle JC, Hobbs LC, Malmstrom HS. Effect of smokeless tobacco use in humans on mucosal immune factors. *Arch Oral Biol* 1991;36:25-31.
60. Hart GT, Brown DM, Mincer HH. Tobacco use and dental disease. *J Tenn Dent Assoc* 1995;75:25-7.
61. Sinusas K, Coroso JG, Sopher MD, Crabtree BF. Smokeless tobacco use and oral pathology in a professional baseball organization. *J Fam Pract* 1992;34:713-8.
62. Fisher MA, Taylor GW, Tilashalski KR. Smokeless tobacco and severe active periodontal disease, NHANES III. *J Dent Res* 2005;84:705-10.
63. Beck JD, Koch GG, Offenbacher S. Incidence of attachment loss over 3 years in older adults-new and progressing lesions. *Community Dent Oral Epidemiol* 1995;23:291-6.
64. Benowitz NL. Nicotine and smokeless tobacco. *CA Cancer J Clin* 1988;38:244-7.
65. Hatsukami DK, Severson HH. Oral spit tobacco: addiction, prevention and treatment. *Nicotine Tob Res* 1999;1:21-44.
66. Henningfield JE, Fant RV, Tomar SL. Smokeless tobacco: an addicting drug. *Adv Dent Res* 1997;11:330-5.
67. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA* 2004;291:1238-45.
68. World Health Organization. *The world health report 2002: reducing risks, promoting healthy life.* Geneva: WHO, 2002.
69. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. *Am J Public Health* 1994;84:399-404.
70. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). *Cancer Causes Control* 2005;16:347-58.
71. Thun MJ, Day-Lally C, Myers DG, et al. Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through

- 1965) and II (1982 through 1988). In: National Cancer Institute. Changes in cigarette-related risks and their implication for prevention and control. Rockville MD: USDHHS, NIH, NCI; 1997. pp. 305-82. NIH Publication No. 97-4213.
72. Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. *Tob Control* 2007;16:22-8.
 73. Bates C, Fagerstrom K, Jarvis MJ, Kunze M, McNeill A, Ramstrom L. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. *Tob Control* 2003;12:360-7.
 74. Kozlowski LT, O'Connor RJ, Edwards BQ. Some practical points on harm reduction: what to tell your lawmaker and what to tell your brother about Swedish snus. *Tob Control* 2003;12:372-3.
 75. USDHHS. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta Georgia: USDHHS, Public Health Service, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1994.
 76. WHO. International Consultation on Tobacco and Youth: what in the world works? Singapore, 28-30 September 1999 final conference report. Geneva: World Health Organization, WHO Tobacco Free Initiative; 2000. WHO/NMH/TFI/00.1.
 77. Backinger CL, Fagan P, Matthews E, Grana R. Adolescent and young adult tobacco prevention and cessation: current status and future directions. *Tob Control* 2003;12(Suppl 4):IV46-53.
 78. Tanski SE, Prokhorov AV, Klein JD. Youth and tobacco. *Minerva Pediatr* 2004;56:553-65.
 79. Haddock CK, Weg MV, DeBon M, et al. Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males. *Prev Med* 2001;32:262-7.
 80. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The U.S. experience. *Nicotine Tob Res* 2003;5:561-9.
 81. O'Connor RJ, Flaherty BP, Quinio Edwards B, Kozlowski LT. Regular smokeless tobacco use is not a reliable predictor of smoking onset when psychosocial predictors are included in the model. *Nicotine Tob Res* 2003;5:535-43.
 82. Severson HH, Forrester KK, Biglan A. Use of smokeless tobacco is a risk factor for cigarette smoking. *Nicotine Tob Res*. In press.
 83. Kozlowski LT, O'Connor RJ, Edwards BQ, Flaherty BP. Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national U.S. sample. *Addiction* 2003;98:1077-85.
 84. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. *Tob Control* 2006;15:210-4.
 85. Furberg H, Bulik CM, Lerman C, Lichtenstein P, Pedersen NL, Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? *Tob Control* 2005;14:422-4.
 86. Statistics Sweden. Use of alcohol and tobacco. Official Statistics of Sweden. Living Conditions Report No. 114. Stockholm: Statistics Sweden, Unit of Social Welfare, 2007.
 87. Braverman MT, Svendsen T, Lund KE, Aaro LE. Tobacco use by early adolescents in Norway. *Eur J Public Health* 2001;11:218-24.
 88. Directorate for Health and Social Affairs (Norway). Tall om Tobakk [number about tobacco]. 1973-2003. [Norwegian]. Oslo: Directorate for Health and Social Affairs, 2004.
 89. Schei E, Fonnebo V, Aaro LE. Use of smokeless tobacco among conscripts: a cross-sectional study of Norwegian army conscripts. *Prev Med* 1990;19:667-74.
 90. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975-2005: Volume I, Secondary school students. Bethesda MD: National Institute on Drug Abuse, 2006.
 91. Tilashalski K, Rodu B, Cole P. A pilot study of smokeless tobacco in smoking cessation. *Am J Med* 1998;104:456-8.
 92. Tilashalski K, Rodu B, Cole P. Seven year follow-up of smoking cessation with smokeless tobacco. *J Psychoactive Drugs* 2005;37:105-8.
 93. Gilljam H, Galanti MR. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. *Addiction* 2003;98:1183-9.
 94. Rodu B, Stegmayr B, Nasic S, Asplund K. Impact of smokeless tobacco use on smoking in northern Sweden. *J Intern Med* 2002;252:398-404.
 95. Rodu B, Stegmayr B, Nasic S, Cole P, Asplund K. Evolving patterns of tobacco use in northern Sweden. *J Intern Med* 2003;253:660-5.
 96. Fiore MC, Novotny TE, Pierce JP, et al. Methods used to quit smoking in the United States. Do cessation programs help? *JAMA* 1990;263:2760-5.
 97. Novotny TE, Pierce JP, Fiore MC, Davis RM. Smokeless tobacco use in the United States: the adult use of tobacco surveys. *NCI Monogr* 1989;8:25-8.
 98. Tomar SL, Loree M. Errors in analyzing associations between use of smokeless tobacco and cigarettes. *Addiction* 2004;99:260-2.
 99. Hatsukami DK, Lemmonds C, Tomar SL. Smokeless tobacco use: harm reduction or induction approach? *Prev Med* 2004;38:309-17.
 100. Tomar SL. Snuff use and smoking in U.S. men: implications for harm reduction. *Am J Prev Med* 2002;23:143-9.
 101. Bombard JM, Pederson LL, Nelson DE, Malarcher AM. Are smokers only using cigarettes? Exploring current polytobacco use among an adult population. *Addict Behav* 2007;32:2411-9.
 102. Giovino GA, Schooley MW, Zhu BP, et al. Surveillance for selected tobacco-use behaviors—United States, 1900-1994. *MMWR CDC Surveill Summ* 1994;43:1-43.
 103. Connolly GN, Winn DM, Hecht SS, Henningfield JE, Walker B Jr, Hoffmann D. The reemergence of smokeless tobacco. *N Engl J Med* 1986;314:1020-7.
 104. Connolly GN. The marketing of nicotine addiction by one oral snuff manufacturer. *Tob Control* 1995;4:73-9.
 105. Nordgren P, Ramstrom L. Moist snuff in Sweden—tradition and evolution. *Br J Addict* 1990;85:1107-12.
 106. Ramstrom L. Snus: part of the problem or part of the solution? *Addiction* 2003;98:1198-9; discussion 1204-7.
 107. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. *Tob Control* 2003;12:349-59.
 108. Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. *Harm Reduct J* 2006;3:37.
 109. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Prevalence Data [Web Page]. Available online at: <http://apps.nccd.cdc.gov/brfss/>. (Accessed 27 November 2006).
 110. Sweanor D. Legal strategies to reduce tobacco-caused disease. *Respirology* 2003;8:413-8.

Genetics and Smoking Cessation

Improving Outcomes in Smokers at Risk

Caryn E. Lerman, PhD, Robert A. Schnoll, PhD, Marcus R. Munafò, PhD

Abstract: This article reviews evidence supporting the potential utility of a pharmacogenetic approach to the treatment of nicotine dependence. There is substantial evidence that nicotine dependence and smoking persistence are heritable, and are determined by a complex interplay of polygenic and environmental influences. The most robust evidence for specific genetic influences on nicotine dependence is found in studies of genetic variation in nicotine-metabolizing enzymes. Data also support the role of genes in the dopamine and opioid pathways as predictors of dependence and smoking relapse; however, the evidence for genetic associations is not always consistent. Emerging data from pharmacogenetic trials of nicotine-dependence treatment are promising, suggesting that genetic profiles of smokers someday may be used by providers to choose the type, dose, and duration of treatment for individual smokers. However, additional trials including larger and more diverse populations are needed before such data can be translated to practice to reduce smoking prevalence and tobacco-related disease.
(Am J Prev Med 2007;33(6S):S398–S405) © 2007 American Journal of Preventive Medicine

Introduction

Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. Although current guidelines recommend the use of nicotine patch as a firstline treatment for tobacco dependence,¹ about 70%–80% of smokers treated with the patch relapse to their former smoking practices in the long-term.^{2,3} Bupropion has been shown to produce higher quit rates than nicotine replacement therapy,^{4,5} yet the large majority of smokers do not quit nor do they remain abstinent. The newly FDA-approved medication for treating nicotine dependence, varenicline, which outperforms bupropion significantly, yields a 1-year abstinence rate of 22%. However, these quit rates were achieved with behavioral counseling lasting for almost 1 year, which may not reflect real-world treatment.^{6,7} Thus, research is needed to identify those smokers who are at increased risk for relapse following a cessation attempt, and to tailor smoking-cessation treatments to smokers' individual risks and needs.

Pharmacogenetics research is generating new knowledge about genetic factors that influence nicotine dependence and smoking-cessation treatment outcomes. The

basic premise of this approach is that inherited differences in drug metabolism (pharmacokinetics) and drug targets (pharmacodynamics) have important effects on treatment outcome.^{8,9} These concepts and key variables are illustrated for nicotine-dependence treatment in Figure 1. Efforts to increase the understanding of the role that inherited variation plays in response to pharmacotherapy for nicotine dependence someday may help practitioners to individualize treatment type, dose, and duration based on genotype, thereby minimizing adverse reactions, increasing treatment compliance, and maximizing treatment efficacy.^{10,11} This article reviews evidence supporting the potential utility of a pharmacogenetic approach to smoking-cessation treatment. Portions of this paper were adapted from a recent book chapter on this topic.¹²

Genetic Influences on Smoking Persistence and Relapse

While the initiation of tobacco use, the progression from use to nicotine dependence, and the ability to quit smoking are influenced by a range of environmental factors (e.g., parental and peer influence, depression), twin studies have shown that genes play a critical role as well.^{13,14} In twin studies, evidence of heritability is based on evaluating the similarity between monozygotic twins (who share 100% of their genes) on a phenotype, compared to dizygotic twins (who share 50% of their genes, similar to nontwin siblings). These studies have shown that approximately 60%–70% of the variability in nicotine dependence and smoking persis-

From the Transdisciplinary Tobacco Use Research Center, University of Pennsylvania (Lerman, Schnoll), Philadelphia, Pennsylvania; and Department of Experimental Psychology, University of Bristol (Munafò), Bristol, United Kingdom

Address correspondence and reprint requests to: Caryn Lerman, PhD, University of Pennsylvania, Tobacco Use Research Center, 3535 Market St., Suite 4100, Philadelphia PA 19104. E-mail: clerman@mail.med.upenn.edu.




Figure 1. A pharmacogenetic model of nicotine-dependence treatment. * indicates that genes shown include the subset examined for pharmacogenetic effects.

nAChRs, nicotinic acetylcholine receptors; NRT, nicotine replacement therapy; SES, socioeconomic status.

tence is due to genetic influences.^{13,15–21} Two recent studies examined smoking-cessation data from twin pairs from the Vietnam Twin Registry^{22,23} and concluded that 51%–54% of the variance in the ability to quit smoking given a quit attempt, was attributable to genetic factors.

Given consistent evidence for the heritability of nicotine dependence, attention has shifted to investigations of specific genetic influences.^{24–26} Genetic variation in enzymes (e.g., CYP2A6) that metabolize nicotine to its inactive forms (cotinine and 3-hydroxycotinine) influence peripheral levels of nicotine and smoking behaviors.²⁵ Genetically faster metabolizers of nicotine (two *1 alleles; ~80% of smokers)²⁷ smoke more cigarettes per day and are more dependent on nicotine than slower metabolizers (carriers of *2, *4, *9A, and *12A alleles; ~20% of smokers)^{27,28} Fast metabolizers are also two times less likely to quit smoking,²⁹ are more likely to relapse following transdermal nicotine-replacement treatment,³⁰ and report higher levels of withdrawal symptoms following cessation.³¹

Candidate genes in neurobiological pathways mediating drug reward have been extensively studied for associations with nicotine dependence. Nicotine binds to neuronal nicotinic acetylcholine receptors (nAChRs) expressed on dopamine and gamma-aminobutyric acid (GABA) neurons in the ventral tegmental area (VTA), resulting in increased dopamine release in the nucleus accumbens.^{32,33} Despite the importance of nAChRs in nicotine dependence, particularly the *CHRNA4* and *CHRN2* subtypes,³⁴ functional polymorphisms in these subunit genes have yet to be identified. Selected genetic polymorphism and haplotypes in *CHRNA4* have

been associated with nicotine dependence,^{35,36} while studies examining the role of *CHRN2* in smoking behavior have been negative.^{35,37,38}

Given the central role of dopamine signaling in the rewarding effects of nicotine, alcohol, and other addictive drugs,^{39–41} many initial studies focused on the common Taq1A polymorphism, originally thought to be in the dopamine D2 receptor (*DRD2*) gene, but later determined to be in a neighboring gene, *ANKK1*.⁴² With respect to smoking behavior, some association studies have reported a higher prevalence of the low-activity *DRD2* Taq1'A1 allele among smokers compared to nonsmokers,^{43,44} while other findings have been negative.⁴⁵ Positive results have also been reported for associations of a variable number tandem repeat (VNTR) polymorphism in the 3' end of the dopamine transporter (*SLC6A3*) gene with smoking behavior^{46,47}; however, this has not been replicated in other studies.⁴⁸ Finally, two independent studies have provided evidence for interacting effects of the *DRD2* Taq1A and *SLC6A3* variants on the likelihood of cessation.^{49,50} A separate study found associations of *SLC6A3* genotypes with cessation following treatment with either nicotine replacement therapy (NRT) or bupropion.⁵¹

More robust findings have been observed for polymorphisms shown to alter protein transcription or translation. For example, the reduced-activity 7-repeat allele of the *DRD4* gene VNTR has been associated with smoking persistence in African Americans.⁵² The high-activity (Val) allele of the catechol-o-methyl-transferase (*COMT*) gene, associated with more rapid degradation of dopamine, has been associated with smoking persis-

tence in a retrospective case-control study and in a prospective smoking-cessation study.⁵³

Nicotine also increases levels of endogenous opioids that bind to mu opioid receptors on GABA interneurons in the VTA.⁴¹ Consistent with neurobiological evidence, the mu opioid receptor (*OPRM1*) Asn40Asp functional variant (low-activity Asp40 allele) has been associated with smoking persistence,⁵⁴ as well as reduced nicotine reward among women.⁵⁵ A recent study comparing smokers with high vs low levels of nicotine dependence did not find associations with this *OPRM1* variant; however, haplotype analysis suggests that other variants, that may be in linkage disequilibrium with the Asn40Asp polymorphism, are linked with this smoking phenotype.⁵⁶ Finally, despite effects of nicotine on serotonin neurotransmission, there is no strong evidence linking smoking cessation with genes in the serotonin pathway,^{57–59} although associations with nicotine dependence have been reported.⁶⁰ Thus, it has proven difficult to identify candidate genes with robust, replicable associations with nicotine dependence and smoking persistence.

Pharmacogenetic Investigations of Treatment for Nicotine Dependence

Pharmacogenetic clinical trials, in which the type and dose of treatment are under experimental control, may provide a stronger signal for genetic effects on smoking cessation and shed light on individual differences in the efficacy of treatments for nicotine dependence (see Table 1).⁶¹ The emerging field of pharmacogenetics is based on the premise that inherited genetic variants contribute to individual variability in treatment toxicity and efficacy.^{8,9} Although this field is in its formative years, identifying genes related to responsiveness to treatments for nicotine addiction can lead to clinical guidelines for tailoring treatments to genetic profiles to increase treatment efficacy.^{10,61}

Nicotine Replacement Therapy Trials

To date, two pharmacogenetic trials of NRT have been conducted. The first of these, conducted in the United Kingdom, compared transdermal nicotine patch to placebo patch among 755 of 1500 smokers who consented to provide DNA following the initial efficacy trial.^{62,63} Based on previous evidence that nicotine's rewarding effects are mediated, in part, by dopaminergic mechanisms,^{64,65} initial pharmacogenetic analyses focused on genes in the dopamine reward pathway. The patch was found to be superior to placebo for carriers of the Taq1 A1 allele of the *DRD2* (ANKK1) gene, but not those homozygous for the more common A2 allele.⁶² Further, the short-term efficacy of the transdermal nicotine patch was modulated by synonymous single-nucleotide polymorphism (SNP) in the

dopamine beta hydroxylase (*DBH*) gene, which codes for an enzyme involved in the conversion of dopamine to norepinephrine.⁶³ A longer-term follow-up of this analysis supported the association of the *DRD2* Taq1A variant with abstinence at 6- and 12-month follow-ups; however, the effect was observed only among women.⁶² These findings suggest that the efficacy of pharmacotherapy may be influenced by different genetic and biological factors in men and women.

In the United States, an open-label randomized trial compared transdermal nicotine and nicotine nasal spray. A recent pharmacogenetic analysis from this trial focused on two functional genetic variants in *DRD2*.⁶⁶ A promoter variant (–141C Ins/Del) is associated with altered transcriptional efficiency.⁶⁷ Another functional SNP in *DRD2* (C957T) alters mRNA stability and protein synthesis.⁶⁸ Smokers carrying the reduced activity *Del* C allele of the –141C had statistically significantly higher quit rates on NRT compared to those homozygous for the *Ins* C allele, independent of NRT type. The C957T variant also was associated with abstinence following NRT. Thus, smokers carrying variants associated with reduced transcriptional efficiency or translation responded better to NRT, perhaps because of nicotine's effects on dopamine release. Separate analyses from this trial reported that success with NRT was predicted by an interaction between the *DRD2* –141 *Ins/Del* SNP and the *NCS-1* gene, coding for a *DRD2* interacting protein.⁶⁹

The role of the *COMT* Val/Met functional polymorphism was also explored for effects on response to NRT in this trial.⁵³ *COMT* is the primary enzyme involved in the degradation and inactivation of the neurotransmitter dopamine. A polymorphism in *COMT* results in conversion of a Val high-activity allele to a Met low-activity allele, resulting in a three- to four-fold reduction in *COMT* activity. In the NRT trial, the Met/Met genotype was associated with a higher probability of abstinence with either nicotine nasal spray or nicotine patch, among women, but not in men.⁵³

The role of the *OPRM1* gene was also examined in the U.S. trial.⁵⁴ The Asp40 variant (G allele) is associated with reduced mRNA and protein levels⁷⁰ and is carried by 25%–30% of individuals of European ancestry. In the NRT trial, smokers carrying the *OPRM1* Asp40 variant were significantly more likely than those homozygous for the Asn40 variant to be abstinent at the end of the treatment phase. The differential treatment response was most pronounced among smokers receiving transdermal nicotine.⁵⁴ In contrast to positive associations for *DRD2* and *OPRM1*, there was no evidence for moderation of treatment response by the serotonin transporter (*5-HTTLPR*) gene in the NRT trial.⁵⁸ Likewise, David et al.⁵⁷ reported that response to NRT was not associated with variants of the *5-HTTLPR* gene.

Finally, a recent paper reported the effects of SNPs in *CHRNA4* ($\alpha 4$ subunit of the acetylcholine nicotinic

Table 1. Summary of pharmacogenetic effects in nicotine-dependence clinical trials

Genes	Treatment	Gender interaction	Main finding	Citation
Pharmacokinetics/drug metabolizing enzymes				
<i>CYP2A6</i>	NRT	Not reported	Genotypes related to 3-HC/cotinine ratio; slow metabolizers smoke fewer cigarettes and are less nicotine dependent; in patch condition, slow metabolizers had higher plasma nicotine but equal patch use; in spray condition, fast metabolizers used more spray but had equal plasma nicotine	28
<i>CYP2A6</i> (3-HC/Cotinine Ratio)	NRT	Not reported	3-HC/cotinine ratio predicted nicotine patch efficacy but not nasal spray; there was a 30% reduction in chance of cessation following patch therapy with each increasing quartile of metabolite ratio	30
<i>CYP2B6</i>	Bupropion	Yes	Slow metabolizers had increased cravings after quitting and higher relapse rates; bupropion attenuated these effects among females	74
	Bupropion	No	Among smokers with decreased bupropion metabolism, bupropion produced significantly higher abstinence rates than placebo; bupropion was no more effective than placebo for smokers with normal bupropion metabolism	75
Pharmacodynamics/drug target genes				
<i>DRD2</i> (Taq 1A)	NRT	Yes	Quit rates from patch therapy were higher for women with the Taq1 A1 allele, but there was no genotype effect for men	62
	NRT	No	Quit rates from patch therapy were significantly greater for smokers with the Taq1 A1 allele and the <i>DBH</i> A allele	63
	Bupropion	Yes	Women with the <i>DRD2</i> A2/A2 allele were more likely to quit smoking, compared to women with A1 alleles	80
	Bupropion	No	Those with <i>DRD2</i> A2/A2 alleles showed better treatment response, versus those with A1/A1 or A1/A2 alleles	78
	Venlafaxine		Smokers with the <i>DRD2</i> A1 allele (A1/A1/A2) quit significantly less often than the homozygous A2s	79
<i>DRD2</i> (-141 <i>Ins/Del</i>)	NRT	No	Smokers homozygous for the <i>Del</i> C allele responded better to NRT than carriers of the <i>Ins</i> C allele	66
	Bupropion	No	Smokers homozygous for the <i>Ins</i> C allele had higher quit rates following bupropion, versus smokers with the <i>Del</i> C allele; smokers with the <i>Del</i> C allele had higher quit rates on placebo	66
	NRT	No	Smokers with at least one copy of the -141 <i>Del</i> allele and two copies of the <i>FREQ</i> rs1054879 A allele were more likely to quit smoking, compared to smokers with other alleles	69
<i>DRD2</i> (C957T)	NRT	No	Smokers with CT/CC genotypes were less than two-thirds as likely to be abstinent, versus participants with TT genotypes	66
	Bupropion	No	Variants of C957T were not associated with quit rates following bupropion therapy	66
<i>DBH</i>	NRT	No	Smokers with the <i>DBH</i> GA/AA genotype had higher quit rates, compared to those with GG alleles	63
<i>COMT</i>	NRT	Yes	Women with the Met/Met genotype showed higher quit rates following NRT, versus women with the Val/Val allele	53
	Bupropion	No	<i>COMT</i> haplotype from SNPs rs165599 and rs373865 affected response to bupropion, with higher quit rates among smokers carrying the A allele of the rs165599 (A/G) SNP	82
<i>SLC6A3</i>	Bupropion	No	Smokers with <i>DRD2</i> -A2 genotypes and <i>SLC6A3</i> -9 genotypes, versus <i>SLC6A3</i> -10 genotypes, had significantly higher quit rates and a longer latency to relapse	50
	NRT or bupropion	No	Smokers with the 9-repeat allele were more likely to quit smoking following treatment than those with 10/10 repeats	51
	Bupropion	No	There were no main effects for <i>DRD2</i> and <i>SLC6A3</i> genotypes on smoking cessation; those with <i>DRD2</i> A1 and <i>SLC6A3</i> 9-repeat alleles show poorer response to bupropion	49
<i>OPRM1</i>	NRT	Yes	Quit rates following treatment were higher for carriers of the <i>OPRM1</i> Asp40 variant, versus carriers of the Asn40	54
<i>5-HTTLPR</i>	NRT	No	<i>5-HTTLPR</i> alleles were not related to NRT response	58
	NRT	No	<i>5-HTTLPR</i> alleles were not related to NRT response	57
<i>CHRNA4</i>	NRT	No	Smokers with the TC genotype were more likely to maintain abstinence on nasal spray, but not transdermal patch	71

3-HC, 3-hydroxycotinine; NRT, nicotine replacement therapy.

receptor) in response to NRT in the U.S. clinical trial.⁷¹ Individuals with the TC genotype for this SNP, which is associated with greater $\alpha 4\beta 2$ binding and greater sensitivity to the acute effects of smoking, were more likely to maintain abstinence on nasal spray, but not transdermal patch.

Bupropion Trials

To date, three independent bupropion pharmacogenetic trials have been conducted in the U.S. An initial report from a placebo-controlled trial focused on the *CYP2B6* gene, which has been implicated in bupropion kinetics⁷² as well as in brain metabolism of nicotine.⁷³ Participants in this trial provided blood samples and received bupropion (300 mg/day for 10 weeks) or placebo, plus counseling. Smokers with a decreased-activity variant of *CYP2B6* (slower metabolizers) reported greater increases in cravings for cigarettes following the target quit date and had significantly higher relapse rates.⁷⁴ These effects were modified by a significant gender X genotype X treatment interaction, suggesting that bupropion attenuated the effects of genotype among female smokers. The absence of a genotype association with bupropion side effects suggests that the genotype effect is not due to bupropion pharmacokinetics, but may be attributable to *CYP2B6*-mediated differences in nicotine metabolism in the central nervous system (CNS). For example, slower metabolizers of CNS-nicotine may experience neuroadaptive changes that promote dependence and abstinence-induced craving. In a subsequent analysis of a novel functional *CYP2B6* *6 variant (a genotype combining 2 SNPs), smokers with this genotype had significantly lower quit rates on placebo, and responded very well to bupropion; in contrast, smokers with the wildtype genotype performed equally well on placebo and bupropion.⁷⁵

Inhibition of dopamine reuptake is one putative mechanism for the beneficial effects of bupropion.^{76,77} Therefore, an analysis of response to bupropion has been conducted relative to two functional genetic variants in *DRD2*. There was a statistically significant interaction between the *DRD2* -141C *Ins/Del* genotype and treatment, at the end of the treatment phase, indicating a more favorable response to bupropion among smokers homozygous for the *Ins* C allele compared to those carrying a *Del* C allele.⁶⁶ The C957T variant was not associated with bupropion response. Given that the -141 *Ins* C allele results in higher transcriptional efficiency compared to the *Del* (N) allele,⁶⁷ individuals with the -141C *Ins/Del* CC genotype may have more D2 receptors available to bind dopamine, yielding a more rewarding experience of the nicotine-induced dopamine release. Blockade of dopamine reuptake by bupropion may be more effective in promoting abstinence

in the *Ins* C genotype group due to greater ability to bind dopamine.

David et al.⁷⁸ examined the *DRD2*, the dopamine transporter gene *SLC6A3*, and the *CYP2B6* (C1459T) genotypes as moderators of treatment response in a placebo-controlled bupropion trial with 283 smokers of European ancestry. Smokers with the *DRD2* Taq1A2/A2 genotype had a significantly better treatment response (35% for bupropion and 12% for placebo), compared to smokers with A1/A1 or A1/A2 genotypes (21% for bupropion and 24% for placebo). Cinciripini and colleagues⁷⁹ examined the *DRD2* Taq1A polymorphism in a placebo-controlled trial of venlafaxine (a serotonin reuptake inhibitor) and reported that smokers carrying the A1 allele were less likely to quit.

Swan and colleagues⁸⁰ examined the role of the *DRD2* Taq1A polymorphism in an open-label, randomized effectiveness trial comparing 150 mg and 300 mg doses of bupropion. Compared to women homozygous for the A2 allele, women with at least one A1 allele were significantly less likely to quit smoking and more likely to report having stopped taking bupropion due to treatment side effects. Finally, a recent analysis from the bupropion placebo-controlled trial provides preliminary evidence for associations of a *COMT* haplotype with bupropion response.⁸¹

Summary, Clinical Implications, and Future Research Directions

Initial findings presented in this review support the role of genetic variation in response to bupropion and NRT for smoking cessation (see Table 1). Variations in genes in the dopamine and opioid pathways, and in nicotine-metabolizing enzymes, appear to play a role in the efficacy of nicotine-replacement therapy, while genetic variation in the dopamine pathway also appears to be important for response to bupropion. Many of these studies also provide evidence for gender heterogeneity in these genetic associations.

While the integration of genetic testing into standard clinical practice would be premature at this time, pharmacogenetic studies of treatments for nicotine dependence eventually may guide individualized smoking-cessation treatments. For instance, carriers of genetic variants that increase nicotine metabolism may not respond as well to standard NRT doses, whereas carriers of reduced-activity variants in *DRD2* (e.g., Taq 1A, -141 DelC) may respond particularly well to NRTs. Selecting smokers with reduced-activity *DRD2* variants for NRT or selecting smokers with genetic variants that increase nicotine metabolism for a higher dose of NRT may enhance long-term quit rates. Importantly, many of the genetic variants linked to nicotine dependence and poor response to treatments are very common, such as *CYP2A6**1 (77%)²⁷ and *DRD2* A1 (43%),⁵⁰

suggesting that genetically-tailored treatment approaches could have a substantial population-level impact on treatment outcomes. In addition, the effect size associated with the presence of genetic alleles linked to smoking phenotypes is typically meaningful. For instance, 35% of smokers homozygous for the *Ins C* allele were abstinent following bupropion treatment, compared to only 20% of smokers carrying a *Del C* allele.⁶⁶ Likewise, at the end of NRT treatment, 23% of carriers of the Taq1 A1 allele of the *DRD2* (*ANKK1*) gene were abstinent, compared to 13% of those homozygous for the more common A2 allele.⁶² Further, pharmacogenetic studies also may help researchers understand the neurobiology of nicotine dependence which, in turn, could guide the development of new treatments. Thus, given the frequency and impact of genetic alleles linked to smoking phenotypes, using genetic information to tailor the selection of treatments may ultimately have a substantial impact on overall rates of smoking.

The use of genetic information to tailor the selection of treatments for nicotine dependence is feasible, yet there are several important policy issues that must be addressed before this technology will become standard clinical practice. First, while genetic testing for smoking genotypes increasingly is becoming more affordable and efficient with advances in technology, testing largely remains confined to the context of research programs. Decisions about how the costs of testing will be covered and whether or not insurance companies will absorb these costs have yet to be bridged. Further, given the limited resources of middle- or low-income countries, it appears likely that the potential benefits of using genetic information to treat nicotine dependence would only be realized in high-income countries. Even with adequate resources in high-income countries to implement genetic testing into treatment for nicotine dependence, researchers will need to demonstrate that such a treatment approach is cost-effective. To date, cost-effectiveness analysis of genetic testing for nicotine-dependence treatment has only recently begun,⁸² and remains as a critical priority for future research.

Further, as genetic testing for nicotine dependence is incorporated into clinical practice, researchers and clinicians must be mindful of the role of race/ethnicity as factors that influence smoking phenotypes and genes related to nicotine dependence. To date, the vast majority of studies have been conducted with Caucasians to avoid population stratification bias. Race/ethnicity influence smoking behavior (e.g., age of initiation, smoking rate, level of dependence)⁸³ and there are large racial differences in allele frequencies for nicotine-metabolizing genes^{25,84} and dopaminergic genes.⁸⁵ Further, since access to healthcare and socioeconomic status vary with race/ethnicity, the potential implementation of genetic testing clinical services may need to consider race/ethnicity as an important

variable if the potential for this technology is to be realized.^{84,86}

Third, there is substantial comorbidity between nicotine dependence and other substance abuse conditions and psychiatric disorders, including depression, schizophrenia, attention-deficit hyperactivity disorder, anxiety, and personality disorders.³³ In addition, genes linked to smoking behavior and treatment response may be related to psychiatric conditions and other addictions.⁸⁷ Thus, genetic testing to tailor treatment for nicotine dependence simultaneously could identify individuals with other dependence or psychiatric disorders,⁸⁸ and treatment programs may need to be prepared to provide more comprehensive interventions to ensure efficacy and to address comorbid psychiatric conditions.

Fourth, several genes and environmental factors likely combine to influence response to treatments for nicotine dependence. To date, most studies have focused on single genes and have not evaluated gene-environment interaction. The development of effective individualized treatments for nicotine dependence and moving beyond a "one size fits all" model may depend on future pharmacogenetic studies that include sufficiently large samples to evaluate gene-gene and gene-environment interactions.

Finally, if genetic testing for nicotine dependence is to be incorporated into clinical practice, primary care physicians, who are often the first point of contact for patients seeking assistance with quitting, will need to be appropriately trained. Many physicians lack confidence to provide genetic testing,⁸⁹ underscoring the need for guidelines to help physicians integrate genetic testing into their practice.

Additional work is needed to validate these findings across independent trials. Meta-analytic techniques also may be applied to overcome issues related to the relatively small sample sizes of the initial trials.⁹⁰ Future studies also should explore the use of more refined outcome measures that account for the longitudinal trajectories of smoking cessation, including multiple lapses, relapses, and changes in smoking rates over time.⁹¹ Increased attention to gender heterogeneity in genetic associations⁵⁵ as well as ethnic heterogeneity is needed. In addition, future studies should also explore the influence of genetic variation in additional genetic pathways relevant to nicotine dependence, including GABA and glutamate. Such studies may hold great promise for the identification of novel biological targets for drug development and improvement in the delivery of nicotine-dependence treatment to reduce the morbidity and mortality caused by smoking.

This work was supported by grants from the National Cancer Institute and National Institutes on Drug Abuse (P50-CA84718), R01-CA63562, and R01-DA17555 (CL), and by

Commonwealth of Pennsylvania Center of Excellence grant SAP# 4100027297 (CL).

Dr. Lerman has served as a consultant to Glaxo Smith Kline, Astra Zeneca, and Pfizer; Dr. Munafò has received consulting fees from G-nostics Ltd. No other authors reported financial disclosures.

References

1. Fiore MC, Bailey W, Cohen S. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville MD: U.S. Department of Health and Human Services (USDHHS). Public Health Service, 2000.
2. Fiore M, Smith S, Jorenby D, Baker T. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. *JAMA* 1994;271:1940–7.
3. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: Six-month results from two multicenter controlled trials. *JAMA* 1991;266:3133–8.
4. Gold PB, Rubey RN, Harvey RT. Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. *Am J Addict* 2002;11:315–31.
5. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med* 1999;340:685–91.
6. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:47–55.
7. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:56–63.
8. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999;286:487–91.
9. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. *J Clin Pharm Ther* 2000;25:197–220.
10. Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. *Oncogene* 2002;21:7412–20.
11. Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. *J Clin Oncol* 2005;23:311–23.
12. Lerman C, Shields A, Munafò M. Pharmacogenetic approaches to the treatment of nicotine dependence. In: George TP, ed. Medications treatments for nicotine dependence. Boca Raton FL: Taylor & Francis, 2006.
13. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. *Addiction* 2003;98:23–31.
14. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. *Nicotine Tob Res* 1999;1 (Suppl 2):S51–7; discussion S69–70.
15. Koopmans J, Slutske WS, Heath AC, Neale MC, Boomsma DI. The genetics smoking initiation and quantity smoked in Dutch adolescent and young adult twins. *Behav Genet* 1999;29:382–93.
16. Carnelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking—a study of male twins. *N Engl J Med* 1992;327:829–33.
17. McGue M, Elkins I, Iacono WG. Genetic and environmental influences on adolescent substance use and abuse. *Am J Med Genet* 2000;96:671–7.
18. True WR, Heath AC, Scherrer JF, et al. Genetic and environmental contributions to smoking. *Addiction* 1997;92:1277–87.
19. Heath A, Kirk K, Meyer J, Martin N. Genetic and social determinants of initiation and age at onset of smoking in Australian twins. *Behav Genet* 1999;29:395–407.
20. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. *Twin Res Hum Genet* 2006;9:64–72.
21. Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in Swedish twins reared apart and reared together. *Arch Gen Psychiatry* 2000; 57:886–92.
22. Xian H, Scherrer JF, Madden PA, et al. Latent class typology of nicotine withdrawal: genetic contributions and association with failed smoking cessation and psychiatric disorders. *Psychol Med* 2005;35:409–19.
23. Xian H, Scherrer JF, Madden PA, et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. *Nicotine Tob Res* 2003;5:245–54.
24. Li MD. The genetics of nicotine dependence. *Curr Psychiatry Rep* 2006; 8:158–64.
25. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. *Clin Pharmacol Ther* 2005;77:145–58.
26. Munafò M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. *Nicotine Tob Res* 2004;6:583–97.
27. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. *Clin Pharmacol Ther* 2006;80:457–67.
28. Malaiyandi V, Lerman C, Benowitz NL, Jepsen C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Mol Psychiatry* 2006;11:400–9.
29. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. *Ann Hum Genet* 2000;64(Pt 5):383–90.
30. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clin Pharmacol Ther* 2006;79:600–8.
31. Kubota T, Nakajima-Taniguchi C, Fukuda T, et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. *Pharmacogenomics J* 2006;6:115–9.
32. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. *Nat Rev Neurosci* 2004; 5:55–65.
33. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. *Nat Neurosci* 2005;8:1465–70.
34. Lukas RJ. Pharmacological effects of nicotine and nicotinic receptor subtype pharmacological profiles. In: George TP, ed. Medication treatments for nicotine dependence. Boca Raton FL: Taylor & Francis, 2006.
35. Li MD, Beuten J, Ma JZ, et al. Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. *Hum Mol Genet* 2005;14:1211–9.
36. Feng Y, Niu T, Xing H, et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. *Am J Hum Genet* 2004;75:112–21.
37. Lueders KK, Hu S, McHugh L, Myakishev MV, Sirota LA, Hamer DH. Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRN2). *Nicotine Tob Res* 2002;4:115–25.
38. Silverman M, Neale M, Sullivan P, Harris-Kerr C, Wormley B, Sadek H. Haplotypes of four novel single nucleotide polymorphisms in the nicotine acetylcholine receptor b2-subunit (CHRN2) gene show no association with smoking initiation or nicotine dependence. *Am J Med Genet (Neuropsych Genet)* 2000;96:646–53.
39. Heinz A, Goldman D, Gällinat J, Schumann G, Puls I. Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. *Psychopharmacology (Berl)* 2004;174:561–70.
40. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. *Science* 1997;278:52–8.
41. Nestler EJ. Is there a common molecular pathway for addiction? *Nat Neurosci* 2005;8:1445–9.
42. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. *Hum Mutat* 2004;23:540–5.
43. Spitz M, Shi H, Yang F, Hudmon K, Jiang H, Chanberlain R. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. *J Natl Cancer Inst* 1998;90:358–63.
44. Comings D, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. *Pharmacogenetics* 1996;6:73–9.
45. Bierut L, Rice J, Edenberg H, Goate A, Foroud T, Cloninger C. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. *Am J Med Genet* 2000;90:299–302.
46. Sabol S, Nelson M, Fisher C, Gunzerath L, Brody C, Hu S. A genetic association for cigarette smoking behavior. *Health Psychol* 1999;18:7–13.
47. Lerman C, Caporaso N, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. *Health Psychol* 1999;18: 14–20.
48. Vandenberg D, Bennett C, Grant M, Strasser A, O'Connor R, Stauffer R, et al. Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: Failure to replicate and finding that never-smokers may be different. *Nicotine Tob Res* 2002; 4:333–40.

49. Swan G, Jack LM, Valdes AM, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. *Health Psychol* 26:361–8.
50. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. *Health Psychol* 2003;22:541–8.
51. O'Gara C, Stapleton J, Sutherland G, et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. *Pharmacogenet Genomics* 2007;17:61–7.
52. Shields P, Lerman C, Audrain J, Main D, Boyd N, Caporaso N. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. *Cancer Epidemiol Biomarkers Prev* 1998;7:453–58.
53. Colilla S, Lerman C, Shields P, et al. Association of Catechol-O-Methyltransferase functional variant with smoking cessation in two independent studies of women. *Pharmacogenetics* 2005;15:393–98.
54. Lerman C, Wileyto EP, Patterson F, et al. The functional μ opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. *Pharmacogenomics J* 2004; 4:184–92.
55. Ray R, Jepson C, Patterson F, et al. Association of OPRM1 Asn40Asp variant with the relative reinforcing value of nicotine in female smokers. *Psychopharmacology* 2006;188:355–63.
56. Zhang L, Kendler KS, Chen X. The μ -opioid receptor gene and smoking initiation and nicotine dependence. *Behav Brain Funct* 2006;2:28.
57. David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. *Nicotine Tob Res* 2007;9:225–31.
58. Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. *Cancer Epidemiol Biomarkers Prev* 2006;15:398–400.
59. Lerman C, Shields PG, Audrain J, et al. The role of the serotonin transporter gene in cigarette smoking. *Cancer Epidemiol Biomarkers Prev* 1998;7:253–5.
60. Munafo M, Roberts K, Johnstone EC, Walton RT, Yidlin P. Association of serotonin transporter gene polymorphism with nicotine dependence. No evidence for an interaction with trait neuroticism. *Personality Individual Diff* 2005;38:843–50.
61. Rutter JL. Symbiotic relationship of pharmacogenetics and drugs of abuse. *AAPS J* 2006;8:E174–84.
62. Yudkin P, Munafo M, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. *BMJ* 2004;328:989–90.
63. Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. *Pharmacogenetics* 2004;14:83–90.
64. Pontieri F, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. *Nature* 1996;382: 255–7.
65. Balfour DJ. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. *Curr Drug Targets CNS Neurol Disord* 2002;1:413–21.
66. Lerman C, Jepson C, Wileyto E, et al. The role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. *Neuropsychopharmacology* 2006;31:231–42.
67. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. *Hum Mol Genet* 1997;6:577–82.
68. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. *Hum Mol Genet* 2003;12:205–16.
69. Dahl JP, Jepson C, Levenson R, et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. *Pharmacogenomics J* 2006;6:194–9.
70. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human μ opioid receptor (OPRM1) caused by variant A118G. *J Biol Chem* 2005;280:32618–24.
71. Hutchison KE, Allen D, Haughey H, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. *Arch Gen Psychiatry* 2007;64:1078–86.
72. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. *Pharmacogenetics* 2003;13:619–26.
73. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. *Neuropharmacology* 2003;45:122–32.
74. Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. *Pharmacogenetics* 2002;12:627–34.
75. Lee AM, Jepson C, Hoffmann E, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. *Biol Psychiatry* 2007;62:635–41.
76. Sanchez C, Hyytel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. *Cell Mol Neurobiol* 1999;19:467–89.
77. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. *J Clin Psychiatry* 1995;56:395–401.
78. David SP, Brown RA, Papandonatos GD, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. *Nicotine Tob Res* 2007;9:821–33.
79. Cinciripini P, Wetter D, Tomlinson G, et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. *Nicotine Tob Res* 2004;6:229–40.
80. Swan GE, Valdes AM, Ring HZ, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. *Pharmacogenomics J* 2005;5:21–9.
81. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O-Methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. *Biol Psychiatry* 2007;61:1111–8.
82. Welton NJ, Johnstone EC, David SP, Munafo MR. A cost-effectiveness analysis of genetic testing to aid treatment choice for smoking cessation. *Nicotine Tob Res*. In press.
83. Payne TJ, Diefenbach L. Characteristics of African American smokers: a brief review. *Am J Med Sci* 2003;326:212–5.
84. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. *Pharmacol Rev* 2005;57:79–115.
85. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. *Neuropsychopharmacology* 2006;31:675–84.
86. Shields AE, Fortun M, Hammonds EM, et al. The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. *Am Psychol* 2005;60:77–103.
87. Comings DE, Comings BG, Muhleman D, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. *JAMA* 1991;266: 1793–800.
88. Shields A, Lerman C, Sullivan P. Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations. *Nicotine Tob Res* 2004;6:675–88.
89. Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currihan D, Lerman C. Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. *J Gen Intern Med* 2005; 20:131–8.
90. Munafo MR, Flint J. Meta-analysis of genetic association studies. *Trends Genet* 2004;20:439–44.
91. Wileyto EP, Patterson F, Niaura R, et al. Do small lapses predict relapse to smoking behavior under bupropion treatment. *Nicotine Tob Res* 2004; 6:357–66.

Nicotine Interventions with Comorbid Populations

Sharon M. Hall, PhD

Abstract: This article reviews and comments on studies of treatment and prevention of cigarette smoking in individuals with comorbid psychiatric and non-nicotine substance abuse disorders. Despite a high prevalence of cigarette smoking in these populations and interest in quitting, treatment interventions and studies of these interventions are sparse. Multiple barriers to implementation of interventions exist. Existing data suggest that provision of cigarette-smoking interventions in substance abuse treatment patients is efficacious and does not appear to interfere with abstinence from alcohol or illicit drugs, but more research is needed. There are few studies in populations with psychiatric disorders, with the exception of studies of individuals with a history of major depressive disorder. The available data suggest at least moderate efficacy and little evidence of exacerbation of these disorders. Integration of interventions into existing treatment clinics appears desirable. Despite the identification of subgroups that are especially likely to adopt cigarette smoking, there have been no targeted prevention efforts. Further research is recommended in both the treatment and prevention of cigarette smoking in individuals with psychiatric and substance abuse disorders. It is reasonable to offer existing treatments to these subgroups of smokers, since there is some evidence of efficacy and little evidence of harm.

(Am J Prev Med 2007;33(6S):S406–S413) © 2007 American Journal of Preventive Medicine

Introduction

The goal of this article, which was first presented as a conference paper at a State of the Science Conference in August 2006, was to selectively review the studies on smoking treatment for individuals with psychiatric or non-nicotine substance abuse disorders. The article outlines five areas felt to be of importance: (1) prevalence of smoking in individuals with psychiatric and substance abuse disorders; (2) readiness for change in comorbid smokers; (3) outcome data on the treatment of cigarette smoking in comorbid individuals; (4) the effect of smoking cessation and smoking treatment on the recurrence of the non-nicotine substance abuse disorders, or on the symptoms of the psychiatric disorder; and (5) prevention, or more accurately, the lack of studies in prevention, and potential areas where prevention efforts and studies might be directed.

This is not a comprehensive review of the studies on smoking cessation in comorbid individuals. Rather, studies were selected that illustrate major issues in the research on the treatment of comorbid smokers. Some studies, especially large-scale clinical trials, studies with particularly important findings, and a meta-analysis, are described in some detail since these studies bring a richness of data and findings to the area. The paper does

not attempt to address the complex etiologic issues relevant to comorbidity in each of these disorders, nor does it present theories that link smoking and mental disorders and non-nicotine substance abuse disorders. Comorbidity in each disorder is linked with different and, in the case of depression and schizophrenia, multiple, etiologic and theoretic models. A discussion of these complex models is beyond the scope of this paper.

Individuals who are dually diagnosed with psychiatric and non-nicotine substance abuse disorders are disproportionately affected by tobacco dependence. Individuals previously treated for alcoholism and/or other non-nicotine drug dependence have an increased cumulative mortality due more to tobacco-related than to alcohol-related causes.¹ A population study using data from the National Comorbidity Survey estimates that 41.0% of the individuals with current major mental disorders smoke cigarettes, and 44.3% of the cigarettes consumed in the United States are smoked by individuals with a mental illness.² In this study, the highest rates of smoking prevalence were among those with bipolar disorder, generalized anxiety disorder, and drug and alcohol dependence. Furthermore, using data from the National Epidemiologic Survey on Alcohol and Related Conditions, Grant et al.³ found high nicotine-dependence prevalence rates in individuals with drug and alcohol disorders, and in individuals with any of seven personality disorders (avoidant, dependent, obsessive–compulsive, paranoid, schizoid, histrionic, and antisocial).³

From the Department of Health Psychology, University of California, San Francisco, San Francisco, California

Address correspondence and reprint requests to: Sharon M. Hall, PhD, University of California, San Francisco, 401 Parnassus Avenue, Box 0984, San Francisco CA 94143-0984. E-mail: shall@lppi.ucsf.edu.

Disproportionate prevalence of smoking also occurs in individuals in treatment for psychiatric and substance abuse disorders. Rates vary among individuals engaged in mental health treatment depending on disorder and treatment modality (i.e., inpatient or outpatient), but are consistently higher than the general population.⁴⁻⁷ Multiple studies show high rates of smoking among drug-treatment patients, ranging from 74% to 88%.^{8,9}

Reasons for Quitting Smoking Unique to Comorbid Smokers

Individuals with comorbid disorders have the same incentives to quit smoking as any smoker, including longer life, better quality of life, and the health of those exposed to environmental tobacco smoke. There are additional reasons to encourage abstinence among smokers with comorbid disorders. For example, studies demonstrate that individuals with non-nicotine substance abuse disorders and nicotine dependence may be more likely to abstain from the other problem substance if they quit smoking.¹⁰ Further, the health impact of smoking in comorbid populations is severe. For example, Hurt et al.¹ found that smokers with alcohol problems were more likely to die of a smoking-related illness than one related to alcohol. Cigarette smoking may interact with other drugs, complicating recovery from psychiatric disorders. Cigarette smoking accelerates the metabolism of many drugs used to treat psychiatric disorders,¹¹ making higher levels of medication necessary and introducing the possibility of fluctuating medical blood levels as a function of changes in smoking. In a similar vein, a cross-sectional study comparing alcohol-dependent smokers and non-alcohol-dependent smokers suggests that nicotine may augment the reinforcing effects of alcohol, thus making abstinence from alcohol more difficult.¹²

Barriers to Nicotine and Mental Health Treatment

Multiple reasons exist for the failure to offer nicotine treatment to patients being treated for substance abuse or mental disorders and the related lack of outcome data. In the substance abuse field, barriers includes staff resistance and lack of training.^{13,14} Clinicians also express concerns about immediate critical needs such as housing and safety. Historically, there has been a belief in the substance abuse community that the preeminent task during recovery is abstinence from non-nicotine drugs or alcohol, and that other health-related tasks should be delayed until that is achieved.¹⁵ Finally, many substance abuse treatment programs are poorly funded, and treatment of nicotine dependence has not been included in their mandate.¹⁶

Some of the same barriers exist in mental health settings, including lack of training of providers.¹⁷ The clinical reality sometimes requires that other acute conditions take precedence. Reimbursement for nicotine-dependence treatment is also a concern among clinicians. There is the belief, held by some clinicians, that smoking cessation may cause a reoccurrence of the psychiatric disorder, especially depression.¹⁸ Another important factor may be the relatively low status of nicotine-dependence treatment among mental health policymakers and providers.^{16,19,20}

Readiness to Quit Smoking

The success of treatment interventions depends on the interest and readiness of smokers to change behaviors. Several studies have assessed readiness based on the Stages of Change (SOC) model in substance abuse and mental health treatment patients. This model conceptualizes smokers as being in one of five stages with respect to quitting smoking²¹:

1. precontemplation (no intention to change),
2. contemplation (intending to quit in the next 6 months),
3. preparation (considering quitting in the next month with at least one quit attempt in the last year),
4. action (quit smoking for less than 6 months), and
5. maintenance (quit smoking for at least 6 months).

Studies of readiness to change in substance abusers report substantial intentions to quit among both alcohol-treatment patients²² and methadone-maintenance patients.²³ One study reports that chronic psychiatric patients in a supervised living setting indicated a low level of readiness to quit smoking,²⁴ but more recent studies present a more favorable picture,^{6,7} with levels of interest in quitting approximating those of the general population. The older study included patients with more severe psychiatric disorders, and was conducted at a time when interest in smoking cessation in the general population was lower. Either of these reasons could explain the discrepancies in findings between the earlier study and the later ones.

Treatment Interventions

Treatment of Smokers Who Abuse Substances in Addition to Nicotine

In a meta-analysis, Prochaska et al.¹⁰ reviewed 19 randomized controlled trials that were published between January 1996 and September 2003. Twelve trials included participants currently in treatment for addictions; seven trials included participants who had completed treatment. There was a significant trend toward greater cigarette abstinence at post-treatment for individuals in addiction treatment, with a 12% abstinence

rate for individuals in smoking-cessation interventions and 3% for the smoking treatment-control condition. In the meta-analysis, the more recent studies and the studies that used nicotine replacement therapies (NRT) were more likely to have significant results. For individuals who had completed treatment and were in recovery, at the end of smoking treatment, cigarette abstinence rates were 38% for those provided with a cessation intervention and 22% for those not provided with an intervention, indicating a significant increase in the likelihood of abstinence if an intervention was provided. Cigarette abstinence rates at long-term follow-up indicated a trend toward greater abstinence among the intervention participants, but differences were not significant. The meta-analysis also indicated that providing smoking-cessation interventions did not impede abstinence from alcohol and illicit drugs. At post-treatment assessment, non-nicotine substance-use abstinence rates were 52% in the intervention group and 54% in the comparison condition. At long-term follow-up, non-nicotine abstinence rates were 37% in the intervention group and 31% in the comparison conditions, indicating a slight increase in the likelihood of abstinence from drugs and alcohol among participants receiving a smoking-cessation intervention relative to participants in the control condition. The meta-analysis suggested that there were few studies where differences in substance use among patients in recovery were reported, but those investigations that examined this phenomenon seem to indicate no differences in smoking intervention and control conditions.¹⁰

A large-scale, controlled clinical trial, published after completion of the meta-analysis, suggests that timing of the intervention may be important. Joseph et al. randomized 499 smokers to concurrent (during alcohol treatment) or delayed (6 months later) smoking intervention.²⁵ Seven-day point-prevalence abstinence was the primary smoking measure, and the main alcohol outcome measure was 6-month prolonged abstinence from alcohol. Joseph et al. found that participants in the concurrent group were more likely to participate in smoking treatment than those in the delayed group, but that there was no significant difference in cessation rates at 18 months. Six-month abstinence from alcohol and 30-day abstinence from alcohol were consistently worse in the concurrent group than in the delayed group at 6, 12, and 18 months. The authors concluded that their data do not show benefit of concurrent treatment, and that the findings suggest that smoking-cessation interventions are best provided with patients after intensive alcohol treatment.

In summary, it appears that providing smoking-cessation interventions during treatment for alcohol abuse, or drugs of abuse other than nicotine, may increase the probability of cigarette abstinence. Most studies suggest that, contrary to beliefs of some in the clinical community, introduction of smoking treatment

in these settings does not impede abstinence from alcohol or non-nicotine drugs. However, the findings of Joseph et al. suggest the need for further research to insure optimal outcome. Further, overall cigarette abstinence rates are low, especially those obtained when smoking-cessation treatment is offered during the active phase of treatment for the other substance abuse disorder. This further reinforces the need for research to optimize results in these populations.

Treatment of Smokers with Psychiatric Disorders

Most of the nicotine-intervention research with psychiatric patients have been completed with smokers who have a history of major depressive disorder (MDD). The studies have excluded actively depressed individuals. This seems to be a by-product of conducting research in freestanding clinics lacking support for acutely ill patients.

History of MDD

While it is clear that smokers with a history of MDD are helped by additional support, it is less clear whether a particular therapeutic content is more useful than others. Hall et al., among others, hypothesized that cognitive-behavioral therapy (CBT) focused on mood management and thought it to be especially helpful to smokers with a history of depression, however this group was unable to clearly support this hypothesis.²⁶⁻²⁸ Later work suggested that CBT may indeed be differentially effective for individuals with a history of recurrent depressive episodes, but this may not be the case for those with a single episode of MDD.^{29,30} The reasons for this specificity are not clear. It may be that individuals with a single episode are false positives who have experienced an MDD-like syndrome as a result of illness or life events. Alternatively, it is possible that individuals with recurrent episodes have, over their lifetimes, learned to use skills to manage depression, anger, irritability, and other poor moods, and find the CBT approach consistent with their well-learned coping styles.

One study evaluated nicotine-cessation treatments for smokers who were diagnosed with current depressive disorders.³¹ The study recruited 322 subjects from three health maintenance organization's (HMO)-based and one university-based mental health clinics in the San Francisco Bay area. Participants all had unipolar depression. The subjects, who did not have to declare a goal of quitting smoking to be included in the study, were randomly assigned to a stepped-care intervention or a brief contact/referral control. The experimental intervention included motivational counseling using a SOC model, followed by provision of nicotine patches and six sessions of smoking-cessation counseling. Participants were assessed at 3, 6, 12, and 18 months. As hypothesized, the experimental intervention increased

7-day point-prevalence abstinence rates at months 12 (20% vs 13%) and 18 (25% vs 19%). Also, as hypothesized, the intervention made it more likely that heavy smokers would be likely to make a quit attempt, but did not change the probability of a quit attempt for light smokers. The hypothesis that the innovative intervention would increase the probability of participants reporting a goal of total abstinence was supported by the study data, but a hypothesis that smokers with more severe symptoms of depression at baseline would be less likely to attain abstinence than those with less severe symptoms was not supported.

Antidepressant Medications

It seems reasonable to assume that medications would be helpful for smokers with either a history of or current depressive disorders. Two antidepressant drugs are considered effective treatments for tobacco dependence, sustained release bupropion and nortriptyline.³² However, neither drug has demonstrated greater efficacy for smokers with a history of depressive disorders when compared to smokers without a history of depressive disorders.^{28,33–35} Due to a lack of studies, it is unclear whether these findings would hold for currently depressed individuals. The most recent version of the Practice Guidelines³² suggests that depressed smokers should be prescribed one of these antidepressants, as both smoking and depressive symptoms might be treated. The picture, however, is more complex than this recommendation would suggest because a drug that is optimal for smoking cessation might not be optimal for depression, and the clinician also may have to consider issues that surround the prescription of multiple antidepressants in such cases.

Abstinence from Nicotine and the Recurrence of Depression

The evidence is mixed on the topic of abstinence from nicotine as an influence on depressive episodes. Two large-scale studies have produced conflicting outcomes. Tsoh et al. studied 304 participants and found no differences in rate of occurrence of episodes of MDD as a function of abstinence status over a 1-year period.³⁶ There was a 14.1% incidence of depressive episodes, independent of history of depression. Among individuals with a MDD history, 23.9% experienced a depressive episode. Among those without a MDD history, 9.7% experienced such an episode. For both history-positive and history-negative subjects, the occurrence of an episode was independent of abstinence status at the time of the assessment. These findings suggest that abstinence and depression are unrelated. There was a higher incidence of depressive episodes than expected, however, therefore care should be taken in considering the relationship between cigarette absence and depres-

sion. It is possible that the process of quitting itself, or even reduction in amount smoked, could precipitate depressive episodes. Further research is needed to address these issues.

In a study of 100 participants, all of whom had a history of MDD, Glassman et al.³⁷ found that 6% of those smoking (2 people) reported a recurrence of depression, and 31% of those abstinent (13 people) reported a recurrence of depression. These results should be interpreted with caution because of the differential dropout rates of smokers in the two abstinence-status categories; 95% of quitters (42 of 44 people) were followed, as compared with 61% of continuing smokers (34 of 56). The authors reported no significant confounding factors between smoking and abstinent participants, yet the fact remains that a much higher proportion of smokers were not contacted and it is reasonable to assume that individuals who were suffering from depressive episodes were less likely to return for follow-up, and hence that the rate of recurrence among smokers may have been underestimated.

The study of patients being treated for depression reported by Hall et al.³¹ was not primarily designed to study the question of recurrence. Nevertheless, the data suggest no evidence of recurrence or worsening of symptoms as a function of cigarette abstinence. There were no differences in outcomes as a function of depression status (recurrent vs single episode), severity of depression, or whether the depression was current or in remission. Smoking status was also unrelated to mental health functioning, days of hospitalization, or changes in severity of suicidal ideation.³⁸

Schizophrenia

Two studies suggest that bupropion enhances smoking-cessation rates in nicotine-dependent smokers with schizophrenia, and that it is safe and well tolerated for these individuals. In both studies, the cessation rates were relatively low and relapse rates were high. In a randomized placebo-controlled trial (N=32), George et al.³⁹ reported higher abstinence rates at treatment discharge using bupropion (50%) compared to the placebo-control group (12%). The rates reported by Evins et al.⁴⁰ from a randomized doubleblind placebo-controlled trial (n=53) were lower, with 36% achieving end-of-treatment abstinence rates in the bupropion group and 7% in the placebo groups. The absolute difference in rates between the two studies may reflect the more stringent screening procedures used by George's study, who required reports of motivation to quit smoking on three separate occasions before acceptance into the study. Both studies reported considerable relapse by 6 months from study start, so the significant differences observed at the end of treatment were no longer evident. There have been no breakthrough interventions to suggest how higher absti-

nence rates might be reached with these patients, but given the high smoking rate in individuals with this disorder, such techniques are certainly needed. There are no published studies of smoking cessation in two other populations with a high smoking prevalence: individuals with generalized anxiety disorder and bipolar disorder.

As is the case with depression, the question of worsening schizophrenic symptoms as a function of cigarette abstinence has been raised. The clinical trials reported above found no evidence of this.^{39,40}

Integration of Treatment

There is evidence that tobacco-dependence interventions are especially effective if integrated into the mental health services, as opposed to being provided independently. McFall et al.⁴¹ randomly assigned smokers in treatment for post-traumatic stress disorder ($n = 66$) to tobacco treatment delivered by mental health providers and integrated with their mental health care (integrated care) or to smoking services delivered by cessation specialists separately (usual care). Seven-day point-prevalence abstinence was measured at 2, 4, 6, and 9 months after study start. Results indicated that subjects assigned to integrated care were five times more likely than subjects undergoing usual care to be abstinent from smoking across the follow-up assessments. They were also more likely to receive NRT and attended more cessation sessions. Treatment for tobacco dependence was not found to be associated with worsening psychiatric symptoms.

Treatment Settings

Drug-abuse treatment settings themselves may facilitate the initiation of smoking, especially if it is allowed among clients and is prevalent among staff. Kohn et al.⁴² studied 749 drug and alcohol treatment patients of a large urban HMO, and assessed smoking status at baseline and 1 year in a subsample ($n=649$) who were retained at 12-month follow-up. They reported that 34.5% (224) of the sample were nonsmokers at both points, and 52.7% (342) were smokers. Fifty-three (8.2%) had quit during the course of the year, but 4.6% (30) reported relapsing or initiating smoking. Of these 30 individuals, 11 were classified as never-smokers at the baseline interview. While this is a small number, it raises the possibility that substance abuse treatment settings with their high smoking rates among patients and staff may induce smoking in some nonsmokers. An effort to prevent initiation within treatment is appropriate.

Prevention

There have been no studies of primary prevention for tobacco dependence for individuals with substance

abuse or mental health disorders. In part, this may stem from the fact that many of these disorders develop concurrently with tobacco dependence or after the initiation of smoking. This is not the case with at least one disorder where high rates of cigarette smoking have been reported: Attention Deficit Hyperactivity Disorder (ADHD), a disorder that is most commonly diagnosed in children aged 7 and 9 years. Rates of smoking for adolescents with ADHD are two to three times higher than those for adolescents without ADHD.^{43,44} Furthermore, there is evidence that adults with childhood ADHD may have more difficulty in quitting smoking than the general population.⁴⁵

Another identifiable group who may be at high risk is children of individuals with alcohol and other substance abuse disorders. For example, Schuckit et al.⁴⁶ reported in a prospective 20-year study that middleclass sons of individuals with alcohol problems ($N=249$) were more likely to be recent smokers than the controls, whether or not they had an alcohol problem themselves. Comparable studies have not been completed on children of those with mental disorders.

Summary and Recommendations

Research on smoking cessation in the treatment of substance-abusing individuals and individuals with mental health disorders is very much in its infancy. Core questions, such as whether the interventions used in the general population work in these populations in a similar fashion, have yet to be fully addressed. Questions of timing, tailoring of the intervention to the specific problems of mental health and substance abuse patients, and the possible effects of cessation on mental health problems need study. Moreover, research on targeted prevention efforts is seriously lacking.

Given the high prevalence of tobacco dependence in populations with psychiatric and substance abuse disorders, studies of effective treatment interventions for these populations are greatly needed. Smokers with substance abuse and psychiatric disorders appear willing to quit. However, with respect to individuals who abuse non-nicotine drugs in addition to tobacco, the evidence suggests that provision of tobacco-dependence treatment can increase cigarette abstinence rates, whether provided during treatment or during the recovery period. There is also little evidence that so doing conflicts with abstinence from alcohol or other drugs.

With respect to other psychiatric illnesses, the existing data are unevenly distributed and there are not enough data to form a model of effective treatment. Data indicate that increased treatment support may be differentially effective for smokers with a history of MDD, and that it is likely that individuals with recurrent episodes are differentially helped by cognitive behavioral approaches that focus on mood management. The two antidepressants that have been found to be effective

for the treatment of tobacco dependence, sustained-release bupropion and nortriptyline, are effective for smokers with a history of depression, but there is no evidence that they are more helpful in that group of smokers than with individuals without such a history. There have been case studies suggesting that smoking cessation is related to recurrence of MDD, but the large-scale studies that addressed this issue have provided mixed results. However, MDD is a chronic relapsing disorder, so awareness of the possibility of recurrence is always prudent. There are few studies that address the treatment of smoking in schizophrenic patients. They suggest that the pharmacologic treatments that work in the general population also will have some effect with schizophrenic patients, but the magnitude of the effects is smaller. There is no evidence that cessation exacerbates schizophrenic symptoms. Cessation interventions remain virtually unstudied in some groups with high prevalence rates, bipolar disorder is a case in point.

There is also some evidence that integration of cessation treatment into mental health treatment may be especially effective, but education and well-designed services and organizational research are needed to overcome multiple barriers to integrating smoking cessation into substance abuse and mental health treatment. Prevention studies targeted at special populations do not exist. However, there are some high-risk populations—children with ADHD, children of diagnosed drug abusers, and perhaps individuals in substance abuse treatment—who might be excellent targets for prevention research.

The strongest recommendation arising from the current literature is, of course, that more research on treatment interventions in these populations is needed. Until such research is completed, it is reasonable to recommend that the field offer interventions that parallel those in the general population. The magnitude of the results may vary, but they exceed the impacts obtained by no treatment and there is little, if any, evidence that harm may be done. While clinical trials in freestanding clinics are of interest to develop innovative interventions, health services research on how best to integrate interventions in substance abuse and mental health treatment are needed. Targeted studies of prevention are possible and should be completed.

Implications for the Field of Tobacco Dependence

The major implications of the findings of this review for the general field of tobacco dependence are fourfold. First, as discussed in the section on readiness for treatment, comorbid smokers appear to have substantial readiness to quit smoking, and they are willing to enter into intervention studies. The field cannot and should not ignore these smokers with the rationale that they are unwilling to quit smoking, or do not have the

motivation to participate in treatment. A second issue is the extent to which special interventions which are targeted at comorbid smokers are needed, or whether these populations will be well served by those interventions that are used in the general population. Data are only beginning to be accrued that might answer this question. For example, Hall et al.³¹ obtained abstinence rates in depressed smokers that were comparable to those obtained in the general population when comparable interventions had been implemented.^{47,48} In contrast, well-controlled studies of bupropion in smokers with schizophrenia have resulted in abstinence rates better than placebo, but the overall rates were lower than those found in the general population and the effect in smokers with schizophrenia were not maintained at long-term follow-ups.^{49,50} Again, this had not been the case in general population studies.⁵¹ It is not known whether this is due to the heavy smoking and resulting high level of dependence that characterizes smokers with schizophrenia^{49,50} or to factors unique to the disease itself, independent of level of dependence. It is possible that some, but not all, treatments used in the general population will generalize well to comorbid smokers. Data relevant to this issue are important to the general field of tobacco dependence and have implications for the more general question about the importance of tailoring treatments to specific subpopulations.

A third issue is the relative importance of comorbid smokers to the field in general. Much has been written about the “hardening” of smokers, in the sense that smokers are becoming less likely to quit smoking.^{52–55} There is controversy about definitions of the hardcore smoker^{53,55} and to what extent this phenomenon should dictate policy.⁵⁵ However, most writers appear to agree that hardcore smokers, such as those with psychiatric disorders, may constitute a growing, if small, proportion of the population.⁵⁵ One might well argue with the assumption that this proportion is, and will remain, small, however. This may be the case if one limits the definition of psychiatric disorder to serious mental illness, particularly schizophrenia. However, an estimated 26.2% of Americans aged 18 and older suffer from a diagnosable mental disorder in a given year.⁵⁶ Another 8.5% suffer from alcohol-related disorders,⁵⁷ and 10.3% suffer from other non-nicotine substance abuse disorders at some time in their lives.⁵⁸ Lasser's data² indicate that both current and historic mental disorders in general, not just serious mental illness, predict lower smoking-cessation rates. Therefore, one can argue that this population represents a substantial proportion of smokers, not a small proportion, and that this proportion may increase in years to come. Thus, the field may find itself increasingly called on to develop effective treatment strategies for individuals with psychiatric and non-nicotine substance abuse disorders. There is a final implication from the develop-

ment of successful treatment strategies and identification of unsuccessful ones. That is the development of a more general understanding of nicotine dependence and the comorbid disorder.

Funded by Grants P50 DA09253, K05 DA016752, R01 DA02538, and R01 DA015732.

Dr. Hall was a co-investigator on varenicline and nicotine vaccine studies for Pfizer, Incorporated and Nabi Biopharmaceuticals.

References

- Hurt RD, Offord KP. Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. *JAMA* 1996;275:1097-102.
- Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. *JAMA* 2000;284:2606-10.
- Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the U.S.: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2004;61:1107-15.
- Hughes JR. Comorbidity and smoking. *Nicotine Tob Res* 1999;1:S149-S152.
- Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. *Am J Psychiatry* 1986;143:993-7.
- Prochaska JJ, Gill P, Hall SM. Treatment of tobacco use in an inpatient psychiatric setting. *Psychiatr Serv* 2004;55:1265-70.
- Acton GS, Prochaska JJ, Kaplan AS, Small T, Hall SM. Depression and stages of change for smoking in psychiatric outpatients. *Addict Behav* 2001;26:621-31.
- Kalman D. Smoking cessation treatment for substance misusers in early recovery: a review of the literature and recommendations for practice. *Subst Use Misuse* 1998;33:2021-47.
- Clemmey P, Brooner R, Chutuape MA, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. *Drug Alcohol Depend* 1997;44:123-32.
- Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. *J Consult Clin Psychol* 2004;72:1144-56.
- Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. *Clin Pharmacokinet* 1999;36:425-38.
- Hertling I, Ramskogler K, Dvorak A, et al. Craving and other characteristics of the comorbidity of alcohol and nicotine dependence. *Eur Psychiatry* 2005;20:442-50.
- Bobo JK, Slade J, Hoffman A. Nicotine addiction counseling for chemically dependent patients. *Psychiatr Serv* 1995;46:945-7.
- Hahn EJ, Warnick T, Plemmons S. Smoking cessation in drug treatment programs. *J Addict Dis* 1999;18:89-101.
- Bobo JK. Nicotine dependence and alcoholism epidemiology and treatment. *J Psychoactive Drugs* 1992;24:123-9.
- Hall SM. Commentary. Paper presented at: VA in the Vanguard: Building on Success in Smoking Cessation, 2004; San Francisco CA.
- Prochaska JJ, Fromont SC, Hall SM. How prepared are psychiatry residents for treating nicotine dependence? *Acad Psychiatry* 2005;29:256-61.
- Glassman AH. Cigarette smoking: implications for psychiatric illness. *Am J Psychiatry* 1993;150:546-53.
- Hughes JR, Zarin DA, Pincus HA. Treating nicotine dependence in mental health settings. *Journal of Practical Psychiatry and Behavioral Health* 2007;3:250-4.
- Himelhoch S, Daumit G. To whom to psychiatrists offer smoking-cessation counseling? *Am J Psychiatry* 2003;160:2228-30.
- Prochaska J, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. *J Consult Clin Psychol* 1983;51:390-5.
- Bobo JK, McIlvain HE, Gilchrist LD, Bowman A. Nicotine dependence and intentions to quit smoking in three samples of male and female recovering alcoholics and problem drinkers. *Subst Use Misuse* 1996;31:17-33.
- Nahvi S, Richter K, Li X, Modali L, Arnsten J. Cigarette smoking and interest in quitting in methadone maintenance patients. *Addict Behav* 2006;31:2127-34.
- Hall RG, Duhamel M, McClanahan R, et al. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. *J Nerv Ment Dis* 1995;183:468-71.
- Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *J Stud Alcohol* 2004;65:681-92.
- Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. *J Consult Clin Psychol* 1994;62:141-6.
- Hall SM, Muñoz RF, Reus VI, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. *J Consult Clin Psychol* 1996;64:1003-9.
- Hall SM, Reus VI, Muñoz RF, et al. Nortriptyline and cognitive behavioral therapy in the treatment of cigarette smoking. *Arch Gen Psychiatry* 1998;55:683-90.
- Haas AL, Munoz RF, Humfleet GL, Reus VI, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. *J Consult Clin Psychol* 2004;72:563-70.
- Brown RA, Kahler CW, Niaura R, et al. Cognitive-behavioral treatment for depression in smoking cessation. *J Consult Clin Psychol* 2001;69:471-80.
- Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: A randomized clinical trial. *Am J Public Health* 2006;96:1808-14.
- Fiore MC. Clinical practice guidelines for treating tobacco use and dependence: a U.S. Public Health Service report. *JAMA* 2000;283:3244-54.
- Hall SM, Humfleet GL, Reus VI, Muñoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. *Am J Psychiatry* 2004;161:2100-7.
- Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry* 2002;59:930-6.
- Prochaska AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. *Arch Intern Med* 2004;164:2229-33.
- Tsoh J, Humfleet G, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression following smoking cessation treatment. *Am J Psychiatry* 2000;157:368-74.
- Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. *Lancet* 2001;357:1129-32.
- Prochaska JJ, Hall SM, Tsoh JY, et al. Treating tobacco dependence in smokers with clinical depression: Impact on mental health functioning. *Am J Public Health* 2007;97:in press.
- George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. *Biol Psychiatry* 2002;52:53-61.
- Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol* 2005;25:218-25.
- McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. *Am J Psychiatry* 2005;162:1311-19.
- Kohn CS, Tsoh JY, Weisner CM. Changes in smoking status among substance abusers: baseline characteristics and abstinence from alcohol and drugs at 12-month follow-up. *Drug Alcohol Depend* 2003;69:61-71.
- Tercyak KP, Lerman C, Audrain J. Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. *J Am Acad Child Adolesc Psychiatry* 2002;41:799-805.
- Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. *Biol Psychiatry* 2006;59:258-64.
- Humfleet GL, Prochaska JJ, Mengis M, et al. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. *Nicotine Tob Res* 2005;7:453-60.
- Schuckit MA, Danko GP, Smith TL. Patterns of drug-related disorders in a prospective study of men chosen for their family history of alcoholism. *J Stud Alcohol* 2004;65:613-20.
- Prochaska JO, DiClemente CC, Velicer WF, Rossi JS. Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. *Health Psychol* 1993;12:399-405.

48. Prochaska JO, Velicer WF, Fava JL, Rossi JS, Tsoh JY. Evaluating a population-based recruitment approach and a stage-based expert system intervention for smoking cessation. *Addict Behav* 2001;26:583–602.
49. George TP, Vessicchio J, Allen T, Weinberger A, Sacco KA. A randomized, double-blind, placebo-controlled trial of sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia: Neuropsychological predictors of treatment outcome. *Neuropsychopharmacology* 2006;31:S254–S255.
50. Evins AE, Cather C, Culhane M. Predictors of smoking cessation in patients with schizophrenia. *Nicotine Tob Res* 2005;7:680–680.
51. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. *JAMA* 2006;296:56–63.
52. Chassin L, Presson C, Morgan-Lopez A, Sherman SJ. “Deviance proneness” and adolescent smoking 1980 versus 2001: Has there been a “hardening” of adolescent smoking? *J Appl Dev Psychol* 2007;28:264–76.
53. Hughes JR, Brandon TH. A softer view on hardening. *Nicotine Tob Res* 2003;5:961–2.
54. Irvin JE, Hendricks PS, Brandon TH. The increasing recalcitrance of smokers in clinical trials II: Pharmacotherapy trials. *Nicotine Tob Res* 2003;5:27–35.
55. Warner KE, Burns DM. Hardening and the hard-core smoker: concepts, evidence, and implications. *Nicotine Tob Res* 2003;5:37–48.
56. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. (published erratum appears in *Arch Gen Psychiatry* 2005;62:709). *Arch Gen Psychiatry* 2005;62:617–27.
57. Grant BF, Moore TC, Shepard J, Kaplan K. Source and Accuracy Statement: Wave 1. National Epidemiologic Survey on Alcohol and Related Conditions (NESARC): National Institute on Alcohol Abuse and Alcoholism, 2003.
58. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry* 2007;64:566–76.

Smoking Cessation

A Critical Component of Medical Management in Chronic Disease Populations

Ellen R. Gritz, PhD, Damon J. Vidrine, DrPH, Michelle Cororve Fingeret, PhD

Abstract: Many innovative and effective smoking-cessation treatments, both behavioral and pharmacologic, have been developed over the past several decades. However, these treatments traditionally have been developed for use with populations of healthy smokers. Despite the disease management implications, efforts to design and evaluate cessation interventions targeting smokers diagnosed with chronic diseases are reported infrequently in the literature. The purpose of this paper is to provide a brief overview of the evidence linking continued smoking to disease progression and adverse treatment outcomes across a range of common chronic diseases: cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), diabetes, asthma, cancer, and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Where studies are available, the efficacy of smoking-cessation interventions specifically developed or applied to these patient populations is reviewed. Finally, limitations and gaps in smoking research and treatment with chronically ill patients are discussed, and future research priorities are recommended. (Am J Prev Med 2007;33(6S):S414–S422) © 2007 American Journal of Preventive Medicine

Introduction

For many years, smoking-cessation efforts have been aimed primarily at healthy people in the general population as a form of primary prevention. Individuals at elevated risk for certain diseases, or who had already experienced an illness, e.g., cardiovascular disease (CVD) or early chronic obstructive pulmonary disease (COPD), were targeted as well. However, smoking and tobacco cessation among people with other types of severe chronic illness has received less attention from healthcare practitioners and researchers. This lack of emphasis may be attributable to the focus on acute treatment of a life-threatening illness, a potential or actual high mortality rate, lack of cessation treatment tailored to these populations, and the perceived lack of relevance of smoking to treatment outcome and survival. Two major examples are cancer and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), both of which have seen increased survival over the last decade. While empirically-validated treatments for smoking cessation are available in the general population, it is critical to evaluate their use for patients with chronic illness and to determine whether important modifications must be made based on disease-specific issues.

From the University of Texas MD Anderson Cancer Center; Department of Behavioral Science, Houston, Texas

Address correspondence and reprint requests to: Ellen R. Gritz, PhD, MD Anderson Cancer Center, Department of Behavioral Science, P.O. Box 301439, Unit 1330, Houston TX 77230-1439. E-mail: egriz@mdanderson.org.

In this article, findings involving smoking-related outcomes are integrated across a range of chronic illnesses: CVD, COPD, diabetes, asthma, cancer, and HIV/AIDS. First, a brief overview is provided of the evidence linking continued smoking to disease progression and adverse treatment outcomes for each illness specified. The effectiveness of smoking-cessation interventions targeting these patient groups is addressed as findings are presented from relevant empirically-tested cessation interventions. Finally, limitations and gaps in smoking research and treatment with chronically ill patients are identified and discussed. This article is organized by disease category to highlight the considerable variability in the scope and strength of the scientific literature on these topics for each group. Considering the breadth of illnesses highlighted, exhaustive coverage of all relevant smoking-related literature is beyond the scope of this article. The focus here is on presenting seminal work and critical studies to elucidate key outcomes and research issues.

Cardiovascular Disease

Cardiovascular disease (CVD) encompasses a number of diseases, including coronary heart disease (CHD), the leading cause of myocardial infarctions (MIs); cerebrovascular disease (stroke); aortic aneurysm; and peripheral vascular disease (PVD). Burns¹ reviews a body of evidence related to continued adverse effects of smoking after the onset of documented disease and concludes that, overall, continued smoking results in

disease progression, recurrent events, and higher mortality, and smoking cessation reduces disease risks over time, depending on the specific condition. Smoking cessation after MI or in angiographically-documented coronary artery disease leads to significantly lower rates of re-infarction within 1 year, compared to continued smoking, and remains much lower over time. Among those with CHD, continued smoking was associated with an increased risk for sudden coronary death. Following coronary artery bypass surgery, continued smoking at 5 years is associated with increased risk for MI, angioplasty, and development of angina. Cessation of smoking following bypass surgery resulted in a 10-year survival of 84% versus 68% among continuing smokers.² In patients with PVD, continued smoking is associated with much lower rates of improvement with medical management alone compared to nonsmoking patients, higher rates of amputation compared to quitters, and higher rates of obstruction following surgery.¹ The Cochrane Collaboration³ meta-analysis (20 studies) estimated the magnitude of risk reduction when a patient with CHD stops smoking; it reported a pooled crude relative risk (RR) of 0.64 (0.58–0.71), representing a 36% reduction in all-cause mortality in former smokers compared to continuing smokers.

In patients with CVD, empirically-tested cessation interventions primarily have been nurse-delivered and conducted with hospitalized men. These studies have demonstrated mixed outcomes prompting disagreement regarding intervention efficacy in this patient population. Barth et al.⁴ recently reviewed 19 randomized controlled trials of psychosocial interventions for smoking cessation in patients with CHD. Across intervention studies, significant positive effects on abstinence were detected after 6 to 12 months (odds ratio [OR]=1.66; 95% confidence interval [CI]=1.24–2.21). Little difference was found when comparing specific treatment strategies such as individual or group therapy, telephone counseling, or provision of self-help materials. Treatment intensity emerged as a critical factor such that brief interventions without follow-up contact did not appear effective (OR=0.092; 95% CI=0.70–1.22), while more intensive intervention showed significantly increased quit rates (OR=1.95; 95% CI=1.61–2.35).

As few trials have included women, a recent study by Froelicher et al.,⁵ conducted exclusively with hospitalized women diagnosed with CVD, warrants attention. In this randomized controlled trial, 277 women were randomly assigned to receive usual care (i.e., strong physician advice, self-help materials, and a list of community resources) or intervention (i.e., strong physician advice, nurse-managed cognitive behavioral relapse prevention intervention at bedside, provision of nicotine replacement therapy [NRT], telephone contact after discharge). Follow-up evaluations were conducted at 6, 12, 24, and 30 months. Results showed high

nonsmoking point prevalence rates (ranging from 40% to 50%) in both groups at all follow-up points, with trends somewhat greater for the intervention group compared to usual care. Although the protocol only included the provision of NRT for eligible intervention group participants, it is of some interest that comparable rates of NRT use were detected in both groups. Significant intervention effects were found for smoke-free time, such that intervention participants demonstrated a significantly longer interval to relapse compared to participants in the control group.

The use of standard pharmacologic treatments (i.e., NRT and bupropion) for smoking cessation has been somewhat controversial in patients with CVD. For nicotine replacement products, safety issues center on the hemodynamic effects of nicotine, which can include an increase in heart rate and blood pressure and increased myocardial contractility.⁶ Adrenergic stimulation associated with bupropion use has raised concerns about increased myocardial work and potential blood pressure increase.⁶ However, mounting evidence supports the safety of NRT and bupropion use in this patient group. Across randomized controlled clinical trials and efficacy studies, NRT use has not been found to affect the frequency of adverse cardiac events among patients with CVD.^{6,7} Additional data have revealed the lack of association between the nicotine patch and acute cardiovascular events even in patients who continue to smoke intermittently while on the nicotine patch.⁷ Although less data are available on the use of bupropion in patients with CVD, studies show that bupropion does not affect heart rate, cardiac conduction, and myocardial function.⁶ A large, randomized, placebo-controlled multicenter trial of bupropion in 626 patients with CVD found bupropion to be well-tolerated by participants and reported a safety profile for the drug similar to that observed in the general population.⁸ In their review of the literature, Joseph and Fu⁶ point to the need for data on the safety of bupropion use in patients with existing cardiac disease as well as additional evaluation of the safety of pharmacologic agents in patients with acute or unstable cardiovascular conditions.

Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) describes a range of conditions involving damage to the lungs, which arises primarily from the inhalation of tobacco smoke: chronic obstructive bronchitis, emphysema, and chronic airflow obstruction. Permanent cessation of smoking by individuals with early COPD (mild to moderate airway obstruction) dramatically reduces the progression to clinically serious lung disease as found in the Lung Health Study.⁹ Intervening once lung disease has become disabling results in a slowing in the rate of decline of lung function, but the benefits

are more limited in terms of symptomatology.¹⁰ Mortality risk from COPD declines following smoking cessation compared to continued smoking, but this decline is less than for heart disease and lung cancer and remains elevated in former smokers even after 20 years of abstinence.¹⁰

In a recent review of randomized controlled trials of smoking-cessation interventions conducted with individuals with COPD, Wagena et al.¹¹ concluded that combination treatment (psychosocial plus pharmacologic intervention) is superior to no treatment or psychosocial intervention alone. This conclusion was based largely on the results of the Lung Health Study, a multicenter clinical trial with 5887 participants who were followed for up to 15 years. The cessation intervention evaluated in this large-scale study was a 10-week program including a strong physician message, 12 group sessions using behavior modification, and nicotine gum. Intervention participants were further randomized to receive either an inhaled bronchodilator or a placebo inhaler. These two intervention groups were compared to a usual care condition. The cessation program with or without the use of a bronchodilator was associated with cumulative reduced decline in lung function at 5-year follow-up. Combining results from the two intervention groups, significant differences in quit rates also were found at 5-year follow-up (21.7% intervention group vs 5.4% usual care, $p < 0.001$).¹²

A recent randomized controlled study not included in previous reviews of the literature was conducted by Hilberink et al.,¹³ who compared a minimal intervention strategy to usual care. Treatment components of the intervention varied based on the participant's motivational stage of change but generally included educational materials, behavioral strategies, and pharmacotherapy recommendations. Significant differences were found in quit attempts between the two groups (44.9% intervention vs 36.5% control, $p = 0.003$) as well as in actual cessation at 6-month follow-up (16.0% intervention vs 8.8% control, $p = 0.046$). Of additional interest is the lack of differences in abstinence rates based on motivational stages, suggesting that this intervention strategy appeared to be equally effective in patients with different levels of motivation to quit smoking.

Particular attention has been given to evaluating the safety and efficacy of pharmacotherapy for patients with COPD. Two large clinical trials have been conducted to evaluate the use of bupropion SR with this patient population. Tashkin et al. conducted a double-blind randomized controlled trial comparing bupropion to placebo in 404 patients with mild to moderate COPD.¹⁴ Bupropion was well-tolerated and associated with significantly higher rates of continuous abstinence throughout the 12-week treatment phase and at the 26 week follow-up visit. At the 6-month follow-up, significantly more participants receiving bupropion remained absti-

nent than those receiving placebo (16% vs 9%, $p = 0.04$). Wagena et al.¹⁵ conducted a randomized trial to assess the efficacy of bupropion and nortriptyline among smokers with or at risk for COPD. Among those with COPD, higher prolonged abstinence rates were found with both bupropion and nortriptyline when compared to placebo, but only the difference between the bupropion and placebo groups was statistically significant (27% vs 8.3%, $p = 0.02$). Among participants at risk for COPD, differences in prolonged abstinence rates between groups were much smaller and not statistically significant.

Diabetes

Both cross-sectional and prospective studies have consistently shown higher risk for micro- and macrovascular disease, as well as for premature mortality in diabetic patients who smoke.¹⁶ Among adults with diabetes, smoking is associated with increased death from CHD, diagnosis of coronary artery disease, stroke, nephropathy and neuropathy. Damage and constriction of blood vessel by smoking can lead to exacerbation of foot ulceration, blood vessel disease, and lower extremity amputation.¹⁷ The increased cardiovascular burden of diabetes among patients who smoke needs to be emphasized by healthcare providers; advice to quit is delivered to only about half of the smokers with diabetes.^{16,18,19} Specific factors identified as contributing to difficulties in achieving long-term abstinence from smoking in the diabetic patient include smoking initiation in adolescence, problems of weight management, negative affect, and low motivation for cessation at the time of hospitalization.¹⁶

Data on the efficacy of smoking-cessation interventions for individuals with diabetes are not readily available because large-scale studies including patients with diabetes do not report results separately for this group. However, several controlled trials targeting patients with diabetes have been published recently. Results were mixed, with positive effects found in studies with larger sample sizes. Canga et al.²⁰ conducted a randomized clinical trial with 280 diabetic smokers, comparing a nurse-delivered intervention with scheduled follow-up to usual care. The intervention consisted of an initial face-to-face interview, optional NRT, and a follow-up support program. Significant intervention effects on cessation were detected at 6-month follow-up (17% nurse-intervention vs 2.3% usual-care quit rate, $p < 0.001$). Among participants who continued smoking, significant intervention effects were also found for decreased cigarette consumption. Positive intervention effects also were found in a study comparing a nurse-delivered motivational interviewing intervention in a control condition (i.e., advice letter).²¹ Participants included 211 smokers with diabetes from primary care intervention centers and 140 smokers with diabetes from primary

care control centers. Intervention participants self-selected to receive either eight group sessions ($n=47$) or telephone interview and follow-up ($n=164$). Despite these variations, significant differences in quit rates were found between participants in the intervention centers compared to the control centers (20% vs 7%, $p<0.01$) at 1-year follow-up. These findings are limited by the lack of biochemical verification of smoking status and the nonrandomization of centers to experimental condition or participants to intervention condition.

In a final study, motivational interviewing and phone counseling were integrated into a standard diabetes self-management training program for current smokers with diabetes.²² The smoking-cessation intervention consisted of a face-to-face counseling session and an additional three to six telephone counseling sessions (based on the participant's readiness to quit smoking). Although a trend toward a higher rate of abstinence was found at 3-month follow-up for intervention participants ($n=57$) compared to control participants receiving standard care ($n=57$), there was no significant difference in group smoking-cessation rates at 6 month follow-up. While this study supported the feasibility of incorporating a smoking-cessation intervention into a diabetes self-management program, it appears further research is needed to determine the most effective means of reducing tobacco use among these high-risk chronically ill patients.

Asthma

Although factors affecting the development of asthma are poorly understood, active smoking and exposure to secondhand smoke are known to trigger and aggravate asthmatic symptoms.^{23,24} Previous studies have linked smoking with more frequent attacks, more severe symptoms, higher hospitalization rates, and accelerated decline in lung function.²⁴⁻²⁷ Adverse outcomes associated with exposure to secondhand smoke include increased symptoms, poor quality of life, reduced lung function, and increased hospitalizations and emergency visits.^{24,26} Research also suggests that the effectiveness of treatments for asthma may be compromised by smoking. Tyc and Throckmorton-Belzer²⁸ reviewed research demonstrating poor responsiveness to inhaled or oral steroid treatments based on cigarette dose-dependent inflammatory responses and altered cytokine regulation in the airways of adult smokers.

Despite the negative health effects of smoking on asthma, smoking prevalence among individuals with this chronic illness consistently has been shown to be similar to or higher than the general population. Prevalence of current smoking among asthmatics ranges from 17% to 35% in different studies, with the highest rates found among those presenting at emergency rooms for acute attacks.^{24-26,28} Empirically-tested cessation studies directly targeting individuals with

asthma are lacking. Available research with this patient population focuses on reducing exposure to secondhand smoke rather than intervening with active smoking. As such, no conclusions can be drawn about the effectiveness of smoking-cessation treatment for this chronically ill patient population.

Cancer

Tobacco use, including exposure to secondhand smoke, has been implicated as a causal or contributory agent in an ever-expanding list of cancers, including lung, oral cavity, pharynx, esophagus, pancreas, urinary bladder, renal pelvis, nasal cavities and nasal sinuses, stomach, liver, kidney, uterine cervix, and myeloid leukemia.²⁹ Independent of the etiologic effects of tobacco carcinogens in numerous cancers, a growing literature also documents the direct and indirect adverse effects of smoking on oncologic treatment efficacy (short- and long-term outcomes), toxicity and morbidity, quality of life (QOL), recurrence, second primary tumors (SPT) and survival time.³⁰⁻³³

Population-based estimates of smoking prevalence across cancer type suggest that smoking rates among individuals surviving cancer are similar to those without a history of cancer (20.2% vs 23.6%).^{34,35} One notable difference is that significantly elevated rates of current smoking (42.6%) have been found among young adults with cancer (18-40 years) compared to noncancer controls (26.5%).³⁴ Beyond these data, research on the smoking behaviors of cancer patients tends to focus on individuals with smoking-related tumors. Across different studies, rates of current smoking among patients with head and neck or lung tumors at diagnosis has ranged from 40% to 60%.^{32,36,37} Research suggests that motivation and interest in smoking cessation greatly increase in people with smoking-related tumors following cancer diagnosis.³⁸⁻⁴⁰ Particular emphasis has been given to promoting cancer diagnosis as a "teachable moment" for healthcare providers to intervene and assist with smoking cessation.^{31,32}

While many of the same factors that influence cessation in the general population (e.g., nicotine dependence, readiness to quit, age) also have been found to influence cessation in cancer patients,³⁸ a variety of unique factors must be taken into account when delivering cessation treatment to this patient population. Previously identified challenges of tailoring cessation interventions to meet the particular needs of individuals with cancer include: (1) particularly high levels of nicotine dependence as evidenced by long histories of heavy tobacco use with continued smoking under life-threatening circumstances, (2) pressure for abrupt and immediate cessation to promote improved cancer treatment efficacy, (3) significantly elevated levels of psychological distress, which are known to impede smoking-cessation efforts, (4) the delayed nature of relapse compared to smokers in the general

population, (5) physical limitations imposed by disease and treatment which can affect recommendations regarding exercise regimens and dietary change, and (6) medical contraindications to certain types of NRT and other pharmacotherapy.^{31,32}

Empirically-tested cessation interventions with cancer patients have been conducted in various settings, ranged in intensity, and showed mixed results. Gritz et al.³⁸ conducted the first randomized trial of a surgeon-/dentist-delivered intervention for 186 newly diagnosed patients with head and neck cancer. The intervention consisted of strong personalized advice to stop smoking, a contracted quit date, tailored written materials, and booster advice sessions, and was compared to a minimal-advice control condition. At 12-month follow-up, 70.2% of all participants were continuous abstainers, regardless of treatment condition. Although no significant differences were found between the enhanced and minimal-advice conditions, the high sustained quit rates across all participants were quite promising and novel. These findings demonstrate the value of systematic brief advice to stop smoking for head and neck cancer patients, which can be readily incorporated into a standard treatment regiment.

An array of empirically-tested nurse-delivered cessation interventions have been conducted with hospitalized cancer patients. These studies included patients with varying cancer diagnoses and contained small samples ranging from 15 to 80 patients. The typical intervention employed in these studies consisted of three in-hospital visits, the provision of educational materials, and five post-discharge telephone calls. Across four separate studies, abstinence rates varied considerably within the intervention group at 6-week follow-up (21%,⁴¹ 40%,⁴² 64%,⁴³ 75%⁴⁴). Among the studies including a control condition, abstinence rates ranged from 14% to 50%.^{41,43,44} Generally, higher quit rates were found in studies with a higher percentage of head and neck cancer patients.

Larger-scale smoking cessation studies conducted more recently with cancer patients emphasize the need for early intervention and reinforce the particular benefits of cessation treatment for patients with smoking-related tumors. In two separate studies conducted at the Mayo Clinic Nicotine Dependence Center,^{45,46} a matched-pair design was used to retroactively analyze abstinence rates at 6-month follow-up for patients with specific smoking-related cancers compared to matched controls. Despite divergent findings regarding overall intervention effects, both studies found that duration of time between cancer diagnosis and smoking-cessation treatment significantly affected tobacco use outcome. Significantly higher abstinence rates were found for both lung and head and neck cancer patients treated within 3 months of diagnosis compared to those treated more than 3 months after diagnosis. In another trial coordinated by the Eastern Cooperative Oncology

Group, cancer patients (N=432) were randomly assigned to physician-based smoking cessation (including brief advice, optional NRT, and written materials) or usual care (unstructured advice from physicians).⁴⁷ Although no significant differences were found at 6- or 12-month follow-up between intervention and control participants, cancer diagnosis emerged as a significant predictor of abstinence. Consistent with other studies, patients with head and neck or lung cancer were significantly more likely to have quit smoking compared to patients with tumors that were not smoking-related.

As cessation research with cancer patients continues to expand, Emmons et al.⁴⁸ recently conducted a randomized control trial of a peer-based telephone-counseling intervention versus self-help intervention for young adult survivors of pediatric cancers (N=796). Childhood cancer survivors smoke at rates that are only slightly lower than the general population, and it is important to recognize that the health consequences of smoking are much greater for these cancer survivors compared to the general population. The cessation intervention was delivered by a trained childhood cancer survivor and included six calls, tailored and targeted written materials, and optional NRT. Significantly higher quit rates were found in the counseling group compared to the self-help group at both the 8-month (16.8% vs 8.5%, $p < 0.0003$) and 12-month (15% vs 9%, $p \leq 0.01$) follow-up.

HIV/AIDS

The first decade of the highly active antiretroviral therapy (HAART) era has witnessed a significantly improved prognosis for people infected with HIV. The risk of many AIDS-related diseases, such as non-Hodgkin's lymphoma, Kaposi sarcoma, and *Pneumocystis carinii*, has decreased significantly while life expectancy has increased significantly.^{49,50} This trend of improved survival along with relatively stable HIV incidence rates has resulted in an ever-growing population of people living with HIV/AIDS. In fact, recent estimates indicate that more than one million individuals in the United States are living with HIV/AIDS, and an additional 40,000 Americans are infected each year.^{51,52} While the improved health outcomes attributable to HAART are certainly positive, other potential health risks, such as cancer and CVD, are now becoming more evident.⁵³⁻⁵⁵ Thus, further efforts to reduce the risk of these conditions in the ever-growing HIV-positive population are critically needed.

Cigarette smoking is not only a highly prevalent behavior among people living with HIV/AIDS, it is also associated with numerous disease- and treatment-related adverse outcomes. Data from several published reports indicate that the prevalence of current smoking within the HIV-positive population is between 50% and

65%.⁵⁶⁻⁵⁸ This elevated prevalence is especially disturbing given the association of smoking with several AIDS-related diseases, including pulmonary infections, oral diseases, and malignancies.^{49,59} While the increased risk of CVD among current smokers is well-established, HIV-positive smokers appear to be particularly at risk. Existing evidence indicates that prolonged use of protease inhibitors, a crucial component of HAART, is associated with metabolic changes. For example, individuals on prolonged HAART regimens frequently experience increases in total cholesterol, triglycerides, and insulin resistance; a reduction in high-density lipoprotein cholesterol; and lipodystrophy.⁶⁰ Thus, the incidence of CVD has been increasing among the HIV-positive population in the HAART era.⁶¹ Because strict adherence to HAART regimens is required to prevent HIV disease progression, it is vital that modifiable risk factors for CVD, such as smoking, be targeted for intervention.

A final area of concern that has received growing attention in recent years is the significantly increased risk of malignancy among people with HIV/AIDS. HIV-associated malignancies, such as anal and cervical cancer, are observed significantly more frequently among HIV/AIDS patients who smoke.^{62,63} Other cancers commonly associated with cigarette smoking, such as lung and head and neck cancers, are observed more frequently among HIV-infected smokers compared to non-infected smokers, indicating a synergistic relationship between smoking and HIV.^{64,65} In fact, because of the growing incidence of lung cancer among people living with HIV/AIDS, some researchers have suggested that a reclassification of lung cancer as an AIDS-related malignancy be considered.^{66,67}

While the true attributable risk of cigarette smoking in the HIV-positive population would be difficult to estimate due to the numerous disease- and treatment-related interrelationships, it appears highly likely that reducing smoking prevalence would result in better disease management and increased survival times. Recently published findings from the WIHS (Women's Interagency HIV Study) cohort support this view: women who were current smokers experienced significantly poorer viral and immunologic response to HAART, and significantly higher risk of death.⁵⁷ A striking trend was also observed by Lewden and colleagues.⁵³ A detailed review of the causes of death among HIV/AIDS patients reported from various hospital wards in France indicated that cigarette smoking was reported in almost 75% of cancer-related deaths. This finding led the authors to conclude that the prevention of non-AIDS malignancies (especially lung cancer) is among the most important priorities for HIV/AIDS management.

Despite the extremely high prevalence of current smoking among people living with HIV/AIDS, and the elevated risk of cancer, CVD (and other adverse health

outcomes) and mortality confronting HIV-positive smokers, there have been few efforts to target this population for smoking-cessation treatment. One of the reasons for this lack of effort is, most likely, the historically poor prognosis of HIV/AIDS. For example, findings from a focus group study suggested that HIV-positive smokers tended to believe that they would not live long enough to experience the adverse consequences of smoking.⁶⁸ Barriers to traditional forms of smoking cessation treatment also may partially explain the lack of research. In a small study designed to identify potential treatment barriers, Lazev and colleagues⁶⁹ found that although interest in cessation treatment was high, lack of access to a working telephone, a high number of household moves, and lack of transportation greatly limited the ability of the HIV-positive population to participate in traditional behavioral-based interventions. However, a small feasibility trial, consisting of peer-led counseling sessions and the nicotine patch, does suggest that targeting HIV-positive individuals able to participate in a traditional Public Health Service (PHS) treatment regime can result in high cessation rates, with 50% abstinent at 8-month follow-up.⁷⁰

Another recently published pilot study attempted to overcome some of the barriers to smoking-cessation treatment in order to reach a more representative sample of HIV-positive smokers. In this trial, the study sample (N=95) consisted of consecutive patients receiving care at a large, inner-city HIV/AIDS clinic who were proactively screened for smoking. Current smokers were then recruited to participate in the trial, which was designed to compare a standard-care treatment approach to a cell phone-delivered intervention. Per PHS recommendations, the standard-care group received physician advice to quit, written materials, and nicotine patch. Participants in the cell phone-delivered intervention received the standard-care elements plus eight proactive counseling sessions delivered via cell phone. Outcome analyses conducted with 3-month follow-up data indicated that participants randomized to the cell phone group were significantly more likely to have quit smoking compared to participants receiving only the standard-care treatment (36.8% vs 10.3%, $p < 0.01$).⁷¹

While preliminary, findings from this pilot trial are encouraging. A larger efficacy trial of the cell phone treatment is currently underway, consisting of more comprehensive assessment of potential treatment mediators/moderators and long-term (12-month) outcome assessments. In addition to this ongoing trial, three other smoking-cessation trials are targeted to the HIV-positive population: (1) Motivation and patch treatment for HIV-positive smokers (5R01DA012344); (2) Motivating HIV-positive Latinos to quit smoking (5R01DA018079); and (3) Smoking treatment in HIV

clinical care settings (K23HL073873).⁷² Findings from these trials have not yet been published.

Research Priorities

Future studies conducted with these populations of chronically ill patients should utilize evidence-based interventions in order to maximize the likelihood of identifying effective treatments. The U.S. Department of Health and Human Services (USDHHS) Smoking-Cessation Clinical Practice Guideline⁷ is currently under revision and will next be published in 2008. Hopefully, it will provide further guidance on the treatment of these special populations. Many studies in the literature, to date, are not theory-driven, are based on less rigorous methodology, have inadequate sample sizes and thus lack statistical power, or are exploratory in nature. Clearly, a stronger body of literature is needed to guide treatment recommendations.

One remaining question is whether interventions evaluated in the general population of smokers require modification or tailoring for chronically ill people and to what degree. Physical limitations, disease-related issues, and medication management obviously need to be considered, but beyond these, what might be important? Some suggestions include comorbidities (physical, psychological, and substance-related), family involvement (and treatment of smoking among other family members), access to treatment, role of the medical provider and treatment team, and specially tailored materials. Related to tailoring is the timing of the intervention and the identification of the "teachable moment." It may be possible to deliver the smoking-cessation intervention concurrent with diagnosis and lasting through initial stages of medical treatment. Surgical treatments provide a substantive period in the hospital, during which smoking is not possible, but that is not true of all medical treatments (e.g., radiation or chemotherapy) and treatment may need to extend into the period of physical recovery to prevent relapse. It is also not known whether people with chronic illnesses who fall into population subgroups distinguished by gender, race/ethnicity, low socioeconomic status (SES), and other underserved groups will have greater difficulty quitting and may benefit from tailoring.

Because those people who continue to smoke while suffering from chronic illness are likely to be more nicotine-dependent and have more comorbidities than those who have quit, combined pharmacologic and behavioral interventions may be particularly important. In healthy populations, standard treatment courses of pharmacotherapy (i.e., NRT, antidepressants) double quit rates over counseling alone⁷; however, relapse over time is a universal problem that is particularly important to address in ill populations. It will be important to test combinations of agents, extended treatment to sustain abstinence and prevent relapse, and to explore

new agents once they are found efficacious in healthy smokers. Clinical acumen will be critical to evaluating potential contraindications due to disease or to medical treatment agents. As in the case of nicotine replacement and CVD, careful testing and evaluation may show benefit where initially there are safety concerns.

Research into provider-level interventions, including best practices and broad healthcare specialty involvement, is clearly indicated in this area. Once efficacious and effective interventions have been identified, these need to be widely disseminated in the appropriate communities of providers and healthcare systems. It would be important to see healthcare system and policy-based interventions supporting smoking cessation in chronically ill populations, providing free coverage of services and medication, and evaluation of care delivery. Equally important for both patients and families is the reduction of secondhand smoke exposure, the disease burden of which was recently definitively documented in the 2006 Surgeon General's Report.²³

Conclusion

Smoking cessation is a critical aspect of the management of many chronic diseases, both in terms of treatment outcome, progression of disease, comorbidities, quality of life, and survival. The evidence, insofar as it exists in the literature, has been summarized for CVD, COPD, diabetes, asthma, cancer, and HIV/AIDS. "Spontaneous" smoking cessation and quits prompted by healthcare provider advice most likely occur in individuals with less nicotine dependence and/or without comorbid conditions. The literature indicates that those people who continue to smoke may be more challenging to treat than healthy populations. Populations with chronic disease may have specific medical and psychosocial issues that must be addressed in targeted and tailored smoking-cessation interventions. However, for some conditions, successful treatments have reduced significantly smoking prevalence compared to controls and improved the health of patient populations. There are many gaps in the literature and it appears that far too little attention has been focused on the smoking behavior of these growing populations of individuals living with chronic disease. To date, the literature is insufficient to draw firm conclusions on effective smoking-cessation treatments for most conditions. More research is strongly warranted and should be highly prioritized. Some areas of research are relatively new, such as smoking cessation for cancer patients/survivors and people living with HIV/AIDS. These need to be pursued vigorously because of the emerging evidence on benefits to health and quality of life. It is hoped that this article will provide a stimulus to researchers, funders, and policymakers.

No financial disclosures were reported by the authors of this paper.

References

1. Burns DM. Epidemiology of smoking-induced cardiovascular disease. *Prog Cardiovasc Dis* 2003;46:11–29.
2. Cavender JB, Rogers WJ, Fisher LD, et al. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. *CASS Investigators. J Am Coll Cardiol* 1992;20:287–94.
3. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Syst Rev* 2004;1:CD003041.
4. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med* 2006;32:10–20.
5. Sivarajan Froelicher ES, Miller NH, Christopherson DJ, et al. High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). *Circulation* 2004;109:587–93.
6. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. *Prog Cardiovasc Dis* 2003;45:429–41.
7. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER. Treating tobacco use and dependence: an introduction to the U.S. Public Health Service Clinical Practice Guideline. U. S. Department of Health and Human Service (USDHHS), Public Health Service (PHS), 2000.
8. Tonstad S, Farsang C, Klaeang G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J* 2003;24:946–55.
9. Anthonisen NR. Lessons from the Lung Health Study. *Proc Am Thorac Soc* 2004;1:143–5.
10. Burns D. Chronic obstructive pulmonary disease. In: Boyle B, Gray N, Henningfield J, Seffrin J, Zatonski W, eds. *Tobacco: Science, policy and public health*. Oxford: Oxford University Press, 2004.
11. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. *Respir Med* 2004;98: 805–15.
12. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med* 2005;142:233–9.
13. Hilberink SR, Jacobs JE, Bottema BJ, de Vries H, Grol RP. Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. *Prev Med* 2005;41:822–7.
14. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet* 2001;357:1571–5.
15. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. *Arch Intern Med* 2005;165:2286–92.
16. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. *Diabetes Care* 1999;22:1887–98.
17. American Diabetes Association. Smoking. Available online at: <http://www.diabetes.org/type-1-diabetes/smoking.jsp>.
18. American Diabetes Association. Smoking and diabetes. *Diabetes Care* 2002;25:S80–81.
19. Malarcher A, Ford E, Nelson D. Trends in cigarette smoking and physicians' advice to quit smoking among people with diabetes living in the U.S. *Diabetes Care* 1995;18:694–7.
20. Canga N, De Irala J, Vara E, Duaso MJ, Ferrer A, Martinez-Gonzalez MA. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. *Diabetes Care* 2000;23:1455–60.
21. Persson LG, Hjalmarson A. Smoking cessation in patients with diabetes mellitus: results from a controlled study of an intervention programme in primary healthcare in Sweden. *Scand J Prim Health Care* 2006;24:75–80.
22. Hokanson JM, Anderson RL, Henrikus DJ, Lando HA, Kendall DM. Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. *Diabetes Educ* 2006;32:562–70.
23. USDHHS. Surgeon General's Report, The health consequences of involuntary exposure to tobacco smoke. USDHHS, Centers for Disease Control and Prevention (CDC), Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Atlanta GA, 2006.
24. Yun S, Chanetsa F, Kelsey A, Zhu BP. Active and passive smoking among asthmatic Missourians: implications for health education. *Prev Med* 2006; 42:286–90.
25. Althuis MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. *J Asthma* 1999;36:257–64.
26. Sippel JM, Pedula KL, Vollmer WM, Buist AS, Osborne ML. Associations of smoking with hospital-based care and quality of life in patients with obstructive airway disease. *Chest* 1999;115:691–6.
27. Siroux V, Pin I, Orszyszyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. *Eur Respir J* 2000;15:470–7.
28. Tyc VL, Throckmorton-Belzer L. Smoking rates and the state of smoking interventions for children and adolescents with chronic illness. *Pediatrics* 2006;118:e471–87.
29. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, Vol. 83, Tobacco smoke and involuntary smoking. Lyon: IARC Press, 2004.
30. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. *Cancer Epidemiol Biomarkers Prev* 2005;14:2287–93.
31. Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta NV, Reece GP. Successes and failures of the teachable moment: smoking cessation in cancer patients. *Cancer* 2006;106:17–27.
32. McBride CM, Ostroff JS. Teachable moments for promoting smoking cessation: the context of cancer care and survivorship. *Cancer Control* 2003;10:325–33.
33. Sanderson Cox L, African NL, Tercyak KP, Taylor KL. Nicotine dependence treatment for patients with cancer: review and recommendations. *Cancer* 2003;98:632–44.
34. Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. *J Clin Oncol* 2005;23:8884–93.
35. Coups EJ, Ostroff JS. A population-based estimate of the prevalence of behavioral risk factors among adult cancer survivors and noncancer controls. *Prev Med* 2005;40:702–11.
36. Gritz ER, Vidrine DJ, Lazev AB. Smoking cessation in cancer patients: never too late to quit. In: Green CW, Given B, Champion VL, Kozachik S, De Voss DN, eds. *Evidence-based cancer care and prevention: behavioral interventions*. New York: Springer, 2003. pp. 107–40.
37. Walker MS, Vidrine DJ, Gritz ER, Larsen RJ, Yan Y, Govindan RC, et al. Smoking relapse during the first year after treatment for early stage non-small cell lung cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15: 2370–7.
38. Gritz ER, Carr CR, Rapkin D, et al. Predictors of long-term smoking cessation in head and neck cancer patients. *Cancer Epidemiol Biomarkers Prev* 1993;2:261–70.
39. Gritz ER, Nisenbaum R, Elashoff RE, Holmes EC. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. *Cancer Causes Control* 1991;2:105–12.
40. Ostroff JS, Jacobsen PB, Moadel AB, et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. *Cancer* 1995;75:569–76.
41. Griebel B, Wewers ME, Baker CA. The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. *Oncol Nurs Forum* 1998;25:897–902.
42. Wewers ME, Jenkins L, Mignery T. A nurse-managed smoking cessation intervention during diagnostic testing for lung cancer. *Oncol Nurs Forum* 1997;24:1419–22.
43. Wewers ME, Bowen JM, Stanislaw AE, Desimone VB. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients— influence of a smoking-related diagnosis: a pilot study. *Heart Lung* 1994; 23:151–6.
44. Stanislaw AE, Wewers ME. A smoking cessation intervention with hospitalized surgical cancer patients: a pilot study. *Cancer Nurs* 1994;17:81–6.
45. Garces YI, Schroeder DR, Nirelli LM, et al. Tobacco use outcomes among patients with head and neck carcinoma treated for nicotine dependence: a matched-pair analysis. *Cancer* 2004;101:116–24.
46. Sanderson Cox L, Patten CA, et al. Tobacco use outcomes among patients with lung cancer treated for nicotine dependence. *J Clin Oncol* 2002;20: 3461–9.

47. Schnoll RA, Zhang B, Rue M, et al. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2003;21:355–65.
48. Emmons KM, Puleo E, Park E, et al. Peer-delivered smoking counseling for childhood cancer survivors increases rate of cessation: the partnership for health study. *J Clin Oncol* 2005;23:6516–23.
49. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. *Int J Epidemiol* 2005;34:121–30.
50. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338:853–60.
51. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report, 2004. Report No. 16. Atlanta GA: CDC USDHHS, 2005.
52. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. In: National HIV Prevention Conference, Abstract 595; Atlanta GA; 2005.
53. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Cancer* 2004;101:317–24.
54. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* 2005;97:425–32.
55. Palfai TP, Ostafin BD. The influence of alcohol on the activation of outcome expectancies: the role of evaluative expectancy activation in drinking behavior. *J Stud Alcohol* 2003;64:111–9.
56. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. *Nicotine Tob Res* 2005;7:511–22.
57. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the Women's Interagency HIV Study. *Am J Public Health* 2006;96:1060–5.
58. Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. *Nicotine Tob Res* 2004;6:71–7.
59. Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. *Community Dent Oral Epidemiol* 2005;33:35–44.
60. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. *Cardiovasc Toxicol* 2004;4:243–60.
61. Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. *J Acquir Immune Defic Syndr* 2004;37:1111–24.
62. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. *J Natl Cancer Inst* 1999;91:226–36.
63. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. *J Acquir Immune Defic Syndr* 1994;7:599–606.
64. Singh B, Balwally AN, Shaha AR, Rosenfeld RM, Har-El G, Lucente FE. Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection. *Arch Otolaryngol Head Neck Surg* 1996;122:639–43.
65. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. *Cancer* 2000;88:563–9.
66. Burke M, Furman A, Hoffman M, Marmor S, Blum A, Yust I. Lung cancer in patients with HIV infection: is it AIDS-related? *HIV Med* 2004;5:110–4.
67. Spano JP, Massiani MA, et al. Lung cancer in patients with HIV Infection and review of the literature. *Med Oncol* 2004;21:109–15.
68. Reynolds NR, Neidig JL, Wewers ME. Illness representation and smoking behavior: a focus group study of HIV-positive men. *J Assoc Nurses AIDS Care* 2004;15:37–47.
69. Lazev A, Vidrine D, Arduino R, Gritz E. Increasing access to smoking cessation treatment in a low-income, HIV-positive population: the feasibility of using cellular telephones. *Nicotine Tob Res* 2004;6:281–6.
70. Wewers ME, Neidig JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. *J Assoc Nurses AIDS Care* 2000;11:37–44.
71. Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. *AIDS* 2006;20:253–60.
72. National Institutes of Health (NIH). Computer retrieval of information on scientific projects (CRISP), 2006. Available online at: <http://www.crisp.cit.nih.gov>.